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Abstract	  
Influenza	   A	   viruses	   (IAV)	   cause	   human	   infections	   in	   both	   seasonal	   and	  pandemic	   forms,	  which	  are	   responsible	   for	   significant	   levels	  of	  human	   infections.	  A	  major	  factor	  underlying	  IAV	  viral	  fitness	  and	  transmissibility,	  and	  therefore	  pandemic	  potential,	  is	  the	  interaction	  of	  the	  virus	  with	  the	  cell	  surface,	  which	  is	  mediated	  by	  the	  two	  surface	  glycoproteins	  haemagglutinin	  (HA)	  and	  neuraminidase	  (NA).	  These	  two	  glycoproteins	   have	   antagonistic	   activities	   with	   the	   HA	   responsible	   for	   receptor	  binding	  and	  the	  NA	  for	  receptor	  destroying	  activities.	   It	  has	   long	  been	  hypothesised	  that	   the	  balance	  between	   these	  antagonistic	   functions	   is	   important	   in	  altering	  virus	  fitness	  and	  transmissibility.	  	  
This	   thesis	   presents	   a	   new	   biophysical	   approach,	   based	   on	   biolayer	  interferometry,	  for	  determining	  the	  relative	  importance	  of	  the	  HA	  and	  NA	  in	  altering	  virus	  binding	  to	  a	  receptor	  coated	  surface.	  These	  experiments	  identified	  a	  number	  of	  fundamental	   characteristics	   of	   virus	   attachment	   and	   interaction	  with	   surfaces.	   This	  new	  technique	  has	  also	  been	  used	  to	  examine	  two	  other	  lineages	  of	  viruses	  that	  are	  at	  different	   stages	   of	   becoming	   transmissible	   in	   humans.	   H7N9	   viruses	   first	   infected	  humans	  in	  2013	  and	  have	  caused	  a	  large	  number	  of	  zoonotic	  infections.	  The	  receptor	  binding	   characteristics	   of	   these	   H7N9	   viruses	   are	   characterised	   with	   a	   particular	  focus	   on	   the	  NA,	   as	  N9	  NAs	   have	   been	   previously	   shown	   to	   have	   receptor	   binding	  properties.	   In	   2009	   a	   new	   H1N1	   pandemic	   emerged,	   which	   was	   formed	   from	   a	  reassortment	   of	   two	   swine	   viruses.	   These	   new	   viruses	   had	   acquired	   a	   number	   of	  substitutions	  in	  the	  HA,	  which	  could	  affect	  receptor	  binding,	  also	  the	  combination	  of	  HA	  and	  NA	  was	  also	  novel.	  A	  number	  of	  HA	  mutants	  and	  combinations	  of	  HA	  and	  NA	  were	   examined	   in	   terms	   of	   receptor	   binding	   in	   an	   attempt	   to	   understand	   what	  changes	  in	  swine	  viruses	  might	  make	  them	  transmissible	  in	  humans.	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293T	   	   	   Human	  embryonic	  kidney	  293T	  cells	  3SL-­‐PAA	   	   α2,3-­‐sialyllactose	  sialoglycopolymer	  3SLN	   	   	   α2,3-­‐sialyl-­‐N-­‐acetyllactosamine	  3SLN-­‐PAA	   	   α2,3-­‐sialyl-­‐N-­‐acetyllactosamine	  sialoglycopolymer	  6SL-­‐PAA	   	   α2,6-­‐sialyllactose	  sialoglycopolymer	  6SLN	   	   	   α2,6-­‐sialyl-­‐N-­‐acetyllactosamine	  6SLN-­‐PAA	   	   α2,6-­‐sialyl-­‐N-­‐acetyllactosamine	  sialoglycopolymer	  6SU-­‐3SLN-­‐PAA	   α2,3-­‐sialyl-­‐N-­‐acetyllactosamine-­‐6’	  sulphated	  GlcNAc	  sialoglycopolymer	  6SU-­‐Sia	  Lex-­‐PAA	   Sialyl	  Lewisx-­‐6’	  sulphated	  GlcNAc	  	  sialoglycopolymer	  Anhui13	   	   A/Anhui/1/2013(H7N9)	  AU	   	   	   Arbitrary	  Units	  BHA	   	   	   Bromelain	  cleaved	  HA	  BLI	   	   	   Biolayer	  Interferometry	  Brij-­‐36T	   	   Decaethylene	  glycol	  monododecyl	  ether	  BSA	   	   	   Bovine	  Serum	  Albumin	  Cal4	   	   	   A/California/4/2009(H1N1)	  Cal7	   	   	   A/California/7/2009(H1N1)	  cDNA	   	   	   Complementary	  DNA	  CPNA	   	   	   Clostridium	  perfringens	  neuraminidase	  cRNA	   	   	   Complementary	  RNA	  csw	   	   	   Classical	  swine	  CV	   	   	   Column	  Volume	  dH2O	   	   	   Distilled	  water	  DMEM	  	   	   Dulbecco’s	  Modified	  Eagle’s	  Medium	  DNA	   	   	   Deoxyribonucleic	  Acid	  dNTP	   	   	   Deoxynucleoside	  Triphosphate	  ECACC	  	   	   European	  Collection	  of	  Cell	  Cultures	  EDTA	   	   	   Ethylenediaminetetraacetic	  acid	  EHA2	   	   	   E.	  coli	  Expressed	  HA2	  ELISA	   	   	   Enzyme-­‐linked	  Immunosorbent	  Assay	  f	   	   	   Fractional	  saturation	  FCS	   	   	   Foetal	  Calf	  Serum	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FPLC	   	   	   Fast	  Protein	  Liquid	  Chromatography	  GISAID	   	   Global	  Initiative	  for	  Sharing	  All	  Influenza	  Data	  GPI	   	   	   Glycophosphatidylinositol	  GlcNAc	   	   N-­‐Acetylglucosamine	  HA	   	   	   Haemagglutinin	  HA0	   	   	   Uncleaved	  HA	  precursor	  HA1	   	   	   N-­‐terminal	  section	  of	  cleaved	  HA	  HA2	   	   	   C-­‐terminal	  section	  of	  cleaved	  HA	  Hb	   	   	   Haemadsorption	  HEPES	  	   	   4-­‐(2-­‐hydroxyethyl)-­‐1-­‐piperazineethanesulfonic	  acid	  HPAI	   	   	   Highly	  Pathogenic	  Avian	  Influenza	  HRP	   	   	   Horseradish	  Peroxidase	  IAV	   	   	   Influenza	  A	  Virus	  Int	   	   	   Fluorescence	  intensity	  (AU)	  Inhib	   	   	   NA	  inhibitors	  Iowa06	   	   A/Iowa/1/2006(H1N1)	  IPTG	   	   	   Isopropyl	  β-­‐D-­‐1-­‐thiogalactopyranoside	  kcat	   	   	   Enzyme	  turnover	  rate	  Kd	  	   	   	   Equilibrium	  dissociation	  constant	  Ki	   	   	   Equilibrium	  dissociation	  constant	  of	  enzyme	  inhibitor	  Km	   	   	   Michaelis-­‐Menten	  constant	  kobs	   	   	   Observed	  rate	  constant	  koff	   	   	   Dissociation	  rate	  constant	  kon	   	   	   Association	  rate	  constant	  LDH	   	   	   Lactate	  Dehydrogenase	  LED	   	   	   Light	  Emitting	  Diode	  LRT	   	   	   Lower	  Respiratory	  Tract	  LSTa	   	   	   LS-­‐Tetrasaccharide	  a	  LSTc	   	   	   LS-­‐Tetrasaccharide	  c	  M	   	   	   Matrix	  M1	   	   	   Matrix	  protein	  1	  M2	   	   	   Matrix	  protein	  2	  mAb	   	   	   Monoclonal	  Antibody	  mc	   	   	   Multiplicity	  coefficient	  MDBK	  	   	   Madin-­‐Derby	  Bovine	  Kidney	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MDCK	   	   	   Madin-­‐Derby	  Canine	  Kidney	  MDCK-­‐SIAT	   MDCK	  cell	  line	  stably	  transfected	  with	  plasmid	  expressing	  2,6	  sialyltransferase	  MES	   	   	   2-­‐(N-­‐morpholino)ethanesulfonic	  acid	  MPK	   	   	   Minipig	  Kidney	  MRC	  NIMR	   Medical	   Research	   Council	   National	   Institute	   for	   Medical	  Research	   (now	   known	   as	   the	   Francis	   Crick	   Institute,	   Mill	   Hill	  Laboratory) mRNA	  	   	   Messenger	  RNA	  MST	   	   	   Microscale	  Thermophoresis	  MU	   	   	   4-­‐Methylumbelliferone	  MUNANA	   	   2’-­‐(4-­‐Methylumbelliferyl)-­‐α-­‐D-­‐N-­‐acetylneuraminic	  acid	  n	   	   	   Hill	  coefficient	   	  NA	   	   	   Neuraminidase	  NADH	   	   	   β-­‐Nicotinamide	  adenine	  dinucleotide	  NANA	  Aldolase	   N-­‐acetyl-­‐neuramininic	  acid	  aldolase	  NEP	   	   	   Nuclear	  export	  protein	  NIMR	  WHOCC	   World	   Health	   Organization	   Collaborating	   Centre	   for	   Reference	  and	   Research	   on	   Influenza,	   Medical	   Research	   Council	   National	  Institute	   for	   Medical	   Research	   (now	   known	   as	   Francis	   Crick	  Institute	  Worldwide	  Influenza	  Centre)	  NMR	   	   	   Nuclear	  Magnetic	  Resonance	  NP	   	   	   Nucleoprotein	  NS1	   	   	   Non-­‐Structural	  protein	  1	  NS2	   	   	   Non-­‐Structural	  protein	  2	  NTA	   	   	   Nanoparticle	  Tracking	  Analysis	  PA	   	   	   Polymerase	  Acidic	  PB1	   	   	   Polymerase	  Basic	  1	  PB2	   	   	   Polymerase	  Basic	  2	  PBS	   	   	   Phosphate	  Buffered	  Saline	  PCR	   	   	   Polymerase	  Chain	  Reaction	  PDB	   	   	   Protein	  Data	  Bank	  pdm09	   	   2009	  H1N1	  pandemic	  Pen/Strep	   	   Penicillin	  and	  Streptomycin	  PR8	   	   	   A/Puerto	  Rico/8/34(H1N1)	  RBS	   	   	   Receptor	  Binding	  Site	  
19	  
RNA	   	   	   Ribonucleic	  Acid	  RNP	   	   	   Ribonucleoprotein	  RSL	   	   	   Relative	  Sugar	  Loading	  RSL0.5	  	   	   	   Relative	  Sugar	  Loading	  when	  fractional	  saturation	  =	  0.5	  RT-­‐PCR	   	   Reverse	  Transcription	  Polymerase	  Chain	  Reaction	  SDS	   	   	   Sodium	  Dodecylsulphate	  SDS-­‐PAGE	   	   Sodium	  Dodecylsulphate	  Polyacrylamide	  Gel	  Electrophoresis	  Sf9	   	   	   Spodoptera	  frugiperda	  cell	  line	  Sia	  Lex-­‐PAA	   	   Sialyl	  Lewisx	  sialoglycopolymer	  SOC	   	   	   Super	  Optimal	  broth	  with	  Catabolite	  repression	  SPR	   	   	   Surface	  Plasmon	  Resonance	  ssRNA	  	   	   Single	  Stranded	  RNA	  TBHA2	   	   BHA	  treated	  with	  low	  pH	  and	  subjected	  to	  trypsin	  and	  	  thermolysin	  digestion	  TEV	   	   	   Tobacco	  Etch	  Virus	  TPCK	   	   	   Tosyl	  Phenylalanyl	  Chloromethyl	  Ketone	  TRBCs	  	   	   Turkey	  Red	  Blood	  Cells	  Tris	   	   	   Tris(hydroxymethyl)aminomethane	  TRS	   	   	   Triple	  Reassortant	  Swine	  URT	   	   	   Upper	  Respiratory	  Tract	  V0	   	   	   Initial	  enzymatic	  reaction	  rate	  VASP	   	   	   Vasodilator-­‐Stimulation	  Phosphoprotein	  vi	   	   	   Inhibited	  enzymatic	  reaction	  rate	  Vmax	   	   	   Maximal	  reaction	  velocity	  Vic361	   	   A/Victoria/361/2012(H3N2)	  vRNA	   	   	   Viral	  RNA	  WHO	   	   	   World	  Health	  Organization	  WSN	   	   	   A/WSN/33(H1N1)	  WT	   	   	   Wild	  Type	  X-­‐31	   High	   growth	   reassortant	   containing	   A/Aichi/2/68(H3N2)	   HA	  and	  NA	  with	  a	  PR8	  background	  X-­‐31	  HAM	   	   X-­‐31	  horse	  adsorption	  mutant	  X-­‐31	  NA	  Δ10	   	   X-­‐31	  with	  residues	  60	  -­‐	  69	  deleted	  from	  NA	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1 Introduction	  
1.1 Influenza	  viruses	  
1.1.1 Classification	  Influenza	   viruses	   are	   enveloped	   viruses	   with	   a	   segmented	   single-­‐stranded	  negative-­‐sense	  RNA	  genome.	  They	  are	  part	  of	  the	  family	  Orthomyxoviridae.	  There	  are	  3	   genera	   of	   Influenza	   viruses	   A,	   B	   and	   C,	   making	   up	   3	   of	   the	   6	   genera	   of	  
Orthomyxoviridae.	  These	  are	  classified	  by	  antigenic	  differences	  between	  the	  M	  and	  NP	  proteins	  (King,	  2011).	  
Influenza	  A,	  B	  and	  C	  viruses	  infect	  humans;	  however,	  only	  influenza	  A	  viruses	  (IAVs)	   have	   been	   responsible	   for	   causing	   pandemics.	   IAVs	   are	   capable	   of	   causing	  pandemics	   because	   of	   their	   wide	   host	   range,	   allowing	   between-­‐host	   transmission	  events,	  which	  can	  allow	  antigenically	  novel	  viruses	  to	  infect	  an	  immunologically	  naïve	  population.	  Because	  of	  the	  pandemic	  potential	  of	  IAVs	  they	  are	  the	  focus	  of	  this	  thesis.	  
IAVs	  are	  classified	  into	  different	  subtypes	  by	  the	  antigenic	  properties	  of	  their	  surface	   glycoproteins	   haemagglutinin	   (HA)	   and	   neuraminidase	   (NA)	   (Gamblin	   &	  Skehel,	  2010).	  There	  are	  currently	  18	  HA	  subtypes	  (H1	  –	  H18)	  and	  11	  NA	  subtypes	  (N1	   –	   N11)	   described.	   H1,	   H2	   and	   H3	   HA	   subtype-­‐containing	   viruses	   have	   caused	  human	  transmissible	  infections	  and	  were	  responsible	  for	  causing	  all	  of	  the	  pandemics	  of	   the	   20th	  and	   21st	   century:	   1918	   H1N1,	   1957	  H2N2,	   1968	  H3N2	   and	   2009	  H1N1	  (Klenk,	  Garten	  &	  Matrosovich,	  2011).	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1.1.2 Virus	  reservoirs	  The	  natural	  reservoir	  of	  most	  IAVs	  is	  held	  to	  be	  wild	  waterfowl,	  as	  all	  H1-­‐H16	  subtypes	   have	   been	   found	   in	   wild	   birds	   (Kawaoka	   et	   al.,	   1988).	  Within	   these	   wild	  waterfowl	  the	  main	  hosts	  are	  from	  the	  orders	  Anseriformes	  (ducks,	  geese	  and	  swans)	  and	  Charadriiformes	  (gulls	  and	  shorebirds)	  (Olsen	  et	  al.,	  2006;	  Vandegrift	  et	  al.,	  2010;	  Yoon,	  Webby	  &	  Webster,	  2014).	  This	  reservoir	  in	  wild	  birds	  has	  been	  found	  to	  infect	  either	  directly	  or	  indirectly,	  via	  an	  intermediate	  host,	  a	  wide	  range	  of	  different	  birds	  and	  mammals	  including	  humans,	  domestic	  poultry,	  pigs,	  horses,	  dogs,	  cats,	  seals	  and	  whales	  (Yoon,	  Webby	  &	  Webster,	  2014).	  
The	  two	  most	  recently	  described	  HA	  subtypes,	  H17	  and	  H18,	  and	  NA	  subtypes,	  N10	  and	  N11,	  are	  only	  found	  in	  recently	  discovered	  influenza	  viruses	  found	  in	  bats.	  The	  H17N10	  virus	  (Tong	  et	  al.,	  2012)	  and	  H18N11	  (Tong	  et	  al.,	  2013)	  viruses	  were	  found	  by	  sequence	  analysis	  of	  bat	  samples,	  without	   isolation	  of	  the	  virus.	  Structural	  studies	   and	   binding	   analyses	   also	   showed	   unusual	   properties	   of	   the	  HA	   and	  NA	   of	  these	  viruses,	  with	  the	  HA	  showing	  no	  binding	  to	  sialic	  acid	  (Zhu	  et	  al.,	  2013b;	  Sun	  et	  
al.,	   2013a)	   and	   the	   NA	   showing	   no	   sialidase	   activity	   (Zhu	   et	   al.,	   2012b).	   After	   full	  synthesis	   of	   the	   genome	   the	   virus	   could	   not	   be	   generated	   by	   reverse	   genetics;	  however,	  when	  replacing	  the	  open	  reading	  frame	  of	  HA	  and	  NA,	  with	  those	  of	  the	  lab	  strain	  PR8,	  replicating	  virus	  could	  be	  generated	  (Zhou	  et	  al.,	  2014).	  
1.1.3 The	  disease	  Influenza	   is	   a	   highly	   transmissible	   respiratory	   pathogen,	   which	   in	   humans	  causes	  a	  significant	  disease	  burden.	  All	  influenza	  types	  A,	  B	  and	  C	  can	  infect	  humans	  although	  influenza	  C	  is	  held	  to	  cause	  a	  very	  low	  number	  of	  minor	  infections	  (Palese	  &	  Shaw,	   2007).	   Seasonal	   human	   infections	   have	   been	   estimated	   to	   account	   for	   3	   –	   5	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million	   cases	   of	   influenza	   related	   illness	   annually,	   resulting	   in	   250	   000	   –	   500	   000	  deaths	  (World	  Health	  Organisation,	  2014a).	  	  
A	   typical	   influenza	   infection,	   in	   humans,	   manifests	   itself	   as	   an	   acute	  respiratory	  infection,	  with	  symptoms	  such	  as	  high	  fever,	  cough,	  headache,	  weakness,	  myalgia	  and	  general	  malaise,	  with	  acute	  symptoms	  generally	  lasting	  in	  the	  order	  of	  5	  days	  (Taubenberger	  &	  Morens,	  2008).	  In	  some	  severe	  cases	  the	  disease	  can	  develop	  into	   primary	   pneumonia	   directly	   from	   the	   viral	   infection	   or,	   in	   others,	   secondary	  bacterial	   pneumonia	   (Chertow	   &	   Memoli,	   2013;	   Smith	   &	   McCullers,	   2014).	   The	  transmission	   of	   IAVs	   between	   humans	   can	   occur	   via	   a	   number	   of	   different	   routes:	  aerosol,	  large	  droplets	  or	  via	  direct	  contact	  with	  substances	  carrying	  the	  virus	  such	  as	  secretions	   or	   bits	   of	   dust	   etc.	   (fomites),	   reviewed	   in	   (Tellier,	   2006).	   Humans	   are	  thought	  to	  be	  contagious	  from	  around	  one	  day	  before	  showing	  symptoms	  up	  to	  5	  –	  7	  days	  after	  developing	  symptoms.	  
1.1.4 Virus	  structure	  
1.1.4.1 The	  virion	  As	  described	  above,	  IAVs	  are	  enveloped	  viruses.	  The	  morphology	  of	  these	  viruses	  is	  variable,	  with	  some	  adopting	  spherical	  or	  elliptical	  morphology	  with	  particles	  100	  –	  150	  nm	  in	  diameter,	  whereas	  other	  viruses	  can	  form	  filamentous	  particles,	  stretching	  to	   over	   1	   µm	   in	   length	   (Calder	   et	   al.,	   2010).	   Figure	   1.1	   shows	   a	   pictorial	  representation	   of	   an	   influenza	   virus	   particle.	   Figure	   1.2	   shows	   a	   cryo	   electron	  micrograph	  of	  a	  typical	  ‘spherical’	  virus	  strain,	  X-­‐31.	  Lab-­‐adapted	  egg-­‐propagated	  IAV	  strains	  are	  typically	  spherical,	  however	  clinical	  isolates	  and	  tissue	  culture-­‐propagated	  viruses	   are	   more	   likely	   to	   be	   filamentous	   in	   nature	   and	   adaptation	   of	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Figure	  1.1:	  Schematic	  representation	  of	  influenza	  A	  virion.	  Virus	  consists	  of	  host-­‐derived	  membrane	  studded	  with	  the	  surface	  glycoproteins	  haemagglutinin	  (HA)	  and	  neuraminidase	   (NA).	   Associated	  with	   the	   inside	   of	   the	  membrane	   is	   a	   layer	   of	   the	  matrix	  protein	  (M1).	  	  Within	  this	  membrane	  and	  layer	  of	  matrix	  protein	  are	  the	  RNPs,	  which	  consist	  of	  the	  single	  stranded	  negative	  sense	  RNA	  genome	  associated	  with	  NP	  and	  the	  viral	  polymerase	  complex.	  Components	  not	  drawn	  to	  scale.	  
	  
Figure	   1.2:	   Cryo	   electron	   micrograph	   of	   X-­‐31	   virus.	   Image	   courtesy	   of	   Lesley	  Calder	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clinical	   isolates	   causes	   a	   loss	   of	   filamentous	   morphology	   (Chu,	   Dawson	   &	   Elford,	  1949;	   Kilbourne	   &	   Murphy,	   1960).	   The	   role	   of	   this	   filamentous	   morphology	   in	  infection	   is	   unclear;	   however,	   the	   presence	   of	   this	   morphology	   in	   clinical	   isolates	  suggests	   that	   it	   could	   be	   relevant	   in	   terms	   of	   human	   infection.	   The	   filamentous	  morphology	  of	   IAVs	  has	  been	   found	   to	  be	  due	   to	   the	  M1	  protein	   (Roberts,	   Lamb	  &	  Compans,	   1998;	   Bourmakina	   &	   García-­‐Sastre,	   2003;	   Elleman	   &	   Barclay,	   2004;	  Burleigh	  et	  al.,	  2005).	  
The	  virus	  consists	  of	  a	  host-­‐derived	  membrane,	  which	  is	  derived	  from	  the	  host	  plasma	  membrane	  upon	  virus	  budding,	  containing	  the	  surface	  glycoproteins	  HA	  and	  NA,	  with	  a	  dense	  layer	  of	  matrix	  (M1)	  protein	  lining	  the	  inside	  of	  the	  membrane.	  As	  well	  as	  the	  HA	  and	  NA	  there	  is	  also	  a	  small	  amount	  of	  the	  integral	  membrane	  protein	  M2.	  This	  protein	  is	  a	  low	  pH	  activated	  ion	  channel,	  which	  is	  responsible	  for	  allowing	  the	   transfer	   of	   protons	   into	   the	   virion	   to	   allow	   acidification	   of	   the	   virion	   and	  dissociation	   of	   the	   M1	   protein,	   an	   important	   step	   in	   releasing	   the	   viral	   genome	  (Helenius,	   1992).	   Inside	   the	   core	   of	   the	   virus	   are	   the	   ribonucleoproteins	   (RNPs).	  These	   RNPs	   consist	   of	   one	   of	   the	   eight	   segments	   of	   single	   stranded	   RNA	   (ssRNA)	  coated	  in	  nucleoprotein	  (NP)	  and	  with	  the	  associated	  heterotrimeric	  RNA	  dependant	  RNA	   polymerase,	   which	   consists	   of	   polymerase	   basic	   2	   (PB2),	   polymerase	   basic	   1	  (PB1)	  and	  polymerase	  acidic	  (PA)	  proteins.	  	  
The	   lipid	  bilayer	   is	   studded	  with	   the	   surface	  glycoproteins	  HA	  and	  NA.	  On	  a	  single	   spherical	   virion	   there	   are	  300	  –	  400	  HA	   trimers	   and	  50	  –	  100	  NA	   tetramers	  (Inglis	   et	   al.,	   1976;	   Ruigrok	   &	   Andree,	   1984;	   Harris	   et	   al.,	   2006),	   although	   these	  numbers	   can	   vary	   dependent	   on	   the	   particular	   virus.	   NA	   has	   been	   shown	   to	   form	  patches	  of	  higher	  density	  at	  one	  end	  of	  the	  virus.	  This	  cluster	  of	  NA	  is	  thought	  to	  be	  at	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the	  end	  of	  the	  virus	  that	  is	  proximal	  to	  the	  membrane	  at	  the	  end	  of	  virus	  budding	  and	  is	   consequently	   is	   at	   the	   opposite	   end	   to	   where	   the	   RNPs	   are	   present.	   This	   is	  particularly	  visible	  in	  filamentous	  viruses	  (Calder	  et	  al.,	  2010).	  
The	   non-­‐structural	   protein	   2	   (NS2),	   also	   known	   as	   nuclear	   export	   protein	  (NEP),	  is	  thought	  to	  be	  present	  at	  a	  low	  level	  in	  the	  interior	  of	  the	  virus	  (Richardson	  &	  Akkina,	   1991).	   Non-­‐structural	   protein	   1	   (NS1)	   is	   not	   thought	   to	   be	   present	   in	   the	  virion,	  rather	  it	  is	  only	  synthesised	  in	  the	  cell	  after	  infection	  and	  transcription	  of	  the	  viral	  genome.	  NS1	  is	  known	  to	  have	  a	  wide	  range	  of	  functions	  including	  suppressing	  various	   antiviral	   responses,	   such	   as	   reducing	   the	   level	   of	   interferon	   released,	  reviewed	  in	  (Hale	  et	  al.,	  2008).	  
1.1.4.2 Genomic	  structure	  The	   IAV	   genome	   consists	   of	   8	   segments	   of	   negative	   sense	   RNA,	   ~14	   kb	   in	  length.	   These	   8	   segments	   can	   produce	   10	   –	   17	   different	   proteins.	   The	   10	   proteins	  essential	   for	   viral	   replication	   are:	   PB2,	   PB1,	   PA,	   HA,	   NP,	   NA,	   M1,	   M2,	   NS1	   and	  NS2/NEP	   (McCauley	  &	  Mahy,	   1983).	  Two	  of	   these	   essential	   proteins	   are	   formed	  as	  gene	   splice	   products:	   M2	   (Lamb,	   Lai	   &	   Choppin,	   1981)	   and	   NS2	   (Inglis,	   Gething	   &	  Brown,	  1980).	  As	  well	  as	  these	  proteins	  there	  are	  a	  number	  of	  other	  proteins	  that	  can	  be	   produced,	   dependent	   on	   the	   particular	   strain	   of	   the	   virus:	   PB1-­‐F2	   (Chen	   et	   al.,	  2001),	  PB1-­‐N40	  (Wise	  et	  al.,	  2009),	  PA-­‐X	  (Jagger	  et	  al.,	  2012),	  M42	  (Wise	  et	  al.,	  2012),	  NS3	  (Selman	  et	  al.,	  2012),	  and	  PA-­‐N155	  and	  PA-­‐N182	  (Muramoto	  et	  al.,	  2013).	  
1.2 Antigenic	  shift	  and	  drift	  Influenza	   viruses	   have	   a	   vast	   potential	   for	   genetic	   variation.	   This	   occurs	   by	  two	   different	   methods	   of	   antigenic	   variation:	   antigenic	   shift	   and	   antigenic	   drift,	  reviewed	  in	  (Scholtissek,	  1995;	  Taubenberger	  &	  Kash,	  2010).	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Antigenic	   shift	   occurs	   when	   a	   virus	   reassorts	   its	   segmented	   genome	   after	  coinfection	  of	  a	  cell	  with	  two	  different	  strains	  (intraspecies	  shift)	  or	  when	  the	  virus	  infects	  a	  different	  host	  (interspecies	  shift).	  The	  product	  can,	  in	  both	  cases,	  be	  a	  virus	  that	   is	   novel	   to	   the	   host	   immune	   system	   of	   a	   population	   of	   individuals	   and	   can	  therefore	  spread	  unimpeded.	  
Antigenic	  drift	  occurs	  due	  to	  point	  mutations	  in	  the	  viral	  genome,	  which	  result	  in	   an	   alteration	   in	   the	   antigenicity.	   Mutant	   viruses	   generated	   can	   be	   selected	   by	  immune	   pressure	   caused	   by	   antibody	   related	   immunity.	   The	   cause	   of	   these	   point	  mutations	  is	  thought	  to	  be	  the	  error	  prone	  method	  of	  viral	  genome	  replication.	  This	  is	  due	  to	  the	  low	  fidelity	  of	  the	  viral	  polymerase,	  which	  lacks	  proof-­‐reading	  capabilities.	  These	  point	  mutations	   are	   then	  amplified	  by	   the	   large	  number	  of	   replicative	   cycles	  undergone	  by	  the	  virus.	  
1.3 Virus	  glycoproteins	  Influenza	   A	   viruses	   are	   enveloped,	   with	   this	  membrane	   derived	   from	   the	   host	   cell	  upon	   virus	   budding.	   Within	   this	   membrane	   are	   the	   two	   viral	   encoded	   surface	  glycoproteins:	  haemagglutinin	  (HA)	  and	  neuraminidase	  (NA).	  The	  HA	  is	  responsible	  for	  binding	  the	  receptor,	  sialic	  (N-­‐acetyl	  neuraminic)	  acid,	  and	  membrane	  fusion.	  The	  NA	  is	  a	  receptor	  destroying	  enzyme,	  with	  a	  number	  of	  functions	  in	  the	  viral	  life	  cycle,	  cleaving	   sialic	   acid,	   to	  which	   the	   virus	  may	  be	  bound,	   to	   allow	  efficient	   replication.	  Figure	   1.3	   shows	   phylogenetic	   trees	   for	   IAV	   HA	   subtypes	   H1	   –	   H16	   and	   IAV	   NA	  subtypes	   N1	   –	   N9.	   Both	   are	   broadly	   classified	   into	   group	   1	   and	   group	   2	   based	   on	  phylogenic	  clustering.	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1.3.1.1 Structure	  of	  HA	  at	  neutral	  pH	  The	  structure	  of	  IAV	  HA	  has	  been	  extensively	  studied	  by	  X-­‐ray	  crystallography.	  For	  reviews	  on	  HA	  structure	  see	  (Wiley	  &	  Skehel,	  1987;	  Skehel	  &	  Wiley,	  2000).	  HA	  is	  a	  homotrimeric	  class	  I	  integral	  membrane	  glycoprotein.	  Each	  monomer	  consists	  of	  a	  protein	  of	  ~550	   residues,	  ~75kDa	  monomeric	  mass,	   dependent	  on	   subtype.	  The	  C-­‐terminal	  ~40	  residues	  of	  each	  monomer	  of	  the	  trimer	  traverse	  the	  membrane,	  with	  a	  short	  cytoplasmic	  tail	  of	  ~15	  residues.	  	  
The	  first	  structure	  of	  HA	  to	  be	  solved	  by	  X-­‐ray	  crystallography	  was	  of	  a	  1968	  pandemic	  H3N2	  HA	   in	   the	  high	  growth	  reassortant	  X-­‐31,	  with	   the	  HA	  derived	   from	  the	   strain	   A/Aichi/2/68	   (H3N2)	   (Wilson,	   Skehel	   &	   Wiley,	   1981).	   This	   and	   many	  subsequent	   structures	   are	   of	   the	   soluble	   ectodomain	   of	   the	   HA.	   In	   this	   case	   the	  protein	  was	  generated	  by	  releasing	  the	  HA	  from	  purified	  virus	  by	  digestion	  with	  the	  protease	   bromelain,	   which	   cuts	   the	   protein	   at	   residue	   503,	   producing	   a	   protein	  fragment	   known	   as	   BHA.	   The	   released	   ectodomain	   contains	   the	   majority	   of	   the	  protein,	  excluding	  the	  transmembrane	  domain	  and	  the	  cytoplasmic	  tail.	  








Figure	   1.4:	   Structure	   of	   the	   HA	   at	   neutral	   pH.	   A)	   Trimeric	   HA	   with	   a	   single	  monomer	  coloured.	  B)	  Monomeric	  HA.	  HA1	  shown	  in	  blue	  and	  HA2	  shown	  in	  red.	  The	  fusion	  peptide	   is	   shown	   in	  yellow.	  Structure	   is	  of	  X-­‐31	  BHA	  with	  receptor	  analogue	  LSTa	  bound	  (coloured	  orange)	   (Eisen	  et	  al.,	  1997)	   (Not	   in	  PDB).	  Figure	  made	  using	  PyMol	  (PyMol	  Molecular	  Graphics	  System,	  Schrödinger).	  













HA	  is	  synthesised	  as	  a	  single	  chain	  protein	  with	  an	  N-­‐terminal	  signal	  peptide,	  which	   is	   co-­‐translationally	   cleaved	   to	   form	   the	   nascent	   precursor	   protein	   HA0.	  Proteolytic	  cleavage,	  at	  position	  329	  (H3	  numbering),	  separates	  each	  monomer	  into	  two	  disulphide-­‐linked	  subunits	  HA1	  and	  HA2.	  HA1	  is	  the	  N-­‐terminal	  domain,	  residues	  1	  –	  328,	  and	  HA2	  is	  the	  C-­‐terminal	  domain,	  residues	  330	  –	  550.	  The	  cleavage	  of	  HA0	  into	  HA1	  and	  HA2	  is	  necessary	  for	  the	  HA	  to	  be	  able	  to	  undergo	  the	  conformational	  change	   needed	   to	   facilitate	   membrane	   fusion	   and	   therefore	   modulates	   virus	  infectivity	  (Klenk	  et	  al.,	  1975;	  Lazarowitz	  &	  Choppin,	  1975;	  Chen	  et	  al.,	  1998).	  	  
The	  majority	  of	  HA0	  molecules	  are	  cleaved	  at	  position	  329	  (H3	  numbering)	  by	  host-­‐derived	  extracellular	  serine	  proteases.	  Highly	  pathogenic	  avian	  influenza	  (HPAI)	  viruses	  have	  acquired	  a	  polybasic	  cleavage	  site.	  This	  reduces	  the	  protease	  specificity	  of	  the	  cleavage	  site,	  allowing	  cleavage	  by	  furin-­‐like	  proteases	  in	  the	  golgi	  apparatus	  of	  the	   host	   cell	   (Stieneke-­‐Gröber	   et	   al.,	   1992).	   This	   cleavage	   of	   the	   HA	   allows	   these	  viruses	   to	   infect	   neighbouring	   cells	   without	   the	   need	   for	   control	   of	   extracellular	  cleavage	  of	  the	  HA.	  This	  allows	  these	  viruses	  to	  cause	  systemic	  infections,	  rather	  than	  localised	  to	  the	  site	  of	  HA	  cleavage.	   	  This	  acquired	  polybasic	  cleavage	  site	  is	  thought	  to	  have	  arisen	  in	  a	  number	  of	  different	  ways,	  including	  the	  slippage	  of	  the	  polymerase,	  which	  is	  the	  most	  common.	  However,	  recombination	  with	  other	  viral	  gene	  segments	  or	   recombination	  with	   ribosomal	   RNAs	   has	   also	   been	   seen,	   reviewed	   in	   (Böttcher-­‐Friebertshäuser	  et	  al.,	  2014).	  
As	  well	  as	  the	  structures	  of	  the	  ectodomain	  described	  above,	  where	  the	  virus	  attached	  HA	  is	  cleaved	  by	  proteases	  present	  in	  hens’	  eggs	  in	  which	  the	  virus	  had	  been	  propagated,	   structures	   have	   been	   solved	   of	   recombinant	   HA0,	   expressed	   using	   a	  vaccinia	   virus	   system,	   with	   the	   cleavage	   site	   removed	   by	   introduction	   of	   the	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substitution	  R329Q	  (Chen	  et	  al.,	  1998).	  This	  structure	  revealed	  that	  the	  cleavage	  site	  presents	  a	  projecting	  loop	  structure,	  enabling	  efficient	  cleavage.	  Comparison	  with	  the	  structure	  of	  the	  viral	  BHA	  showed	  a	  large	  movement	  of	  the	  cleaved	  ends	  of	  this	  loop.	  A	  comparison	  of	  uncleaved	  HA0	  and	  cleaved	  HA1/HA2	  shown	  in	  Figure	  1.5.	  	  
At	   the	   distal	   tip	   of	   the	   HA	   there	   is	   a	   depression	   which,	   from	   the	   original	  structure	   obtained	   without	   bound	   receptor,	   was	   hypothesised	   to	   be	   the	   site	   of	  receptor	   binding	   (Fig.	   1.4B)	   due	   to	   the	   conservation	   of	   a	   number	   of	   residues	   in	  different	   strains	   and	   also	   the	   structural	   similarity	   to	   another	   lectin,	   wheat	   germ	  agglutinin	   (Wilson,	   Skehel	   &	  Wiley,	   1981).	   This	   conjecture	   was	   later	   shown	   to	   be	  correct	  when	  structures	  were	  solved	  with	  bound	  sialic	  acid	  receptor	  analogues	  (Weis	  
et	  al.,	  1988;	  Sauter	  et	  al.,	  1992b;	  Watowich,	  Skehel	  &	  Wiley,	  1994;	  Eisen	  et	  al.,	  1997).	  	  
1.3.1.2 Receptor	  binding	  HA	   is	   the	  protein	  primarily	   responsible	   for	   the	  virus	  binding	   to	   the	   receptor	  sialic	   acid.	   For	   reviews	   see	   (Skehel	   &	  Wiley,	   2000;	   Xiong,	   McCauley	   &	   Steinhauer,	  2014).	  








Figure	   1.5:	   Comparison	   of	   HA0,	   neutral	   pH	   HA1/HA2,	   TBHA2	   and	   EHA2	  
structures.	  HA1	   is	  shown	   in	  blue	  and	  HA2	  shown	   in	  red.	  The	   fusion	  peptide,	  when	  present	  in	  the	  structure,	  shown	  in	  yellow.	  Figure	  made	  using	  PyMol	  (PyMol	  Molecular	  Graphics	  System,	  Schrödinger)	  using	  structures	  of	  X-­‐31	  HA:	  HA0	  (PDB:	  1HA0)	  (Chen	  
et	   al.,	   1998);	   HA1/HA2	   (PDB:	   2YPG)	   (Eisen	   et	   al.,	   1997);	   TBHA2	   (PDB:	   1HTM)	  (Bullough	  et	  al.,	  1994a)	  and	  EHA2	  (PDB:	  1QU1)	  (Chen,	  Skehel	  &	  Wiley,	  1999).	  
	   	  







of	   the	   sialic	   acid	   lies	   flat	   against	   the	   RBS,	   with	   the	   glycerol	   side	   chain	   projecting	  towards	   the	   190-­‐helix,	   with	   the	   8’-­‐hydroxyl	   group	   forming	   a	   hydrogen	   bond	   with	  tyrosine	  98	  and	  the	  9’-­‐hydroxyl	  sometimes	  forming	  hydrogen	  bonds	  with	  glutamine	  190,	   histidine	   183	   and	   serine	   228	   (depending	   on	   the	   virus	   strain).	   The	   acetamido	  nitrogen	   group	   forms	   a	   hydrogen	   bond	   with	   the	   carbonyl	   backbone	   residue	   of	  position	  135	  and	  the	  acetamido	  methyl	  group	  forms	  van	  der	  Waals	  contacts	  with	  the	  ring	  of	  tryptophan	  153.	  	  
A	   secondary	   sialic	   acid	   binding	   site	   has	   also	   been	   identified	   near	   to	   the	   site	  described	  above,	  at	  the	  interface	  of	  two	  monomers	  (Sauter	  et	  al.,	  1992a).	  By	  soaking	  HA	   crystals	   with	   different	   concentrations	   of	   receptor	   it	   was	   estimated	   that	   this	  secondary	  site	  has	  around	  a	  four-­‐fold	  lower	  affinity	  for	  receptor.	  There	  is	  no	  evidence	  for	  this	  second	  site	  binding	  to	  the	  human-­‐like	  receptor	  α2,6-­‐linked	  sialic	  acid	  or	  for	  it	  having	  any	  influence	  on	  overall	  virus	  receptor	  binding.	  
1.3.1.2.2 Receptor	  specificity	  As	   well	   as	   these	   conserved	   interactions	   of	   the	   sialic	   acid	   with	   the	   receptor	  binding	   site	   there	   are	   a	   number	   of	   other	   interactions	   that	   are	   more	   variable	  depending	   on	   the	   individual	   viral	   strain	   and	   the	   linkages	   of	   the	   terminal	   sugar	  residues.	  Sialic	  acid	  presents	  itself	  in	  three	  different	  linkages	  α2,3,	  α2,6	  or	  α2,8.	  These	  linkages	  are	  formed	  when	  the	  2’	  hydroxyl	  of	  sialic	  acid	  is	  linked	  to	  either	  the	  3’	  or	  6’	  carbon	  of	  the	  galactose	  or	  in	  the	  case	  of	  α2,8-­‐linked	  sialic	  acid	  the	  2’	  of	  one	  sialic	  acid	  is	  bound	  to	  the	  8’	  carbon	  of	  another.	  2,8-­‐linked	  sialic	  acid	  can	  also	  form	  poly	  2,8	  sialic	  acid	  structures.	  The	  major	  linkages	  involved	  in	  IAV	  receptor	  binding	  are	  2,6	  and	  2,3	  linked,	   see	   Figure	   1.7	   for	   structures	   of	   two	   trisaccharide	   receptor	   analogues,	   one	  α2,6-­‐linked	   (6SLN)	   and	   the	   other	   α2,3-­‐linked	   (3SLN),	   used	   for	   experiments
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presented	   in	  this	  thesis.	  These	  analogues	  consist	  of	   the	  terminal	   three	  sugars	  of	   the	  more	  complex	  glycan	  structures	  present	  on	  cell	  surface	  glycoproteins	  and	  glycolipids.	  There	  has	  been	  one	  report	  of	  IAVs	  binding	  to	  2,8	  linked	  sialic	  acid	  (Wu	  &	  Air,	  2004),	  although	   this	   work	   was	   carried	   out	   using	   the	   mouse	   adapted	   neurotropic	   strain	  A/NWS/33,	  which	  has	  inherently	  unusual	  binding	  characteristics.	  	  
The	   ability	   of	   the	   virus	   to	   preferentially	   bind	   to	   α2,6-­‐	   and	   α2,3-­‐linked	   sialic	  acid	  is	  thought	  to	  be	  a	  major	  factor	  in	  determining	  host	  restriction	  of	  viruses.	  Rogers	  and	  Paulson	  were	  the	  first	  to	  observe	  that	  avian	  viruses	  have	  been	  found	  to	  typically	  bind	   to	  α2,3-­‐linked	   sialic	   acid	  whereas	   human	   viruses	   typically	   bind	   to	  α2,6-­‐linked	  sialic	  acid	  by	  selective	  resialylation	  of	  NA	  treated	  red	  blood	  cells	  (Rogers	  &	  Paulson,	  1983).	   	   This	   receptor	   specificity	   of	  HA	   is	   thought	   to	   be	   a	  major	  determinant	   of	   the	  zoonotic	  potential	  of	  viruses	  from	  different	  animal	  reservoirs	  into	  humans	  and	  their	  subsequent	  transmissibility	  within	  the	  human	  population	  (Skehel	  &	  Wiley,	  2000).	  In	  birds	   IAV	   infection	   is	   primarily	   an	   enteric	   infection,	   with	   transmission	   occurring	  typically	   via	   the	   faecal-­‐oral	   route	   (Yoon,	  Webby	   &	  Webster,	   2014).	   The	   sialic	   acid	  present	  in	  the	  alimentary	  canal	  of	  birds	  is	  primarily	  α2,3-­‐linked	  (França,	  Stallknecht	  &	  Howerth,	  2013)	  and	  consequently	  the	  receptor	  binding	  of	  avian	  infecting	  viruses	  is	  attuned	   to	   this	   sialic	   acid	   linkage.	  The	  primary	   site	  of	   infection	   in	  humans	   is	   in	   the	  upper	   respiratory	   tract	   (URT).	  The	   sialic	   acid	  present	   in	   the	  URT	   is	  primarily	  α2,6-­‐	  linked	  (Couceiro,	  Paulson	  &	  Baum,	  1993)	  and	  consequently	  viruses	  infecting	  humans	  must	  contain	  an	  HA	  that	  possess	  affinity	  for	  these	  receptors.	  	  
A	   number	   of	   viruses	   have	   been	   found	   to	   infect	   the	   lower	   respiratory	   tract	  (LRT)	   of	   humans.	   Present	   in	   the	   LRT	   is	   a	   higher	   density	   of	   α2,3-­‐linked	   sialic	   acid	  receptors	   (Nicholls	   et	   al.,	   2007).	   This	   higher	   density	   of	   α2,3-­‐linked	   sugars	   allows	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viruses	   to	   infect	   the	   LRT	  which	   would	   not	   typically	   infect	   the	   URT	   because	   of	   the	  incompatible	  receptor,	  such	  as	  avian	  H5N1	  viruses	  (van	  Riel	  et	  al.,	  2006).	  
It	   has	   also	   been	   shown	   that	   IAVs	   with	   different	   receptor	   preferences	   infect	  different	  cell	  types	  within	  the	  respiratory	  tract.	  Matrosovich	  et	  al.	  demonstrated	  that	  non-­‐ciliated	   URT	   cells	   express	   higher	   levels	   of	   the	   human	   α2,6-­‐linked	   sialic	   acid	  receptors	  and	  are	  more	  efficiently	  infected	  with	  viruses	  with	  an	  α2,6-­‐linked	  sialic	  acid	  receptor	  preference.	  The	   inverse	  was	  also	   true	  with	  viruses	  with	  an	  avian	   receptor	  preference	   bound	  primarily	   to	   ciliated	  URT	   cells,	  which	   have	   higher	   levels	   of	   α2,3-­‐linked	  sialic	  acid	  (Matrosovich	  et	  al.,	  2004a).	  However,	  later	  work	  demonstrated	  that	  this	  partitioning	  of	   receptor	   specificity	   and	   infection	   tropism	  between	  different	   cell	  types	  is	  not	  as	  distinct	  as	  previously	  thought	  (Thompson	  et	  al.,	  2006;	  Ibricevic	  et	  al.,	  2006;	  Oshansky	  et	  al.,	  2011).	  
The	   respiratory	   tract	   of	   pigs	   contains	   both	   α2,6-­‐	   and	   α2,3-­‐linked	   sialic	   acid.	  For	  this	  reason	  pigs	  have	  been	  postulated	  as	  a	  possible	  mixing	  vessel	   for	  viruses	  by	  allowing	  viruses	  with	  either	  avian	  or	  human	  specificities	  to	  reassort	  or	  to	  allow	  avian	  viruses	   to	  gain	  an	  HA	  gene	  with	  a	  preference	   for	  binding	   to	   the	  human	  α2,6-­‐linked	  sialic	  acid	  receptor	  before	  entering	  the	  human	  population	  (Ito	  et	  al.,	  1998).	  	  
Although	   the	   binding	   of	   the	   terminal	   sialic	   acid	   residue	   is	   highly	   conserved	  between	  different	   receptors	  and	  subtypes,	   there	   is	  more	  variation	   in	   the	  binding	  of	  distal	   sugar	  residues.	  Eisen	  et	  al.	  solved	  structures	  of	  pentasaccharides,	  LSTa	  (α2,3-­‐linked	   sialic	   acid)	   and	   LSTc	   (α2,6-­‐linked	   sialic	   acid)	   bound	   to	   X-­‐31	   BHA.	   These	  structures	   showed	   a	   folded	   conformation	   of	   the	   α2,6-­‐linked	   LSTc	   and	   an	   extended	  conformation	   of	   the	   α2,3-­‐linked	   LSTa.	   Figure	   1.6B	   shows	   a	   structure	   of	   the	   HA	  receptor	   binding	   comparing	   the	   binding	   of	   LSTa	   and	   LSTc.	   These	   structures	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demonstrated	   the	   importance	   of	   a	   number	   of	   residues	   in	   controlling	   the	   receptor	  specificity	  of	  the	  receptor-­‐binding	  site.	  Residues	  225,	  226	  and	  227	  are	  located	  at	  the	  bond	   between	   the	   sialic	   acid	   and	   the	   galactose	   of	   the	   receptor	   and	   are	   well	  characterised	   as	   being	   important	   in	   altering	   receptor	   specificity.	   The	   folded	  conformation	   of	   the	   α2,6	   linked	   receptors	   also	   highlights	   the	   importance	   of	  interactions	  of	  the	  distal	  sugar	  residues	  with	  the	  190-­‐helix,	  labelled	  in	  Figure	  1.6B.	  
It	  has	  also	  been	  hypothesised	   that	   the	   topology	  of	   glycans	   can	  play	  a	   role	   in	  host	  specificity	  of	  viruses,	  adding	  another	  level	  of	  complexity	  to	  the	  relative	  levels	  of	  α2,6	  and	  α2,3	  binding.	  Chandrasekaran	  et	  al.	  suggest	  that	  α2,3-­‐linked	  receptors	  adopt	  a	   ‘cone-­‐like’	   topology	   and	   α2,6-­‐linked	   receptors	   an	   ‘umbrella-­‐like’	   topology,	  suggesting	  an	  important	  role	  in	  binding	  of	  receptors	  further	  down	  the	  glycan	  chains	  (Chandrasekaran	  et	  al.,	  2008).	  
The	  residue	  at	  position	  226	  has	  been	  identified	  as	  a	  major	  determinant	  of	  the	  receptor	  specificity	  of	   IAV	  HA.	  Evidence	   for	   the	   importance	  of	   this	  residue	  was	   first	  seen	  when	  Rogers	  et	  al.	  adapted	  the	  receptor	  binding	  preference	  of	  a	  1968	  H3	  strain,	  X-­‐31,	  to	  a	  more	  avian-­‐like	  receptor	  binding	  preference	  by	  passaging	  the	  virus	  in	  the	  presence	  of	  horse	  serum	  (Rogers	  et	  al.,	  1983),	  which	  is	  rich	  in	  α2,6-­‐linked	  sialic	  acid	  (Pritchett	  &	  Paulson,	  1989).	  This	  passage	  with	  excess	  α2,6-­‐linked	  sialic	  acid	  present	  caused	   the	   substitution	   L226Q.	   This	   shifted	   the	   receptor	   binding	   specificity	   of	   the	  ‘human	  virus’	  X-­‐31	  from	  a	  predominant	  preference	  for	  α2,6-­‐	  to	  a	  preference	  for	  α2,3-­‐linked	   sialic	   acid,	   shown	   by	   measuring	   the	   ability	   to	   agglutinate	   rederivatised	   red	  blood	   cells	   (Rogers	   et	   al.,	   1983).	   Likewise,	   in	   vitro	   selection	   of	   an	   avian	   virus	  produced	   the	   reverse	   mutation	   Q226L,	   which	   made	   the	   avian	   virus	   bind	  predominantly	  to	  α2,6	  rederivatised	  blood	  cells	  (Rogers	  et	  al.,	  1985).	  This	  alteration,	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Q226L,	  accompanied	  by	  G228S	  are	   thought	   to	  be	   important	   to	   the	  adaption	  of	  both	  the	   1957	   H2N2	   and	   1968	   H3N2	   pandemics	   to	   humans	   from	   wild	   birds,	   altering	  receptor	   binding	   characteristics	   (Rogers	   et	   al.,	   1983;	   Naeve,	   Hinshaw	   &	   Webster,	  1984;	  Bean	  et	  al.,	  1992;	  Connor	  et	  al.,	  1994;	  Matrosovich	  et	  al.,	  2000).	  H1N1	  viruses	  have	   quite	   different	   binding	   characteristics,	   with	   less	   reliance	   on	   the	   residues	   at	  position	  226	  and	  228	  with	  viruses	  with	  avian-­‐like	  226	  and	  228	  residues	  not	  having	  such	   clear	   alterations	   in	   binding,	  with	   the	   important	   residues	   for	   altering	   receptor	  specificity	  appearing	  to	  be	  225,	  190	  and	  186	  (Rogers	  &	  D'Souza,	  1989;	  Matrosovich	  et	  
al.,	  1997),	  reviewed	  in	  (Xiong,	  McCauley	  &	  Steinhauer,	  2014).	  
1.3.1.2.3 Receptor	  binding	  affinity	  The	   receptor	   binding	   affinity	   of	   monomeric	   HA	   for	   monomeric	   sialic	   acid	  containing	  receptors	  has	  been	  found	  to	  be	  very	  weak,	  in	  the	  mM	  range,	  determined	  by	  NMR	   (Sauter	  et	  al.,	   1989;	   1992b)	   and	  more	   recently	   by	  microscale	   thermophoresis	  (MST)	  (Xiong	  et	  al.,	  2013a).	  The	  strong	  binding	  of	  viruses	  to	  the	  cell	  surface	  to	  initiate	  infection	   must	   therefore	   be	   due	   to	   multivalency	   and	   cooperativity	   between	   HA	  binding	  sites	  on	  the	  same	  virus.	  The	  multivalency	  of	  IAV	  binding	  has	  been	  confirmed	  by	  experiments	  measuring	  unbinding	  events	  using	  optical	  tweezers	  and	  atomic	  force	  microscopy,	  which	  measured	  a	  number	  of	  sequential	  events	  of	  unbinding	  necessary	  to	   release	   a	   single	   virus	   bound	   to	   a	   cell	   (Sieben	   et	   al.,	   2012).	   The	   necessary	  multivalent	   interaction	   of	   HA	  with	   receptors	   can	   also	   be	   seen	  when	   attempting	   to	  make	   sialic	   acid	   based	   inhibitors	   of	   virus	   binding,	  which	   need	   to	   be	  multivalent	   to	  have	   any	   significant	   affinity,	   reviewed	   in	   (Mammen,	   Choi	   &	   Whitesides,	   1998;	  Matrosovich	  &	  Klenk,	  2003).	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The	  relationship	  between	  the	  monomeric	  binding	  of	  a	  single	  HA	  binding	  site	  to	  a	  monomeric	  receptor	  has	  been	  described	  by	  comparing	  monomeric	  protein-­‐receptor	  affinities	  with	  data	  collected	  for	  viruses	  binding	  to	  receptor-­‐coated	  surfaces.	  Xiong	  et	  
al.	  related	  the	  dissociation	  constant	  of	  a	  monomeric	  interaction,	  Kd(receptor),	  to	  that	  of	  a	  multivalent	  virus	  interaction,	  Kd(virus),	  in	  terms	  of	  a	  multiplicity	  coefficient,	  mc	  (Kd(virus)	  =	  Kd(receptor)mc).	  These	  studies	  identified	  that	  this	  multiplicity	  coefficient	  is	  in	  the	  range	  of	   3	   –	   5.5	   giving	   an	   effective	   lower	   limit	   on	   the	  number	  of	  monomeric	   interactions	  required	  for	  IAV	  interactions	  with	  a	  receptor-­‐coated	  surface	  (Xiong	  et	  al.,	  2013a).	  
1.3.1.3 Membrane	  fusion	  HA	  is	  the	  virus	  surface	  protein	  responsible	  for	  causing	  membrane	  fusion.	  For	  reviews	  see	  (Skehel	  &	  Wiley,	  2000;	  Cross	  et	  al.,	  2009).	  
As	   previously	   described	   in	   section	   1.3.1.1	   HA	   is	   synthesised	   as	   a	   precursor,	  HA0,	   which	   must	   be	   cleaved	   by	   proteases	   into	   the	   two	   subunits	   HA1	   and	   HA2,	  priming	  the	  membrane	  fusion	  potential	  of	  the	  HA.	  	  The	  cleavage	  of	  the	  HA	  into	  these	  two	  subunits	  generates	  the	  fusion	  peptide,	  a	  short	  stretch	  of	  23	  hydrophobic	  amino	  acids	   at	   the	   N	   terminus	   of	   HA2,	   which	   is	   then	   buried	   within	   the	   neutral	   pH	  conformation	  of	  HA.	  	  
Upon	  induction	  of	  fusion	  activity	  by	  low	  pH	  in	  the	  endosome	  the	  HA	  undergoes	  a	  large	  conformational	  change,	  which	  is	  thought	  to	  force	  this	  fusion	  peptide	  into	  the	  endosomal	  membrane,	  followed	  by	  another	  conformational	  change,	  which	  is	  thought	  to	  force	  the	  viral	  and	  endosomal	  membranes	  together,	  leading	  to	  membrane	  fusion.	  	  
There	   have	   been	   a	   large	   number	   of	   structural	   and	   biochemical	   studies	   that	  have	   shed	   light	   on	   the	   fusion	   process	   of	   HA.	   The	   structure	   of	   a	   protease	   treated	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fragment	   of	   viral	   HA	   in	   a	   low	   pH	   treated	   conformation	   has	   been	   determined	  (Bullough	  et	  al.,	  1994a).	  The	  BHA	  of	  X-­‐31	  was	  treated	  with	  low	  pH	  (5.0)	  and	  protease	  treated	  with	   trypsin	  and	   thermolysin,	   yielding	  a	   soluble	  protein	   fragment	   including	  residues	  1	  –	  27	  of	  HA1	  and	  38	  –	  175	  of	  HA2	  known	  as	  TBHA2	  (Ruigrok	  et	  al.,	  1988;	  Bullough	   et	   al.,	   1994b).	   This	   low	   pH	   structure	   was	   found	   to	   have	   a	   very	   different	  conformation	  from	  that	  in	  the	  original	  neutral	  pH	  structure	  (Wilson,	  Skehel	  &	  Wiley,	  1981).	  The	  HA2	  undergoes	  a	   large	  structural	  rearrangement	  with	  the	  major	   feature	  being	   the	   formation	   of	   an	   extended	  helix	   at	   the	  N	   terminus	   of	  HA2	   that	  moves	   the	  fusion	   peptide	   100	   Å	   away	   from	   its	   previously	   buried	   position	   near	   the	   viral	  membrane.	  As	  well	  as	  this	  movement	  of	  the	  fusion	  peptide	  there	  is	  rearrangement	  of	  the	   C-­‐terminus	   of	   the	   protein,	   which	   appears	   to	   move	   the	   membrane	   bound	   C-­‐terminus	  toward	  the	  fusion	  peptide,	  see	  Figure	  1.5	  for	  comparison	  of	  neutral	  and	  low	  pH	  structures.	  
A	  structure	  of	  HA2	  has	  been	  obtained	  for	  protein	  expressed	  in	  E.	  coli	  (residues	  38-­‐175	  HA2).	  This	  protein	  (EHA2)	  was	  found	  to	  adopt	  a	  similar	  conformation	  to	  that	  seen	  for	  the	   low	  pH	  treated	  TBHA2	  (Chen	  et	  al.,	  1995;	  Chen,	  Skehel	  &	  Wiley,	  1999).	  The	   formation	  of	   this	   protein	   conformation	   in	  E.	  coli	   implies	   that	   this	   is	   the	   lowest	  energy	  conformation	  of	  HA2,	  suggesting	  that	  the	  neutral	  pH	  form	  of	  HA	  is	  held	  in	  an	  unstable	  form	  that,	  upon	  induction	  of	  fusion	  by	  HA0	  cleavage	  and	  low	  pH,	  will	  refold	  to	   form	   the	   lowest	   energy	   conformation,	   similar	   to	   EHA2.	   For	   a	   comparison	   of	  structures	  of	  TBHA2	  and	  EHA2	  see	  Figure	  1.5.	  
The	  precise	  mechanism	  by	  which	  the	  HA	  induces	  membrane	  fusion	  is	  unclear.	  The	  induction	  of	  low	  pH	  has	  been	  shown	  to	  cause	  insertion	  of	  residues	  1	  –	  22	  of	  HA2	  into	  the	  membrane,	  indicating	  that	  the	  fusion	  peptide	  is	  the	  only	  part	  of	  the	  HA	  that	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interacts	  with	  the	  membrane	  (Tsurudome	  et	  al.,	  1992;	  Weber	  et	  al.,	  1994;	  Durrer	  et	  
al.,	   1996).	   The	   interaction	   of	   the	   fusion	   peptide	   with	   the	   membrane	   and	   the	  associated	   conformational	   changes	   of	   the	   HA	   lead	   to	   fusion	   of	   the	   viral	   and	  endosomal	  membranes.	  The	  fusion	  of	  the	  two	  membranes	  is	  thought	  to	  happen	  via	  a	  hemifusion	  intermediate	  before	  the	  formation	  of	  a	  fusion	  pore	  owing	  to	  experiments	  carried	   out	   using	   GPI-­‐anchor	   tethered	   BHA	   which	   allow	   fluorescent	   lipid	   dye	   to	  transfer	   from	  one	  membrane	   to	   another	   but	   does	   not	   allow	   the	  mixing	   of	   aqueous	  dyes	   separated	   by	   the	   two	   membranes	   (Kemble,	   Henis	   &	   White,	   1993;	   Kemble,	  Danieli	  &	  White,	  1994;	  Melikyan,	  White	  &	  Cohen,	  1995;	  Floyd	  et	  al.,	  2008).	  	  
The	   pH	   at	   which	  membrane	   fusion	   is	   initiated	   is	   variable	   between	   different	  HAs.	  The	  fusion	  pH	  of	  a	  typical	  human	  infecting	  HA	  is	  in	  the	  range	  5.0	  –	  5.5	  (Wharton,	  Skehel	   &	   Wiley,	   1986;	   Galloway	   et	   al.,	   2013).	   This	   pH	   of	   membrane	   fusion	   can,	  however,	  vary	  greatly	  and	  a	   large	  number	  of	  substitutions	  have	  been	   found	  to	  alter	  fusion	   pH,	   reviewed	   in	   (Russell,	   2014).	   The	   pH	   of	   fusion	   is	   thought	   to	   be	   a	  determinant	   in	   the	   transmissibility	   of	   viruses	   from	   avian	   to	   human	   sources.	   Avian	  virus	  HAs	  typically	  have	  a	  higher	  pH	  of	   fusion,	   thus	  reducing	  their	  relative	  stability,	  reviewed	   in	   (Russell,	   2014).	   Recent	   studies	   which	   involved	   the	   passage	   of	   H5N1	  viruses	   in	   ferrets	   in	   order	   to	   increase	   transmissibility	   both	   introduced	   mutations	  which	  are	  thought	  to	  reduce	  the	  pH	  of	  fusion,	  thus	  stabilising	  the	  HA,	  suggesting	  that	  this	   increase	   in	   HA	   stability	   could	   be	   a	   necessary	   alteration	   for	   increased	   human	  transmissibility	  of	  some	  avian	  viruses	  (Imai	  et	  al.,	  2012;	  Herfst	  et	  al.,	  2012).	  
1.3.1.4 Glycosylation	  IAV	   HA	   is	   a	   glycoprotein,	   which	   can	   have	   a	   variable	   number	   of	   N-­‐linked	  glycosylations	   present.	   A	   number	   of	   these	   are	   conserved	   between	   subtypes	   and	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considered	   vital	   for	   the	   structure	   of	   the	   HA,	   as	   they	   are	   involved	   in	   intra	   subunit	  interactions	  (Wilson,	  Skehel	  &	  Wiley,	  1981).	  The	  number	  of	  theoretical	  glycosylation	  sites	   present,	   found	   by	   analyzing	   sequences	   for	   the	   Asn-­‐Xaa-­‐Ser/Thr	  motif	   (where	  Xaa	   is	   any	   amino	   acid	   but	   Pro),	   in	  HAs	   varies	   between	   5	   and	   12	   (Nobusawa	   et	  al.,	  1991;	   Skehel	  &	  Wiley,	   2000;	  Vigerust	  &	   Shepherd,	   2007;	  Reading	  et	  al.,	   2007).	  The	  presence	  of	  glycans	  near	  the	  RBS	  of	  HA	  have	  been	  found	  to	  reduce	  receptor	  binding	  of	  a	  number	  of	  different	  viruses	  (Aytay	  &	  Schulze,	  1991;	  Ohuchi	  et	  al.,	  1997;	  Gambaryan,	  Robertson	   &	   Matrosovich,	   1999;	   Wagner	   et	   al.,	   2000;	   Baigent	   &	   McCauley,	   2001;	  Ohuchi	   et	   al.,	   2002;	   Tsuchiya	   et	   al.,	   2002;	   Abe	   et	   al.,	   2004;	   Wang	   et	   al.,	   2009).	  Acquisition	  of	  glycosylation	  is	  also	  a	  major	  mechanism	  of	  epitope	  shielding	  acquired	  to	  enhance	  immune	  evasion	  by	  IAVs	  (Blackburne,	  Hay	  &	  Goldstein,	  2008),	  reviewed	  in	  (Reading	  et	  al.,	  2007).	  
1.3.1.5 Antigenic	  variation	  HA	   is	   the	  major	   surface	  protein	   component	  of	   the	   virus	   and	   consequently	   is	  the	   major	   antigenic	   target	   of	   the	   virus.	   This	   therefore	   selects	   for	   considerable	  variation	   within	   the	   HA,	   which	   is	   particularly	   focused	   around	   the	   globular	   head	  region	  of	   the	  protein.	  The	  major	   antigenic	   sites	  have	  been	   classified	   for	  H1	  and	  H3	  virus	   subtypes	   by	   epitope	   mapping	   (Wiley,	   Wilson	   &	   Skehel,	   1981;	   Gerhard	   et	   al.,	  1981;	   Caton	   et	   al.,	   1982;	   Underwood,	   1982).	   These	   epitopes	   are	   generally	   surface	  exposed	  flexible	  loops.	  Many	  of	  these	  loops	  are	  also	  part	  of	  the	  RBS	  and	  consequently	  antigenicity	  and	  receptor	  binding	  are	  inextricably	  linked.	  
1.3.2 Neuraminidase	  NA	   is	   a	   sialidase	  and	   is	   responsible	   for	   cleaving	   terminal	   sialic	   acid	   residues	  from	   complex	   glycans	   to	   which	   the	   virus	   may	   be	   bound	   at	   different	   stages	   in	   the	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infection	  cycle.	  For	  reviews	  see	  (Colman,	  1994;	  Garman	  &	  Laver,	  2005;	  Itzstein,	  2007;	  Air,	  2012).	  
1.3.2.1 Structure	  NA	   is	   a	   homotetrameric	   class	   II	   integral	   membrane	   glycoprotein	   protein	  consisting	  of	  ~470	  residues	  with	  a	  monomeric	  mass	  of	  ~50	  kDa.	  When	  attached	   to	  the	  virus	  the	  protein	  is	  ‘mushroom-­‐shaped’,	  with	  a	  globular	  head	  region	  sitting	  atop	  a	  narrow	  stalk	  (Harris	  et	  al.,	  2006;	  Calder	  et	  al.,	  2010).	  	  	  
The	   three	   dimensional	   structure	   of	   the	   head	   region	   of	   the	   IAV	   NA	   was	   solved	   by	  releasing	   the	  protein	   from	  purified	  virus	  using	   the	   enzyme	  mixture	  pronase,	  which	  releases	   a	  ~200	  kDa	   tetramer	   from	   the	   virus,	   followed	  by	   crystallisation	   and	  X-­‐ray	  diffraction	  (Varghese,	  Laver	  &	  Colman,	  1983;	  Colman,	  Varghese	  &	  Laver,	  1983).	  The	  head	  domain	   of	   the	  protein	   is	  made	  up	   of	   a	   structure	   largely	   consisting	   of	   β-­‐sheet,	  consisting	   of	   six	   4-­‐stranded	   anti-­‐parallel	   sheets.	   The	   sialidase	   site	   of	   NA	   is	   located	  centrally	  within	   the	  monomeric	   structure	  within	  a	  deep	  pocket,	   see	  Figure	  1.8.	  The	  sialidase	  site	  has	  been	  defined	  owing	  to	  the	  highly	  conserved	  nature	  of	  the	  residues	  and	  their	  role	  in	  binding	  to	  sialic	  acid	  (Colman,	  Varghese	  &	  Laver,	  1983;	  Varghese	  et	  
al.,	   1992).	   The	   residues	   which	   are	   involved	   in	   binding	   to	   sialic	   acid	   are	   shown	   in	  Figure	   1.9A.	   The	   exact	   mechanism	   of	   enzyme	   catalysis	   is	   unknown.	   It	   has	   been	  suggested	   that	   the	   NA	   could	   cleave	   via	   a	   sialosyl	   cation	   transition-­‐state	   complex	  (Chong	   et	   al.,	   1992)	   but	   it	   has	   also	   been	   proposed	   that	   it	   could	   proceed	   via	   a	  covalently	   linked	   intermediate	  which	  attaches	  via	  Tyr	  406.	  This	  has	  been	  proposed	  because	  a	  number	  of	  NA	   inhibitors	   that	  have	  been	  characterised	   that	  can	   inhibit	  by	  forming	  a	  covalent	  bond	  with	  the	  active	  site	  (Kim	  et	  al.,	  2013;	  Vavricka	  et	  al.,	  2013).	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A	  high	  affinity	  calcium	  binding	  site	  was	  identified	  in	  the	  first	  structure	  of	  NA	  (Varghese,	   Laver	   &	   Colman,	   1983),	   as	   well	   as	   in	   a	   number	   of	   other	   subsequent	  structures.	  The	  exact	  role	  of	  this	  and	  other	  bound	  calcium	  ions	  is	  unknown;	  however,	  the	  presence	  of	  calcium	  ions	  has	  been	  found	  to	  be	  essential	  for	  full	  enzymatic	  activity	  (Carroll	  &	  Paulson,	  1982;	  Chong,	  Pegg	  &	  Itzstein,	  1991)	  and	  also	  for	  influenza	  B	  virus	  NA	  protein	  stability	  (Burmeister,	  Cusack	  &	  Ruigrok,	  1994).	  
1.3.2.2 Sialidase	  activity	  The	  sialidase	  activity	  of	  NA	  has	  been	  proposed	  to	  have	  a	  number	  of	  roles	  in	  the	  virus	   infection	   cycle.	   The	  NA	   is	   involved	   in	   releasing	   progeny	   virions	   from	   the	   cell	  surface	   after	   virus	   budding	   and	   also	   in	   preventing	   virus	   aggregation	   due	   to	   the	  binding	   of	  HA	   to	   sialic	   acid	   that	   is	   part	   of	   the	   glycosylation	   of	  HA	   and	  NA	   of	   other	  nearby	   virions.	   The	   role	   of	   NA	   in	   these	   activities	   can	   be	   seen	   when	   viruses	   are	  propagated	  with	  reduced	  NA	  activity,	  leading	  to	  aggregation	  of	  virus	  particles	  both	  to	  other	   viruses	   as	  well	   as	   to	   the	   cell	   surface.	   This	   has	   been	   seen	  with	   viruses	   either	  lacking	  NA	  activity	  (Palese	  et	  al.,	  1974)	  or	  with	  their	  NA	  inhibited	  (Palese	  &	  Compans,	  1976;	   Baigent,	   Bethell	   &	   McCauley,	   1999).	   Another	   role	   of	   the	   sialidase	   activity	   is	  thought	  to	  be	  that	  of	  evading	  non-­‐specific	  inhibition	  by	  sialylated	  substances	  such	  as	  mucins	  (Matrosovich	  et	  al.,	  2004b;	  Cohen	  et	  al.,	  2013;	  Yang	  et	  al.,	  2014).	  NA	  has	  been	  found	  to	  have	  a	  low	  pH	  optimum	  of	  5.5	  –	  6.5	  and	  a	  temperature	  optimum	  of	  37°C	  (Air,	  2012).	  
A	  number	  of	  viruses	  have	  been	  found	  which	  appear	  to	  use	  the	  NA	  as	  a	  receptor	  binding	  protein	  via	  the	  sialidase	  site,	  rather	  than	  the	  haemadsorption	  site	  discussed	  below	  (Lin	  et	  al.,	  2010;	  Zhu	  et	  al.,	  2012a)	  (Stephen	  Wharton,	  unpublished	  data).	  This	  binding	   activity	   is	  mediated	   by	   a	  mutation	   around	   the	   sialidase	   site,	   D151G,	  which	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lowers	  the	  catalytic	  turnover	  rate	  (kcat)	  as	  well	  as	  reducing	  the	  Km,	  for	  cleavage	  of	  the	  fluorogenic	   substrate	   2’-­‐(4-­‐Methylumbelliferyl)-­‐α-­‐D-­‐N-­‐acetylneuraminic	   acid	  (MUNANA),	   indicating	  that	  this	  mutation	  makes	  the	  sialidase	  site	  adopt	  more	  of	  the	  characteristics	  of	  a	  receptor	  binding	  protein,	   increasing	  the	  affinity	  of	  the	  sialic	  acid	  interaction	  whilst	  simultaneously	  reducing	  the	  probability	  of	  substrate	  cleavage	  (Zhu	  
et	  al.,	  2012a)	  (Stephen	  Wharton,	  unpublished	  data).	  
NA	  has	  been	  found	  to	  cleave	  α2,3-­‐linked	  sialic	  acid	  much	  more	  efficiently	  than	  α2,6-­‐linked	   sialic	   acid.	   A	   number	   of	   studies	   have	   found	   that	   the	   ability	   of	   NAs	   to	  cleave	  α2,6-­‐linked	  sialic	  acid	  derivatives	   increases	  as	   they	  adapt	   to	   the	  human	  host	  (Baum	  &	  Paulson,	  1991;	  Kobasa	  et	  al.,	  1999);	  however,	  2,3-­‐linked	  sialic	  acid	  remains	  the	  more	  efficiently	  cleaved	  substrate.	  This	  has	  also	  been	  measured	  more	  recently	  for	  wider	  ranges	  of	  sugars,	  with	  a	  similar	  pattern	  of	  an	  overall	  preference	  for	  α2,3-­‐linked	  receptors	  (Li	  et	  al.,	  2011b;	  Xu	  et	  al.,	  2012b;	  Zhu	  et	  al.,	  2012a).	  
1.3.2.3 Haemadsorption	  activity	  Neuraminidases	   of	   the	   subtype	   N9	   have	   been	   found	   to	   have	   a	   second	   sialic	  acid	   binding	   site.	   Laver	   et	  al.	  showed	   that	   full	   length	   detergent	   extracted	  N9	  made	  into	   rosettes	   possessed	   haemagglutination	   activity	   and	   also	   that	   this	  haemagglutination	   activity	  was	   unaffected	   by	   inhibition	   of	   the	   sialidase	   site	  with	   a	  specific	   inhibitor,	  suggesting	  that	  this	  haemagglutination	  site	  was	  separate	  from	  the	  sialidase	  site	  (Laver	  et	  al.,	  1984).	  NA	  from	  an	  H7N1	  virus	  has	  also	  been	  found	  to	  have	  haemadsorbing	  activities	  (Hausmann	  et	  al.,	  1995).	  This	  haemadsorption	  activity	  has	  been	   found	   in	   a	   wide	   range	   of	   other	   NAs,	   particularly	   those	   from	   avian	   viruses.	  Human	  virus	  NAs	  do	  not	  appear	  to	  possess	  these	  haemadsorbing	  properties	  (Kobasa	  
et	  al.,	  1997).	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The	   structure	   has	   been	   determined	   by	   X-­‐ray	   crystallography	   of	   N9	  NA	  with	  sialic	  acid	  bound	  in	  this	  secondary,	  haemadsorbtion	  (Hb),	  site	  (Varghese	  et	  al.,	  1997).	  	  This	  structure	  revealed	  sialic	  acid	  bound	  both	  to	  the	  Hb	  site	  in	  a	  shallow	  depression	  on	  the	  top	  of	  the	  NA	  and	  the	  sialidase	  site,	  Figure	  1.8.	  The	  sialic	  acid	  in	  the	  Hb	  site	  is	  bound	   in	   the	   chair	   conformation	   rather	   than	   the	   twisted	   boat	   of	   the	   sialidase	   site	  previously	  reported.	  The	  residues	  involved	  in	  binding	  the	  sialic	  acid	  at	  this	  Hb	  site	  are	  Ser367,	  Ser370,	  Ser372,	  Asn400	  and	  Trp403	  (N2	  numbering),	   see	  Figure	  1.9B.	  This	  original	   structure	   of	   sialic	   acid	   bound	   to	   the	   Hb	   site	   and	   subsequent	   structures	   of	  different	  subtypes	  have	  shown	  that	  the	  2’	  hydroxyl	  of	   the	  bound	  sialic	  acid	  projects	  upwards,	   away	   from	   the	   structure,	   indicating	   that	   this	  Hb	   site	   is	   unlikely	   to	  have	   a	  sialic	   acid	   linkage	   specificity	   (Varghese	   et	   al.,	   1997;	   Rudino	   et	   al.,	   2006;	   Sun	   et	   al.,	  2014).	   This	   is	   also	   backed	   up	   by	   the	   similar	   haemadsorption	   of	   erythrocytes	   from	  chicken	  and	  human	  sources	  (Kobasa	  et	  al.,	  1997;	  Uhlendorff	  et	  al.,	  2009),	  which	  are	  thought	  to	  contain	  different	  sialic	  acid	  linkages	  (Ito	  et	  al.,	  1997).	  	  
Uhlendorff	   et	   al.	   introduced	   Hb	   properties	   into	   a	   1957	   N2	   by	   site	   directed	  mutagenesis,	   introducing	   the	   mutation	   N367S.	   This	   Hb	   activity	   could	   then	   be	  removed	   by	   introducing	   the	  mutations	   S370L,	   N400S	   and	  W403R.	   This	   study	   also	  examined	  the	  influence	  of	  the	  presence	  of	  this	  Hb	  site	  on	  the	  activity	  of	  the	  NA.	  The	  Hb+	   virus	   allowed	   elution	   of	   the	   virus	   from	   erythrocytes	   bound	   at	   4°C	   (to	   reduce	  sialidase	  activity),	   followed	  by	  elution	  at	  37°C.	  This	  elution	  could	  not	  be	  achieved	  in	  the	  Hb-­‐	  virus,	  suggesting	  a	  role	  of	  the	  Hb	  site	  in	  the	  activity	  of	  the	  NA.	  Measurements	  of	  the	  Hb+	  and	  Hb-­‐	  NA	  cleaving	  small	  monomeric	  substrates	  showed	  no	  difference	  in	  activity	  between	  the	  two	  NAs;	  however,	  when	  measuring	  the	  cleavage	  of	  multivalent	  substrates	   there	   was	   enhanced	   cleavage	   when	   the	   Hb	   activity	   was	   present.	   This	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suggested	   that	   the	  Hb	   site	   could	   be	   involved	   in	   tethering	  multivalent	   substrates	   to	  allow	  more	  efficient	  cleavage	  by	  the	  sialidase	  site	  (Uhlendorff	  et	  al.,	  2009).	  
Lai	  et	  al.	  have	  measured	  by	  NMR	  the	  binding	  of	  sialic	  acid	  containing	  receptors	  to	  the	  Hb	  site	  of	  NA.	  They	  also	  suggest	  that	  the	  sialic	  acid	  can	  be	  competed	  out	  of	  the	  Hb	  site	  by	  adding	  the	  NA	  inhibitor	  oseltamivir	  carboxylate	  (Lai	  et	  al.,	  2012).	  
1.3.2.4 Stalk	  length	  The	  length	  of	  the	  stalk	  attaching	  the	  NA	  head	  region	  to	  the	  viral	  membrane	  has	  been	   found	   to	   vary.	  Deletions	   of	   stalk	   length	  have	  been	   found	   ranging	   from	  1	   –	   36	  amino	  acids	   in	   length.	  Changes	   in	  NA	  stalk	   length	  are	   found	  especially	   to	  occur	  as	  a	  deletion	  when	  viruses	  transmit	  from	  wild	  birds	  to	  domestic	  poultry	  (Li	  et	  al.,	  2011a).	  	  
This	   deletion	   of	   NA	   stalk	   has	   been	   found	   to	   alter	   the	   propagation	  characteristics	  of	  the	  virus	  (Castrucci	  &	  Kawaoka,	  1993;	  Luo,	  Chung	  &	  Palese,	  1993;	  Baigent	  &	  McCauley,	  2001;	  Zhou	  et	  al.,	  2009;	  Sorrell	  et	  al.,	  2010;	  Blumenkrantz	  et	  al.,	  2013;	  Sun	  et	  al.,	  2013b),	  reduce	  the	  ability	  to	  elute	  virus	  from	  erythrocytes	  (Els	  et	  al.,	  1985;	  Castrucci	  &	  Kawaoka,	  1993;	  Baigent,	  Bethell	  &	  McCauley,	  1999;	  Matsuoka	  et	  al.,	  2009;	  Zhou	  et	  al.,	  2009;	  Blumenkrantz	  et	  al.,	  2013;	  Sun	  et	  al.,	  2013b),	  or	  alter	  virus	  transmissibility/pathogenicity	  (Matsuoka	  et	  al.,	  2009;	  Zhou	  et	  al.,	  2009;	  Sorrell	  et	  al.,	  2010;	   Munier	   et	   al.,	   2010;	   Blumenkrantz	   et	   al.,	   2013).	   However,	   this	   stalk	   length	  reduction	   does	   not	   alter	   the	   NA	   cleavage	   characteristics	   for	   small	   monovalent	  substrates	  (Matsuoka	  et	  al.,	  2009;	  Blumenkrantz	  et	  al.,	  2013;	  Sun	  et	  al.,	  2013b).	  The	  reduction	  in	  NA	  stalk	  length	  is	  likely	  to	  reduce	  the	  effective	  cleavage	  ability	  of	  the	  NA	  for	  natural	  substrates,	  as	  there	  will	  be	  reduced	  substrate	  accessibility;	  however,	  it	  is	  unclear	  as	  yet	  what	   the	  evolutionary	  pressure	   is	   for	   stalk	   truncation	  and	   its	   role	   in	  altering	  virus	  transmissibility.	  However,	  one	  can	  conjecture	  that	  the	  loss	  of	  NA	  stalk	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length	   could	   be	   selected	   because	   of	   the	   nature	   and	   density	   of	   sialic	   acid	   receptors	  present	  at	   the	   site	  of	   infection,	  which	  could	   require	  a	   lower	  effective	  NA	  activity	   to	  allow	  the	  efficient	  binding	  of	  the	  HA	  for	  the	  initiation	  of	  infection.	  
1.4 Virus	  replication	  cycle	  See	  Figure	  1.10	  for	  a	  schematic	  representation	  of	  the	  IAV	  replication	  cycle.	  
1.4.1 Attachment	  Virus	  attachment	  is	  mediated	  by	  the	  HA	  and	  NA,	  as	  described	  in	  further	  detail	  in	  section	  1.3,	  Figure	  1.10	  step	  1.	  
1.4.2 Entry	  The	   attachment	   of	   the	   virus	   to	   the	   cell	  membrane	   by	   HA	   leads	   to	   receptor-­‐mediated	   endocytosis,	   Figure	   1.10	   step	   2.	   This	   is	   thought	   to	   proceed	   either	   via	   a	  clathrin	  dependent	  or	   independent	  pathway	  because	  electron	  microscopy	   images	  of	  virus	  endocytosis	  show	  virions	  in	  both	  smooth	  and	  coated	  endosomes	  (Matlin	  et	  al.,	  1981).	  The	  entry	  of	  filamentous	  viruses	  has	  been	  found	  to	  occur	  via	  macropinocytosis	  because	  of	  the	  increased	  size	  of	  these	  viruses	  (Rossman,	  Leser	  &	  Lamb,	  2012).	  





Figure	  1.10:	  Schematic	  representation	  of	  IAV	  replication	  cycle.	  1)	  Virus	  attaches	  to	   sialic	   acid	   containing	   cellular	   receptors	   before	   2)	   internalisation	   by	   receptor	  mediated	   endocytosis.	   3)	   Virus	   releases	   RNPs	   after	   HA	   mediated	   virus	   membrane	  fusion	   and	   M2	   mediated	   virion	   acidification	   is	   induced	   by	   low	   pH	   in	   the	   late	  endosome.	   4)	  RNPs	   enter	   the	  nucleus	   and	  undergo	   transcription	   and	   replication	   to	  generate	   more	   RNPs	   and	   to	   synthesise	   viral	   proteins.	   5)	   RNPs	   and	   viral	   proteins	  assemble	   at	   the	   plasma	   membrane	   and	   bud	   to	   form	   new	   virus	   particles.	   6)	   Virus	  release	  is	  facilitated	  by	  NA	  cleaving	  cell	  surface	  sialic	  acid	  receptors.	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1.4.3 Replication	  In	  order	  for	  replication	  of	  the	  viral	  RNPs	  to	  occur	  they	  must	  be	  trafficked	  into	  the	  nucleus.	  The	  movement	  of	   the	  RNPs	  from	  the	  cytoplasm	  to	  the	  periphery	  of	   the	  nucleus	   seems	   to	   simply	   rely	   on	   diffusion,	   as	  microtubules,	   intermediate	   filaments	  and	  actin	  filaments	  do	  not	  appear	  to	  be	  involved	  in	  the	  movement	  of	  RNPs	  (Babcock,	  Chen	  &	  Zhuang,	  2004).	  Nuclear	  import	  of	  RNPs	  is	  aided	  by	  nuclear	  localisation	  signals	  present	  both	   in	   the	  NP	  and	   the	  polymerase	  subunits,	  which	  allows	   interaction	  with	  nuclear	   pore	   complexes.	   RNP	   entry	   into	   the	   nucleus	   is	   mediated	   by	   the	   classical	  importin	  pathway,	  reviewed	  in	  (Hutchinson	  &	  Fodor,	  2013).	  
In	   order	   for	   the	   virus	   to	   replicate	   the	   RNPs	   must	   undergo	   replication,	   to	  generate	  more	  of	  the	  single	  stranded	  negative	  sense	  vRNA,	  and	  also	  transcription,	  to	  generate	   mRNAs	   to	   allow	   viral	   protein	   synthesis,	   reviewed	   in	   (Portela	   &	   Digard,	  2002;	  Fodor,	  2013),	  Figure	  1.10	  step	  4.	  
vRNA	   transcription	   is	   carried	  out	  by	  a	  cis	   acting	   IAV	  polymerase	  attached	   to	  the	  RNP,	  which	  has	  both	  the	  5’	  and	  3’	  terminal	  sequences	  of	  the	  vRNA	  bound	  (Hagen	  
et	   al.,	   1994;	   Fodor,	   Pritlove	   &	   Brownlee,	   1994).	   This	   binding	   is	   to	   RNA	   sequences	  which	  share	  a	  high	  level	  of	  homology	  in	  all	  IAV	  segments	  and	  between	  subtypes,	  a	  13	  base	  section	  at	  the	  5’	  end	  of	  the	  vRNA	  and	  a	  12	  base	  section	  at	  the	  3’	  end	  of	  the	  RNA	  (Skehel	   &	   Hay,	   1978;	   Robertson,	   1979;	   Desselberger	   et	   al.,	   1980).	   The	   mRNAs	  generated	   by	   the	   polymerase	   complex	   require	   a	   5’	   cap	   and	   polyadenylation	   of	   the	  transcript.	  Both	  of	  these	  are	  added	  to	  the	  mRNA	  by	  an	  unusual	  mechanism.	  The	  5’	  7-­‐methylguanylate	  cap	  is	  taken	  from	  a	  cellular	  pre-­‐mRNA	  by	  a	  process	  known	  as	  ‘cap-­‐snatching’	  (Plotch	  et	  al.,	  1981).	  This	  process	  is	  thought	  to	  be	  aided	  by	  the	  association	  of	   the	   cellular	  RNA	  polymerase	   II,	  which	   is	   thought	   to	   aid	   the	   binding	   of	   a	   nascent	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pre-­‐mRNA	   by	   the	   PB2	   subunit	   (Engelhardt,	   Smith	   &	   Fodor,	   2005).	   The	   5’	   cap	   is	  removed	   from	  the	  pre-­‐mRNA	  by	  endonuclease	  activity	  of	   the	  PA	  subunit	  and	   the	  3’	  end	  of	  this	  RNA	  primer	  is	  moved	  to	  the	  PB1	  subunit	  in	  order	  to	  allow	  the	  initiation	  of	  transcription.	   Transcription	   proceeds	   until	   the	   polymerase	   meets	   a	   stretch	   of	   U	  residues,	   which	   acts	   as	   a	   polyadenylation	   signal	   (Robertson,	   Schubert	   &	   Lazzarini,	  1981).	   This	   polyadenylation	   is	   carried	   out	   by	   the	   viral	   polymerase	   rather	   than	   a	  cellular	  poly(A)	  polymerase.	  
vRNA	  replication	  is	  carried	  out	   in	  two	  steps:	   first	  the	  negative	  sense	  vRNA	  is	  replicated	  into	  the	  positive	  sense	  cRNA,	  a	  full	  length	  copy	  of	  the	  vRNA	  (Hay,	  Skehel	  &	  McCauley,	  1980),	  followed	  by	  the	  replication	  of	  cRNA	  back	  into	  vRNA.	  The	  replicated	  cRNA	  and	  vRNA	  are	  full	  length	  viral	  segments	  without	  a	  5’	  cap	  or	  polyadenylation	  and	  therefore	   they	   require	   a	   separate	   initiation	   and	   termination	   mechanism,	   which	   is	  currently	  not	  well	  understood.	  	  
Initially	  the	  transcription	  activity	  of	  the	  polymerase	  predominates	  in	  order	  to	  produce	  large	  amounts	  of	  mRNA	  to	  generate	  the	  viral	  proteins	  required	  for	  efficient	  viral	  replication.	  Later	  on	  the	  vRNA	  replication	  predominates	  (Hay	  et	  al.,	  1977;	  Smith	  &	  Hay,	  1982),	  which	  could	  simply	  be	  due	  to	  the	  higher	  levels	  of	  NP	  present	  to	  prevent	  cleavage	  of	  the	  nascent	  vRNA	  by	  cellular	  endonucleases.	  Accumulation	  of	  the	  nuclear	  export	  protein	  (NEP),	  otherwise	  known	  as	  NS2,	  has	  been	  shown	  to	  be	  involved	  in	  the	  down	   regulation	   of	   transcription	   and	   an	   increase	   in	   replication	   (Robb,	   Smith	   &	  Vreede,	  2009).	  
	   The	  newly	  replicated	  RNPs	  must	  be	  exported	  from	  the	  nucleus	  so	  that	  they	  can	  assemble	  new	  virus	  particles	   at	   the	   cell	   surface.	  This	   export	  mechanism	   is	  not	  well	  understood;	  however,	  it	  is	  believed	  to	  involve	  the	  binding	  of	  M1	  to	  RNPs	  and	  also	  the	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association	   of	   the	   NEP,	   which	   aids	   the	   interaction	   of	   RNPs	   with	   the	   nuclear	   pore	  complexes	  (O'Neill,	  Talon	  &	  Palese,	  1998).	  	  
1.4.4 Assembly	  and	  budding	  In	  order	   for	  virus	  assembly	  and	  budding	  to	  occur	   the	  various	  components	  of	  the	  virus	  must	  be	  made	  and	  trafficked	  to	  the	  cell	  surface.	  The	  vRNPs,	  as	  described	  in	  the	  previous	  section,	  are	  assembled	  and	  exported	   from	  the	  nucleus.	  The	  other	  viral	  components	   are	   translated	   and	   processed	   outside	   the	   nucleus.	   The	  HA	   and	  NA	   are	  synthesised	   in	   the	   endoplasmic	   reticulum.	   These	   proteins	   undergo	   N-­‐linked	   core	  glycosylation	  within	  the	  ER.	  The	  HA	  and	  NA	  then	  undergo	  further	  glycan	  processing	  in	   the	   Golgi	   apparatus.	   The	   process	   of	   N-­‐linked	   glycosylation	   is	   reviewed	   in	  (Weerapana	  &	  Imperiali,	  2006).	  
Influenza	   viruses	   bud	   at	   the	   apical	   plasma	   membrane	   of	   cells	   (Rodriguez	  Boulan	  &	  Sabatini,	  1978),	  Figure	  1.10	  step	  5.	  The	  HA,	  NA	  and	  M2	  are	  transported	  to	  the	  plasma	  membrane	  via	   the	  Golgi	   apparatus.	  Budding	   is	   thought	   to	  occur	   at	   lipid	  rafts,	   which	   are	   areas	   of	   the	   plasma	   membrane	   enriched	   in	   cholesterol	   and	  glycosphingolipids.	   It	   has	   been	   found	   that	   HA	   and	   NA	   embedded	   in	   the	   plasma	  membrane	   are	   located	  within	   these	   lipid	   rafts	   and	   the	  M2	   ion	   channel	   is	   excluded	  (Rossman	  &	  Lamb,	  2011).	  It	  is	  thought	  that	  the	  initiation	  of	  budding	  is	  caused	  by	  the	  recruitment	   of	   M1	   by	   HA	   and/or	   NA	   to	   the	   plasma	  membrane.	   The	  M1	   layer	   that	  forms	   under	   the	   plasma	   membrane	   forms	   an	   ordered	   helix	   (Calder	   et	   al.,	   2010),	  which	  the	  newly	  replicated	  RNPs	  bind	  to	  via	  the	  NP	  (Bui,	  Whittaker	  &	  Helenius,	  1996;	  Zhang	  &	  Lamb,	  1996).	  The	  polymerisation	  of	   the	  M1	  protein	   is	   thought	  to	  drive	  the	  formation	   of	   a	   new	   virus	   particle.	   After	   the	   virus	   particle	   has	   formed	   it	   needs	   to	  undergo	  membrane	  scission	  to	  form	  the	  virus	  particle.	  It	  is	  thought	  that	  M2	  may	  play	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a	   role	   in	   this	   scission	   (Rossman	  et	  al.,	  2010a;	  2010b).	  There	   is	  also	   thought	   to	  be	  a	  clustering	  of	  NA	  at	  the	  proximal	  end	  of	  the	  virus	  after	  membrane	  scission	  (Calder	  et	  
al.,	  2010).	  Whether	  this	  NA	  plays	  a	  role	  in	  allowing	  scission	  or	  whether	  it	  is	  there	  to	  enhance	  sialic	  acid	  cleavage	  in	  a	  localised	  area	  to	  facilitate	  virus	  release	  is	  unclear.	  It	  is	   thought	   that	   a	   filamentous	   morphology	   is	   generated	   either	   due	   to	   excessive	  polymerisation	   of	   M1	   protein,	   generating	   extended	   structures	   or	   poor	   membrane	  scission,	  which	  terminates	  budding,	  reviewed	  in	  (Rossman	  &	  Lamb,	  2011).	  
1.4.5 Release	  Release	  of	  viruses	   from	   the	  cell	   surface	   is	  mediated	  by	   the	  action	  of	   the	   two	  surface	  glycoproteins	  HA	  and	  NA,	  particularly	  the	  activity	  of	  NA	  upon	  the	  cell	  surface,	  which	   removes	   terminal	   sialic	   acids	   from	  cell	   surface	   receptors,	  which	   could	   tether	  the	  virus	  to	  the	  cell	  surface,	  as	  described	  in	  further	  detail	   in	  section	  1.3,	  Figure	  1.10	  step	  6.	  
1.5 Current	  influenza	  infection	  prevention	  and	  therapy	  The	  current	  approaches	   for	   IAV	  prevention	  and	  therapy	  can	  be	  grouped	   into	  two	  broad	  classes:	  vaccination	  and	  antivirals.	  
1.5.1 Vaccination	  Currently	   there	   are	   two	   predominant	   vaccination	   strategies	   in	   use.	   These	  involve	  vaccination	  with	   influenza	  antigens	  derived	   from	  inactivated	  virus,	   typically	  administered	   as	   an	   intra-­‐muscular	   injection,	   or	   vaccination	   with	   a	   live	   attenuated	  virus,	  typically	  administered	  via	  a	  nasal	  spray.	  The	  most	  common	  method	  for	  vaccine	  manufacture	   currently	   is	   the	   propagation	   of	   high	   growth	   reassortants	   of	   candidate	  virus	  strains	  in	  embryonated	  hens’	  eggs.	  As	  well	  as	  vaccines	  produced	  in	  eggs	  there	  is	  also	  a	  licensed	  vaccine,	  which	  is	  virus	  propagated	  in	  suspension	  MDCK	  cells;	  however,	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the	  seed	  viruses	  used	  for	  manufacture	  are	  the	  same	  egg-­‐propagated	  strains	  used	  for	  manufacture	  of	  the	  egg-­‐propagated	  vaccine	  (Flucelvax,	  Novartis).	  	  
These	   vaccines	   currently	   contain	   two	   different	   IAV	   subtypes,	   a	   H1N1	   2009	  pandemic	   virus,	   a	   seasonal	   H3N2	   virus	   and	   either	   one	   or	   two	   influenza	   B	   viruses,	  dependent	   on	  whether	   the	   vaccine	   is	   trivalent	   or	   quadrivalent.	   The	   composition	   of	  this	  vaccine	   is	  chosen	  to	  closely	  match	   the	  currently	  circulating	  viruses	  detected	  by	  the	  World	  Health	  Organization	  Global	   Influenza	   Surveillance	   and	  Response	   System.	  The	  vaccine	  recommendation	   is	  reviewed	  biannually,	  once	  a	  year	   for	  both	  northern	  and	  southern	  hemispheres,	  with	  the	  recommendations	  for	  the	  northern	  hemisphere	  in	   February	   and	   the	   southern	   hemisphere	   in	   September.	   The	   current	  recommendations	   for	   both	   the	   2015	   southern	   hemisphere	   season	   and	   the	   2015	   –	  2016	  northern	  hemisphere	  seasons	  trivalent	  vaccine	  are	  for	  an	  A/California/7/2009	  (H1N1)pdm09-­‐like	  virus,	  an	  A/Switzerland/9715293/2013	  (H3N2)-­‐like	  virus	  and	  a	  B/Phuket/3073/2013-­‐like	  (Yamagata	  lineage)	  virus	  (and	  a	  B/Brisbane/60/2008-­‐like	  [Victoria	   lineage]	   virus	   in	   addition	   for	   quadrivalent	   vaccines)	   (World	   Health	  Organisation,	  2014b;	  2015b).	  The	  primary	  purpose	  of	  these	  vaccines	  is	  inducing	  the	  production	   of	   antibodies,	   which	   provide	   a	   short-­‐lived	   protection	   against	   infection.	  Consequently	   the	   vaccine	   has	   to	   be	   readministered	   annually	   to	   ensure	   adequate	  protection.	  
There	   are	   a	   number	   of	   alternative	   lesser-­‐used	   vaccine	   strategies	   both	   in	  development	  and	  use	   including:	   the	  manufacture	  of	  antigen	   from	  a	  different	   source	  than	  propagated	  virus	  or	  vaccines	  designed	  to	  give	  a	  broader	  immunity	  to	  influenza	  infection,	   so	   termed	   ‘universal	   vaccines’,	   reviewed	   in	   (Wong	   &	   Webby,	   2013;	  Krammer	  &	  Palese,	  2015).	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1.5.2 Antivirals	  There	   are	   a	   number	   of	   IAV	   antivirals	   that	   are	   approved	   for	   use	   as	  well	   as	   a	  number	   in	   development.	   The	   approved	   antivirals	   fall	   broadly	   into	   four	   broad	  categories:	  M2	  inhibitors,	  NA	  inhibitors,	  arbidol	  and	  polymerase	  inhibitors.	  
The	  M2	   inhibitors	   belong	   to	   the	   class	   of	   molecules	   known	   as	   adamantanes.	  There	   are	   two	   adamantine	   derivatives	   licensed	   for	   anti-­‐influenza	   use:	   amantadine	  and	  rimantidine.	  These	   inhibitors	  work	  by	  blocking	   the	  M2	   ion	  channel,	  preventing	  acidification	   of	   the	   virion,	   thereby	   preventing	   the	   release	   of	   the	   RNPs	   into	   the	  cytoplasm.	   These	   antivirals	   have	   little	   therapeutic	   use	   for	   recent	   viruses	   as	   the	  majority	   of	   currently	   circulating	   viruses	   have	   developed	   resistance,	   reviewed	   in	  (Hayden,	  2006).	  Adamantanes	  are	  not	  currently	  recommended	  for	  use	  by	  the	  WHO	  as	  an	  antiviral	  due	  to	  this	  high	  level	  of	  resistance	  (World	  Health	  Organisation,	  2010).	  
There	   have	   been	   a	   number	   of	   NA	   inhibitors	   developed	   that	   have	   been	  approved	   for	   use	   either	   as	   a	   prophylactic	   treatment	   or	   to	   treat	   infection.	   These	  include	   the	  drugs	  oseltamivir	   (Tamiflu),	   zanamivir	   (Relenza)	  and	   the	  more	  recently	  approved	  peramivir	  (Rapivab)	  and	  laninamivir	  (Inavir).	  All	  of	  these	  NA	  inhibitors	  are	  designed	  to	  be	  transition	  state	  analogues	  of	  sialic	  acid	  containing	  glycans,	  which	  bind	  to	   the	  NA	  with	   low	  nM	  affinity,	   reviewed	   in	  (Itzstein,	  2007).	  These	   inhibitors	  act	  as	  competitive	   inhibitors	  directly	  occupying	   the	   sialidase	   active	   site.	  This	   inhibition	  of	  sialidase	  activity	   causes	  viral	   aggregation	  by	  preventing	   the	  viruses	   from	  detaching	  from	   each	   other	   and	   the	   cell	   surface	   (Palese	   &	   Compans,	   1976;	   Baigent,	   Bethell	   &	  McCauley,	  1999).	  
Arbidol	  is	  an	  influenza	  therapeutic	  currently	  licensed	  only	  in	  Russia.	  Arbidol	  is	  thought	   to	   act	   by	   binding	   to	   the	   HA2,	   stabilising	   the	   HA,	   therefore	   preventing	   the	  
59	  
conformational	  change	  of	  HA	  associated	  with	  membrane	  fusion	  (Leneva	  et	  al.,	  2009).	  The	   WHO	   currently	   does	   not	   recommend	   the	   use	   of	   arbidol,	   owing	   to	   a	   lack	   of	  sufficient	  clinical	  trial	  data	  (World	  Health	  Organisation,	  2010).	  	  
There	   is	  a	  single	  RNA	  polymerase	   inhibitor	  which	  has	  recently	  been	   licensed	  for	  use	  in	  Japan,	  Favipiravir,	  reviewed	  in	  (Furuta	  et	  al.,	  2013).	  
1.6 Balance	  between	  activities	  of	  haemagglutinin	  and	  neuraminidase	  It	   has	   been	   hypothesized	   that	   the	   balance	   between	   the	   action	   of	   the	   two	  antagonistic	  glycoproteins,	  the	  receptor	  binding	  HA	  and	  the	  receptor	  destroying	  NA,	  can	   modulate	   virus	   infectivity	   and	   therefore	   transmissibility.	   A	   number	   of	   studies	  have	  shown	  the	  interrelated	  nature	  of	  the	  activities	  of	  the	  two	  proteins,	  reviewed	  in	  (Wagner	  et	  al.,	  2000).	  
1.6.1 Passage	   of	   viruses	   with	   altered	   NA	   sialidase	   activity	   acquire	  
compensatory	  mutations	  in	  the	  HA	  There	  are	  a	  number	  of	  studies	  which	  have	  propagated	  IAVs	  in	  the	  presence	  of	  NA	   inhibitors,	   which	   led	   to	   escape	  mutations	   which	   alter	   the	   HA	   receptor	   binding	  (McKimm-­‐Breschkin	  et	  al.,	  1996;	  Blick	  et	  al.,	  1998;	  Bantia	  et	  al.,	  1998).	  These	  studies	  imply	  that	  reduction	  of	  NA	  activity	  can	  be	  compensated	  for	  by	  reducing	  HA	  binding,	  therefore	  facilitating	  virus	  release.	  	  
Rudneva	   et	   al.	  showed	   that	  when	   the	   NA	   from	   an	   H1N1	   virus	   is	   reassorted	  with	  a	  number	  of	  different	  HA	  subtypes	  it	  can	  lead	  to	  a	  reduction	  in	  the	  propagation	  efficiency	   of	   virus	   in	   embryonated	   eggs	   due	   to	   the	   formation	   of	   aggregated	   virus	  (Rudneva	  et	  al.,	  1993).	  Some	  of	  these	  low	  efficiency	  viruses	  were	  passaged	  to	  rescue	  higher	  propagation	  characteristics	  (Rudneva	  et	  al.,	  1996).	  These	  viruses	  were	  found	  to	  have	  substitutions	  in	  their	  HA	  which	  reduced	  the	  overall	  receptor	  binding	  (Kaverin	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et	  al.,	  1998),	  showing	  that	  the	  reduction	  of	  NA	  activity	  can	  be	  compensated	  for	  by	  a	  reduction	  of	  HA	  receptor	  binding,	  restoring	  some	  viral	  fitness.	  
Hughes	  et	  al.	   selected	  a	  virus	  that	   lacks	  NA	  activity	  by	  passaging	  the	  virus	   in	  the	  presence	  of	  anti-­‐NA	  antibodies	  and	  supplementation	  with	  bacterial	  NA.	  This	  virus	  had	  gained	  a	  deletion	  in	  its	  open	  reading	  frame	  and	  also	  acquired	  a	  stop	  codon,	  which	  truncated	   the	   NA	   protein	   to	   little	   more	   than	   the	   cytoplasmic	   tail	   and	   the	  transmembrane	  domain.	  This	  virus	  was	  passaged	   in	   the	  presence	  of	  bacterial	  NA	  at	  reducing	   concentrations	   until	   a	   number	   of	   NA	   independent	   viruses	   were	   selected.	  These	   viruses	  had	   gained	   a	  number	  of	  HA	   substitutions	  which	  had	   greatly	   reduced	  the	  HA	  receptor	  binding	  (Hughes	  et	  al.,	  2000).	  
1.6.2 Viruses	   reassorted	   with	   altered	   NA	   stalk	   require	   altered	   HA	   binding	  
properties	  for	  efficient	  replication.	  Castrucci	   and	   Kawaoka	   generated	   a	   number	   of	   viruses	   with	   both	   increased	  and	  decreased	  stalk	  lengths.	  There	  was	  a	  general	  pattern	  seen:	  the	  NA	  stalk	  deletion	  mutants	   had	   much	   less	   efficient	   elution	   of	   virus	   from	   erythrocytes	   and	   the	   stalk	  insertion	  mutants	  eluted	  faster.	  Stalk	  deletion	  viruses	  had	  impaired	  virus	  replication	  in	  eggs	  although	  there	  was	  no	  alteration	  of	  virus	  replication	  in	  tissue	  culture.	  A	  virus	  with	  the	  whole	  NA	  stalk	  removed,	  SD0	  (24	  amino	  acid	  deletion),	  caused	  less	  efficient	  infections	   when	   inoculated	   into	  mice	   (Castrucci	   &	   Kawaoka,	   1993).	   Later	   work	   by	  Mitnaul	   et	   al.	   using	   the	   same	   stalk	   deletion	   virus,	   SD0,	   adapted	   the	   virus	   to	  propagation	  in	  eggs	  by	  serial	  passage.	  The	  resulting	  viruses	  had	  undergone	  a	  number	  of	  alterations.	  Some	  virus	  clones	  had	  acquired	  insertions	  in	  the	  stalk	  region	  of	  the	  NA,	  thus	  elongating	  the	  stalk	  to	  become	  more	  like	  the	  wild-­‐type	  WSN	  virus.	  These	  viruses	  appeared	  to	  have	  obtained	  the	  insertion	  from	  the	  PB2,	  PB1	  or	  NP.	  Some	  of	  the	  viruses	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had	   also	   gained	   HA	   substitutions	   which	   reduced	   the	   virus	   avidity	   for	   binding	   to	  sialoglycopolymers	  (Mitnaul,	  Matrosovich	  &	  Castrucci,	  2000).	  	  
Luo	   et	  al.	  also	   generated	   a	   panel	   of	   viruses	  with	   a	   number	   of	   different	   stalk	  deletions	  and	   insertions.	  Viruses	  with	  18	  and	  28	   residues	  deleted	   from	   the	   stalk	  of	  WSN	  virus	  had	  impaired	  virus	  replication	  in	  MDCK	  cell	  culture	  (Luo,	  Chung	  &	  Palese,	  1993).	   This	   does	   not	   completely	   agree	   with	   experiments	   described	   above	   by	  Castrucci	  et	  al.,	  which	  showed	   little	  change	   in	  propagation	  characteristics	  of	   similar	  stalk	  deletion	  viruses	  in	  MDCK	  cells	  (Castrucci	  &	  Kawaoka,	  1993).	  The	  reason	  for	  the	  difference	  in	  results	  could	  be	  due	  to	  slight	  differences	  in	  the	  stalk	  deletions	  made	  and	  also	   a	   difference	   in	   the	   MDCK	   line	   used,	   as	   receptor	   density	   could	   be	   an	   issue	   in	  carrying	  out	  these	  experiments,	  as	  Luo	  et	  al.	  do	  not	  see	  any	  differences	  in	  MDBK	  cells,	  which	  are	  likely	  to	  have	  different	  surface	  glycans	  than	  MDCK	  cells.	  	  
Wagner	   et	   al.	   generated	   a	   panel	   of	   reverse	   genetics	   viruses	   with	   different	  levels	  of	  glycosylation	  around	  the	  RBS	  on	  the	  HA	  as	  well	  as	  a	  more	  active	  N2	  NA	  and	  a	  less	   active	   N1	   NA.	   Viruses	   that	   contained	   the	   less	   active	   NA	   and	   had	   fewer	  glycosylations	  around	  the	  RBS	  saw	  a	  greater	  reduction	  in	  virus	  replication	  efficiency	  when	  compared	  to	  viruses	  with	  the	  more	  active	  N2.	  This	  is	  most	  likely	  due	  to	  the	  fact	  that	   the	   higher	   level	   of	   HA	   receptor	   binding	   caused	   by	   the	   loss	   of	   glycosylation	   is	  compensated	   for	  by	   the	  higher	  NA	  activity.	  Similar	  patterns	  were	  also	  seen	  of	  virus	  elution	  from	  erythrocytes	  and	  MDCK	  cells	  (Wagner	  et	  al.,	  2000).	  
Baigent	  and	  McCauley	  also	  examined	  a	  panel	  of	  viruses	  with	  differences	  in	  HA	  glycosylation	  and	  NA	  activity,	  mediated	  by	  altering	  stalk	  length.	  It	  was	  found	  that	  in	  order	   for	   viruses	   lacking	   a	   glycosylation	   near	   the	   RBS	   to	   replicate	   efficiently	   there	  was	  a	  requirement	  for	  a	  long	  stalk	  NA	  for	  efficient	  replication	  in	  order	  to	  compensate	  
62	  
for	   the	   increased	   HA	   receptor	   binding.	   Viruses	   with	   inadequate	   NA	   activity,	   i.e.	  viruses	   lacking	   the	   glycosylation	   and	   with	   a	   short	   stalk	   NA,	   could	   have	   their	  replication	  enhanced	  by	  the	  addition	  of	  exogenous	  bacterial	  NA	  (Baigent	  &	  McCauley,	  2001).	  
1.7 Non-­‐specific	  inhibitors	  of	  influenza	  infection	  There	  are	  a	  number	  of	  non-­‐specific	   inhibitors	  of	   influenza	   replication.	  These	  typically	   act	   by	   binding	   to	   the	   HA,	   blocking	   receptor	   binding,	   reviewed	   in	  (Matrosovich	  &	  Klenk,	  2003).	  
Non-­‐specific	  inhibitors	  have	  been	  split	  into	  a	  number	  of	  different	  classes	  based	  on	   their	   particular	   properties	   (Hoyle,	   1968).	   α	   (Francis)	   inhibitors	   are	   heat	   stable	  sialic	  acid	  containing	  mucoproteins,	  which	  are	  cleavable	  by	  NA.	  β	  (Chu)	  inhibitors	  are	  heat	   labile	   serum	   proteins,	   most	   likely	   to	   be	   antibodies	   or	   collagenous	   lectins	  (collectins).	   γ	   inhibitors	   are	   heat	   stable	   sialic	   acid	   containing	   proteins	   and	   are	  particularly	  prevalent	  in	  guinea	  pig	  and	  horse	  sera.	  They	  have	  been	  primarily	  linked	  to	   the	   protein	   α2-­‐macroglobulin,	  which	   contains	   high	   levels	   of	   4-­‐O-­‐acetyl-­‐N-­‐acetyl-­‐neuraminic	   acid	   (Hanaoka	   et	   al.,	   1989;	   Pritchett	   &	   Paulson,	   1989;	   Ryan-­‐Poirier	   &	  Kawaoka,	  1991).	  This	  particular	  form	  of	  sialic	  acid	  can	  be	  bound	  by	  the	  HA,	  of	  some	  viruses,	  but	  not	  cleaved	  by	  the	  NA.	  C	  inhibitors	  are	  found	  in	  rat	  serum,	  however,	  they	  are	  not	  well	  characterised.	  	  
Mucus	  has	   long	  been	  known	  to	   inhibit	   influenza	  virus	  binding,	  shown	  by	   the	  inhibition	  of	  red	  blood	  cell	  binding	  (Fazekas	  de	  St	  Groth,	  1952),	  and	  it	  is	  thought	  to	  be	  an	   important	   factor	   when	   IAVs	   infect	   the	   respiratory	   tract	   of	   humans.	   Mucus	   is	  secreted	   by	   the	   goblet	   cells	   in	   the	   respiratory	   epithelium,	   reviewed	   in	   (Thornton,	  Rousseau	   &	   McGuckin,	   2008).	   Mucins	   are	   heavily	   O-­‐glycosylated	   proteins	   and	   can	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take	  a	  number	  of	  different	  forms	  including	  membrane	  bound,	  and	  secreted.	  They	  are	  able	  to	  form	  large	  multimeric	  structures,	  reviewed	  in	  (Perez-­‐Vilar	  &	  Hill,	  1999).	  The	  glycosylation	  of	  human	  mucins	  is	  thought	  to	  consist	  primarily	  of	  glycans	  terminated	  with	  α2,3-­‐linked	  sialic	  acid	  (Lamblin	  et	  al.,	  1984a;	  1984b;	  Breg	  et	  al.,	  1987;	  Royle	  et	  
al.,	  2008),	  however	  there	  have	  been	  reports	  of	  higher	  levels	  of	  α2,6-­‐linked	  sialic	  acid	  present	  in	  porcine	  mucins,	  measured	  by	  binding	  of	  linkage	  specific	  lectins	  (Yang	  et	  al.,	  2014).	  The	  specific	  linkages	  present	  in	  the	  human	  respiratory	  mucus	  remain	  unclear,	  as	  do	  their	  effective	  concentrations	  at	  the	  site	  of	  infection.	  
The	  role	  of	  NA	  in	  preventing	  non-­‐specific	  inhibition	  of	  IAV	  infection	  has	  been	  seen	  by	   infecting	  human	  airway	  epithelial	   cell	   cultures,	  with	  active	  goblet	   cells	   that	  provide	   mucus	   conditions	   similar	   to	   that	   of	   the	   human	   airway.	   When	   the	   NA	   of	  viruses	  was	  inhibited	  there	  was	  much	  less	  efficient	  infection	  of	  these	  airway	  cultures,	  thought	   to	   be	   due	   to	   the	   virus	   particles	   being	   unable	   to	   remove	   bound	   mucus,	  therefore	   halting	   their	   progression	   towards	   the	   cell	   surface	   (Matrosovich	   et	   al.,	  2004b).	   Cohen	   et	  al.	  also	   identified	   that	   IAVs	   bind	   to	   the	   layer	   of	  mucus	   above	   the	  airway	   epithelium	   of	   human	   trachea	   sections	   in	   a	   sialic	   acid	   dependent	   manner.	  	  Supplementing	  infected	  tissue	  culture	  samples	  with	  mucus	  also	  caused	  a	  reduction	  in	  virus	   replication	   in	   a	   mucus-­‐dependent	   manner	   and	   the	   viral	   NA	   was	   capable	   of	  cleaving	  sialic	  acid	  from	  the	  mucus	  used	  (Cohen	  et	  al.,	  2013).	  Biophysical	  studies	  that	  monitored	  the	  movement	  of	  fluorescently	  labelled	  viruses	  by	  microscopy	  found	  that	  swine	   viruses	   have	   a	   large	   reduction	   in	   their	   diffusion	   coefficient	   when	   porcine	  respiratory	  mucus	  was	  present,	  indicating	  a	  slower	  diffusion	  rate.	  The	  diffusion	  rate	  was	   further	   reduced	   upon	   the	   addition	   of	   NA	   inhibitors	   and	   increased	   when	  supplemented	   with	   exogenous	   NA	   (Yang	   et	   al.,	   2014).	   Mucus	   inhibition	   of	   viral	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infection	  has	  also	  been	   found	  to	  be	   lower	  when	  a	  virus	  possesses	  a	   longer	  stalk	  NA	  (Blumenkrantz	   et	   al.,	   2013),	   again	   implying	   that	   increased	   effective	   NA	   activity	  enhances	  mucus	  cleavage	  and	  so	  the	  NA	  can	  play	  a	  role	  in	  the	  initiation	  of	  infection.	  
1.8 Human	  influenza	  A	  virus	  circulation	  history	  It	   is	   believed	   that	   there	   have	   been	   a	   large	   number	   of	   influenza	   pandemics	  stretching	  back	  for	  many	  centuries	  (Taubenberger	  &	  Morens,	  2009).	  There	  have	  been	  four	   well-­‐documented	   pandemics	   of	   the	   past	   100	   years:	   1918	   H1N1,	   1957	   H2N2,	  1968	  H3N2	  and	  2009	  H1N1.	  	  	  
1.8.1 Previous	  pandemics:	  1918	  -­‐	  2009	  The	   1918	   H1N1	   (Spanish	   ‘flu)	   pandemic	   is	   thought	   to	   have	   been	   the	   most	  devastating	  of	   the	  past	  150	  years.	  The	  virus	  was	  thought	  to	  have	  killed	  ~50	  million	  people	  worldwide	  (Taubenberger	  &	  Morens,	  2006).	  The	  pandemic	  occurred	  in	  three	  separate	  waves	  with	  mortality	  rates	  estimated	  at	  ~3%,	  compared	  to	  the	  usual	  <0.1%	  for	  seasonal	  infections	  (Klenk,	  Garten	  &	  Matrosovich,	  2011).	  The	  genetic	  origin	  of	  this	  pandemic	  is	  described	  in	  greater	  detail	  in	  the	  following	  section.	  	  
The	   1957	   H2N2	   (Asian	   ‘flu)	   pandemic	   emerged	   from	   a	   reassortment	   of	   the	  1918	  H1N1	  virus	   lineage	  with	  an	  avian	   lineage,	  gaining	   the	  H2	  HA,	  N2	  NA	  and	  also	  PB1	   from	   an	   avian	   source,	   with	   the	   remaining	   gene	   segments	   coming	   from	   the	  endemic	  H1N1	  descendants	  of	  the	  1918	  pandemic	  (Scholtissek	  et	  al.,	  1978;	  Kawaoka,	  Krauss	  &	  Webster,	  1989).	  This	  pandemic	  is	  thought	  to	  have	  caused	  ~1	  million	  deaths,	  making	  it	  less	  severe	  than	  the	  1918	  pandemic	  (Klenk,	  Garten	  &	  Matrosovich,	  2011).	  
The	  1968	  H3N2	  (Hong	  Kong	  ‘flu)	  was	  caused	  by	  a	  reassortment	  of	  the	  endemic	  H2N2	  virus	  with	  an	  avian	  H3	  HA	  containing	  virus.	  The	  new	  H3N2	  reassorted	  to	  gain	  a	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new	  HA	  (Scholtissek	  et	  al.,	  1978)	  and	  also	  a	  new	  PB1	  segment	   (Kawaoka,	  Krauss	  &	  Webster,	  1989).	  These	  viruses	  caused	  relatively	  mild	  infections	  compared	  to	  the	  two	  preceding	   pandemic	   strains	   (Klenk,	   Garten	   &	   Matrosovich,	   2011).	   These	   H3N2	  viruses	   continue	   to	   circulate	   to	   this	   day	   as	   seasonal	   strains,	   although	   they	   have	  undergone	  extensive	  antigenic	  drift	  in	  the	  intervening	  time.	  
The	  2009	  H1N1	  pandemic,	  unlike	  the	  previous	  pandemics	  detailed	  above,	  was	  caused	   by	   a	   virus	   of	   swine	   rather	   than	   avian	   origin.	   It	   arose	   as	   a	   reassortment	  between	  two	  swine	  viruses	  (Garten	  et	  al.,	  2009),	  as	  described	  in	  greater	  detail	  in	  the	  following	  section.	  	  
1.8.2 H1N1	  circulation	  history	  H1N1	   viruses	   are	   known	   to	   have	   been	   circulating	   for	  much	   of	   the	   previous	  century	   in	  a	  number	  of	  different	  hosts	   including	  birds,	  pigs	  and	  humans.	  The	  avian	  reservoir	   of	   H1N1	   is	   believed	   to	   have	   been	   constantly	   present	   for	   the	   previous	  century,	  leading	  to	  a	  number	  of	  new	  lineages	  by	  transferal	  into	  new	  hosts	  (Zimmer	  &	  Burke,	  2009).	  
1.8.2.1 Human	  H1N1	  1918	  –	  1957	  and	  1977	  –	  2009	  H1N1	  was	   responsible	   for	   causing	   the	   1918	   pandemic.	   This	   pandemic	   virus	  persisted	   as	   one	   of	   the	   major	   human	   seasonal	   viruses	   until	   the	   H2N2	   pandemic	  appeared	   in	   1957.	   These	   viruses	   are	   thought	   to	   be	   responsible	   for	   infecting	   pigs,	  leading	  to	  the	  ‘classical	  swine’	  lineage	  of	  H1N1	  viruses	  (Brown,	  2000).	  The	  sequence	  of	   the	  1918	  virus	  HA	  has	  been	  determined	   from	  RNA	  extracted	   from	  both	   formalin	  fixed	  tissue	  (Taubenberger	  et	  al.,	  1997)	  and	  from	  lung	  tissue	  preserved	  in	  permafrost	  (Reid	   et	   al.,	   1999).	   This	   virus	   was	   reconstructed	   by	   gene	   synthesis	   and	   reverse	  genetics	  (Tumpey	  et	  al.,	  2005).	  Analysis	  of	  these	  sequences	  suggest	  that	  the	  virus	  was	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likely	  to	  have	  emerged	  from	  an	  avian	  source	  although	  it	  has	  been	  suggested	  that	  this	  may	  have	  not	  been	  a	  direct	   transfer,	   as	   fragments	  of	  RNA	  sequence	  extracted	   from	  preserved	   birds	   in	   1917	   are	   not	   very	   similar	   to	   the	   determined	   1918	   sequences	  (Fanning	   et	  al.,	   2002).	   	   Computer	  modeling	   has	   also	   suggested	   that	   the	   avian	   virus	  that	   caused	   the	   1918	   pandemic	   moved	   into	   a	   mammalian	   host	   earlier	   than	   1918,	  suggesting	   that	   it	   was	   not	   a	   direct	   avian-­‐human	   zoonosis	   (Reis,	   Hay	   &	   Goldstein,	  2009).	  
After	   the	   apparent	   disappearance	   of	   H1N1	   viruses	   circulating	   in	   humans	   in	  1957,	   upon	   the	   emergence	   of	   H2N2	   viruses,	   there	   were	   a	   number	   of	   years	   where	  H1N1	   viruses	   were	   not	   isolated	   from	   humans.	   H1N1	   viruses	   reemerged	   in	   1977.	  These	  H1N1	  viruses	   co-­‐circulated	  with	  H3N2	  seasonal	   viruses	  until	  2009	  when	   the	  swine-­‐origin	  pandemic	  H1N1	  predominated.	  The	  reemergence	  of	  these	  H1N1	  viruses	  is	   thought	   to	   be	   an	   accidental	   release	   of	   virus,	   as	   there	   is	   high	   sequence	   similarity	  between	   the	   newly	   emerged	   viruses	   and	   those	   isolated	   just	   prior	   to	   the	   1957	  pandemic	   (Scholtissek,	   Hoyningen	   &	   Rott,	   1978;	   Nakajima,	   Desselberger	   &	   Palese,	  1978;	  Raymond	  et	  al.,	  1983).	  It	  has	  been	  suggested	  that	  the	  release	  of	  this	  virus	  could	  be	  a	  result	  of	  the	  improper	  inactivation	  of	  virus	  in	  a	  vaccine	  trial.	  
1.8.2.2 Classical	  and	  Eurasian	  swine	  viruses	  There	  have	  been	  two	  predominant	  lineages	  of	  swine	  H1N1	  viruses	  in	  the	  past	  century:	  the	  classical	  swine	  and	  Eurasian	  swine	  viruses.	  
Viruses	   from	   the	   classical	   swine	   lineage	   have	   a	   closely	   related	   origin	   to	   the	  1918	   pandemic	   H1N1	   viruses	   and	   have	   been	   circulating	   in	   pigs	   in	   North	   America	  since	   that	   time	   (Brown,	   2000).	   A	   classical	   swine	   virus	   was	   responsible	   for	   an	  outbreak	   in	  humans	   in	  1976	  at	   a	  US	  military	  base,	   Fort	  Dix	   (Goldfield	  et	  al.,	   1977).	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The	  virus	  was	  identified	  to	  be	  similar	  to	  the	  earliest	  known	  H1N1	  virus	  isolates	  of	  the	  time,	  descended	  from	  the	  1918	  pandemic,	  consequently	  there	  was	  a	  mass	  vaccination	  campaign	   in	   the	  USA,	  mounted	   to	  attempt	   to	  prevent	  a	   further	  pandemic	   (Sencer	  &	  Millar,	  2006).	  
Eurasian	   swine	   viruses	   are	   believed	   to	   have	   emerged	   directly	   from	   birds	   in	  around	   1979	   (Brown,	   2000).	   These	   viruses	   retain	   a	   number	   of	   avian	   virus	  characteristics	  such	  as	  a	  general	  preference	  for	  α2,3-­‐linked	  sialic	  acid,	  although	  this	  preference	  has	  reduced	  over	  time	  (Matrosovich	  et	  al.,	  2000).	  These	  viruses	  circulate	  in	  pigs	  in	  Europe	  and	  Asia	  to	  the	  present	  day.	  
1.8.2.3 Triple-­‐reassortant	  swine	  viruses	  From	  1998	  onwards	  triple	  reassortant	  swine	  (TRS)	  viruses	  were	  found	  in	  pigs	  in	   the	   USA	   (Zhou	   et	   al.,	   1999;	   Webby	   et	   al.,	   2000).	   This	   virus	   was	   made	   up	   of	   a	  mixture	  of	  segments	  from	  avian,	  human	  and	  swine	  viruses.	  The	  PB2	  and	  PA	  segments	  were	  from	  an	  avian	  H1N1	  lineage,	  the	  PB1,	  HA	  and	  NA	  segments	  were	  from	  a	  human	  H3N2	   lineage	  and	   the	  NP,	  M	  and	  NS	   segments	  were	   from	   the	   classical	   swine	  H1N1	  lineage,	   see	   Figure	   1.11.	   This	   TRS	   virus	   reassorted	   again	   with	   the	   H1N1	   classical	  swine	  virus	   to	   form	  a	  number	  of	  different	  subtype	  viruses:	  H1N1,	  H1N2,	  H3N1	  and	  H3N2.	  These	  viruses	  became	  enzootic	  in	  North	  American	  swine	  populations	  (Vincent	  
et	  al.,	  2008;	  Olsen,	  2002;	  Garten	  et	  al.,	  2009)	  and	  have	  been	  responsible	  for	  a	  number	  of	  zoonotic	  infections,	  reviewed	  in	  (Shinde	  et	  al.,	  2009).	  	  








Figure	  1.11:	  Reassortment	  events	  that	  led	  to	  the	  emergence	  of	  the	  2009	  H1N1	  



































































































the	  other	  six	  segments	  from	  the	  TRS	  virus	  (Garten	  et	  al.,	  2009),	  see	  Figure	  1.11.	  These	  2009	   pandemic	   viruses	   (pdm09)	   cause	   widespread	   infections,	   leading	   to	   the	  classification	   of	   the	   pdm09	   viruses	   as	   a	   pandemic.	   The	   pdm09	   viruses	   infected	   an	  estimated	   60	  million	   people	   between	   April	   2009	   and	   April	   2010	   in	   the	   USA	   alone,	  with	  an	  estimated	  12500	  deaths,	  which	  gives	  a	  death	  rate	  of	  ~0.02%,	  which	  is	  low	  in	  comparison	  with	  typical	  seasonal	  strains	  (Shrestha	  et	  al.,	  2011).	  
There	  have	  been	  a	  number	  of	  studies	  that	  have	  examined	  the	  receptor	  binding	  of	  pdm09	  and/or	  pre-­‐pandemic	  TRS	  viruses.	  Both	  glycan	  microarray	  and	  other	  solid	  phase	  binding	  experiments	  have	  identified	  a	  predominance	  of	  affinity	  for	  α2,6-­‐linked	  receptors	  in	  both	  the	  pdm09	  and	  TRS	  H1	  HAs,	  with	  little	  or	  no	  binding	  measurable	  for	  α2,3-­‐linked	  receptors	  (Childs	  et	  al.,	  2009;	  Maines	  et	  al.,	  2009;	  Yang,	  Carney	  &	  Stevens,	  2010;	  Chen	  et	  al.,	  2011;	  Yen	  et	  al.,	  2011;	  Bradley	  et	  al.,	  2011;	  de	  Vries	  et	  al.,	  2011;	  Xu	  
et	  al.,	  2010;	  2012b).	  Glycan	  microarray	  experiments	  showed	  a	  similar	  binding	  profile	  for	   both	   TRS	   and	   pdm09	   viruses	   (Childs	   et	   al.,	   2009;	   Chen	   et	   al.,	   2011;	   Yen	   et	   al.,	  2011;	  Bradley	  et	  al.,	  2011).	  de	  Vries	  et	  al.	  and	  Xu	  et	  al.	  found	  that	  the	  binding	  affinity	  of	  purified	  pdm09	  HA	  was	  significantly	  weaker	  than	  that	  of	  purified	  TRS	  H1	  HA	  (de	  Vries	   et	  al.,	   2011;	   Xu	  et	  al.,	   2012b).	   de	  Vries	  et	  al.	  attributed	   the	   difference	   seen	   in	  binding	  to	  the	  HA	  residues	  200	  and	  227	  (H3	  Numbering)	  (de	  Vries	  et	  al.,	  2011).	  Xu	  et	  
al.	  attributed	  the	  differences	  they	  measured	  in	  HA	  binding	  to	  residues	  134,	  219	  and	  227	  (H3	  Numbering).	  This	  study	  also	  suggested	  that	  the	  emergence	  of	  the	  pandemic	  was	   due	   to	   the	   balance	   between	   the	   low	   binding	   pdm09	  HA	   and	   the	   acquired	   low	  activity	  N1	  NA	   from	  Eurasian	   swine	   (Xu	   et	  al.,	   2012b).	   There	   is	   a	   difference	   in	   the	  receptor	   binding	   data	   between	   the	   pdm09	   and	   TRS	  HA	   dependent	   on	  whether	   the	  experiments	   are	   done	   with	   purified	   proteins	   or	   virus.	   There	   are	   also	   a	   number	   of	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other	  substitutions	  present	  in	  the	  H1	  HA	  that	  could	  alter	  receptor	  binding	  but	  these	  were	  not	  investigated	  in	  the	  studies	  detailed	  above.	  	  
1.8.3 Major	  zoonotic	  viruses	  As	  well	  as	  human	  seasonal	  and	  pandemic	  strains	  there	  have	  been	  a	  number	  of	  viruses	  that	  have	  transferred	  from	  animal	  reservoirs	  into	  the	  human	  population	  but	  which	  have	  not	  been	  capable	  of	  sustained	  human-­‐to-­‐human	  transmission.	  Two	  major	  recent	   zoonotic	   viruses	   are	  H5N1	  and	  H7N9	  viruses	   that	  have	  been	   found	   to	   infect	  humans	  through	  direct	  zoonoses	  from	  their	  reservoir	  host	  of	  wild	  and	  domesticated	  birds.	  
1.8.3.1 H5N1	  High	   pathogenicity	   avian	   influenza	   (HPAI)	   H5N1	   viruses	   were	   first	   found	  infecting	  humans	  in	  2003	  and	  are	  still	  causing	  a	  large	  number	  of	  infections	  to	  this	  day,	  with	   842	   confirmed	   cases	   worldwide	   and	   at	   least	   447	   mortalities,	   as	   of	   23rd	   June	  2015,	  giving	  a	  high	  case	   fatality	  ratio	  of	  ~55%	  (World	  Health	  Organisation,	  2015a).	  These	   viruses	   remain	   a	   public	   health	   concern	   owing	   to	   their	   perceived	   pandemic	  potential,	  although	  there	  has	  been	  limited	  evidence	  of	  human-­‐to-­‐human	  transmission.	  	  
These	   viruses	   are	   classified	   as	   high	   pathogenicity	   as	   they	   cause	  mortality	   in	  poultry	  and	  also	  owing	  to	  the	  presence	  of	  a	  polybasic	  cleavage	  site	  in	  the	  HA,	  which	  allows	  cleavage	  of	  HA0	  into	  HA1	  and	  HA2	  by	  a	  wider	  range	  of	  proteases,	  as	  described	  in	  section	  1.3.1.1.	  H5N1	  infection	  in	  humans	  is	  thought	  to	  be	  a	  primarily	  LRT	  infection,	  owing	   to	   the	   virus	   receptor	   binding	   being	   primarily	   to	   α2,3-­‐linked	   sialic	   acid,	   as	  described	  in	  section	  1.3.1.2.2.	  The	  location	  of	  these	  infections	  in	  the	  LRT	  is	  thought	  to	  be	  one	  of	  the	  reasons	  that	  these	  viruses	  have	  such	  a	  high	  mortality	  rate	  owing	  to	  the	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higher	   incidence	  of	  pneumonia	  associated	  with	  H5N1	   infection	   (Abdel-­‐Ghafar	  et	  al.,	  2008).	  	  
1.8.3.2 H7N9	  H7N9	  viruses	  were	  first	   found	  infecting	  humans	  in	  February	  2013	  in	  eastern	  China.	  These	  viruses	  were	  found	  to	  be	  a	  reassortment	  with	  the	  HA	  similar	  to	  that	  of	  a	  duck	  H7N3	  virus,	  the	  NA	  was	  similar	  to	  that	  of	  an	  H7N9	  virus	  found	  in	  wild	  birds	  and	  the	  remaining	  six	  internal	  genes	  from	  an	  H9N2	  virus	  (Gao	  et	  al.,	  2013).	  Until	  23rd	  June	  2015	   there	   had	   been	   672	   confirmed	   cases	   with	   at	   least	   271	   deaths,	   giving	   a	   case	  fatality	  ratio	  of	  ~40%.	  There	  has	  been	  a	  wave	  of	  H7N9	  every	  year	  since	  2013,	  with	  the	  majority	   of	   infections	   taking	  place	   in	   the	  winter	   in	   both	  2014	   and	  2015.	   These	  viruses	  are	  thought	  to	  have	  infected	  as	  direct	  zoonoses	  from	  avian	  populations.	  There	  is	  limited	  evidence	  of	  human-­‐to-­‐human	  transmission	  with	  reports	  of	  a	  small	  number	  of	  clusters	  of	  infected	  individuals	  (World	  Health	  Organisation,	  2015c).	  These	  viruses	  also	  have	  poor	  aerosol	  transmission	  in	  ferrets	  (Zhu	  et	  al.,	  2013a;	  Belser	  et	  al.,	  2013;	  Richard	   et	   al.,	   2013;	   Xu	   et	   al.,	   2014a).	   These	   H7N9	   viruses	   are	   now	   thought	   to	   be	  enzootic	   in	   the	   avian	   population	   of	   eastern	   China	   (Lam	   et	   al.,	   2015)	   and	   are	  consequently	  a	  major	  risk	  to	  the	  human	  population.	  
These	  H7N9	  viruses	  are	  quite	  different	  from	  the	  HPAI	  H5N1	  viruses	  described	  above.	  They	  do	  not	  have	  the	  typical	  hallmarks	  of	  a	  high	  pathogenicity	  virus,	  lacking	  a	  polybasic	  cleavage	  site	  in	  the	  HA	  (Gao	  et	  al.,	  2013)	  they	  also	  are	  of	  low	  pathogenicity	  in	  avian	  species.	  These	  viruses	  do,	  however,	  have	  a	  Q226L	  substitution	  present	  in	  the	  HA,	  which	   is	   associated	  with	   an	   increase	   in	   binding	   of	   the	   HA	   to	   the	   human	   α2,6-­‐linked	  sialic	  acid	  (Rogers	  et	  al.,	  1983),	  and	  also	  a	   five	  amino	  acid	  deletion	  in	  the	  NA	  stalk,	  which	  can	  alter	  the	  transmission	  characteristics,	  as	  described	  in	  section	  1.3.2.4.	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There	  have	  been	  a	  number	  of	  studies	  that	  have	  examined	  the	  structure	  and/or	  receptor	   binding	   properties	   of	   the	   these	   viruses,	   either	   examining	   virus	   binding	  (Xiong	  et	  al.,	   2013b;	   Shi	  et	  al.,	   2013;	  Belser	  et	  al.,	   2013;	  Zhou	  et	  al.,	   2013;	  Xu	  et	  al.,	  2014b)	  or	  the	  binding	  of	  purified	  HA	  to	  immobilised	  receptors	  (Yang	  et	  al.,	  2013;	  Shi	  
et	  al.,	   2013;	  Dortmans	  et	  al.,	   2013;	  Ramos	  et	  al.,	   2013).	  These	   studies	  have	  a	  broad	  agreement	  that	  the	  H7N9	  viruses	  have	  a	  preference	  for	  binding	  to	  α2,3-­‐linked	  sialic	  acid	   receptors,	   as	   would	   be	   expected	   for	   an	   avian	   virus;	   however,	   they	   also	   have	  increased	  affinity	   for	  α2,6-­‐linked	   receptors	   in	   comparison	  with	  other	  avian	  viruses,	  although	  it	  is	  weaker	  than	  that	  of	  the	  α2,3-­‐linked	  receptor	  binding.	  	  
The	  NA	  of	  the	  H7N9	  virus	  has	  also	  been	  characterised,	  showing	  that	  the	  N9	  NA	  has	  a	  poor	  catalytic	  efficiency	  at	  cleaving	  an	  artificial	  NA	  substrate	  (MUNANA)	  (Wu	  et	  
al.,	  2013).	  It	  has	  also	  been	  described	  that	  the	  N9	  NA	  appears	  to	  have	  a	  low	  efficiency	  at	  cleaving	  α2,6-­‐linked	  receptors	  (Xiong	  et	  al.,	  2013b).	  
1.9 Summary	  One	  of	  the	  major	  aims	  in	  IAV	  virology	  is	  attempting	  to	  anticipate	  which	  viruses	  will	   cause	   the	   next	   pandemic	   and	   attempt	   to	   either	   prevent	   the	  movement	   of	   this	  virus	   into	  the	  human	  population	  or	  prepare	  prophylactic	  or	  therapeutic	  approaches	  to	  control	   the	  virus	   infection.	  The	  defining	   factor	   in	  predicting	   the	  viral	   spread	   into	  and	   between	   humans	   is	   the	   transmissibility.	   This	   is	   a	   complex	   and	   multifactorial	  property	  that	  involves	  a	  large	  number	  of	  viral	  characteristics	  such	  as	  the	  fitness	  of	  the	  virus	   to	   replicate	   in	   human	   cells	   and	   the	   ability	   for	   efficient	   virus	   shedding	   and	  transmission	  to	  a	  new	  human	  host.	  	  
A	  major	  factor	  in	  determining	  viral	  fitness	  and	  therefore	  transmissibility	  is	  the	  initial	  stage	  of	   infection,	  receptor	  binding.	  This	  binding	  is	  controlled	  by	  both	  the	  HA	  
73	  
and	  NA	  surface	  glycoproteins	  which	  have	  antagonistic	   functions	  of	  receptor	  binding	  and	  receptor	  destroying.	  It	  has	  been	  hypothesised	  that	  for	  efficient	  virus	  infection	  and	  release	  from	  the	  cell	  there	  needs	  to	  be	  the	  correct	  balance	  between	  the	  functions	  of	  these	  two	  glycoproteins.	  Until	  now	  studies	  into	  the	  balance	  of	  these	  two	  proteins	  has	  involved	   altering	   the	   characteristics	   of	   one	   of	   the	   proteins	   and	   looking	   at	   escape	  mutations	   induced	   or	   looking	   at	   the	   effects	   that	   these	   changes	   have	   on	   virus	  characteristics.	   There	   have	   also	   been	   studies	   that	   have	   examined	   the	   two	  glycoproteins	  in	  isolation	  that	  then	  attempt	  to	  relate	  the	  antagonistic	  activities	  of	  the	  two	  proteins	  by	   correlating	   characteristics.	  There	   is	   consequently	   a	   requirement	   to	  understand	  the	  role	  of	  these	  two	  proteins	  in	  directly	  altering	  receptor	  binding	  in	  the	  context	  of	  a	  viral	  particle.	  
1.10 Objectives	  of	  thesis	  This	  thesis	  aims	  to	  investigate	  the	  question	  of	  the	  balance	  between	  HA	  and	  NA	  by	  directly	  measuring	   the	   role	   of	   these	   two	  proteins	   in	   affecting	   virus	   binding	   to	   a	  receptor	  analogue	  coated	  surface	  by	  a	  biophysical	  technique.	  The	  methods	  developed	  to	   measure	   these	   characteristics	   are	   then	   used,	   in	   combination	   with	   a	   number	   of	  other	   biophysical	   techniques,	   to	   better	   understand	   a	   number	   of	   different	  combinations	  and	  properties	  of	  HA	  and	  NA,	  namely	   the	  properties	  of	   the	  H7N9	  NA	  with	  respect	  to	  its	  role	  in	  receptor	  binding	  and	  also	  the	  novel	  combination	  of	  HA	  and	  NA	  seen	  upon	  the	  emergence	  of	  the	  2009	  H1N1	  pandemic.	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2 Materials	  and	  Methods	  
2.1 Materials	  
2.1.1 Viruses	  
Virus	  Name	   Short	  Name	   Origin	   Description	  X-­‐31	   -­‐	   NIMR	  WHOCC	   A/Hong	  Kong/2/68(H3N2)	  high	  growth	  reassortant	  with	  PR8	  background	  X-­‐31	  HAM	   HAM	   NIMR	  WHOCC	  	   X-­‐31	  L226Q	  Mutant	  X-­‐31	  Δ10	  NA	   Δ10	  NA	   Reverse	  Genetics*	   X-­‐31	  with	  residues	  60-­‐69	  removed	  from	  NA	  stalk	  A/Anhui/1/2013	  (H7N9)	   Anhui13	   Reverse	  Genetics*	   H7N9	  6+2	  reassortant	  with	  PR8	  	  A/Anhui/1/2013	  (H7N9)	  S367N	  NA	   Anhui13	  S367N	   Reverse	  Genetics*	   H7N9	  6+2	  reassortant	  with	  PR8	  and	  S367N	  mutant	  NA	  A/Anhui/1/2013	  HA	  +	  PR8	  NA	  Reassortant	   H7N1	   Reverse	  Genetics*	   H7N1	  7+1	  reassortant	  with	  PR8	  PR8	  HA	  +	  A/Anhui/1/2013	  NA	  Reassortant	   H1N9	  WT	   Reverse	  Genetics*	   H1N9	  7+1	  reassortant	  with	  PR8	  PR8	  HA	  +	  A/Anhui/1/2013	  NA	  S367N	  Reassortant	   H1N9	  S367N	   Reverse	  Genetics*	   H1N9	  7+1	  reassortant	  with	  PR8	  and	  S367N	  mutant	  NA	  A/Victoria/361/2012	  HA	  +	  A/Anhui/1/2013	  NA	  Reassortant	   H3N9	  WT	   Reverse	  Genetics*	   H3N9	  6+2	  reassortant	  with	  PR8	  A/Victoria/361/2012	  HA	  +	  A/Anhui/1/2013	  NA	  S367N	  Reassortant	   H3N9	  S367N	   Reverse	  Genetics*	   H3N9	  6+2	  reassortant	  with	  PR8	  and	  S367N	  mutant	  NA	  A/California/7/09	  WT	   Cal7	  WT	   Reverse	  Genetics*	   Full	  8	  segment	  Cal7	  (H1N1)	  A/California/7/09	  S132T	   Cal7	  S132T	   Reverse	  Genetics*	   Full	  8	  segment	  Cal7	  with	  S132T	  mutant	  HA	  A/California/7/09	  K134R	   Cal7	  K134R	   Reverse	  Genetics*	   Full	  8	  segment	  Cal7	  with	  K134R	  mutant	  HA	  A/California/7/09	  R149K	   Cal7	  R149K	   Reverse	  Genetics*	   Full	  8	  segment	  Cal7	  with	  R149K	  mutant	  HA	  A/California/7/09	  P186S	   Cal7	  P186S	   Reverse	  Genetics*	   Full	  8	  segment	  Cal7	  with	  P186S	  mutant	  HA	  A/California/7/09	  A189T	   Cal7	  A189T	   Reverse	  Genetics*	   Full	  8	  segment	  Cal7	  with	  A189T	  mutant	  HA	  A/California/7/09	  K208R	   Cal7	  K208R	   Reverse	  Genetics*	   Full	  8	  segment	  Cal7	  with	  K208R	  mutant	  HA	  A/California/7/09	  I219T	   Cal7	  I219T	   Reverse	  Genetics*	   Full	  8	  segment	  Cal7	  with	  I219T	  mutant	  HA	  A/California/7/09	  I219A	   Cal7	  I219A	   Reverse	  Genetics*	   Full	  8	  segment	  Cal7	  with	  I219A	  mutant	  HA	  A/California/7/09	  E227A	   Cal7	  E227A	   Reverse	  Genetics*	   Full	  8	  segment	  Cal7	  with	  E227A	  mutant	  HA	  A/California/7/09	  I219A	  E227A	   Cal7	  I219A	  E227A	   Reverse	  Genetics*	   Full	  8	  segment	  Cal7	  with	  I219A	  E227A	  mutant	  HA	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A/California/7/09	  I219T	  E227A	   Cal7	  I219T	  E227A	   Reverse	  Genetics*	   Full	  8	  segment	  Cal7	  with	  I219T	  E227A	  mutant	  HA	  A/Iowa/1/2006	  WT	   Iowa06	  WT	   Reverse	  Genetics*	   Iowa06	  HA	  and	  NA	  in	  a	  PR8	  Background	  A/Iowa/1/2006	  T132S	   Iowa06	  T132S	   Reverse	  Genetics*	   Iowa06	  T132S	  HA	  and	  NA	  in	  a	  PR8	  Background	  A/Iowa/1/2006	  K134R	   Iowa06	  K134R	   Reverse	  Genetics*	   Iowa06	  K134R	  HA	  and	  NA	  in	  a	  PR8	  Background	  A/Iowa/1/2006	  R149K	   Iowa06	  R149K	   Reverse	  Genetics*	   Iowa06	  R149K	  HA	  and	  NA	  in	  a	  PR8	  Background	  A/Iowa/1/2006	  P186S	   Iowa06	  P186S	   Reverse	  Genetics*	   Iowa06	  P186S	  HA	  and	  NA	  in	  a	  PR8	  Background	  A/Iowa/1/2006	  T189A	   Iowa06	  T189A	   Reverse	  Genetics*	   Iowa06	  T189A	  HA	  and	  NA	  in	  a	  PR8	  Background	  A/Iowa/1/2006	  K208R	   Iowa06	  K208R	   Reverse	  Genetics*	   Iowa06	  K208R	  HA	  and	  NA	  in	  a	  PR8	  Background	  A/Iowa/1/2006	  A219I	   Iowa06	  A219I	   Reverse	  Genetics*	   Iowa06	  A219I	  HA	  and	  NA	  in	  a	  PR8	  Background	  A/Iowa/1/2006	  A219T	   Iowa06	  A219T	   Reverse	  Genetics*	   Iowa06	  A219T	  HA	  and	  NA	  in	  a	  PR8	  Background	  A/Iowa/1/2006	  A227E	   Iowa06	  A227E	   Reverse	  Genetics*	   Iowa06	  A227E	  HA	  and	  NA	  in	  a	  PR8	  Background	  A/Iowa/1/2006	  A219I	  A227E	   Iowa06	  A219I	  A227E	   Reverse	  Genetics*	   Iowa06	  A219I	  A227E	  HA	  and	  NA	  in	  a	  PR8	  Background	  A/Iowa/1/2006	  A219T	  A227E	   Iowa06	  A219T	  A227E	   Reverse	  Genetics*	   Iowa06	  A219T	  A227E	  HA	  and	  NA	  in	  a	  PR8	  Background	  A/Iowa/1/2006	  P186S	  T189A	   Iowa06	  P186S	  T189A	   Reverse	  Genetics*	   Iowa06	  P186S	  T189A	  HA	  and	  NA	  in	  a	  PR8	  Background	  A/Iowa/1/2006	  WT	  +	  Iowa	  Bkg	   Iowa06	  +	  Iowa	  bkg	   Reverse	  Genetics*	   Full	  8	  segment	  WT	  Iowa06	  A/California/7/2009	  HA	  A/Iowa/1/2006	  NA	  +	  Cal7	  Bkg	   Cal7	  HA	  Iowa06	  NA	  +	  Cal	  bkg	   Reverse	  Genetics*	   WT	  Cal7	  HA	  and	  Iowa06	  NA	  in	  a	  Cal7	  Background	  A/California/7/2009	  HA	  A/Iowa/1/2006	  NA	  +	  Iowa06	  Bkg	   Cal7	  HA	  Iowa06	  NA	  +	  Iowa06	  bkg	   Reverse	  Genetics*	   WT	  Cal7	  HA	  and	  Iowa06	  NA	  in	  an	  Iowa06	  Background	  A/WSN/33	  +	  A/California/7/2009	  NA	   WSN	  +	  Cal7	  NA	   Reverse	  Genetics*	   7	  +	  1	  reassortant	  of	  WSN	  with	  Cal7	  NA	  A/WSN/33	  +	  A/Iowa/1/2006	  NA	   WSN	  +	  Iowa06	  NA	   Reverse	  Genetics*	   7	  +	  1	  reassortant	  of	  WSN	  with	  Iowa06	  NA	  *	  Generated	  in	  these	  studies
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2.1.2 Purified	  proteins	  
Protein	  Name	   Production/Purification	  Method	   Protein	  Source	  X-­‐31	  NA	   Bromelain	  cleaved	  from	  purified	  virus.	  Purified	  by	  ion	  exchange	  and	  gel	  filtration.	   Patrick	  Collins	  Cal7	  HA	   Insect	  cell	  expressed.	  Purified	  using	  cobalt	  column	  and	  gel	  filtration.	  Purification	  tag	  remains	  attached.	   Generated	  during	  these	  studies	  Iowa06	  HA	   Insect	  cell	  expressed.	  Purified	  using	  cobalt	  column	  and	  gel	  filtration.	  Purification	  tag	  remains	  attached.	   Generated	  during	  these	  studies	  Cal7	  NA	   Bromelain	  cleaved	  from	  purified	  virus.	  Purified	  by	  ion	  exchange	  and	  gel	  filtration.	   Generated	  during	  these	  studies	  Iowa06	  NA	   Detergent	  extracted	  from	  purified	  virus.	  Purified	  by	  ion	  exchange	  and	  gel	  filtration.	  Made	  into	  rosettes	  by	  removing	  detergent	  with	  hydrophobic	  beads.	   Generated	  during	  these	  studies	  Anhui13	  NA	  WT	   Insect	  cell	  expressed.	  Purified	  using	  cobalt	  column	  and	  gel	  filtration.	  Purification	  tag	  remains	  attached.	   Generated	  during	  these	  studies	  Anhui13	  NA	  S367N	   Insect	  cell	  expressed.	  Purified	  using	  cobalt	  column	  and	  gel	  filtration.	  Purification	  tag	  remains	  attached.	   Generated	  during	  these	  studies	  
2.1.3 PCR	  primers	  
2.1.3.1 Primers	  used	  for	  reverse	  genetics	  cloning	  
Target	   Primer	  Name	   Sequence	  Full	  Length	  HA	  +	  AarI	  restriction	  sites	   AarI-­‐HA-­‐F1	   TATTCACCTGCCTCAGGGAGCAAAAGCAGGGG	  AarI-­‐NS-­‐R890	   ATATCACCTGCCTCGTATTAGTAGAAACAAGGGTGTTTT	  Full	  length	  NA	  +	  AarI	  restriction	  sites	   AarI-­‐NA-­‐F1	   TATTCACCTGCCTCAGGGAGCAAAAGCAGGAGT	  AarI-­‐NA-­‐R1413	   ATATCACCTGCCTCGTATTAGTAGAAACAAGGAGTTTTTT	  Full	  length	  HA	  +	  BsmBI	  restriction	  sites	   Bm-­‐HA-­‐F1	   TATTCGTCTCAGGGAGCAAAAGCAGGGG	  Bm-­‐NS-­‐R890	   ATATCGTCTCGTATTAGTAGAAACAAGGGTGTTTT	  
Cal7	  HA	  splicing	  PCR	   cswHAR873	   CAGATCCAGCATTTCTTTCCATTGC	  	  cswHAF848	   GCAATGGAAAGAAATGCTGGATCTG	  HAFUc	   TATTCGTCTCAGGGAGCAAAAGCAGGGG	  HARUc	   ATATCGTCTCGTATTAGTAGAAACAAGGGTGTTTT	  Universal	  IAV	  primer	   Uni12	   AGCAAAAGCAGG	  
2.1.3.2 Primers	  for	  baculovirus	  subcloning	  
Target	   Primer	  Name	   Sequence	  Anhui	  NA	  expression	  construct	   N9_infusion_F	   GGTCCGAAAACCATGGATGCTACTAGTAAATCAGTCACACCAAGGCTTCAATAA	  N9_infusion_R	   GCTCGAATTCGGATCCTCATTAGAGGAAGTACTCGATCTTAGCGCCGTCA	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2.1.3.3 Primers	  for	  viral	  RNA	  sequencing	  
2.1.3.3.1 H3N2	  sequencing	  
X-­‐31	  sequencing	  
Target	   Primer	  Name	   Sequence	  5’	  HA	  sequencing	   HAFUc*	   TATTCGTCTCAGGGAGCAAAAGCAGGGG	  H3A1R1*	   GTCTATCATTCCCTCCCAACCATT	  3’	  HA	  sequencing	   H3A1F3*	   TGCATCACTCCAAATGGAAGCATT	  	  HARUc*	   ATATCGTCTCGTATTAGTAGAAACAAGGGTGTTTT	  5’	  NA	  sequencing	   NAFUc*	   TATTGGTCTCAGGGAGCAAAAGCAGGAGT	  N2R3*	   TTAGTATCAGCTCTTCCTGAAGCA	  3’	  NA	  sequencing	   N2F2*	   CATGCGATCCTGGCAAGTGTTATC	  NARUc*	   ATATGGTCTCGTATTAGTAGAAACAAGGAGTTTTTT	  *	  Primers	  used	  in	  one-­‐step	  RT-­‐PCR	  
Vic361	  HA	  sequencing	  
Target	   Primer	  Name	   Sequence	  
5’	  HA	  sequencing	   HAFUc*	   TATTCGTCTCAGGGAGCAAAAGCAGGGG	  H3A1R2	   AATGCTTCCATTTGGAGTGATGCA	  H3A1R1*	   GTCTATCATTCCCTCCCAACCATT	  3’	  HA	  sequencing	   H3A1F3*	   TGCATCACTCCAAATGGAAGCATT	  	  HARUc*	   ATATCGTCTCGTATTAGTAGAAACAAGGGTGTTTT	  *	  Primers	  used	  in	  one-­‐step	  RT-­‐PCR	  
2.1.3.3.2 H7N9	  sequencing	  
Target	   Primer	  Name	   Sequence	  
5’	  HA	  sequencing	   H7HAF1*	   AAAAGCAGGGGATACAAAATGAA	  H7HAR2	   GGAGCTATGAARGCCCCATTGAA	  H7R3*	   ATTGCCGATTGRGTGCTTTTGTA	  3’	  HA	  sequencing	   H7F3*	   TCTGGAAGRATTGACTTTCAYTGG	  HARUc*	   ATATCGTCTCGTATTAGTAGAAACAAGGGTGTTTT	  5’	  NA	  sequencing	   N9F1*	   AAGCAGGGTCAAGATGAATCC	  N9R3*	   GTGCTTATTGTYCTYCCTAGCCA	  3’	  NA	  sequencing	   N9F3*	   CCAGGATGTCAATATGTATATC	  NARUc*	   ATATGGTCTCGTATTAGTAGAAACAAGGAGTTTTTT	  *	  Primers	  used	  in	  one-­‐step	  RT-­‐PCR	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2.1.3.3.3 H1N1	  sequencing	  
Cal7	  sequencing	  
Target	   Primer	  Name	   Sequence	  
5’	  HA	  sequencing	   cswHAF1*	   TATTCGTCTCAGGGAGCAAAAGCAGGGG	  cswHAR873	   CAGATCCAGCATTTCTTTCCATTGC	  	  cswHAR1264*	   CCTACTGCTGTGAACTGTGTATTC	  3’	  HA	  sequencing	   cswHAF848*	   GCAATGGAAAGAAATGCTGGATCTG	  	  HARUc*	   ATATCGTCTCGTATTAGTAGAAACAAGGGTGTTTT	  5’	  NA	  sequencing	   NAFUc*	   TATTGGTCTCAGGGAGCAAAAGCAGGAGT	  cswN1R1099*	   CCTATCCAAACACCATTGCCGTAT	  3’	  NA	  sequencing	   cswN1F401*	   GGAATGCAGAACCTTCTTCTTGAC	  NARUc*	   ATATGGTCTCGTATTAGTAGAAACAAGGAGTTTTTT	  *	  Primers	  used	  in	  one-­‐step	  RT-­‐PCR	  
Iowa06	  sequencing	  
Target	   Primer	  Name	   Sequence	  
5’	  HA	  sequencing	   IowaF1*	   CCAAAATGAAGGCAATAATAGTAGTCT	  IowaHAR873	   CAGATCCAGAGCCTCTTTTCATTGC	  IowaR1295*	   AAACTCTCTATTCTTTTTTCCAATTG	  3’	  HA	  sequencing	   IowaHAF848*	   GCAATGAAAAGAGGCTCTGGATCTG	  	  HARUc*	   ATATCGTCTCGTATTAGTAGAAACAAGGGTGTTTT	  5’	  NA	  sequencing	   NAFUc*	   TATTGGTCTCAGGGAGCAAAAGCAGGAGT	  IowaNAR953*	   TCACCGAAAACCCCACTGCAT	  3’	  NA	  sequencing	   IowaNAF421*	   GGAACCGTCAAGGACAGGAGT	  NARUc*	   ATATGGTCTCGTATTAGTAGAAACAAGGAGTTTTTT	  *	  Primers	  used	  in	  one-­‐step	  RT-­‐PCR	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2.1.4 Plasmids	  
2.1.4.1 Background	  plasmids	  for	  reverse	  genetics	  
Plasmid	  Name	   Source	   Description	  pHW2000	   Laboratory	  of	  Robert	  Webster	   Empty	  pHW2000	  vector	  pHW2000	  PR8	  PB2	   Laboratory	  of	  Robert	  Webster	   PR8	  PB2	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  PR8	  PB1	   Laboratory	  of	  Robert	  Webster	   PR8	  PB1	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  PR8	  PA	   Laboratory	  of	  Robert	  Webster	   PR8	  PA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  PR8	  NP	   Laboratory	  of	  Robert	  Webster	   PR8	  NP	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  PR8	  M	   Laboratory	  of	  Robert	  Webster	   PR8	  M	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  PR8	  NS	   Laboratory	  of	  Robert	  Webster	   PR8	  NS	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  WSN	  PB2	   Laboratory	  of	  Robert	  Webster	   WSN	  PB2	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  WSN	  PB1	   Laboratory	  of	  Robert	  Webster	   WSN	  PB1	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  WSN	  PA	   Laboratory	  of	  Robert	  Webster	   WSN	  PA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  WSN	  NP	   Laboratory	  of	  Robert	  Webster	   WSN	  NP	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  WSN	  M	   Laboratory	  of	  Robert	  Webster	   WSN	  M	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  WSN	  NS	   Laboratory	  of	  Robert	  Webster	   WSN	  NS	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Cal7	  PB2	   Previously	  cloned	  by	  Haxia	  Xiao	   A/California/7/2009	  PB2	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Cal7	  PB1	   Previously	  cloned	  by	  Haxia	  Xiao	   A/California/7/2009	  PB1	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Cal7	  PA	   Previously	  cloned	  by	  Haxia	  Xiao	   A/California/7/2009	  PA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Cal7	  NP	   Previously	  cloned	  by	  Haxia	  Xiao	   A/California/7/2009	  NP	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Cal7	  M	   Previously	  cloned	  by	  Haxia	  Xiao	   A/California/7/2009	  M	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Cal7	  NS	   Previously	  cloned	  by	  Haxia	  Xiao	   A/California/7/2009	  NS	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Iowa06	  PB2	   Previously	  cloned	  by	  Haxia	  Xiao	   A/Iowa/1/2006	  PB2	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Iowa06	  PB1	   Previously	  cloned	  by	  Haxia	  Xiao	   A/Iowa/1/2006	  PB1	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Iowa06	  PA	   Previously	  cloned	  by	  Haxia	  Xiao	   A/Iowa/1/2006	  PA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Iowa06	  NP	   Previously	  cloned	  by	  Haxia	  Xiao	   A/Iowa/1/2006	  NP	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Iowa06	  M	   Previously	  cloned	  by	  Haxia	  Xiao	   A/Iowa/1/2006	  M	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Iowa06	  NS	   Previously	  cloned	  by	  Haxia	  Xiao	   A/Iowa/1/2006	  NS	  segment	  cloned	  into	  pHW2000	  vector	  
80	  
2.1.4.2 HA	  and	  NA	  plasmids	  for	  reverse	  genetics	  
Plasmid	  Name	   Source	   Description	  pHW2000	  PR8	  HA	   Laboratory	  of	  Robert	  Webster	   PR8	  HA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  PR8	  NA	   Laboratory	  of	  Robert	  Webster	   PR8	  NA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  WSN	  HA	   Laboratory	  of	  Robert	  Webster	   WSN	  HA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  X-­‐31	  HA	   Cloned	  from	  viral	  cDNA*	   X-­‐31	  HA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  X-­‐31	  NA	   Cloned	  from	  viral	  cDNA*	   X-­‐31	  NA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  X-­‐31	  NA	  Δ10	   Mutagenesis	  of	  WT	  plasmid*	   X-­‐31	  NA	  with	  residues	  60	  –	  69	  deleted	  cloned	  into	  pHW2000	  vector	  	  pHW2000	  Anhui13	  HA	   Laboratory	  of	  Munir	  Iqbal	   A/Anhui/1/2013	  HA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Anhui13	  NA	   Laboratory	  of	  Munir	  Iqbal	   A/Anhui/1/2013	  NA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Anhui13	  NA	  S367N	   Mutagenesis	  of	  WT	  plasmid*	   A/Anhui/1/2013	  S367N	  NA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Vic361	  HA	   Previously	  cloned	  by	  Lauren	  Parker	   A/Victoria/361/2012	  HA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Cal7	  HA	   Cloned	  from	  viral	  cDNA*	   A/California/7/2009	  HA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Cal7	  NA	   Cloned	  from	  viral	  cDNA*	   A/California/7/2009	  NA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Cal7	  HA	  S132T	   Mutagenesis	  of	  WT	  plasmid*	   A/California/7/2009	  S132T	  HA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Cal7	  HA	  K134R	   Mutagenesis	  of	  WT	  plasmid*	   A/California/7/2009	  K134R	  HA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Cal7	  HA	  K149R	   Mutagenesis	  of	  WT	  plasmid*	   A/California/7/2009	  K149R	  HA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Cal7	  HA	  S186P	   Mutagenesis	  of	  WT	  plasmid*	   A/California/7/2009	  S186P	  HA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Cal7	  HA	  A189T	   Mutagenesis	  of	  WT	  plasmid*	   A/California/7/2009	  A189T	  HA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Cal7	  HA	  R208K	   Mutagenesis	  of	  WT	  plasmid*	   A/California/7/2009	  R208K	  HA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Cal7	  HA	  I219T	   Mutagenesis	  of	  WT	  plasmid*	   A/California/7/2009	  I219T	  HA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Cal7	  HA	  I219A	   Mutagenesis	  of	  WT	  plasmid*	   A/California/7/2009	  I219A	  HA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Cal7	  HA	  E227A	   Mutagenesis	  of	  WT	  plasmid*	   A/California/7/2009	  E227A	  HA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Cal7	  HA	  I219A	  E227A	   Mutagenesis	  of	  WT	  plasmid*	   A/California/7/2009	  I219A	  E227A	  HA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Cal7	  HA	  I219T	  E227A	   Mutagenesis	  of	  WT	  plasmid*	   A/California/7/2009	  I219T	  E227A	  HA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Iowa06	  HA	   Cloned	  from	  viral	  cDNA*	   A/Iowa/1/2006	  HA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Iowa06	  NA	   Cloned	  from	  viral	  cDNA*	   A/Iowa/1/2006	  NA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Iowa06	  HA	  T132S	   Mutagenesis	  of	  WT	  plasmid*	   A/Iowa/1/2006	  T132S	  HA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Iowa06	  HA	  K134R	   Mutagenesis	  of	  WT	  plasmid*	   A/Iowa/1/2006	  K134R	  HA	  segment	  cloned	  into	  pHW2000	  vector	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pHW2000	  Iowa06	  HA	  R149K	   Mutagenesis	  of	  WT	  plasmid*	   A/Iowa/1/2006	  R149K	  HA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Iowa06	  HA	  P186S	   Mutagenesis	  of	  WT	  plasmid*	   A/Iowa/1/2006	  P186S	  HA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Iowa06	  HA	  T189A	   Mutagenesis	  of	  WT	  plasmid*	   A/Iowa/1/2006	  T189A	  HA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Iowa06	  HA	  K208R	   Mutagenesis	  of	  WT	  plasmid*	   A/Iowa/1/2006	  K208R	  HA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Iowa06	  HA	  A219I	   Mutagenesis	  of	  WT	  plasmid*	   A/Iowa/1/2006	  A219I	  HA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Iowa06	  HA	  A219T	   Mutagenesis	  of	  WT	  plasmid*	   A/Iowa/1/2006	  A219T	  HA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Iowa06	  HA	  A227E	   Mutagenesis	  of	  WT	  plasmid*	   A/Iowa/1/2006	  A227E	  HA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Iowa06	  HA	  A219I	  A227E	   Mutagenesis	  of	  WT	  plasmid*	   A/Iowa/1/2006	  A219I	  A227E	  HA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Iowa06	  HA	  A219T	  A227E	   Mutagenesis	  of	  WT	  plasmid*	   A/Iowa/1/2006	  A219T	  A227E	  HA	  segment	  cloned	  into	  pHW2000	  vector	  pHW2000	  Iowa06	  HA	  P186S	  T189A	   Mutagenesis	  of	  WT	  plasmid*	   A/Iowa/1/2006	  P186S	  T189A	  HA	  segment	  cloned	  into	  pHW2000	  vector	  *Generated	  in	  these	  studies	  
2.1.4.3 Plasmids	  for	  insect	  cell	  protein	  expression	  
Plasmid	  
Name	  
Source	   Description	   Expression	  
System	  pHAEM1	   Sebastian	  Vachieri	   Altered	  version	  of	  pAcGP67-­‐A	  baculovirus	  expression	  plasmid,	  altered	  to	  include	  a	  trimerisation	  motif	  (foldon)	  a	  TEV	  protease	  cleavage	  site	  and	  a	  6x	  His-­‐tag	  	  
BaculoGold	  
pHAEM1	  Cal7	  HA	   Generated	  in	  these	  studies	   pHAEM1	  with	  insect	  optimised	  gene	  encoding	  the	  ectodomain	  of	  Cal7	  HA	   BaculoGold	  pHAEM1	  Iowa06	  HA	   Generated	  in	  these	  studies	   pHAEM1	  with	  insect	  optimised	  gene	  encoding	  the	  ectodomain	  of	  Cal7	  HA	   BaculoGold	  pAcGP67-­‐A	  Anhui13	  NA	   Xiaoli	  Xiong	   pAcGP67-­‐A	  with	  expression	  construct	  for	  Anhui13	  NA	  	   BaculoGold	  pFB-­‐LIC-­‐Bse	   Xiaoli	  Xiong	   Transfer	  vector	  compatible	  with	  the	  Bac-­‐to-­‐Bac	  system.	   Bac	  to	  Bac	  pFB-­‐LIC-­‐Bse	  Anhui13	  NA	   Generated	  in	  these	  Studies	   pFB-­‐LIC-­‐Bse	  containing	  Anhui13	  NA	  expression	  construct	   Bac	  to	  Bac	  pFB-­‐LIC-­‐Bse	  Anhui13	  NA	  S367N	   Generated	  in	  these	  Studies	   pFB-­‐LIC-­‐Bse	  containing	  Anhui13	  S367N	  NA	  expression	  construct	   Bac	  to	  Bac	  
	  	   	  
82	  
2.1.5 Small	  molecules	  
Molecule	  Name	   Short	  Name	   Source	  
Catalogue	  
Number	  α2,6-­‐Sialyl-­‐N-­‐acetyllactosamine	   6SLN	   Dextra	  Laboratories	  Ltd.,	  Reading,	  UK	   SLN306	  α2,3-­‐Sialyl-­‐N-­‐acetyllactosamine	   3SLN	   Dextra	  Laboratories	  Ltd.,	  Reading,	  UK	   SLN302	  α2,6-­‐Sialyl-­‐N-­‐acetyllactosamine	  sialoglycopolymer	  (attached	  to	  polyacrylamide	  and	  biotin)	   6SLN-­‐PAA	   Lectinity	  Holdings,	  Moscow,	  Russia	   0997-­‐BP	  α2,3-­‐Sialyl-­‐N-­‐acetyllactosamine	  sialoglycopolymer	  (attached	  to	  polyacrylamide	  and	  biotin)	   3SLN-­‐PAA	   Lectinity	  Holdings,	  Moscow,	  Russia	   0036-­‐BP	  α2,6-­‐Sialyllactose	  sialoglycopolymer	  (attached	  to	  polyacrylamide	  and	  biotin)	   6SL-­‐PAA	   Lectinity	  Holdings,	  Moscow,	  Russia	   0063-­‐BP	  α2,3-­‐Sialyllactose	  sialoglycopolymer	  (attached	  to	  polyacrylamide	  and	  biotin)	   3SL-­‐PAA	   Lectinity	  Holdings,	  Moscow,	  Russia	   0060-­‐BP	  α2,3-­‐Sialyl-­‐N-­‐acetyllactosamine-­‐6’	  sulphated	  GlcNAc	  sialoglycopolymer	  (attached	  to	  polyacrylamide	  and	  biotin)	   6SU-­‐3SLN-­‐PAA	   Lectinity	  Holdings,	  Moscow,	  Russia	   0951-­‐BP	  Sialyl	  Lewisx	  sialoglycopolymer	  (attached	  to	  polyacrylamide	  and	  biotin)	   Sia	  Lex-­‐PAA	   Lectinity	  Holdings,	  Moscow,	  Russia	   0062-­‐BP	  Sialyl	  Lewisx-­‐6’	  sulphated	  GlcNAc	  	  sialoglycopolymer	  (attached	  to	  polyacrylamide	  and	  biotin)	   6SU-­‐Sia	  Lex-­‐PAA	   Lectinity	  Holdings,	  Moscow,	  Russia	   0020-­‐BP	  Oseltamivir	  carboxylate	   -­‐	   Kind	  gift	  from	  Roche,	  Welwyn	  Garden	  City,	  UK	   -­‐	  Zanamivir	   -­‐	   Kind	  gift	  from	  GSK,	  Stevenage,	  UK	   -­‐	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2.1.6 Bacterial	  media	  
L-­‐broth:	  1%	  (w/v)	  Bacto	  Tryptone	  0.5%	  (w/v)	  Yeast	  Extract	  1%	  (w/v)	  NaCl	  	  
L-­‐agar:	  L-­‐broth	  +	  1.5%	  (w/v)	  agar	  	  
SOC:	   2%	  (w/v)	  Bacto	  Tryptone	  0.5%	  (w/v)	  Yeast	  Extract	  10	  mM	  NaCl	  2.5	  mM	  KCl	  10	  mM	  MgCl2	  10	  mM	  MgSO4	  20	  mM	  Glucose	  
2.1.7 Buffers	  
PBS-­‐A:	  12	  mM	  NaH2PO4/Na2HPO4	  pH	  7.4	  172	  mM	  NaCl	  3.4	  mM	  KCl	  
2.1.7.1 Electrophoresis	  buffers	  
50	  x	  TAE:	  2	  M	  Tris-­‐base	  pH	  8.3	  (pH	  adjusted	  using	  glacial	  acetic	  acid)	  0.05	  M	  EDTA	  	  
10	  x	  SDS	  Running	  Buffer:	  250	  mM	  Tris-­‐base	  1.92	  M	  Glycine	  1%	  (w/v)	  SDS	  Adjusted	  to	  pH	  8.3	  with	  HCl	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5x	  SDS	  loading	  buffer:	  	   0.2	  M	  Tris-­‐HCl	  (pH	  7.4)	  	   20%	  Glycerol	  	   10%	  SDS	  	   0.1%	  Bromophenol	  Blue	  	   2	  M	  β-­‐Mercapto-­‐ethanol	  (in	  reducing	  buffer	  only)	  
2.1.7.2 Buffer	  for	  making	  competent	  cells	  
TB	  Buffer:	  10mM	  HEPES	  15mM	  CaCl2	  250mM	  KCl	  55mM	  MnCl2	  Adjusted	  to	  pH	  6.7	  with	  KOH	  
2.1.7.3 ELISA	  buffers	  
PBS-­‐Tween:	  PBS-­‐A	  0.05%	  (v/v)	  Tween-­‐80	  
	  
Block	  Buffer:	  PBS-­‐A	  2.5%	  (w/v)	  BSA	  20	  mM	  EDTA	  0.05%	  (v/v)	  Tween-­‐20	  	  
Substrate	  Solution:	  25	  mM	  citrate	  buffer	  pH	  4.5	  0.1	  mg/ml	  3,3’,5,5’	  –	  Tetramethylbenzidine	  dihydrochloride	  (TMB)	  	   	   	   	   (Sigma:	  T5525)	  0.03%	  (v/v)	  H2O2	  
2.1.7.4 Protein	  purification	  buffers	  
His	  Buffer	  A:	  25	  mM	  NaH2PO4/Na2HPO4	  pH	  8.0	  300	  mM	  NaCl	  10%	  (v/v)	  Glycerol	  5	  mM	  Imidazole	  0.01%	  (w/v)	  NaN3	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His	  Buffer	  B:	  25	  mM	  NaH2PO4/Na2HPO4	  pH	  8.0	  300	  mM	  NaCl	  10%	  (v/v)	  Glycerol	  500	  mM	  Imidazole	  0.01%	  (w/v)	  NaN3	  	  
Tris-­‐Saline:	  25mM	  Tris-­‐HCl	  pH	  8.0	  150mM	  NaCl	  0.01%	  (w/v)	  NaN3	  	  
2.1.7.5 Virus	  binding	  assay	  buffers	  
HBS-­‐EP:	  10mM	  HEPES-­‐NaOH	  pH	  7.4	  150mM	  NaCl	  3mM	  EDTA	  0.005%	  (v/v)	  Tween-­‐20	  0.01%	  (w/v)	  NaN3	  	  
HBS-­‐P	  +	  CaCl2:	  10mM	  HEPES-­‐NaOH	  pH	  7.4	  150mM	  NaCl	  0.005%	  (v/v)	  Tween-­‐20	  4mM	  CaCl2	  0.01%	  (w/v)	  NaN3	  
2.1.7.6 Enzyme	  kinetics	  buffers	  
HBS-­‐P	  +	  CaCl2:	  Same	  as	  above	  (section	  2.1.7.5)	  	  




Madin-­‐Derby	   Canine	   Kidney	   (MDCK)	   ECACC,	   MDCK	   Parent	   and	   Human	  Embryonic	  Kidney	  293T	   (293T)	  cells	  were	  obtained	   from	  stocks	  held	  by	   the	  World	  Health	  Organisation	   Collaborating	   Centre	   for	   Reference	   and	  Research	   on	   Influenza,	  MRC	   National	   Institute	   for	   Medical	   Research	   (NIMR	   WHOCC),	   now	   known	   as	   the	  Francis	  Crick	   Institute	  Worldwide	   Influenza	  Centre.	  These	   cells	  were	  maintained	   in	  adherent	   cultures	   in	   Dulbecco’s	  Modified	   Eagle’s	  Medium	   (DMEM)	   (Sigma:	   D6429)	  supplemented	  with	  10%	  (v/v)	  heat	  inactivated	  (1hr	  at	  56°C)	  foetal	  calf	  serum	  (FCS)	  (Labtech:	  FCS-­‐SA/500)	  and	  antibiotics	  (Pen/Strep	  [penicillin	  100	  U/ml,	  streptomycin	  100	  µg/ml])	  (Sigma:	  P4333)	  at	  37°C,	  5%	  (v/v)	  CO2.	  	  
Sf9	  cells	  were	  obtained	  from	  stocks	  held	  by	  the	  Division	  of	  Molecular	  Structure,	  MRC	  NIMR.	  These	  cells	  were	  maintained	  in	  suspension	  culture	  in	  SF-­‐900	  II	  SFM	  (Life	  Technologies:	   10902)	   at	   densities	   ranging	   from	   5	   x	   105	   –	   1	   x	   107/ml.	   Cells	   were	  counted	  using	  Countess	  Automated	  Cell	  Counter	  (Life	  Technologies),	  according	  to	  the	  manufacturer’s	   instructions.	  Cells	  were	   incubated	  at	  28°C	  with	  shaking	  at	  150	  rpm.	  Protein	   expression	   was	   carried	   out	   by	   culturing	   the	   cells	   in	   Insect	   Xpress	   media	  (Lonza:	  12-­‐730Q)	  
2.2.2 Influenza	  virus	  propagation	  
2.2.2.1 Egg-­‐propagation	  Viruses	  were	  propagated	  in	  the	  allantoic	  cavity	  of	  11-­‐12	  day	  old	  fertilised	  hens’	  eggs.	   Eggs	   were	   infected	   with	   100	   µl	   of	   virus	   diluted	   in	   PBS-­‐A	   +	   Pen/Strep.	   Virus	  propagated	   from	   stocks	   of	   previously	   propagated	   virus	   was	   infected	   at	   a	   dilution	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ranging	   from	   10-­‐3	   –	   10-­‐6-­‐fold.	   Viruses	   propagated	   from	   a	   transfection	   supernatant	  were	  infected	  at	  dilutions	  ranging	  from	  100	  –	  10-­‐4-­‐fold.	  Eggs	  were	  incubated	  at	  34°C	  in	  a	  humidified	  incubator	  for	  a	  time	  ranging	  from	  48	  –	  72	  hrs.	  Eggs	  were	  chilled	  at	  4°C	  overnight	  and	  allantoic	  fluid	  harvested.	  	  
Allantoic	   fluid	   used	   to	   generate	   virus	   stocks	   was	   subjected	   to	   a	   low	   speed	  centrifugation	  at	  2500	  x	  g	  for	  15	  mins	  to	  remove	  debris.	  Allantoic	  fluid	  was	  then	  filter	  sterilized	  through	  a	  0.45	  µm	  syringe	  filter	  and	  stored	  in	  1	  ml	  aliquots	  at	  -­‐80°C.	  
2.2.2.2 Tissue	  culture-­‐propagation	  Confluent	  monolayers	  of	  MDCK	  cells	  were	  washed	  twice	  with	  PBS-­‐A	  to	  remove	  residual	  serum.	  Virus	  diluted	  in	  serum-­‐free	  medium	  (DMEM	  +	  Pen/Strep)	  was	  added	  to	   the	  monolayer	   in	   a	   small	   volume,	   typically	   1	  ml	   to	   every	   25	   cm2	   tissue	   culture	  surface	  area.	  Viruses	  were	  diluted	  in	  serum-­‐free	  medium	  and	  inoculated	  at	  dilutions	  ranging	  from	  10-­‐3	  –	  10-­‐6-­‐fold.	  Virus	  was	  allowed	  to	  attach	  for	  1	  hr	  in	  a	  37°C,	  5%	  CO2	  incubator.	   Inoculum	   was	   left	   on	   the	   cells	   and	   additional	   serum-­‐free	   medium	  supplemented	  with	  2.5	  µg/ml	  TPCK	  Trypsin	  (Sigma:	  T1426)	  was	  added.	  Infected	  cells	  were	  incubated	  at	  37°C,	  5%	  CO2	  for	  48	  –	  72	  hrs.	  	  
Cell	   culture	   supernatant	   used	   for	   virus	   stocks	  was	   subjected	   to	   a	   low	   speed	  centrifugation	  2500	  x	  g	  for	  15	  mins	  and	  stored	  in	  1	  ml	  aliquots	  at	  -­‐80°C.	  
2.2.3 Influenza	  virus	  purification	  
2.2.3.1 Egg-­‐propagated	  virus	  purification	  For	   purification,	   the	   allantoic	   fluid	   from	   >100	   eggs	   was	   used.	   Virus	   was	  clarified	  by	  a	   low	  speed	  centrifugation	  2500	  x	  g	   for	  15	  mins.	  Virus	  was	  pelleted	  by	  centrifugation	   at	   6400	   x	   g	   4°C	   overnight	   (Beckman	   Coulter	   F10	   6x500	   FiberLite	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rotor).	   The	   virus	   pellet	   was	   resuspended,	   homogenised	   using	   a	   glass	   Dounce	  homogeniser	   and	   placed	   briefly	   (~2	   mins)	   in	   a	   sonicating	   waterbath	   to	   ensure	   a	  homogeneous	   resuspension.	   This	   suspension	   was	   layered	   onto	   a	   15	   –	   40%	   (w/v)	  continuous	   gradient	   of	   sucrose	   in	   PBS-­‐A	   +	   0.01%	   (w/v)	   NaN3.	   Gradients	   were	  centrifuged	  at	  110	  000	  x	  g	  for	  45	  mins	  at	  4°C	  (Beckman	  Coulter	  SW32Ti	  rotor).	  The	  virus-­‐containing	  band,	  identified	  by	  visual	  inspection,	  was	  removed	  from	  the	  gradient	  and	  diluted	  in	  PBS-­‐A	  +	  0.01%	  (w/v)	  NaN3.	  Virus	  was	  pelleted	  at	  165	  000	  x	  g	   for	  60	  mins	   at	   4°C	   (Beckman	   Coulter	   SW32Ti	   rotor)	   and	   the	   pellet	  was	   resuspended	   in	   a	  small	  volume	  of	  PBS-­‐A	  +	  0.01%	  (w/v)	  NaN3,	  typically	  100	  –	  500	  µl,	  and	  stored	  at	  4°C.	  
2.2.3.2 Tissue	  culture-­‐propagated	  virus	  purification	  Cell	  supernatant	  from	  virus	  propagation	  was	  pooled	  and	  centrifuged	  twice	  at	  low	  speed	  (2500	  x	  g)	  for	  15	  mins	  to	  remove	  debris.	  Virus	  was	  then	  pelleted	  either:	  at	  6400	  x	  g	  4°C	  overnight	  (Beckman	  Coulter	  F10	  6x500	  FiberLite	  rotor)	  or	  165	  000	  x	  g	  for	  60	  mins	   at	   4°C	   (Beckman	  Coulter	   SW32ti	   rotor).	   Pellets	  were	   resuspended	   in	   a	  small	  volume	  of	  residual	  fluid,	  repelleted	  at	  160	  000	  x	  g	  for	  20	  mins	  at	  4°C	  (Beckman	  Coulter	  TLA-­‐100.3	  rotor),	  resuspended	  in	  a	  small	  volume	  of	  PBS	  +	  0.01%	  (w/v)	  NaN3,	  typically	  100	  –	  500	  µl,	  and	  stored	  at	  4°C.	  
For	  virus	  binding	  assays	  tissue	  culture-­‐propagated	  viruses	  were	  typically	  not	  purified	   further,	   as	   lack	   of	   purification	   was	   found	   not	   to	   affect	   virus	   binding	   to	  receptor	   coated	   surfaces	   and	   there	  was	   no	  measurable	   non-­‐specific	   binding	   of	   cell	  debris.	   For	  biophysical	   binding	   analyses	   virus	  was	   grown	   in	  bulk	   tissue	   culture	  ~1	  Litre	  in	  volume,	  which	  was	  typically	  the	  third	  passage	  after	  virus	  rescue.	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2.2.4 Haemagglutination	  titre	  
2.2.4.1 Preparation	  of	  blood	  Turkey	   red	   blood	   cells	   (TRBCs)	   were	   obtained	   stored	   in	   Alsever’s	   solution	  (Public	   Health	   England	   Centre	   for	   Infectious	   Disease	   Surveillance	   and	   Control,	  Colindale,	  UK).	  Blood	  was	  pelleted	  by	  centrifugation	  at	  850	  x	  g	   for	  15	  mins	  and	   the	  supernatant	  was	   removed	   by	   aspiration.	   Blood	  was	  washed	   twice	   by	   resuspending	  the	  pellet	   in	  a	   large	  excess	  of	  PBS-­‐A	  by	  gentle	   inversion	  of	   the	  tube	  and	  pelleting	  at	  850	  x	  g	  for	  15	  mins.	  The	  blood	  was	  stored	  as	  a	  pellet	  at	  4°C.	  
2.2.4.2 Titration	  method	  Haemagglutination	  titres	  were	  determined	  for	  all	  propagated	  viruses.	  50	  µl	  of	  allantoic	  fluid	  or	  tissue	  culture	  supernatant	  was	  diluted	  2-­‐fold	  across	  a	  v-­‐bottom	  96	  well	  plate	   (Greiner	  Bio	  One:	  651101)	   in	  50	  µl	  of	  PBS-­‐A.	  50	  µl	  of	  0.5%	  (v/v)	  TRBCs,	  diluted	   in	   PBS-­‐A,	   was	   added	   to	   each	   well.	   The	   plate	   was	   incubated	   at	   room	  temperature	  for	  30	  mins.	  The	  haemagglutination	  titre	  was	  taken	  to	  be	  the	  reciprocal	  of	   the	   highest	   dilution	   which	   still	   showed	   agglutination.	   Lack	   of	   agglutination	   was	  determined	  to	  be	  a	  well	  where	  the	  pellet	  of	  blood	  formed	  a	  teardrop	  shape	  when	  the	  plate	  was	  tilted.	  
2.2.4.3 Haemagglutination	  assay	  elution	  Elution	  of	  HA	  assays	  were	  measured	  by	  placing	  the	  HA	  assay	  microtitre	  plate,	  prepared	   as	   described	   in	   the	   previous	   section,	   covered	  with	   plastic	   film,	   in	   a	   37°C	  incubator	   for	  ~18	  hrs.	  The	   loss	  of	  agglutination	  was	   then	  measured	  by	  comparison	  with	  the	  haemagglutination	  assay	  prior	  to	  incubation.	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2.2.5 Influenza	  virus	  reverse	  genetics	  
Reverse	   genetics	   was	   carried	   out	   using	   an	   8	   plasmid	   system	   described	   by	  Hoffmann	  et	  al.	  (Hoffmann	  et	  al.,	  2000).	  In	  this	  method	  a	  cDNA	  of	  each	  of	  the	  8	  viral	  segments	  is	  cloned	  into	  the	  pHW2000	  plasmid	  and	  all	  8	  plasmids	  are	  co-­‐transfected	  into	  293T	  cells	  to	  generate	  virus.	  
1	   µg	   of	   each	   of	   the	   8	   plasmids,	   prepared	   in	   midiprep	   quantity	   using	   the	  QIAGEN	  Plasmid	  Plus	  Midiprep	  kit,	  used	  according	  to	  the	  manufacturer’s	  instructions	  (Qiagen:	   12945),	   were	   mixed	   together	   and	   diluted	   in	   250	   µl	   of	   Opti-­‐MEM	   (Life	  Technologies:	  31985070).	  This	  plasmid	  and	  Opti-­‐MEM	  mixture	  was	  added	  to	  10	  µl	  of	  Lipofectamine	   2000	   (Life	   Technologies:	   11668019),	   which	   had	   previously	   been	  diluted	  in	  250	  µl	  of	  Opti-­‐MEM.	  This	  mixture	  was	  incubated	  at	  room	  temperature	  for	  20	  mins.	  25	  cm2	  flasks	  of	  293T	  cells	  at	  70	  –	  90%	  confluency	  were	  washed	  twice	  with	  Opti-­‐MEM.	  The	  500	  µl	  mixture	  of	  plasmids	  and	  Lipofectamine	  were	  added	  to	  the	  flask	  of	  cells	  to	  a	  total	  volume	  of	  3	  ml	  with	  Opti-­‐MEM,	  flasks	  were	  incubated	  at	  37°C,	  5%	  CO2.	  After	  5	  –	  6	  hrs	  medium	  was	  changed	  for	  3	  ml	  of	  Opti-­‐MEM	  +	  Pen/Strep.	  Flasks	  were	  further	  incubated	  for	  24	  hrs	  before	  adding	  TPCK	  trypsin	  (Sigma:	  T1426)	  to	  the	  cell	  supernatant	  at	  a	  concentration	  of	  0.5	  µg/ml.	  After	  further	  incubation	  for	  18	  –	  24	  hrs	   the	   cell	   supernatant	  was	   harvested	   and	   clarified	   by	   a	   low	   speed	   centrifugation	  (2500	  x	  g	  for	  10	  mins).	  This	  cell	  supernatant	  was	  either	  directly	  inoculated	  into	  eggs	  or	  cell	  culture,	  or	  stored	  at	  -­‐80°C.	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2.2.6 Nucleic	  acid	  work	  
2.2.6.1 Agarose	  gel	  electrophoresis	  DNA	  samples	  were	  diluted	  in	  5	  x	  Gelpilot	  DNA	  Loading	  dye	  (QIAGEN:	  239901)	  and	  run	  on	  1%	  agarose	  (Bioline:	  BIO-­‐41027)	  gels	  were	  made	  and	  run	  using	  1	  x	  TAE	  buffer.	  A	  typical	  10	  x	  10	  cm	  gel	  was	  run	  for	  20	  -­‐	  40	  mins	  at	  120	  V	  (12	  V/cm).	  	  
2.2.6.2 DNA	  purification	  DNA	  was	  purified	  from	  solution	  using	  the	  illustra	  GFX	  PCR	  DNA	  and	  gel	  band	  purification	  kit	  (GE	  Healthcare:	  28-­‐9034-­‐71)	  as	  per	  the	  manufacturer’s	   instructions.	  DNA	  was	  eluted	  from	  the	  column	  in	  10	  –	  30	  µl	  of	  dH2O.	  
2.2.6.3 Gel	  purification	  of	  DNA	  samples	  DNA	  was	  purified	  from	  an	  agarose	  gel	  by	  excising	  the	  appropriate	  band	  using	  a	  gel	   extraction	   tool	   (Starlab:	   N2000-­‐0100)	   and	   purifying	   with	   the	   illustra	   GFX	   PCR	  DNA	   and	   gel	   band	   purification	   kit	   (GE	   Healthcare:	   28-­‐9034-­‐71)	   as	   per	   the	  manufacturer’s	  instructions.	  As	  above,	  DNA	  was	  eluted	  from	  the	  column	  in	  10	  –	  30	  µl	  of	  dH2O.	  
2.2.6.4 Determination	  of	  DNA	  concentration	  DNA	   was	   quantified	   using	   a	   Nanodrop	   2000	   spectrophotometer	   (Thermo	  Scientific)	  using	  the	  built	  in	  nucleic	  acid	  quantification	  software.	  
2.2.6.5 Oligonucleotide	  synthesis	  Oligonucleotide	   PCR	   primers	   were	   synthesised	   by	   Eurofins	   Genomics	  (Ebersberg,	  Germany).	  They	  were	  synthesised	  and	  purified	  to	  HPSF	  (High	  purity,	  Salt-­‐Free)	  standard	  and	  delivered	  in	  dH2O	  at	  a	  concentration	  of	  100	  µM.	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2.2.6.6 DNA	  sequencing	  Sanger	   DNA	   sequencing	   was	   carried	   out	   by	   GATC	   Biotech	   (Konstanz,	  Germany).	  PCR	  products	  were	  sent	  at	  a	  concentration	  of	  10	  –	  50	  ng/µl	  and	  plasmids	  at	  50	  –	  150	  ng/µl.	  Primers	  were	  either	  synthesised	  and	  held	  by	  GATC	  biotech	  or	  were	  sent	  separately	  with	  DNA	  samples	  (synthesised	  by	  Eurofins	  Genomics).	  
2.2.6.7 Sequence	  analysis	  DNA	   sequences	   were	   constructed	   from	   ABI	   trace	   files	   using	   the	   Staden	  package	  (Bonfield,	  Smith	  &	  Staden,	  1995).	  Sequences	  of	  virus	  segments	  were	  checked	  by	   visual	   inspection	   for	   mixtures	   in	   sequence	   traces.	   Assembled	   sequences	   were	  aligned	  using	  BioEdit	  (Hall,	  1999).	  
2.2.6.8 Virus	  library	  sequences	  Library	  sequences	  of	  viral	  segments	  were	  obtained	  from	  the	  Global	   Initiative	  for	  Sharing	  All	  Influenza	  Data	  (GISAID)	  Epiflu	  database	  (http://gisaid.org).	  
2.2.6.9 Competent	  cells/transformation	  Competent	   cells	   used	   for	  bacterial	  work	  were	   either	   commercial	   XL-­‐10	  Gold	  (Agilent:	  200315)	  or	  cells	  made	  chemically	  competent	  with	  the	  following	  protocols:	  
A	  3	  ml	  overnight	  pre-­‐culture	  of	  the	  desired	  strain	  was	  grown	  from	  a	  glycerol	  stock	   streaked	   on	   an	   L-­‐agar	   plate.	   Cells	   for	   typical	   transformations	   were	   grown	  without	  antibiotics,	  cells	  generated	   for	  baculovirus	  generation	  [DH10EmBacY]	  were	  grown	   in	   the	   presence	   of	   50	   µg/ml	   kanamycin	   (Sigma:	   K0254);	   30	   µg/ml	  chloramphenicol	   (Sigma:	   C0378)	   and	   10	   µg/ml	   tetracycline	   (Sigma:	   T7660).	   The	  starter	   culture	   was	   inoculated	   into	   500	   ml	   L-­‐broth	   (containing	   antibiotics	   if	  necessary).	  Cells	  were	  grown	  at	  25°C	  until	  the	  cell	  density	  gave	  A600	  of	  0.4	  –	  0.6.	  The	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culture	  was	   chilled	   on	   ice	   for	  ~15	  mins	   and	   pelleted	   at	   4000	   x	   g	   for	   15	  mins.	   The	  pellet	  was	  resuspended	   in	  100	  ml	  of	   ice-­‐cold	  TB	  buffer	  and	   incubated	  on	   ice	   for	  10	  mins.	  The	  suspension	  was	  pelleted	  at	  4000	  x	  g	   for	  15	  mins,	  resuspended	  in	  18.4	  ml	  ice-­‐cold	  TB	  buffer	  and	  1.4	  ml	  DMSO	  and	  incubated	  on	  ice	  for	  10	  mins.	  The	  cells	  were	  flash	  frozen	  in	  an	  ethanol/dry	  ice	  bath	  and	  stored	  at	  -­‐80°C	  in	  250	  µl	  aliquots.	  
Cells	   were	   transformed	   by	   the	   same	   method	   whether	   they	   were	   the	  commercial	   or	   in-­‐house	   prepared	   cells.	   Competent	   cells	   were	   thawed	   on	   ice	   and	  mixed	  by	  gentle	  pipetting.	  50	  µl	  of	  cells	  were	  transferred	  to	  a	  prechilled	  1.5	  ml	  tube.	  DNA	  was	  added	  in	  a	  volume	  of	  up	  to	  5	  µl	  to	  the	  competent	  cells,	  mixed	  and	  incubated	  on	  ice	  for	  15	  mins.	  Cells	  were	  heat-­‐shocked	  at	  42°C	  for	  1	  min.	  450	  µl	  of	  SOC	  medium	  was	  added	  and	  tubes	  were	  incubated	  at	  37°C	  with	  250	  rpm	  shaking	  for	  1	  hr. 
2.2.6.10 RNA	  extraction	  RNA	  was	  extracted	  from	  virus	  using	  the	  QIAamp	  Viral	  RNA	  Mini	  Kit	  (QIAGEN:	  52906)	  according	  to	  the	  manufacturer’s	  protocol.	  RNA	  was	  eluted	  from	  the	  column	  in	  50	  µl	  of	  dH2O	  and	  stored	  at	  -­‐20°C.	  RNA	  extraction	  was	  carried	  out	  either	  with	  140	  µl	  of	  allantoic	  fluid	  or	  cell	  culture	  supernatant	  or	  for	  a	  purified	  or	  concentrated	  virus	  the	  extraction	  was	  carried	  out	  on	  1	  µl	  of	  the	  virus	  suspension,	  diluted	  in	  140	  µl	  of	  PBS-­‐A.	  	  
2.2.6.11 RT-­‐PCR	  of	  viral	  RNA	  Amplification	   of	   viral	   RNA	   segments	   for	   sequencing	  was	   carried	   out	   using	   a	  one-­‐step	   RT-­‐PCR	   protocol	   developed	   by	   the	  NIMR	  WHOCC.	   This	   protocol	   amplifies	  each	   viral	   segment	   in	   two	   separate	   overlapping	   parts,	   to	   allow	   segment	   specific	  amplification,	   as	   there	   is	   considerable	   sequence	   homology	   between	   the	   non-­‐coding	  regions	  at	  the	  end	  of	  different	  segments	  (see	  section	  2.1.3	  for	  primer	  sequences).	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50	  µl	  PCR	  reactions	  contained	  the	  following	  components:	  1.5	  x	  Pfx	  buffer	  (Life	  Technologies),	  1	  mM	  MgSO4,	  0.5	  mM	  of	  each	  of	  the	  dNTPs,	  0.3	  µM	  forward	  primer,	  0.3	  µM	  reverse	  primer,	  200	  U	  Superscript	  III	  RT	  (Life	  Technologies,	  18080-­‐085),	  1.25	  U	  Platinum	  Pfx	  polymerase	  (Life	  Technologies,	  11708-­‐039),	  2	  µl	  of	  extracted	  RNA.	  	  
RT-­‐PCR	  cycling	  conditions	  were:	  50°C:	  30	  mins,	  94°C:	  10	  mins,	  40x	  (94°C:	  30	  s,	  55°C:	  30	  s,	  68°C:	  3	  mins),	  68°C:	  10	  mins,	  4°C	  hold.	  
2.2.6.12 Cloning	  
2.2.6.12.1 Cloning	  for	  reverse	  genetics	  Reverse	  genetics	  was	  carried	  out	  by	  cloning	  the	  HA	  and	  NA	  gene	  segments	  for	  the	  virus	  into	  the	  pHW2000	  vector.	  Gene	  amplification	  was	  carried	  out	  with	  two-­‐step	  RT-­‐PCR,	  with	  the	  majority	  of	  genes	  amplified	  in	  a	  single	  reaction.	  	  
The	  cDNA	  synthesis	  step	  generated	  cDNAs	  for	  all	  of	   the	  viral	  segments	  using	  the	   Influenza	   A	   universal	   primer	   uni12	   (see	   section	   2.1.3.1	   for	   sequence).	   cDNA	  synthesis	  was	  carried	  out	  using	  the	  Verso	  cDNA	  synthesis	  kit	  (Thermo:	  AB-­‐1453).	  The	  reaction	  mixture	  was	  made	  as	  per	  the	  manufacturer’s	  recommendations.	  The	  cycling	  conditions	  were:	  42°C	  for	  30	  mins	  followed	  by	  95°C	  for	  5	  mins.	  	  
Following	   cDNA	   synthesis	   PCR	   amplification	   was	   carried	   out	   using	   the	  following	  reaction	  mixture:	  1.5	  x	  Pfx	  buffer	  (Life	  Technologies),	  1	  mM	  MgSO4,	  0.5	  mM	  of	  each	  of	  the	  dNTPs,	  0.3	  µM	  forward	  primer,	  0.3	  µM	  reverse	  primer,	  1.25	  U	  Platinum	  Pfx	  polymerase	  (Life	  Technologies,	  11708-­‐039),	  2	  µl	  of	  generated	  cDNA.	  PCR	  cycling	  conditions	  were:	  94°C:	  10	  mins,	  40x	  (94°C:	  30	  s,	  55°C:	  30	  s,	  68°C:	  4	  mins),	  68°C:	  10	  mins,	  4°C	  hold.	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The	  majority	   of	   cloned	  HA	   and	  NA	   genes	  were	   amplified	   using	   a	   single	   PCR	  amplification,	  see	  section	  2.1.3.1	  for	  sequences	  of	  primers	  used.	  The	  primers	  amplify	  the	  full-­‐length	  gene	  segment	  including	  non-­‐coding	  regions	  whilst	  adding	  sites	  for	  the	  restriction	   enzymes	   BsmBI	   or	   AarI.	   Gene	   sequences	   were	   first	   analysed	   using	  RestrictionMapper	   (http://www.restrictionmapper.org/)	   to	   check	   for	   internal	  restriction	  sites	  and	  the	  primers	  used	  were	  chosen	  accordingly.	  HA	  amplification	  was	  typically	  inefficient	  owing	  to	  a	  similarity	  in	  primer	  sequence	  to	  the	  primers	  used	  for	  NS	  cloning	  and	  so	   two	  50	  µl	  reactions	  were	  carried	  out	   for	  HA	  amplification,	  which	  were	  then	  pooled	  at	  a	  later	  stage.	  	  A/California/7/2009	  HA	  could	  not	  be	  amplified	  in	  a	   single	   PCR	   reaction	   and	   so	   a	   splicing	   PCR	   was	   carried	   out,	   where	   the	   gene	   was	  amplified	   in	   two	  separate	  overlapping	  sections	  and	  assembled.	  The	  HA	  was	   initially	  amplified	  using	  two	  pairs	  of	  primers:	  for	  the	  5’	  section	  HAFUc	  and	  HAR873;	  and	  for	  the	  3’	  section	  HAF848	  and	  HARUc	  (see	  section	  2.1.3.1	  for	  primer	  sequences)	  using	  the	  same	  PCR	  conditions	  as	  listed	  above.	  The	  two	  PCR	  products	  were	  purified	  by	  agarose	  gel	  electrophoresis	  and	  a	  second	  PCR	  was	  set	  up	  with	  all	  of	   the	  components	  except	  the	  primers	   and	  using	  50	  ng	  of	   each	  product	   from	   the	  previous	  PCRs	  as	   templates.	  The	   PCR	  was	   carried	   out	   for	   20	   cycles	   as	   detailed	   above.	   The	   primers	   HAFUc	   and	  HARUc	  were	  then	  added	  to	  the	  mixture	  at	  the	  usual	  concentrations	  (0.3	  µM	  of	  each)	  and	   the	   PCR	   was	   carried	   out	   for	   a	   further	   20	   cycles.	   The	   full	   length	   product	   was	  purified	   and	   used	   as	   template	   for	   a	   PCR	   using	   the	   typical	   HA	   cloning	   primers,	   as	  detailed	  above.	  
After	  PCR	   amplification	   the	  products	  were	   run	  on	   an	   agarose	   gel	   to	   confirm	  that	  the	  correct	  sized	  product	  was	  produced	  (~1800	  bp	  for	  HA	  and	  ~1400	  bp	  for	  NA).	  When	  the	  correct	  band	  was	  seen	  the	  remainder	  of	  the	  50	  µl	  reaction	  was	  gel	  purified.	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The	  pHW2000	  vector	  was	  cut	  using	  the	  enzyme	  BsmBI	  (NEB:	  R0580).	  Inserts	  were	   cut	   using	   either	   BsmBI	   or	   AarI	   (Thermo:	   ER1582)	   depending	   on	   the	   primers	  used	  for	  amplification.	  Up	  to	  2	  µg	  of	  DNA	  was	  cut	  in	  a	  50	  µl	  reaction	  according	  to	  the	  manufacturer’s	   instructions.	  BsmBI	   reactions	  were	   incubated	  at	  55°C	   for	  1	  hr;	  AarI	  reactions	  were	  incubated	  at	  37°C	  for	  1	  hr.	  Digested	  pHW2000	  was	  dephosphorylated	  using	   Antarctic	   Phosphatase	   (NEB:	   M0289)	   according	   to	   the	   manufacturer’s	  instructions.	   The	   cut	   DNA	   was	   then	   purified,	   as	   described	   in	   section	   2.2.6.2,	   and	  eluted	  in	  20	  µl	  of	  dH2O.	  
Ligation	  was	  carried	  out	  using	  T4	  DNA	  ligase	  (NEB:	  M0202).	  20	  µl	  Reactions	  contained:	  1	  µl	  of	  T4	  DNA	  ligase	  (400	  U),	  2	  µl	  of	  10	  x	  T4	  DNA	  ligase	  buffer	  plus	  vector	  and	  insert	  at	  a	  molar	  ratio	  of	  1:5	  (vector:insert).	  The	  reaction	  was	  mixed	  and	  left	  for	  30	  mins	   at	   room	   temperature.	   A	   no	   insert	   control	   ligation	  was	   also	   carried	   out	   to	  assess	  the	  efficiency	  of	  ligation.	  
4	  µl	   of	   ligation	  mixtures	  was	   transformed	   into	   competent	  bacterial	   cells	   and	  spread	   on	   L-­‐agar	   plates	   containing	   100	   µg/ml	   ampicillin	   (Sigma:	   A9393).	   Colonies	  were	  picked	  from	  each	  ligation	  and	  cultured	  in	  5	  ml	  of	  L-­‐broth	  containing	  100	  µg/ml	  ampicillin.	   The	   plasmid	   DNA	   was	   prepared	   using	   the	   QIAprep	   Spin	   Miniprep	   Kit	  (Qiagen:	   27106).	   Prepared	   plasmids	   were	   run	   on	   an	   agarose	   gel	   alongside	   empty	  vector	  as	  well	  as	  a	  previously	  cloned	  HA	  or	  NA	  in	  pHW2000	  and	  a	  Supercoiled	  DNA	  Ladder	   (NEB:	   N0472).	   This	   gel	   allowed	   the	   selection	   of	   clones	   that	   contained	   an	  insert	   of	   the	   correct	   size.	   2	   –	   4	   clones	   with	   the	   correct	   insert	   size	   were	   then	  sequenced.	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2.2.6.12.2 Cloning	  for	  protein	  expression	  
Cloning	  of	  H1N1	  HA	  Genes	   encoding	   the	   ectodomain	   of	   the	   HA	   of	   Cal7	   and	   Iowa06	   were	  synthesised	   by	   GeneArt	   (Life	   Technologies).	   A	   construct	   was	   synthesised	   that	  encoded	   a	   protein	   that	   lacked	   the	   17	   residue	   signal	   peptide	   and	  was	   truncated	   to	  residue	  502	  (H1	  Numbering)	  to	  remove	  the	  transmembrane	  domain.	  Two	  restriction	  sites	  were	  added	  to	  the	  ends	  of	  the	  construct,	  BamHI	  at	  the	  N	  terminal	  and	  NotI	  at	  the	  C	   terminal,	   to	   allow	   subcloning	   into	   the	   pHAEM1	   vector,	   a	  modified	   version	   of	   the	  pAcGP67-­‐A	  vector	  (BD	  Biosciences).	  This	  vector	  had	  been	  engineered	  to	  contain	  an	  N-­‐terminal	   gp67	   signal	  peptide	   to	   allow	  expression	  by	   secretion	  by	  Sf9	   cells	   and	  a	  C-­‐terminal	  protein	  purification	  tag	  containing	  a	  TEV	  protease	  cleavage	  site,	  T4	  fibritin	  trimerisation	  motif	  (foldon)	  and	  a	  6x	  His	  tag.	  The	  sequences	  of	  the	  H1	  HA	  constructs	  are	  shown	  in	  the	  Appendix.	  These	  genes	  were	  codon	  optimised	  for	  insect	  cells	  using	  GeneArt	  software	  prior	  to	  synthesis.	  	  
The	   synthesised	   genes	   were	   delivered	   in	   a	   carrier	   vector,	   which	   was	  transformed	  and	  purified	  in	  miniprep	  quantities.	  6	  µg	  of	  this	  gene	  containing	  vector	  and	  the	  destination	  vector	  pHAEM1	  was	  digested	  with	  BamHI-­‐HF	  (NEB:	  R3136S)	  and	  also	   NotI-­‐HF	   (NEB:	   R3189)	   in	   100	   µl	   reactions	   according	   to	   the	   manufacturer’s	  recommendations.	   Digested	   pHAEM1	   was	   dephosphorylated	   using	   Antarctic	  Phosphatase	   (NEB:	   M0289)	   according	   to	   the	  manufacturer’s	   instructions.	   Both	   the	  desired	  insert	  and	  the	  pHAEM1	  vector	  were	  purified	  by	  agarose	  gel	  electrophoresis.	  100	  ng	   of	   cut	   pHAEM1	  was	   added	   to	   75	  ng	   of	   insert,	   (giving	   a	  molar	   ratio	   of	  ~1:5	  vector:insert)	   in	   a	   20	   µl	   ligation	  mixture,	   including	   2	   µl	   10x	   T4	   DNA	   ligase	   buffer	  (NEB)	  and	  1	  µl	  T4	  DNA	  Ligase	  (400	  U)(NEB:	  M0202).	  The	  reaction	  was	  carried	  out	  at	  room	   temperature	   for	   30	  mins.	  A	  no	   insert	   control	   ligation	  was	   also	   carried	   out	   to	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assess	   the	   efficiency	   of	   ligation.	   This	   ligation	   was	   transformed	   into	   competent	  bacteria	  and	  plated	  on	  L-­‐agar	  plates	  containing	  100	  µg/ml	  ampicillin.	  Colonies	  were	  picked,	   amplified	  and	   the	  plasmid	  DNA	  purified.	  These	  plasmids	  were	   tested	   to	   see	  that	  they	  contained	  the	  correct	  insert	  by	  agarose	  gel	  electrophoresis.	  Plasmids	  of	  the	  correct	  size	  were	  sequenced	  to	  verify	   the	  correct	   insertion	  site	  and	  sequence	  of	   the	  construct.	  
Subcloning	  H7N9	  NA	  The	  A/Anhui/1/2013	  (Anhui13)	  NA	  ectodomain	  (residues	  75	  –	  465)	  had	  been	  previously	   synthesised	   by	   Geneart	   (Life	   Technologies)	   and	   cloned	   into	   a	   modified	  version	  of	  the	  pHAEM1	  vector,	  which	  included	  an	  N	  terminal	  6	  x	  His-­‐tag,	  vasodilator-­‐stimulator	  phosphoprotein	  (VASP)	  tetramerisation	  domain	  (Kühnel	  et	  al.,	  2004;	  Xu	  et	  
al.,	  2008)	  and	  TEV	  cleavage	  site,	   for	  construct	  sequence	  see	  Appendix.	  The	  reagents	  used	  for	  the	  later	  stages	  of	  baculovirus	  expression	  using	  the	  BaculoGold	  system	  (BD	  Biosciences)	  had	  been	  discontinued;	  therefore	  the	  gene	  was	  subcloned	  into	  a	  vector,	  pFB-­‐LIC-­‐Bse,	  to	  use	  the	  Bac-­‐to-­‐Bac	  system	  (Life	  Technologies).	  	  
Anhui	   NA	   was	   subcloned	   using	   the	   In-­‐Fusion	   HD	   Cloning	   Kit	   (Clontech)	  following	   the	   manufacturer’s	   instructions.	   The	   full	   expression	   construct	   was	  amplified	   by	   PCR,	   from	   the	   previously	   cloned	   construct	   in	   the	   pAcGP67-­‐A	   vector	  using	   oligonucleotides	   designed	   using	   the	   In-­‐Fusion	   primer	   design	   tool	  (http://bioinfo.clontech.com/infusion/convertPcrPrimersInit.do)	   (for	   primer	   sequences	  see	   section	   2.1.3.2).	   4	   µl	   of	   the	   transformation	   mixture	   was	   transformed	   into	  competent	  cells	  and	  plated	  on	  L-­‐agar	  plates	  containing	  100	  µg/ml	  ampicillin.	  Colonies	  were	  picked	  and	  sequenced	  to	  check	  the	  insertion	  site	  and	  construct	  sequence.	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2.2.6.13 Mutagenesis	  
2.2.6.13.1 Point	  mutations	  Point	   mutations	   were	   introduced	   into	   plasmids	   using	   the	   Quikchange	  Lightning	   Site-­‐Directed	   Mutagenesis	   Kit	   (Agilent:	   210519)	   according	   to	   the	  manufacturer’s	   instructions.	  Mutagenesis	   oligonucleotides	  were	   designed	   using	   the	  Quikchange	   primer	   design	   software	  
(http://www.genomics.agilent.com/primerDesignProgram.jsp).	   All	   mutant	   plasmids	   were	  checked	  by	  sequencing	  to	  verify	  successful	  mutagenesis.	  
2.2.6.13.2 Large	  deletion	  mutagenesis	  Large	   deletions	  were	  made	   in	   the	   X-­‐31	  NA	   to	   generate	   truncated	  NA	   stalks.	  These	   were	   generated	   in	   the	   reverse	   genetics	   plasmid	   using	   the	   Q5	   Site-­‐Directed	  Mutagenesis	   Kit	   (NEB:	   E0554S)	   according	   to	   the	   manufacturer’s	   instructions.	  Mutagenesis	   oligonucleotides	   were	   designed	   using	   NEBaseChanger	   software	  
(http://nebasechanger.neb.com/).	   All	   mutant	   plasmids	   were	   checked	   by	   sequencing	   to	  verify	  correct	  mutagenesis.	  
2.2.7 Insect	  cell	  protein	  expression	  
Insect	   cell	   protein	   expression	   was	   carried	   out	   using	   two	   different	   systems.	  Initially	   expression	  was	   carried	   out	   using	   the	  BaculoGold	   system	   (BD	  Biosciences);	  however,	   owing	   to	   the	  discontinuation	  of	   reagents	   for	   this	   system,	   later	   expression	  was	  done	  using	  a	  system	  based	  around	  the	  Bac-­‐to-­‐Bac	  system	  (Life	  Technologies).	  	  
2.2.7.1 BaculoGold	  baculovirus	  production	  The	   desired	   protein	   expression	   constructs	   were	   cloned	   into	   the	   pHAEM1	  vector	   (as	   described	   in	   section	   2.2.6.12.2).	   The	   vector	   was	   amplified	   and	   purified	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using	  the	  Plasmid	  plus	  Midi	  kit	  (Qiagen:	  129450).	  Insect	  cells	  were	  transfected	  using	  Cellfectin	  II	  reagent	  (Life	  Technologies:	  10362-­‐100).	  Sf9	  cells	  were	  plated	  at	  a	  density	  of	  1	  x	  106	  cells/well	  in	  6-­‐well	  plates.	  5	  µg	  of	  plasmid	  was	  mixed	  with	  0.5	  µg	  (5	  µl)	  of	  BaculoGold	  Bright	  Baculovirus	  DNA	  (BD	  Biosciences:	  552846)	  and	  10	  µl	  of	  Cellfectin	  II	   diluted	   in	   SF-­‐900	   II	   SFM	   (Life	   Technologies:	   10902)	   and	   incubated	   at	   room	  temperature	   for	   20	   mins.	   DNA	   and	   Cellfectin	   mix	   was	   added	   to	   the	   cells	   and	  incubated	  at	  28°C	  for	  6	  hrs.	  Medium	  was	  changed	  for	  2	  ml	  of	  fresh	  SF-­‐900	  II	  SFM	  and	  plates	   were	   incubated	   at	   28°C	   for	   72	   –	   96	   hrs	   and	   baculovirus	   production	   was	  examined	  by	  looking	  for	  fluorescent	  cells	  using	  an	  inverted	  fluorescence	  microscope.	  Supernatant	  was	  harvested	  and	  clarified	  by	  low-­‐speed	  centrifugation	  (2500	  x	  g)	  and	  stored	  at	  4°C	  in	  the	  dark.	  
2.2.7.2 Bac-­‐to-­‐Bac	  baculovirus	  production	  Protein	   expression	   constructs	   were	   cloned	   into	   the	   pFB-­‐LIC-­‐Bse	   vector	   (as	  described	   in	   section	   2.2.6.12.2).	   0.5	   –	   1	   µg	   of	   plasmid	   was	   transformed	   into	  competent	   cells	   made	   from	   DH10EmBacY	   glycerol	   stock	   (Geneva	   Biotech)	   (see	  section	  2.2.6.9	  for	  details).	  100	  µl	  of	  competent	  cells	  were	  incubated	  with	  DNA	  on	  ice	  for	  30	  mins,	  cells	  were	  heat	  shocked	  at	  42°C	  for	  1	  min	  and	  900	  µl	  of	  SOC	  medium	  was	  added.	  Transformations	  were	  incubated	  at	  37°C	  with	  shaking	  at	  250	  rpm	  for	  4	  –	  6	  hrs.	  Dilutions	  of	   transformations	  were	  plated	  out	  on	  L-­‐agar	  plates	   containing:	  50	  µg/ml	  kanamycin	   (Sigma:	   K0254);	   30	   µg/ml	   chloramphenicol	   (Sigma:	   C0378);	   10	   µg/ml	  tetracycline	  (Sigma:	  T7660);	  7	  µg/ml	  gentamicin	  (Sigma:	  G1272);	  100	  µg/ml	  Bluogal	  (Life	  Technologies:	  15519-­‐028)	  and	  40	  µg/ml	  IPTG	  (Life	  Technologies:	  15529-­‐019).	  Plates	   were	   incubated	   at	   37°C	   for	   48	   hrs.	   Bacterial	   colonies	   that	   had	   undergone	  recombination	   of	   the	   protein	   expression	   gene	   with	   baculovirus	   DNA	   gave	   a	   white	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colony.	  White	  colonies	  were	  then	  picked	  and	  restreaked	  on	  a	  fresh	  plate	  to	  verify	  the	  white	  phenotype.	  White	  colonies	  were	  picked	  and	  grown	  in	  10	  ml	  L-­‐broth	  containing	  50	  µg/ml	  kanamycin,	  30µg/ml	  chloramphenicol,	  10	  µg/ml	   tetracycline	  and	  7	  µg/ml	  gentamicin	   and	   grown	   at	   37°C	  with	   shaking	   at	   200	   rpm	   for	  ~18	  hrs.	   The	   required	  baculovirus	  DNA	  (bacmid)	  is	  very	  large	  (>100	  kb)	  and	  it	  was	  therefore	  prepared	  by	  isopropanol	  precipitation	  rather	  than	  a	  column	  spin	  kit.	  Cells	  were	  pelleted	  at	  2500	  x	  g	  for	  10	  mins.	  Pellets	  were	  resuspended	  in	  300	  µl	  of	  15	  mM	  Tris-­‐HCl,	  pH	  8.0,	  10	  mM	  EDTA,	  100	  µg/ml	  RNase	  A.	  Cells	  were	   lysed	  by	  adding	  300	  µl	  of	  0.2	  M	  NaOH	  +	  1%	  (w/v)	   SDS.	   Lysis	  was	   incubated	   at	   room	   temperature	   for	   5	  mins.	   The	  mixture	  was	  neutralised	   with	   300	   µl	   of	   3	   M	   Potassium	   Acetate,	   pH	   5.5.	   The	   sample	   was	   then	  incubated	   on	   ice	   for	   10	  mins	   and	   then	   centrifuged	   at	   14	   000	   x	   g	   for	   10	  mins.	   The	  supernatant	  was	  added	  to	  800	  µl	  of	  isopropanol	  and	  incubated	  on	  ice	  for	  10	  mins.	  The	  sample	  was	  centrifuged	  at	  14	  000	  x	  g	  for	  15	  mins,	  the	  supernatant	  was	  removed	  and	  the	   pellet	   was	   washed	   by	   adding	   500	   µl	   of	   70%	   (v/v)	   ethanol	   followed	   by	  centrifugation	  at	  14	  000	  x	  g	  for	  5	  mins.	  The	  washing	  step	  was	  repeated	  a	  further	  time.	  The	  supernatant	  was	  removed	  and	  the	  pellet	  was	  air	  dried	  for	  ~10	  mins	  to	  remove	  residual	   ethanol.	   Finally	   the	   pellet	  was	   resuspended	   in	   50	   µl	   of	   TE	   buffer	   (10	  mM	  Tris-­‐HCl	  pH	  8.0,	  1	  mM	  EDTA)	  and	  stored	  at	  4°C.	  
Sf9	  cells	  were	  transfected	  by	  plating	  1	  x	  106	  cells/well	  in	  a	  6-­‐well	  plate.	  4	  µl	  of	  Cellfectin	  II	  reagent	  (Life	  Technologies:	  10362-­‐100)	  was	  diluted	  in	  100	  µl	  of	  SF-­‐900	  II	  SFM	  (Life	  Technologies:	  10902)	  and	  incubated	  at	  room	  temperature	  for	  5	  mins.	  5	  µg	  of	  the	  recombined	  baculovirus	  DNA	  (bacmid)	  was	  diluted	  in	  100	  µl	  of	  SF-­‐900	  II	  SFM	  and	  added	  to	  the	  Cellfectin	  mixture	  and	  incubated	  at	  room	  temperature	  for	  20	  mins.	  The	  DNA/Cellfectin	  mixture	  was	  added	  to	  the	  Sf9	  cells	  and	  incubated	  at	  28°C	  for	  6	  hrs.	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Media	  was	  replaced	  with	  2	  ml	  of	  SF-­‐900	  II	  SFM	  and	  transfections	  were	  incubated	  at	  28°C	   for	   72	   –	   96	  hrs.	   Baculovirus	   production	  was	   assayed	  by	  detecting	   fluorescent	  cells	   using	   an	   inverted	   fluorescence	   microscope.	   Supernatant	   was	   harvested	   and	  clarified	  by	  low-­‐speed	  centrifugation	  and	  stored	  at	  4°C	  in	  the	  dark.	  
2.2.7.3 Protein	  expression	  from	  generated	  baculovirus	  Baculovirus	  propagation	  and	  protein	  expression	  was	  carried	  out	  by	  the	  same	  protocol	   whether	   initial	   virus	   was	   generated	   using	   the	   BaculoGold	   or	   Bac-­‐to-­‐Bac	  system.	  Passage	  1	  (P1)	  of	  baculoviruses	  was	  carried	  out	  by	  inoculating	  50-­‐500	  µl	  of	  transfection	  supernatant	  into	  a	  10	  ml	  suspension	  culture	  of	  Sf9	  cells	  at	  a	  density	  of	  2	  x	  106	   cells/ml.	   This	   culture	   was	   incubated	   at	   28°C	   shaken	   at	   150	   rpm	   for	   72	   hrs.	  Passage	  2	  (P2)	  was	  initiated	  by	  inoculating	  a	  20	  ml	  suspension	  culture	  of	  Sf9	  cells	  (2	  x	  106	  cells/ml)	  with	  50	  –	  500	  µl	  of	  P1.	  The	  aim	  was	  for	  all	  cells	  to	  be	  fluorescent	  72	  hrs	  after	  infection.	  P2	  virus	  was	  clarified	  by	  low	  speed	  centrifugation,	  filtered	  through	  a	  0.2	  µm	  syringe	  filter,	  supplemented	  with	  FCS	  to	  a	  final	  concentration	  of	  2%	  (v/v)	  and	  stored	  at	  4°C	  in	  the	  dark.	  
Large/Medium	   scale	   protein	   expression	   was	   carried	   out	   by	   infecting	   2	   –	   3	  litres	  of	  Sf9	  cells	  grown	  in	  Insect	  Xpress	  media	  (Lonza:	  12-­‐730Q)	  at	  a	  density	  ranging	  from	   3	   x	   106	   –	   4	   x	   106	   cells/ml	  with	   sufficient	   of	   the	   P2	   stock	   virus	   to	   allow	   total	  infection	  of	  the	  cells	  in	  the	  first	  virus	  replication	  cycle	  (all	  cells	  fluorescent	  by	  48	  hrs),	  typically	  0.5	   –	  2	  ml	  per	  500	  ml	   culture.	  Expression	  was	   carried	  out	   in	  2	   litre	   roller	  bottles,	  each	  containing	  500	  ml	  of	  cells,	  at	  28°C,	  with	  shaking	  at	  200	  rpm	  for	  72	  hrs.	  The	  culture	  was	  harvested	  and	  cell	  debris	  was	  removed	  by	  centrifugation	  at	  4000	  x	  g	  for	  20	  mins.	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2.2.8 Protein	  work	  
2.2.8.1 SDS-­‐PAGE	  SDS-­‐PAGE	  was	   carried	  out	  using	  4	   –	  20%	  Mini-­‐PROTEAN	  TGX	   (Biorad:	  456-­‐1093)	   precast	   gels.	   Samples	   were	   diluted	   in	   5	   x	   SDS	   loading	   buffer,	   under	   either	  reducing	  or	  non-­‐reducing	  conditions,	  and	  heated	  to	  95°C	  for	  ~5	  mins.	  Precision	  Plus	  All	  Blue	  Standards	  protein	  ladder	  (Biorad:	  161-­‐0373)	  was	  run	  as	  a	  molecular	  weight	  standard.	  Gels	  were	  run	  in	  1	  x	  SDS	  buffer	  at	  150	  V	  (~20	  V/cm)	  for	  50	  mins.	  Gels	  were	  stained	   using	   InstantBlue	   protein	   stain	   (Expedion:	   ISB1L)	   according	   to	   the	  manufacturer’s	  instructions.	  
2.2.8.2 Protein	  concentration	  determination	  Purified	  protein	  concentration	  was	  determined	  using	  a	  measurement	  of	  A280.	  Measurements	  were	  made	   using	   an	   ultra-­‐micro	   volume	   quartz	   cuvette	  with	   a	   path	  length	  of	  10	  mm	  in	  a	   Jasco	  V-­‐550	  spectrophotometer.	  A	  baseline	  measurement	  was	  made	   with	   buffer	   alone	   and	   subtracted	   from	   the	   measured	   spectrum.	   Protein	  concentrations	   were	   determined	   using	   extinction	   coefficients	   calculated	   using	   the	  Expasy	  ProtParam	  software	  (http://web.expasy.org/protparam/).	  	  
2.2.8.3 Purification	  of	  N1	  NA	  from	  purified	  virus	  
Cal7	  NA	  purification	  Proteins	  were	  digested	  from	  purified	  virus	  using	  bromelain	  (Sigma:	  B4882)	  at	  a	  1	   :	  5	  ratio	  (w/w)	  (assuming	  that	  100	  nM	  virus	  ≈	  10	  mg/ml)	  in	  the	  presence	  of	  50	  mM	  β-­‐mercaptoethanol	  for	  1hr	  at	  37°C.	  Virus	  cores	  were	  removed	  by	  centrifugation	  at	  160	  000	  x	  g	  for	  20	  mins	  at	  4°C	  (Beckman	  Coulter	  TLA-­‐100.3	  rotor).	  The	  buffer	  of	  the	  cleaved	  protein	  was	  exchanged	  into	  25	  mM	  Tris	  pH	  8.0,	  5	  mM	  NaCl,	  0.01%	  (w/v)	  NaN3	  using	  an	  Amicon	  Ultra	  –	  15	  ml	  50	  kDa	  cutoff	  filter	  (Millipore:	  UFC905024).	  The	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protein	  was	  loaded	  onto	  an	  anion	  exchange	  5	  ml	  HiTrap	  Q	  Sepharose	  FF	  column	  (GE:	  17-­‐5156-­‐01)	   using	   an	   ÄKTA	   FPLC	   system	   (GE),	   to	   remove	   contaminating	   HA.	   The	  flow	  through,	  which	  contained	  the	  NA	  was	  retained.	  Protein	  bound	  to	  the	  column	  was	  eluted	  with	  25	  mM	  Tris,	  pH	  8.0,	  1	  M	  NaCl,	  0.01%	  (w/v)	  NaN3.	  The	  flow	  through	  was	  concentrated	  to	  a	  small	  volume	  using	  an	  Amicon	  Ultra	  –	  15	  ml	  50	  kDa	  cutoff	  filter	  to	  a	  volume	  of	  ~2	  ml.	  A	  HiLoad	  Superdex	  16/600	  200	  pg	  column	  was	  equilibrated	  in	  Tris-­‐saline	  by	  washing	  through	  150	  ml	  at	  a	  flow	  rate	  of	  1.5	  ml/min	  using	  an	  ÄKTA	  FPLC	  system.	   The	   small	   volume	   of	   concentrated	   ion	   exchange	   flow	   through	   was	   loaded	  onto	  the	  gel	  filtration	  column	  using	  a	  5	  ml	  injection	  loop	  and	  the	  chromatography	  was	  carried	  out	  by	  passing	  buffer	   through	  the	  column	  at	  a	   flow	  rate	  of	  1.5	  ml/min	  for	  1	  column	  volume	  (CV)	  (120	  ml)	  collecting	  1ml	  fractions,	  while	  monitoring	  absorbance	  at	   280	   nm.	   Peak	   fractions	   were	   analysed	   by	   SDS-­‐PAGE.	   Desired	   fractions	   were	  collected,	  pooled	  and	  concentrated	  using	  an	  Amicon	  Ultra	  –	  15	  ml	  50	  kDa	  cutoff	  filter.	  The	  protein	  was	  dispensed	  into	  aliquots,	  snap	  frozen	  in	  liquid	  N2	  and	  stored	  at	  -­‐80°C.	  
Iowa06	  NA	  purification	  Proteins	  were	  detergent	  extracted	  from	  purified	  virus	  with	  2%	  (v/v)	  Brij-­‐36T	  (decaethylene	   glycol	   monododecyl	   ether)(Sigma:	   P9769)	   by	   incubating	   at	   room	  temperature	  for	  30	  mins,	  followed	  by	  centrifugation	  at	  160	  000	  x	  g	  for	  20	  mins	  at	  4°C	  (Beckman	   Coulter	   TLA-­‐100.3	   rotor)	   to	   remove	   the	   debris.	   The	   supernatant	   was	  concentrated	  using	  an	  Amicon	  Ultra	  –	  15	  ml	  50	  kDa	  cutoff	   filter	  and	  the	  buffer	  was	  exchanged	  for	  25	  mM	  Tris	  pH	  8.0,	  5	  mM	  NaCl,	  0.01%	  (w/v)	  NaN3,	  0.5%	  (v/v)	  Brij-­‐36T.	  The	   protein	   was	   loaded	   onto	   a	   5	   ml	   HiTrap	   Q	   Sepharose	   FF	   column,	   previously	  equilibrated	   in	   buffer	   (GE:	   17-­‐5156-­‐01)	   using	   an	   ÄKTA	   FPLC	   system,	   to	   remove	  contaminating	  HA.	  The	  flow	  through,	  which	  contained	  the	  NA,	  was	  concentrated	  to	  1-­‐
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2	  ml	  using	  an	  Amicon	  Ultra	  –	  15	  ml	  50	  kDa	  cutoff	  filter.	  The	  concentrated	  protein	  was	  loaded	  onto	  a	  HiLoad	  Superdex	  16/600	  200	  pg	  column	  equilibrated	   in	  Tris-­‐saline	  +	  0.5%	   (v/v)	   Brij-­‐36T.	   Peak	   fractions	   were	   analysed	   by	   SDS-­‐PAGE	   and	   fractions	  containing	  NA	  were	  pooled	  and	  concentrated	  using	  an	  Amicon	  Ultra	  –	  15	  ml	  50	  kDa	  cutoff	   filter.	  NA	  rosettes	  were	  made	  by	  adding	  a	  ratio	  of	  1:4	  (v/v)	  of	  Biobeads	  SM-­‐2	  Adsorbent	  (Biorad:	  152-­‐3920)	  to	  the	  protein	  solution.	  	  
2.2.8.4 Purification	  of	  insect	  cell	  expressed	  proteins	  Baculovirus	   expression	   supernatants	   were	   concentrated	   by	   the	   NIMR	   large-­‐scale	   lab	  using	   a	  Quixstand	  hollow	   fiber	   filtration	  unit	   (GE)	  using	   a	   filter	  with	   a	  10	  kDa	  cutoff.	  This	   concentrated	   the	  expresed	  proteins	   into	  a	  volume	  of	  ~100	  ml.	  The	  concentrated	   protein	   solution	  was	   supplemented	  with	   cOmplete	   protease	   inhibitor	  tablets,	   EDTA-­‐free	   (Roche:	   04693132001)	   and	   stored	   at	   4°C.	   Concentrated	   buffer	  components	   were	   added	   to	   the	   solution	   to	   give	   final	   concentrations	   of:	   25	   mM	  phosphate	   pH	   8.0,	   300	   mM	   NaCl,	   5	   mM	   Imidazole.	   Debris	   was	   removed	   by	  centrifugation	  at	  44	  000	  x	  g	  for	  30	  mins	  (Beckman-­‐Coulter	  JA-­‐25.50	  rotor).	  Four	  5	  ml	  HisTALON	   superflow	   cartridges	   (Clontech:	   635682)	   were	   connected	   in	   series	   and	  washed	  in	  five	  column	  volumes	  (CV)	  of	  His	  Buffer	  B.	  Columns	  were	  then	  equlibrated	  with	   five	   CV	   of	   His	   Buffer	   A.	   Concentrated	   protein	   supernatant	   was	   loaded	   and	  recirculated	  through	  the	  columns	  for	  ~2	  hrs	  using	  a	  peristaltic	  pump	  at	  a	  flow	  rate	  of	  ~5	  ml/min.	  The	  column	  was	  attached	  to	  an	  ÄKTA	  FPLC	  system	  and	  the	  protein	  was	  eluted	   using	   the	   following	   protocol:	   the	   column	   was	   washed	   with	   15	   x	   CV	   of	   His	  buffer	  A;	  protein	  eluted	  with	  10	  x	  CV	  of	  a	  0	  –	  100%	  gradient	  (100%	  His	  buffer	  A	  to	  100%	  His	  buffer	  B,	  5	  –	  500	  mM	  imidazole)	  all	  at	  a	  flow	  rate	  of	  5	  ml/min,	  collecting	  10	  ml	  fractions.	  Small	  volumes	  of	  elution	  fractions	  were	  analysed	  by	  SDS-­‐PAGE	  to	  verify	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the	  presence	  of	  recombinant	  protein.	  Recombinant	  protein	  fractions	  were	  pooled	  and	  concentrated	   using	   an	   Amicon	   Ultra	   –	   15	   ml	   50	   kDa	   cutoff	   filter	   (Millipore:	  UFC905024)	   and	   buffer	   was	   exchanged	   using	   the	   same	   filter	   into	   Tris-­‐saline	   by	  repeated	  washing	  with	  Tris-­‐saline.	  
Proteins	  were	   further	  purified	  by	   size	  exclusion	  chromatography.	  The	  buffer	  exchange	  step	  after	  HisTALON	  purification	  was	  also	  used	  to	  concentrate	  the	  protein	  to	  a	  volume	  of	  1	  –	  3	  ml.	  A	  HiLoad	  Superdex	  16/600	  200	  pg	  column	  was	  equilibrated	  in	  Tris-­‐saline	  by	  washing	  through	  150	  ml	  at	  a	  flow	  rate	  of	  1.5	  ml/min	  using	  an	  ÄKTA	  FPLC	  system.	  The	  small	  volume	  of	  concentrated	  sample	  was	  loaded	  onto	  the	  column	  using	   a	   5	   ml	   injection	   loop	   and	   the	   gel	   filtration	   was	   carried	   out	   by	   washing	   the	  column	  with	  Tris-­‐saline	  at	  a	  flow	  rate	  of	  1.5	  ml/min	  for	  1	  CV	  (120	  ml),	  collecting	  1.5	  ml	   fractions.	  Peak	   fractions	  were	  analysed	  by	  SDS-­‐PAGE	  and	  desired	   fractions	  were	  pooled	  and	  concentrated	  using	  an	  Amicon	  Ultra	  –	  15	  ml	  50	  kDa	  cutoff	  filter.	  
All	   purification	   of	   insect	   cell	   expressed	   proteins	   was	   carried	   out	   at	   room	  temperature.	  	  
2.2.8.5 Magnetic	  bead	  red	  blood	  cell	  pull	  down	  100	   μl	   of	   His-­‐tag	   Isolation	   Dynabeads	   (Life	   Technologies:	   10103D)	   were	  washed	   3	   x	   in	   200	   μl	   of	   HBS-­‐P	   +	   CaCl2	   by	   pulling	   down	   the	   beads	  with	   a	  magnet,	  removing	   the	   supernatant	   and	   resuspending	   the	   beads	   in	   fresh	   buffer.	   The	   beads	  were	   resuspended	   in	   100	   μl	   of	   fresh	   buffer.	   50	   μl	   of	   10	   μM	   (monomeric	  concentration)	  purified	  NA	  was	  added,	  mixed	  and	  incubated	  at	  room	  temperature	  for	  30	  mins.	  The	  beads	  were	  washed	  3	  x	  with	  200	  μl	  of	  HBS-­‐P	  +	  CaCl2	  and	  resuspended	  in	  100	  μl	  HBS-­‐P	  +	  CaCl2.	  3	  μl	  of	  coated	  beads	  were	  added	  to	  100	  μl	  of	  0.5%	  (v/v)	  TRBCs	  suspended	  in	  HBS-­‐P	  +	  CaCl2	   in	  a	  v-­‐bottom	  96	  well	  plate	  (Greiner	  Bio	  One:	  651101),	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washed	  as	  described	   in	   section	  2.2.4.1.	   Some	  experiments	  were	  supplemented	  with	  100	  μM	  oseltamivir	  carboxylate.	  The	  TRBC	  and	  bead	  mixture	  was	  incubated	  at	  room	  temperature	  for	  15	  mins,	  mixed	  thoroughly	  and	  the	  beads	  pulled	  down	  with	  a	  magnet.	  The	  supernatant	  was	  removed	  and	  transferred	  to	  another	  v-­‐bottom	  96	  well	  plate	  and	  allowed	  to	  settle.	  Control	  experiments	  were	  carried	  out	  with	  no	  protein	  attached	  to	  the	  beads	  (a	  ‘no	  protein’	  control),	  and	  a	  well	  where	  blood	  was	  allowed	  to	  settle	  in	  the	  absence	  of	  a	  magnetic	  bead	  pull	  down	  (a	  ‘no	  bead’	  control).	  For	  quantitation	  of	  blood	  remaining	   in	   the	   supernatant	   the	  blood	  was	   lysed	  by	   the	   addition	   of	   SDS	   to	   a	   final	  concentration	  of	  0.5%	  (w/v)	  (Sigma:	  L3771).	  Debris	  was	  removed	  by	  centrifugation	  at	  3000	  x	  g	   for	  15	  mins.	   Supernatant	  was	   removed	  and	   the	  absorbance	  of	   released	  haemoglobin	  measured	  at	  540	  nm	  using	  a	  Biotek	  synergy	  2	  plate	  reader.	  Absorbance	  values	  obtained	  were	  corrected	  for	  background	  absorbance	  of	  buffer	  and	  normalised	  to	   the	   no	   protein	   control	   values	   obtained.	   Data	   shown	   are	   a	   repeat	   of	   three	  independent	  experiments.	  
2.2.9 Influenza	  virus	  quantification	  
Virus	  was	  quantified	  using	   two	  different	  methods:	   SDS-­‐PAGE	  or	  ELISA.	   SDS-­‐PAGE	   quantification	   was	   used	   only	   to	   quantify	   egg-­‐propagated	   gradient-­‐purified	  viruses.	   ELISA	   quantification	  was	   used	   for	   both	   egg-­‐	   and	   tissue	   culture-­‐propagated	  viruses	  whether	  gradient-­‐purified	  or	  not.	  
2.2.9.1 SDS-­‐PAGE	  quantification	  A	  small	  volume	  of	  egg	  propagated	  virus	  (typically	  0.5	  –	  5µl)	  was	  analysed	  by	  SDS-­‐PAGE	  under	   non-­‐reducing	   conditions	   alongside	   a	   set	   of	   bovine	   serum	   albumin	  (BSA)	   standards	   made	   from	   a	   2	   mg/ml	   stock	   (Thermo:	   23209)	   under	   reducing	  conditions.	  The	  standard	  amounts	  of	  protein	  used	  were	  typically	  0.8,	  1.6,	  2.4,	  3.2	  and	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4.0	  µg	  of	  BSA.	  The	  gel	  was	  stained	  and	  scanned	  using	  an	  Epson	  Perfection	  V750	  pro	  on	   transmission	   mode.	   Gel	   bands	   were	   quantified	   using	   Image	   J	   software	  (http://imagej.nih.gov/ij).	  The	  values	  for	  quantification	  of	  the	  BSA	  were	  used	  to	  plot	  a	   standard	   curve	   of	   band	   intensity	   against	   protein	  mass	   using	  Microsoft	   Excel.	   The	  virus	  NP	  band,	  which	  typically	  runs	  at	  50	  –	  60	  kDa	  was	  quantified	  and	  the	  amount	  of	  protein	   present	   was	   determined	   from	   the	   standard	   curve	   plotted	   for	   BSA.	   This	  amount	   of	   protein	   was	   then	   converted	   into	   a	   molar	   quantity,	   using	   a	   molecular	  weight	   of	   NP	   of	   ~55	   kDa.	   This	   molar	   quantity	   was	   then	   converted	   to	   a	   molar	  concentration.	  The	  concentration	  of	  virus	  was	  determined	  using	  the	  assumption	  that	  a	  single	  virion	  contains	  590	  molecules	  of	  NP,	  based	  on	  a	  total	  genome	  size	  of	  13588	  nucleotides	  and	  23	  nucleotides	  bound	  per	  NP	  (Ruigrok,	  1998).	  	  
2.2.9.2 Virus	  quantification	  by	  ELISA	  Viruses	  were	  adsorbed	  to	  Immulon	  2HB	  (Thermo:	  10795026)	  plates	  in	  PBS-­‐A	  overnight	  at	  4°C.	  Each	  virus	  was	  diluted	  1	  in	  100	  in	  PBS-­‐A	  and	  then	  diluted	  in	  a	  2-­‐fold	  dilution	  series	  across	  24	  wells.	  The	  plate	  was	  blocked	  with	  200	  µl	  of	  block	  buffer	  for	  1	  hr	   at	   room	   temperature.	   The	   virus	  membranes	  were	   permeabilised	  with	   200	   µl	   of	  0.2%	  (v/v)	  Triton	  X-­‐100	   in	  PBS-­‐A	  at	   room	   temperature	   for	  30	  mins.	  The	  plate	  was	  washed	  once	  with	  PBS-­‐Tween	  and	   incubated	  with	  100	  µl	  of	  a	  1	   in	  2000	  dilution,	   in	  block	  buffer,	  of	  an	  anti-­‐influenza	  A	  NP	  mAb	  (FR-­‐51	  Mouse	  mAb,	  Anti-­‐influenza	  type	  A	  NP,	   USA	   Centers	   for	   Disease	   Control,	   Atlanta,	   GA,	   USA)	   and	   incubated	   at	   room	  temperature	   for	   1	   hr.	   The	   plate	   was	   then	   washed	   three	   times	   in	   PBS-­‐Tween	   and	  incubated	  with	  a	  1	  in	  1000	  dilution	  of	  a	  HRP-­‐conjugated	  goat	  anti-­‐mouse	  IgG	  (Biorad:	  172-­‐1011)	  in	  block	  buffer	  at	  room	  temperature	  for	  1	  hr.	  The	  plate	  was	  washed	  three	  times	   in	   PBS-­‐Tween	   and	   100	   µl	   of	   substrate	   solution	   was	   added	   and	   the	   plate	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incubated	  at	  room	  temperature	  for	  5	  mins.	  100	  µl	  of	  0.1	  M	  H2SO4	  was	  added	  to	  stop	  the	  reaction.	  The	  plate	  was	  read	  at	  450	  nm	  with	  a	  Biotek	  synergy	  2	  plate	  reader.	  The	  absorbance	  values	  for	  an	  unknown	  virus	  concentration	  were	  compared	  to	  a	  sample	  of	  a	  purified	  SDS-­‐PAGE	  quantified	  control	  virus,	  X-­‐31.	  A450	  values	  for	  X-­‐31	  were	  plotted	  against	  Log10[virus]	  using	  Graphpad	  Prism	  (GraphPad	  Software,	  San	  Diego,	  California,	  USA.).	  A	  curve	  was	  fitted	  using	  the	  sigmoidal	  dose-­‐response	  (variable	  slope)	  function.	  Two	  absorbance	  values	  of	  each	  virus	  with	  unknown	  concentrations	  were	  chosen	  from	  the	  linear	  section	  of	  the	  sigmoidal	  values	  generated.	  These	  values	  were	  converted	  to	  a	  Log10[virus]	  value	  by	  interpolation,	  using	  the	  X-­‐31	  standard	  curve.	  These	  values	  were	  converted	   back	   to	   a	   virus	   concentration,	   corrected	   for	   dilution	   and	   averaged	   to	  determine	  the	  virus	  concentration.	  	  
2.2.10 Biolayer	  interferometry	  influenza	  virus	  binding	  assays	  
Virus	   binding	   assays	   were	   carried	   out	   using	   an	   Octet	   RED	   system	   (Pall	  ForteBio	  Corp.,	  Menlo	  Park,	  CA,	  USA).	  Binding	  was	  measured	  to	  receptor	  analogues,	  which	   consisted	   of	   trisaccharide	   sugar	   moieties	   attached	   to	   a	   biotinylated	  polyacrylamide	   backbone	   (Lectinity	   Holdings,	   Moscow,	   Russia).	   These	   receptor	  analogues	   consisted	   of	   20%	   mol	   sugar	   and	   5%	   mol	   biotin.	   A	   number	   of	   different	  receptor	   analogues	   were	   used,	   listed	   in	   section	   2.1.5.	   Receptor	   analogue	  sialoglycopolymers	  were	  resuspended	  in	  HBS-­‐EP	  at	  a	  concentration	  of	  0.5	  mg/ml	  and	  stored	  at	  -­‐20°C.	  Working	  stocks	  were	  diluted	  to	  10	  µg/ml	  in	  HBS-­‐EP	  and	  stored	  at	  4°C.	  
2.2.10.1 Equilibrium	  binding	  assays	  The	   purpose	   of	   the	   equilibrium	   binding	   assays	   is	   to	   generate	   data	   giving	  information	   on	   the	   relative	   avidity	   of	   the	   virus	   for	   particular	   receptor	   analogues.	  Virus	   equilibrium	   binding	  was	   carried	   out	   by	  measuring	   the	   binding	   of	   a	   constant	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concentration	   of	   virus	   to	   a	   range	   of	   different	   immobilisation	   densities	   of	   receptor	  analogues	   loaded	   onto	   streptavidin-­‐coated	   biosensors	   (Pall	   ForteBio	   Corp.,	   Menlo	  Park,	   CA,	   USA).	   Receptor	   analogues	   were	   typically	   loaded	   to	   8	   biosensors	  simultaneously	   at	   concentrations	   starting	   at	   0.5	   µg/ml,	   serially	   diluted	   1.75-­‐fold	  across	   the	   8	  wells.	   The	   level	   of	   sugar	   loading	  was	   altered	   by	   changing	   the	   time	   of	  association	  to	  suit	  the	  avidity	  of	  the	  particular	  virus	  being	  studied	  (180	  –	  600	  s).	  All	  experiments	  were	  carried	  out	   in	  HBS-­‐EP.	  Virus	  was	  diluted	   to	  100	  pM	   in	  HBS-­‐EP	  +	  100	   µM	   each	   of	   oseltamivir	   carboxylate	   (Roche,	   Welwyn	   Garden	   City,	   U.K.)	   and	  zanamivir	  (GSK,	  Stevenage,	  U.K.)	  to	  prevent	  the	  cleavage	  of	  receptor	  analogues	  by	  the	  viral	  NA. A	  typical	  experiment	  for	  measuring	  virus	  avidity	  was:	  240	  s	  baseline	  in	  HBS-­‐EP,	  180	  –	  600	  s	  sugar	  loading,	  240	  s	  baseline	  in	  HBS-­‐EP,	  1800	  s	  association	  in	  virus,	  600	   s	   dissociation	   in	   HBS-­‐EP.	   Experiments	   were	   repeated	   at	   least	   twice	   for	   each	  virus-­‐receptor	  combination.	  
Raw	   data	   of	   the	   experiments	   were	   extracted	   using	   the	   ForteBio	   Analysis	  package	   and	   the	   data	  were	   fitted	   using	   in-­‐house	   software	   packages	  written	   by	   Dr.	  Stephen	  Martin	  (Francis	  Crick	  Institute,	  Mill	  Hill	  Laboratory).	  The	  amplitude	  of	  sugar	  loading	  was	  determined	  by	  measuring	   an	   average	  value	  of	   the	   last	  30	   s	   of	   the	   first	  baseline	  and	  subtracting	  it	   from	  an	  averaged	  number	  for	  the	  last	  30	  s	  of	  the	  second	  baseline.	  The	  association	  phase	   for	  virus	  binding	  was	   fitted	   to	  a	  double	  exponential	  function	   using	   non-­‐linear	   least-­‐squares	   methods	   to	   determine	   the	   offset,	   or	  extrapolated	  plateau	  value,	  and	  hence	  the	  amplitude	  for	  the	  curve.	  	  
The	   amplitude	   values	   were	   plotted	   as	   a	   function	   of	   sugar	   loading	   using	  Graphpad	  Prism	  (GraphPad	  Software,	  San	  Diego,	  California,	  USA.).	  A	  curve	  was	  fitted	  using	  the	  sigmoidal	  dose	  response	  (variable	  slope)	   function.	  Amplitude	  values	  were	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converted	  to	  fractional	  saturation	  values	  by	  normalising	  the	  data,	  between	  the	  best	  fit	  values	   determined	   for	   Bottom	   and	   Top	   plateau,	   to	   values	   between	   0	   and	   1.	   The	  normalised	  data	  were	  then	  fitted	  to	  a	  modified	  version	  of	  the	  Hill	  equation	  (Equation	  2.1)	  using	  the	  custom	  non-­‐linear	  least	  squares	  curve	  fitting	  programme	  in	  Graphpad	  Prism:	  
	   (2.1)	  
(Where	  f	  =	  fractional	  saturation,	  RSL	  =	  Relative	  sugar	  loading,	  RSL0.5	  =	  Relative	  sugar	  loading	  value	  where	  f	  =	  0.5,	  n	  =	  a	  Hill	  coefficient).	  
These	   f	   values	   can	   be	   converted	   to	   apparent	   affinities	   for	   virus	   binding	  (Kd(Virus))	  using	  Equation	  2.2:	  
Kd (Virus) =
[Virus](1− f )
f 	   	  	   	   	  	  	  	  	   	  	  	  	  	  	  	  (2.2)	  
Inspection	   of	   data	   obtained	   for	  more	   than	   ten	   different	   viruses	   showed	   that	  the	   ratio	   of	   the	   apparent	   affinities	   for	   any	   two	   receptor	   analogues	   (typically	   3SLN-­‐PAA	   and	   6SLN-­‐PAA)	   is	   given	   to	   a	   good	   approximation	   by	   Equation	   2.3	   (Stephen	  Martin,	  personal	  communication):	  











4.5 	   	   	  	  	  	  (2.3)	  
This	   equation	  with	   appropriate	  modification	   is	   also	   applicable	   in	   calculating	  the	  ratio	  of	  the	  apparent	  affinities	  for	  two	  different	  viruses	  binding	  to	  the	  same	  sugar.	  
f = RSL
n
0.5RSL n + nRSL
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2.2.10.2 Measurement	  of	  HA/NA	  balance	  Experiments	   to	  measure	  HA/NA	   balance	  were	   carried	   out	   in	  HBS-­‐P	   +	   CaCl2.	  Experiments	  were	  carried	  out	  in	  the	  presence	  and	  absence	  of	  NA	  inhibitors	  (100µM	  both	  of	  oseltamivir	  carboxylate	  and	  zanamivir).	  	  	  
A	  typical	  experiment	  consisted	  of	  the	  following	  steps:	  240	  s	  baseline	  in	  buffer;	  600	  s	   loading	  of	  0.5	  µg/ml	  6SLN-­‐PAA/3SLN-­‐PAA	  to	  give	  a	  saturated	  loading	  of	  ~0.6	  nm;	  240	  s	  baseline	  in	  buffer;	  3600	  s	  virus	  association	  in	  the	  presence	  and	  absence	  of	  inhibitors	   at	   the	   desired	   virus	   concentration	   (ranging	   from	   10	   –	   1000	   pM);	   600	   s	  dissociation	  in	  buffer.	  Association	  measurements	  in	  the	  presence	  and	  absence	  of	  NA	  inhibitors	   for	   the	   same	   virus	   were	   made	   concurrently,	   with	   a	   no	   virus	   control	   to	  correct	  for	  drift	  in	  the	  signal	  throughout	  the	  measurement.	  
Data	  for	  the	  virus	  association	  step	  were	  extracted	  as	  a	  raw	  data	  file	  using	  the	  ForteBio	  data	  analysis	  package.	  Data	  were	  recorded	  with	  5	  data	  points	  per	  second	  (5	  Hz)	  so	  consequently	  gives	  very	  large	  datasets.	  Datasets	  were	  reduced	  in	  size	  by	  taking	  every	   fifth	   value.	   Data	   were	   corrected	   for	   signal	   drift	   by	   subtracting	   the	   control	  dataset	   from	   all	   channels	  with	   virus	   binding	   data.	   These	   corrected	   data	  were	   then	  normalised	   to	   the	  extrapolated	  plateau	  point	  observed	   for	  100	  pM	  virus	  binding	   in	  the	   presence	   of	  NA	   inhibitors,	   as	   described	   in	   section	   2.2.10.1.	   	   This	   normalization	  makes	  the	  response	  values	  for	  this	  curve	  range	  between	  values	  of	  0	  and	  1,	  with	  the	  eventual	   plateau	   point	   reaching	   1	   (all	   data	   processing	   carried	   out	   using	   Microsoft	  Excel).	  
Normalised	  response	  data	  were	  plotted	  as	  a	  function	  of	  time	  using	  Graphpad	  Prism	  (GraphPad	  Software,	  San	  Diego,	  California,	  USA.).	  Curves	  were	  smoothed	  using	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the	  built	  in	  function,	  carrying	  out	  moving	  average	  Savitsky-­‐Golay	  smoothing,	  using	  5	  points	  on	  either	  side	  and	  smoothing	  with	  a	  2nd	  order	  polynomial.	  	  
Measurements	  were	  repeated	  and	  were	  found	  to	  be	  highly	  consistent.	  All	  data	  presented	  were	  representative	  runs	  of	  experiments	  which	  had	  been	  repeated	  at	  least	  twice.	  
2.2.10.3 Measurement	  of	  sugar	  depletion	  Sialic	  acid	  depletion	  of	  6SLN-­‐PAA	  and	  3SLN-­‐PAA	  was	  measured	  for	  100	  pM	  X-­‐31.	  This	  was	  done	  by	  stopping	  the	  balance	  measurements	  in	  the	  absence	  of	  drugs	  at	  a	  number	   of	   different	   time	   points:	   320	   –	   3600	   s	   for	   6SLN-­‐PAA	   and	   30	   –	   3600	   s	   for	  3SLN-­‐PAA.	   At	   these	   time	   points	   the	   sensors	  were	  moved	   directly	   into	   virus	   of	   the	  same	  concentration	  with	  NA	   inhibitors	  present.	  The	   total	   response	  of	  virus	  binding	  was	  measured	  by	  determining:	  the	  initial	  binding	  response	  value	  before	  moving	  the	  sensor	  to	  the	  virus	  +	  inhibitors	  and	  the	  extrapolated	  plateau	  point	  for	  virus	  binding	  in	  the	  presence	  of	  inhibitors.	  These	  two	  response	  values	  were	  added	  together	  and	  used	  as	   the	   total	   response	   for	   virus	   binding.	   These	   response	   values	   were	   converted	   to	  fractional	   saturation	   values	   based	   on	   previous	   virus	   avidity	   measurements	   (see	  section	  2.2.10.1).	  	  These	  fractional	  saturation	  values	  (f)	  were	  converted	  to	  values	  for	  relative	   sugar	   loading	   (RSL)	   using	   a	   rearranged	   version	   of	   Equation	   2.1	   (Equation	  2.4):	  




These	   determined	   RSL	   values	   were	   converted	   to	   a	   percentage	   of	   remaining	  sugar,	  assuming	  that	  for	  a	  saturated	  sensor	  RSL	  =	  0.6	  nm.	  Each	  data	  point	  determined	  is	  the	  mean	  of	  three	  independent	  repeats.	  Percentage	  sugar	  remaining	  was	  plotted	  as	  a	   function	  of	   time,	   showing	   the	  standard	  deviation	   from	  the	  mean	  of	   the	  repeats	  as	  error	   bars.	   A	   point	   was	   inserted	   at	   time	   =	   0	   as	   by	   definition	   100%	   of	   sugar	   will	  remain.	  A	  curve	  was	  fitted	  using	  the	  two-­‐phase	  decay	  function,	  using	  Graphpad	  Prism.	  
2.2.11 Enzyme	  kinetics	  
2.2.11.1 MUNANA	  kinetics	  All	  MUNANA	  assays	  were	  carried	  out	  using	  a	  Jasco	  FP-­‐6300	  fluorimeter,	  fitted	  with	  an	  ETC-­‐273T	  Peltier	  control	  unit,	  using	  an	  excitation	  wavelength	  of	  365	  nm	  and	  an	  emission	  wavelength	  of	  450	  nm	  (bandwidths	  5	  nm)	  at	  low	  sensitivity	  setting.	  
2.2.11.1.1 Km	  determination	  NA	   assays	   were	   carried	   out	   by	   fluorimetry	   for	   the	   small	   substrate	   2’-­‐(4-­‐Methylumbelliferyl)-­‐α-­‐D-­‐N-­‐acetylneuraminic	   acid	   (MUNANA)	   (Sigma:	   M8639).	  MUNANA	  was	  dissolved	  in	  the	  analysis	  buffer	  at	  a	  concentration	  of	  1	  mM	  and	  stored	  in	   aliquots	   at	   -­‐20°C.	   Experiments	   were	   carried	   out	   in	   disposable	   2	   ml	   cuvettes	  (Fisher:	  10368834).	  2	  ml	  of	  buffer	  warmed	   to	  assay	   temperature	  was	  added	   to	   the	  cuvette	  with	  a	  dilution	  of	  protein	  or	  purified	  virus.	  Typical	  concentrations	  were	  1	  –	  5	  pM	   virus	   and	   0.1	   –	   0.5	   nM	   purified	   NA.	   Assays	   were	   carried	   out	   in	   a	   continuous	  fashion,	   with	   increasing	   amounts	   of	   MUNANA	   added	   to	   a	   single	   cuvette	   after	  measuring	  the	  initial	  rate	  of	  reaction	  for	  ~30	  s	  at	  each	  stage.	  MUNANA	  was	  added	  at	  concentrations	  ranging	  from	  5	  –	  200	  µM.	  Data	  were	  corrected	  for	  dilution	  caused	  by	  the	  addition	  of	  further	  substrate.	  Data	  measured	  were	  in	  arbitrary	  units	  of	  dInt/min.	  These	  data	  were	  converted	  into	  µM/min	  using	  data	  relating	  fluorescence	  to	  cleaved	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MUNANA	   concentration,	   determined	   by	   measuring	   the	   fluorescence	   of	   a	   known	  concentration	  of	  fully	  cleaved	  MUNANA.	  The	  difference	  in	  fluorescence	  measured	  was	  converted	  into	  a	  correction	  factor	  for	  each	  temperature	  and	  pH	  of	  buffer	  used	  (Table	  2.1).	  These	  correction	   factors	  were	  used	  to	  convert	  values	  to	  µM/min	  values.	  These	  were	   then	   converted	   to	   an	   observed	   rate,	   when	   possible,	   by	   dividing	   by	   the	  monomeric	  concentration	  of	  NA	  present	  in	  the	  assay.	  The	  observed	  rate	  was	  plotted	  as	  a	  function	  of	  substrate	  concentration	  and	  fitted	  to	  the	  Michaelis-­‐Menten	  equation	  (Equation	  2.6)	  using	  Graphpad	  Prism	  to	  determine	  Km	  and	  kcat	  values.	  
Buffer	   Temperature	   Conversion	  factor	  (Int*/µM)	  
MES	  
25°C	   2.49	  
37°C	   2.42	  
HBS	  +	  CaCl2	  
25°C	   11.35	  
37°C	   10.89	  *Int	  =	  Fluorescence	  Intensity	  (Arbitrary	  Units)	  
Table	  2.1:	  Conversion	  factors	  for	  fluorescence	  of	  MU	  released	  from	  MUNANA.	  
	  
2.2.11.1.2 Determination	  of	  Ki	  values	  Ki	  values	   for	  NA	  substrate	   inhibition	  were	  determined	   in	  a	  continuous	  assay.	  The	  NA	  used	  must	  have	  a	  known	  Km	  value	  for	  MUNANA	  (determined	  as	  described	  in	  section	   2.2.11.1.1).	   NA	   was	   used	   at	   a	   similar	   concentration	   to	   that	   used	   for	   Km	  determination	  and	  MUNANA	  at	   a	   concentration	  of	  50	  µM.	   Initial	   reaction	   rates	   (v0)	  were	  measured,	  followed	  by	  an	  inhibited	  rate	  (vi)	  after	  the	  addition	  of	  inhibitors.	  
Ki	  values	  of	  inhibition	  by	  substrates	  6SLN	  and	  3SLN	  were	  determined	  using	  a	  100	  µl	  micro	  volume	  quartz	  fluorescence	  cuvette.	  v0	  was	  measured	  of	  a	  100	  µl	  before	  adding	  1	  –	  10	  µl	  of	  a	  74.1	  mM	  (50	  mg/ml)	  stock	  of	  monomeric	  6SLN	  or	  3SLN	  (Dextra).	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The	   inhibited	   rate	  was	  measured	   immediately,	   as	   the	   substrates	   are	   added	   at	   high	  concentration,	  consequently	  the	  binding	  of	  the	  substrate	  is	  rapid.	  
Ki	  was	   calculated	   by	   first	   correcting	   the	   vi	   value	   for	   dilution	   of	   the	   enzyme,	  followed	   by	   a	   correction	   for	   MUNANA	   dilution	   by	   addition	   of	   the	   inhibitor	   using	  Equation	  2.5:	  

















	   	   	   	   	  (2.5)	  
(Where	  [MU]	  =	  concentration	  of	  MUNANA)	  
The	  Ki	  value	  was	  determined	  using	  Equation	  2.8,	  a	  rearrangement	  of	  Equations	  2.6	  and	  2.7:	  
v0 =
Vmax[S]
Km +[S] 	   	   	   	   	   	  	  	  	  (2.6)	  
vi =
Vmax[S]










−1) Km +[S]( ) 	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (2.8)	  
	  (Where	  [I]	  =	  concentration	  of	  inhibitor,	  [S]	  =	  Substrate	  (MUNANA)	  concentration)	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All	  Ki	  values	  are	  a	  mean	  value	  of	  three	  independent	  measurements.	  Ki	  values	  for	  6SLN	  and	  3SLN	  are	  expressed	  as	  Km	  values,	  as	  they	  are	  the	  same	  parameter	  for	  a	  competing	  substrate.	  
2.2.11.2 6SLN	  and	  3SLN	  kinetics	  Measurement	  of	  6SLN	  and	  3SLN	  cleavage	  was	  studied	  using	  a	  coupled	  enzyme	  system.	   Measurements	   were	   made	   using	   a	   Jasco	   V-­‐550	   spectrophotometer	   in	   an	  ultra-­‐micro	   volume	   cuvette	   with	   a	   10	   mm	   path	   length.	   Measurements	   were	   made	  using	  the	  Buffer	  HBS-­‐P	  +	  CaCl2	  supplemented	  with	  1	  mM	  MgCl2	  at	  37°C.	  Each	  100	  µl	  reaction	   contained:	   25	   U	   β-­‐galactosidase	   (Sigma:	   G5635);	   0.25	   U	   β-­‐galactose	  dehydrogenase	  (Roche:	  10662046001);	  5	  mM	  NAD+	  (Sigma:	  N7004).	  The	  substrates	  6SLN	  and	  3SLN	  (Dextra)	  were	  added	  at	  concentrations	  ranging	   from	  50	  –	  7000	  µM	  and	   purified	   NA	   at	   concentrations	   ranging	   from	   0.5	   –	   25	   nM.	   The	   6SLN	   and	   3SLN	  were	   found	   to	   have	   a	   small	   quantity	   (2	   –	   3%)	   of	   a	   contaminant	   that	  was	   found	   to	  generate	  a	  change	  in	  absorbance	  in	  the	  absence	  of	  NA.	  According	  to	  the	  manufacturer	  of	   the	   receptor	   analogues	   (Dextra	   Laboratories,	   Reading)	   this	   is	   likely	   to	   be	   N-­‐acetyllactosamine.	  This	  contaminant	  was	  broken	  down	  by	  incubating	  each	  receptor	  at	  a	  concentration	  of	  10	  mg/ml	  in	  the	  presence	  of	  the	  reaction	  components	  listed	  above	  and	   incubated	   at	   37°C	   for	   ~2	   hrs.	   This	   was	   found	   to	   adequately	   remove	   this	  contaminating	   substance	   so	   that	   a	   change	   in	   absorbance	   was	   only	   seen	   upon	   the	  addition	  of	  NA.	  Absorbance	  at	  340	  nm	  was	  measured	  as	  a	   function	  of	   time	  and	   the	  maximal	   rate	   was	   measured.	   A340	   rate	   measurements	   were	   converted	   into	   molar	  rates	   by	   using	   the	   extinction	   coefficient	   of	   NADH	   (ε	   =	   6220	  M-­‐1cm-­‐1).	   These	  molar	  rates	   were	   then	   converted	   to	   an	   observed	   rate	   by	   dividing	   values	   by	   the	   protein	  concentrations	  used	  in	  the	  assays.	  These	  observed	  rates	  were	  plotted	  as	  a	  function	  of	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substrate	  concentration	  and	  fitted	  to	  the	  Michaelis-­‐Menten	  equation	  to	  determine	  Km	  and	  kcat	  using	  the	  Graphpad	  Prism	  software.	  	  
2.2.11.3 Fetuin	  kinetics	  Measurements	   of	   fetuin	   cleavage	   kinetics	   by	   NA	   were	   made	   an	   enzyme	  coupled	  system	  based	  on	  the	  measurement	  of	  released	  sialic	  acid	  by	  NA	  by	  using	  the	  two	   enzymes	   N-­‐acetyl-­‐neuramininic	   acid	   aldolase	   (NANA	   aldolase)	   and	   lactate	  dehydrogenase	  (LDH).	  Measurements	  were	  made	  in	  Jasco	  V-­‐550	  spectrophotometer	  using	  the	  buffer	  HBS-­‐P	  +	  CaCl2	  in	  an	  ultra-­‐microvolume	  10	  mm	  path	  cuvette	  at	  37°C.	  100	  μl	  reactions	  contained	  0.5	  U	  NANA	  aldolase	  (Sigma:	  A6680),	  5	  U	  LDH	  from	  bovine	  heart	   (Sigma:	  L2625),	  200	  µM	  NADH	  (Sigma:	  N9410)	  and	   fetuin	   from	   foetal	  bovine	  serum	   (Sigma:	   F3004).	   The	   fetuin	   used	   was	   found	   to	   have	   a	   small	   quantity	   of	  contaminating	  free	  sialic	  acid	  and	  was	  pretreated	  under	  the	  assay	  conditions	  listed	  in	  the	  previous	  section	  at	  a	  stock	  fetuin	  concentration	  of	  300	  µM	  and	  incubated	  at	  37°C	  for	  ~2	  hrs.	  The	  readout	  of	  NA	  rate	  was	  the	  reduction	  in	  absorbance	  at	  340	  nm.	  The	  initial	  rate	  of	  reduction	  in	  absorbance	  determined	  using	  the	  supplied	  Jasco	  software.	  Rates	  of	  change	   in	  absorbance	  were	  changed	   to	  molar	  rates	  by	  using	   the	  extinction	  coefficient	   of	   NADH	   (ε	   =	   6220	   M-­‐1cm-­‐1).	   These	   molar	   rates	   were	   converted	   to	  observed	  rates	  by	  dividing	  values	  by	  the	  concentration	  of	  NA	  used	  in	  the	  assay.	  These	  observed	   rates	  were	   plotted	   as	   a	   function	   of	   fetuin	   concentration	   and	   fitted	   to	   the	  Michaelis-­‐Menten	  equation	  to	  determine	  Km	  and	  kcat	  using	  Graphpad	  Prism	  software.	  
2.2.12 Low	  pH	  treatment	  of	  virus	  and	  trypsin	  digestion	  
Viruses	  were	  diluted	  to	  a	  concentration	  of	  10	  nM	  in	  PBS-­‐A,	  based	  on	  NP	  ELISA	  quantitation,	  as	  described	  in	  section	  2.2.9.2.	  The	  pH	  was	  lowered	  to	  4.95	  –	  5.05	  by	  the	  addition	  of	  150	  mM	  citrate	  buffer	   (citric	  acid/sodium	  citrate)	  pH	  3.5	  at	  ~5%	  of	   the	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volume	  of	  virus.	  The	  pH	  was	  checked	  using	  a	  microscale	  pH	  electrode.	  Samples	  were	  incubated	  in	  a	  37°C	  water	  bath	  for	  15	  mins.	  5%	  sample	  volume	  of	  1M	  Tris-­‐HCl	  pH	  8.0	  was	   added	   to	   neutralise	   the	   pH	   of	   the	   sample	   which	   was	   then	   treated	   with	   TPCK	  trypsin	  (Sigma:	  T1426)	  at	  a	  1:10	  (w/w)	  ratio	  of	  trypsin:virus,	  assuming	  that	  a	  10	  nM	  virus	  suspension	  is	  ~1	  mg/ml.	  Samples	  were	  incubated	  at	  room	  temperature	  for	  1	  hr	  and	  the	  trypsin	  was	  inhibited	  with	  an	  equal	  mass	  of	  soybean	  tryspin	  inhibitor	  (Sigma:	  T6522).	  Virus	  was	  pelleted	  160	  000	  x	  g	  for	  20	  mins	  at	  4°C	  (Beckman	  Coulter	  TLA-­‐100	  0.2	  ml	  rotor).	  The	  supernatant	  was	  removed	  and	  the	  pellet	  was	  resuspended	   in	   the	  same	  volume	  of	  PBS-­‐A	  +	  0.01%	  (w/v)	  NaN3.	  
2.2.13 Microscale	  thermophoresis	  (MST)	  
Microscale	   thermophoresis	   (MST)	   experiments	   were	   carried	   out	   using	   a	  Nanotemper	  Monolith	  NT.115	  instrument.	  Protein	  labeling	  was	  carried	  out	  using	  the	  Monolith	   protein	   labeling	   kit	   RED-­‐NHS	   (Nanotemper:	   MO-­‐L001)	   according	   to	  manufacturer’s	  instructions.	  Labeling	  was	  optimised	  to	  ensure	  a	  low	  level	  of	  labeling,	  ~1	   dye	   molecule	   per	   protein	   multimer.	   The	   amine	   reactive	   dye	   was	   added	   at	   a	  concentration	  ~3-­‐fold	   higher	   than	   the	   trimeric	   HA	   concentration	   or	   tetrameric	   NA	  concentration.	   The	   labeling	   efficiency	   was	   checked	   by	   comparing	   protein	  concentration,	   determined	   by	   A280,	   as	   described	   in	   section	   2.2.8.2,	   with	   the	  concentration	   of	   the	   dye	   by	   measuring	   A650,	   as	   described	   in	   the	   manufacturer’s	  instructions.	  	  
Experiments	   were	   carried	   out	   by	   diluting	   protein	   and	   adjusting	   the	   light-­‐emitting	  diode	   (LED)	  power	   that	   gave	  a	   fluorescence	  of	  500	  –	  2000	  AU	   in	   the	  MST	  instrument.	   All	   experiments	   were	   carried	   out	   in	   Hydrophilic	   treated	   capillaries	  (Nanotemper).	   Experiments	   were	   carried	   out	   using	   a	   constant	   concentration	   of	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fluorescently	  labelled	  protein	  in	  all	  capillaries	  and	  adding	  a	  varying	  concentration	  of	  either	  6SLN	  or	  3SLN	  (Dextra	  Laboratories	  Ltd.,	  Reading,	  UK).	  Experiments	  measured	  thermophoresis	   of	   H1	   HAs	   at	   25°C	   using	   30%	   excitation	   LED	   power	   and	   50%	  infrared-­‐laser	  power.	  Experiments	  consisted	  of:	  5	  s	  laser-­‐off	  time,	  30	  s	  laser-­‐on	  time,	  5	  s	  laser-­‐off	  time.	  Measurements	  were	  made	  with	  at	  least	  10	  dilutions	  of	  the	  receptor	  analogues.	  	  
Raw	   thermophoresis	   fluorescence	   data	   were	   fitted	   and	   extracted	   using	   the	  provided	  Nanotemper	   software.	   Data	  were	   fitted	   to	   Equation	   2.9	   using	   the	   custom	  equation	  function	  in	  Graphpad	  Prism.	  
F = Fmax[L][L]+Kd
+Fmin 	   	   	   	   (2.9)	  
	  (Where	  F	  is	  raw	  fluorescence	  value;	  [L]	  is	  concentration	  of	  ligand;	  and	  Fmax	  and	  Fmin	  are	  the	  maximum	  and	  minimum	  plateau	  values	  for	  the	  fitted	  curve)	  
Data	   were	   then	   converted	   to	   fractional	   saturation	   by	   subtracting	   Fmin	   and	  dividing	  by	  Fmax.	  Fractional	  saturation	  values	  (f)	  were	  plotted	  as	  a	   function	  of	  sugar	  concentration.	  Curves	  were	  fitted	  using	  Equation	  2.10:	  
f = [L][L]+Kd 	   	   	   	   	  	  (2.10)	  
Previous	   studies	   (Xiong	  et	  al.,	   2013a)	  using	  MST	  have	   shown	   that	   the	  major	  change	  in	  thermophoretic	  mobility	  occurs	  upon	  binding	  of	  the	  third	  sialic	  acid	  to	  an	  HA	  trimer.	  The	  experiment	  therefore	  primarily	  monitors	  the	  formation	  of	  this	  species	  and	   the	   observed	   binding	   constant,	   effectively	   the	   third	   stoichiometric	   dissociation	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constant	   for	   a	   protein	   with	   three	   identical	   non-­‐interacting	   sites,	   is	   equal	   to	   the	  intrinsic	   dissociation	   constant	   for	   a	   single	   site	  multiplied	  by	   three.	   Fitted	  Kd	   values	  were	  therefore	  corrected	  by	  dividing	  the	  value	  by	  three.	  
2.2.14 Nanoparticle	  tracking	  analysis	  (NTA)	  
Virus	  size	  was	  determined	  using	  nanoparticle	   tracking	  analysis	  (NTA)	  with	  a	  Nanosight	  LM-­‐10	  instrument	  (Malvern	  Instruments	  Ltd.,	  Malvern,	  UK).	  Virus	  samples	  were	   introduced	   into	   the	   sample	   chamber	   at	   a	   dilution	   which	   allowed	   ~20	   –	   100	  particles	   in	   a	   single	   field	   of	   view,	   typically	   a	   1	   in	   5	   000	   –	   50	   000	   dilution.	   Five	  individual	   60	   s	   measurements	   were	   made	   for	   each	   virus	   sample	   with	   the	   camera	  sensitivity	   set	   at	   12.	   Particle	   sizes	   were	   fitted	   using	   the	   provided	   Nanosight	   NTA	  software	  using	  a	  detection	  cutoff	  of	  5.	  Raw	  data	  for	  each	  of	  the	  5	  runs	  were	  combined	  for	   each	   virus,	   yielding	  10	  000	   –	   20	  000	  particle	   sizes	   for	   each	   sample.	   These	  data	  were	   converted	   to	   a	   frequency	  distribution	  with	  Graphpad	  Prism	   using	   the	  built	   in	  frequency	  distribution	  function	  with	  a	  bin	  size	  of	  20	  nm.	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3 Development	  of	  Assays	  to	  Measure	  the	  Balance	  of	  
Influenza	  Hemagglutinin	  and	  Neuraminidase	  Activities	  
3.1 Introduction	  
As	  described	  in	  the	  Introduction,	  section	  1.6,	  the	  balance	  between	  the	  activities	  of	   IAV	  HA	   and	  NA	   is	   thought	   to	   be	   a	  major	   factor	   in	   determining	   virus	   fitness	   and	  transmissibility.	  The	  contributions	  of	   the	  activities	  of	   these	  two	  proteins,	   in	  altering	  virus	  receptor	  binding,	  has	  never	  been	  directly	  measured.	  In	  this	  chapter	  experiments	  are	  described	  which	  are	  devised	  to	  directly	  measure	  the	  effects	  of	  these	  two	  proteins	  on	  the	  interaction	  of	  viruses	  with	  receptor	  analogue	  coated	  surfaces.	  
The	   interaction	   of	   a	   virus	  with	   a	   receptor	   coated	   surface	   is	   dependent	   on	   a	  number	   of	   viral	   characteristics:	   1)	  HA	   receptor	   binding	   affinity,	   Kd;	   2)	  NA	   receptor	  destroying	  activity,	  Km	  and	  kcat;	  3)	  distribution	  and	  relative	  proportions	  of	  HA	  and	  NA	  on	  the	  virus	  surface;	  4)	  virus	  morphology,	  which	  can	  affect	  protein	  distributions	  and	  5)	  NA	  stalk	  length,	  which	  can	  influence	  accessibility	  of	  the	  NA	  to	  the	  substrate.	  
In	   this	   chapter	   a	   new	   technique	   is	   described,	   which	   can	   make	   real-­‐time	  measurements	  of	  virus	  binding	  both	  in	  the	  presence	  and	  absence	  of	  IAV	  NA	  inhibitors.	  This	  allows	   the	  quantitative	  analysis	  of	   the	  activity	  of	   the	  HA	  and	  NA	   in	  controlling	  interactions	  of	   the	  virus	  with	   surface	   immobilised	   receptor	  analogues.	  This	   chapter	  presents	  measurements	  performed	  to	  analyse	   the	  binding	  of	   the	  H3N2	  high	  growth	  reassortant	  X-­‐31	  and	  related	  mutants	  in	  order	  to	  study	  the	  effects	  of	  making	  changes	  in	  the	  characteristics	  of	  the	  HA	  and	  NA.	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3.2 Results	  
3.2.1 Choice	  of	  virus	  for	  binding	  studies	  
X-­‐31	   is	   a	   high	   growth	   reassortant	   of	   A/Aichi/2/68(H3N2)	   HA	   and	   NA	  combined	   with	   the	   remaining	   six	   gene	   segments	   from	   PR8	   (A/Puerto	  Rico/8/34(H1N1)).	  This	  virus	  was	  chosen	  as	  a	   suitable	  candidate	   for	  establishing	  a	  new	  binding	   assay	   because	   it	   has	   been	   extensively	   characterised	   in	  many	   previous	  studies.	  X-­‐31	  HA	  was	   the	   first	  haemagglutinin	   to	  have	   its	   structure	   solved	  by	  X-­‐ray	  crystallography	   (Wilson,	  Skehel	  &	  Wiley,	  1981)	  and	   its	  binding	  characteristics	  have	  been	  extensively	  studied	  both	   in	  NMR	  experiments	  (Sauter	  et	  al.,	  1989;	  1992b)	  and	  more	   recently	   using	  microscale	   thermophoresis	   (MST)	   and	   biolayer	   interferometry	  (BLI)	   (Xiong	  et	  al.,	  2013a).	  The	  virus	  also	  propagates	   to	  a	  high	   titre	  and	   is	  stable	   in	  purified	  form,	  as	  are	  the	  HA	  and	  NA	  glycoproteins	  purified	  from	  the	  virus.	  As	  well	  as	  extensive	  studies	  of	  wild-­‐type	  X-­‐31	  there	  is	  also	  a	  well	  characterised	  receptor	  binding	  mutant	   of	   X-­‐31,	   known	   as	   X-­‐31	   Horse	   Adsorption	  Mutant	   (X-­‐31	   HAM),	   which	   was	  generated	  by	  passaging	  X-­‐31	   in	   eggs	   in	   the	  presence	  of	   horse	   serum	   (Rogers	  et	  al.,	  1983).	   X-­‐31	   HAM	   carries	   the	   receptor	   binding	   substitution	   L226Q	   and	   the	   HA	   has	  been	  shown	  to	  have	  significantly	  reduced	  affinity	  for	  α2,6-­‐linked	  sialic	  acid	  receptors	  and	  a	  slightly	  increased	  affinity	  for	  α2,3-­‐linked	  receptors	  (Rogers	  et	  al.,	  1983;	  Sauter	  




Figure	  3.1:	  BLI	  data	  measuring	  HA	  mediated	  viral	  avidity	  of	  X-­‐31	  and	  X-­‐31	  HAM.	  Experiments	  measured	   fractional	   saturation	   by	   100	   pM	  X-­‐31	   and	   X-­‐31	  HAM	   in	   the	  presence	  of	  NA	  inhibitors	  as	  a	  function	  of	  sugar	  loading	  of	  6SLN-­‐PAA	  and	  3SLN-­‐PAA.	  X-­‐31	  HAM	  contains	  the	  substitution	  L226Q.	  Data	  obtained	  by	  Dr.	  Stephen	  Martin.	  
Figure	  3.2:	  BLI	  data	  for	  100	  pM	  X-­‐31	  binding	  to	  sugar	  coated	  biosensors	  in	  the	  
presence	   and	   absence	   of	   NA	   inhibitors.	   Biosensors	   were	   saturated	   with	  sialoglycopolymers	   bearing	   the	   receptor	   analogues	   6SLN	   and	   3SLN.	  Measurements	  are	   presented	   for	   virus	   binding	   in	   the	   presence	   (solid	   lines)	   and	   absence	   (dashed	  lines)	  of	  NA	  inhibitors	  (Inhib).	  	   	  






































3.2.2 Development	   of	   binding	   assays	   to	   measure	   the	   balance	   of	   HA	   and	   NA	  
activities	  
Experiments	  were	  carried	  out	  to	  measure	  the	  balance	  of	  HA	  and	  NA	  activities	  using	   biolayer	   interferometry	   (BLI).	   This	   approach	   has	   been	   used	   extensively	   to	  measure	  HA	  mediated	  virus	  binding	  in	  the	  presence	  of	  NA	  inhibitors	  (Lin	  et	  al.,	  2012;	  Xiong	  et	  al.,	  2013a;	  2013b;	  2013c;	  Crusat	  et	  al.,	  2013;	  Vachieri	  et	  al.,	  2014;	  Xiong	  et	  al.,	  2014;	  Collins	  et	  al.,	  2014).	  These	  experiments	  measured	  the	  binding	  of	  purified	  virus	  at	   a	   fixed	   concentration	   (typically	   100	   pM)	   to	   biosensors	   with	   different	   levels	   of	  immobilised	   sialoglycopolymers.	   The	   amount	   of	   sialoglycopolymer	   immobilised	   is	  characterised	   by	   the	   response	   observed	   during	   loading	   (known	   as	   relative	   sugar	  loading	   (RSL)).	   The	   total	   equilibrium	   response	   of	   virus	   binding	   to	   these	   different	  sugar	   loadings	   is	   measured,	   converted	   to	   a	   fractional	   saturation,	   and	   plotted	   as	   a	  function	   of	   the	   RSL.	   These	  measurements	   allow	   the	   quantification	   of	   virus	   binding	  affinity,	   as	   stronger	   binding	   viruses	   will	   reach	   saturation	   at	   lower	   relative	   sugar	  loadings.	  	  
The	  basis	  of	  the	  experiments	  developed	  to	  measure	  HA/NA	  balance	  is	  similar	  to	  the	  experiments	  described	  above.	  Two	  experiments	  are	  run	  concurrently:	  one	  with	  the	   NA	   inhibited	   with	   high	   concentrations	   of	   the	   two	   NA	   inhibitors,	   oseltamivir	  carboxylate	  and	  zanamivir,	  and	  the	  other	  uninhibited.	  The	  experiment	  with	  inhibited	  NA	   allows	   the	   measurement	   of	   the	   binding	   of	   the	   virus	   mediated	   by	   the	   HA	   only,	  whereas	  in	  measurements	  without	  inhibitors	  the	  combination	  of	  the	  effects	  of	  HA	  and	  NA	  activities	  on	  receptor	  binding	  can	  be	  seen.	  
As	  well	  as	  carrying	  out	  some	  experiments	  in	  the	  absence	  of	  NA	  inhibitors	  there	  were	  also	  a	  number	  of	  other	  changes	  in	  the	  experimental	  approach.	  Previous	  assays	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were	  carried	  out	  using	  the	  buffer	  HBS-­‐EP	  (10	  mM	  HEPES-­‐NaOH,	  pH	  7.4,	  150	  mM	  NaCl,	  3	  mM	  EDTA	  and	  0.005%	  Tween-­‐20),	  which	  is	  unsuitable	  for	  assays	  where	  NA	  activity	  is	   important,	   as	   it	   contains	   EDTA	   and	   no	   Calcium,	   which	   can	   be	   important	   for	   NA	  activity	   (as	   described	   in	   Introduction,	   section	   1.3.2.1).	   An	   altered	   buffer,	   HBS-­‐P	   +	  CaCl2	   (10	  mM	  HEPES-­‐NaOH	  pH	  7.4,	   150	  mM	  NaCl,	   0.005%	  Tween-­‐20,	   4	  mM	  CaCl2)	  was	  used	  for	  all	  HA/NA	  balance	  measurements.	  Rather	  than	  carrying	  out	  experiments	  at	  different	  sugar	  loadings	  as	  with	  previous	  experiments,	  binding	  was	  measured	  to	  a	  biosensor	   saturated	   with	   sialoglycopolymers.	   These	   included	   sialoglycopolymers	  bearing	  the	  receptor	  analogues	  α2,6-­‐Sialyl-­‐N-­‐acetyllactosamine	  (6SLN-­‐PAA)	  or	  α2,3-­‐Sialyl-­‐N-­‐acetyllactosamine	   (3SLN-­‐PAA).	   The	  measurements	   are	   designed	   to	   look	   at	  the	   ability	  of	  NA	   to	   cleave	   sialic	   acid	   from	   the	   surface,	   and	  a	   fully	   saturated	   sensor	  allows	  for	   the	  highest	  virus	  binding	  capacity	  (and	  hence	   largest	  signal)	  before	  virus	  dissociates	  following	  cleavage	  of	  the	  sugars	  from	  the	  surface	  of	  the	  biosensor	  by	  the	  NA.	  The	  method	  for	  these	  measurements	  are	  described	  in	  greater	  detail	  in	  Materials	  
and	  Methods,	  section	  2.2.10.2.	  
Figure	  3.2	  shows	  a	  typical	  balance	  measurement	  for	  the	  binding	  of	  100	  pM	  X-­‐31	  to	  the	  α2,6	  and	  α2,3	  linked	  sialic	  acid	  receptor	  analogues	  6SLN-­‐PAA	  and	  3SLN-­‐PAA.	  The	  curves	  with	  inhibited	  NA	  show	  similar	  binding	  to	  both	  6SLN-­‐PAA	  and	  3SLN-­‐PAA,	  indicating	   a	   similar	   rate	   of	   binding	   to	   saturated	   sensors	   for	   both	   receptors.	   The	  binding	   curves	   for	   inhibited	  and	  uninhibited	  NA	  show	  a	  very	   similar	   initial	  binding	  phase.	  There	  is	  then	  a	  point	  at	  which	  the	  curves	  diverge,	  with	  a	  reduction	  in	  overall	  binding	   when	   the	   NA	   is	   active	   (without	   inhibitors	   present).	   The	   curves	   of	   virus	  binding	  in	  the	  absence	  of	  NA	  inhibitors	  then	  exhibit	  a	  turning	  point	  where	  the	  curve	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flattens	  out	  and	  then	  starts	   to	  decrease	  slowly	  to	  very	   low	  levels	  of	  binding	  at	   later	  time	  points.	  
The	  overall	  shape	  of	  the	  curves	  for	  X-­‐31	  binding	  to	  6SLN-­‐PAA	  and	  3SLN-­‐PAA	  are	  similar;	  however,	  there	  is	  a	  substantial	  difference	  in	  the	  point	  at	  which	  the	  curves	  diverge.	  The	  3SLN-­‐PAA	  binding	  curves	  diverge	  at	  a	  much	  earlier	  time	  point	  (~30	  s),	  whereas	  the	  6SLN-­‐PAA	  binding	  curves	  diverge	  at	  a	  later	  point	  (~320	  s).	  The	  binding	  to	   3SLN-­‐PAA	   only	   reaches	   a	   total	   binding	   of	   ~10%	   of	   the	   total	   attainable	   virus	  binding	  capacity,	  whereas	  6SLN-­‐PAA	  reaches	  ~50%	  of	  total	  capacity.	  This	  difference	  in	  binding	  levels	  reflects	  the	  different	  properties	  of	  the	  HA	  and	  NA	  in	  binding	  to	  (HA)	  and	  cleaving	  (NA)	  the	  immobilised	  receptor.	  A	  striking	  feature	  of	  the	  6SLN-­‐PAA	  curve	  is	   that	   it	  does	  not	  reach	  a	  relative	  binding	   level	  of	  zero	  (no	  virus	  remaining	  bound)	  even	  at	  very	  long	  reaction	  times.	  	  
3.2.3 Effect	  of	  altering	  virus	  concentration	  on	  HA/NA	  balance	  measurements	  




Figure	   3.3:	   HA/NA	   balance	   curves	   to	   investigate	   effect	   of	   altering	   virus	  
concentration.	   Curves	   show	   the	   binding	   of	   different	   concentrations	   of	   X-­‐31	   in	   the	  presence	   (solid	   lines)	   and	  absence	   (dashed	   lines)	  of	  NA	   inhibitors	   (Inhib).	  A)	  Virus	  binding	   to	   6SLN-­‐PAA	   and	   B)	   Virus	   binding	   to	   3SLN-­‐PAA	   with	   inlay	   showing	   an	  expanded	  section	  of	  initial	  binding.	  	   	  

































(Stephen	   Martin,	   personal	   communication)	   and	   therefore	   they	   should	   give	   very	  similar	  saturation	  values.	  This	  increase	  in	  binding	  signal	  could	  be	  due	  to	  some	  form	  of	  virus	   aggregation	   on	   the	   sensor	   at	   high	   concentration,	   which	   would	   increase	   the	  signal	  in	  the	  way	  seen	  in	  these	  experiments.	  
The	  curve	  for	  the	  lowest	  virus	  concentration	  (10	  pM)	  appears,	  at	  first	  sight,	  to	  saturate	  at	  a	  lower	  level	  (<1)	  but	  the	  reaction	  is	  very	  slow	  at	  this	  concentration	  and	  the	  binding	   is	  clearly	  not	  complete	  within	   the	   time	  scale	  over	  which	  measurements	  were	  made.	  
Without	  NA	  inhibitors	  present	  the	  curve	  for	  the	  highest	  concentration	  of	  virus	  (1	  nM)	  shows	  faster	  initial	  binding	  with	  a	  higher	  peak	  of	  binding	  compared	  with	  the	  standard	  curve	  (100	  pM).	  This	  binding	  then	  starts	  to	  reduce	  at	  an	  earlier	  time	  point	  and	  reduces	  to	  a	  level	  that	  is	  higher	  than	  that	  seen	  with	  100	  pM	  virus.	  The	  curve	  with	  the	   lowest	   virus	   concentration	   (10	  pM)	   shows	   slower	   overall	   binding	  with	   a	   lower	  peak	  at	  a	  later	  time	  point	  and	  then	  lower	  amounts	  of	  virus	  remaining	  bound	  at	  long	  times.	   The	   data	   have	   the	   same	   pattern	   of	   differences	   for	   binding	   curves	   for	   both	  6SLN-­‐PAA	  and	  3SLN-­‐PAA;	  however,	  as	  seen	  in	  Figure	  3.2,	  the	  loss	  of	  receptor	  binding	  in	  the	  absence	  of	  NA	  inhibitors	  happens	  much	  faster	  at	  all	  virus	  concentrations	  with	  the	  α2,3	  linked	  receptor	  analogue.	  In	  the	  light	  of	  these	  results	  it	  was	  decided	  to	  carry	  out	  all	  further	  experiments	  using	  virus	  at	  100	  pM	  since	  it	  provides	  a	  good	  balance	  of	  adequate	  signal	  at	  early	  time	  points,	  without	  demanding	  the	  use	  of	  large	  amounts	  of	  virus.	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3.2.4 Effect	  of	  assay	  temperature	  on	  measurements	  
As	   noted	   elsewhere,	   BLI	   experiments	   were	   typically	   carried	   out	   at	   25°C.	  However,	   as	   the	   instrument	   has	   the	   facility	   for	   sample	   heating	   some	   experiments	  were	   carried	   out	   to	   examine	   the	   effect	   of	   performing	   measurements	   at	   more	  biologically	   relevant	   elevated	   temperatures.	  Experiments	  were	  not	   typically	   carried	  out	   at	   this	   temperature	   for	   practical	   reasons.	   Since,	   the	   BLI	   instrument	   holds	   the	  samples	   in	   an	   open	   96-­‐well	   plate	   significant	   evaporation	   from	   the	   wells	   occurs	   at	  higher	   temperatures.	   	   During	   long	   data	   accumulations	   this	   results	   in	   significant	  changes	  in	  sample	  concentrations.	  	  
Figure	  3.4	  shows	  a	  comparison	  of	  X-­‐31	  binding	  to	  6SLN-­‐PAA	  and	  3SLN-­‐PAA	  at	  25˚C	  and	  37˚C.	  Virus	  binding	  profiles	   in	  the	  presence	  of	   inhibitors	  are	  similar	  at	  the	  two	  temperatures,	  with	  slightly	  faster	  binding	  at	  the	  higher	  temperature	  (consistent	  with	   the	   normal	   effect	   of	   temperature	   on	   association	   rate	   constants).	   There	   does,	  however,	  appear	  to	  be	  significant	  loss	  of	  virus	  from	  the	  sensor	  at	  the	  later	  time	  points,	  particularly	  with	  3SLN-­‐PAA.	  This	  probably	  derives	  from	  two	  effects:	  the	  lower	  affinity	  of	   the	   virus	   and	   incomplete	   inhibition	   of	   the	   NA	   activity	   by	   the	   inhibitors	   at	   the	  elevated	  temperature.	  	  






Figure	   3.4:	   HA/NA	   balance	   measurements	   of	   X-­‐31	   binding	   at	   25˚C	   and	   37˚C.	  Measurements	   are	  made	  of	   100pM	  X-­‐31	  binding	   to	   sensors	   saturated	  with	   the	   two	  receptor	  analogue	  sialoglycopolymers	  A)	  6SLN-­‐PAA	  and	  B)	  3SLN-­‐PAA	  in	  the	  presence	  and	  absence	  of	  NA	  inhibitors	  (Inhib).	   	  












































3.2.5 Investigation	   of	   complementing	   HA/NA	   balance	   measurements	   with	  
soluble	  NA	  
The	  viral	  NA	  is	  tethered	  to	  the	  virion	  and	  therefore	   is	   limited	  in	   its	  ability	  to	  encounter	   substrate	   by	   the	   nature	   of	   the	   interaction	   of	   the	   virus	   with	   the	   sensor	  surface.	  Experiments	  were	  devised	  to	  remove	  this	  limitation	  by	  blocking	  the	  viral	  NA	  and	  complementing	  the	  solutions	  with	  soluble	  bacterial	  NA.	  Experiments	  consisted	  of	  measuring	   the	   binding	   of	   100	   pM	   X-­‐31	   in	   the	   presence	   of	   influenza	   NA	   specific	  inhibitors:	  oseltamivir	  carboxylate	  and	  zanamivir.	  The	  NA	  activity	  of	  the	  solution	  was	  then	  supplemented	  with	  different	  amounts	  of	  soluble	  bacterial	  NA	   from	  Clostridium	  
perfringens	  (CPNA)	  added	  to	  the	  virus	  dilutions.	  This	  bacterial	  NA	  is	  not	  inhibited	  by	  inhibitors	  of	  the	  viral	  NA.	  The	  action	  of	  the	  CPNA	  is	  then	  that	  of	  random	  depletion	  of	  the	   sugar	   affected	   only	   by	   the	   ability	   of	   the	   soluble	   protein	   to	   meet	   the	   tethered	  substrate,	  with	  these	  interactions	  unaffected	  by	  other	  proteins	  and	  the	  complexities	  of	  multivalency.	  
Figure	   3.5	   shows	   typical	   experiments	   with	   this	   CPNA	   supplementation	   at	  different	  concentrations.	  It	  is	  apparent	  from	  these	  results	  that	  the	  curves	  are	  similar	  in	   shape	   to	   those	   seen	  with	   the	  uninhibited	  viral	  NA	   (see	  Fig.	  3.2).	  Higher	   levels	  of	  CPNA	  cause	  lower	  overall	  virus	  binding,	  owing	  to	  faster	  depletion	  of	  the	  sugars	  on	  the	  surface.	  	  




Figure	  3.5:	  HA/NA	  balance	  curves	  investigating	  the	  effect	  of	  complementing	  X-­‐
31	   receptor	   binding	  with	   bacterial	   NA.	  These	  BLI	   experiments	  were	   carried	  out	  with	   X-­‐31	   at	   100	   pM	   in	   the	   presence	   of	   NA	   inhibitors,	   with	   viral	   binding	  complemented	   with	   bacterial	   NA	   from	   Clostridium	   perfringens	   (CPNA)	   at	   different	  concentrations.	   Binding	   was	   measured	   to	   sialoglycopolymers	   bearing	   the	   two	  receptor	  analogues	  A)	  6SLN-­‐PAA	  and	  B)	  3SLN-­‐PAA.	  	   	  



























amount	   of	   sugar	   is	   cleaved	   from	   the	   sensor	   surface	   in	   the	   initial	   part	   of	   the	   virus	  binding	  process	  by	   the	  viral	  NA	  or	   the	  CPNA.	  However,	   in	   the	  CPNA	  complemented	  experiment	  a	  relative	  binding	  value	  close	  to	  zero	  is	  reached	  much	  more	  quickly.	  This	  indicates	   that	   the	  cleavage	  at	  earlier	   time	  points	  by	   the	  virus	   is	  similar	   in	  nature	   to	  that	   of	   random	   depletion	   by	   a	   soluble	   NA	   and	   at	   later	   time	   points	   there	   are	  constraints	  upon	  the	  viral	  NA,	  reducing	  the	  effectiveness	  of	  cleavage	  compared	  to	  the	  soluble	  CPNA.	  	  
3.2.6 Determination	  of	  residence	  times	  of	  virus	  
As	   the	   virus	   cleaves	   sugar	   from	   the	   surface	   of	   the	   biosensor	   the	   number	   of	  interactions	  the	  viral	  HAs	  can	  make	  with	  the	  receptor	  surface	  will	  be	  reduced.	  Viruses	  will	  then	  be	  bound	  with	  lower	  affinity	  and	  this	  is	  most	  likely	  to	  be	  associated	  with	  an	  increased	  dissociation	  rate	  constant.	  When	  viruses	  are	  bound	  with	  very	  high	  affinity	  the	  dissociation	  rate	  constant	  will	  be	  very	  low	  and	  low	  dissociation	  rates	  are	  difficult	  to	   determine	   using	   BLI.	   However,	   dissociation	   rate	   constants	   (and	   hence	   average	  residence	   times)	   of	   the	   virus	   in	   the	  presence	  of	  NA	   inhibitors	   can	  be	   estimated	   for	  different	  sugar	  loadings	  if	  the	  virus	  affinity	  and	  association	  rate	  constant	  are	  known,	  or	  can	  be	  estimated.	  Assuming	  the	  following	  simple	  scheme	  for	  binding	  of	  a	  virus	  (V)	  to	  a	  surface	  (S),	  where	  kon	  and	  koff	  are	  the	  association	  and	  dissociation	  rate	  constants:	  
	  
An	  apparent	  dissociation	  constant	  (Kd)	  can	  be	  determined	  from	  the	  fractional	  saturation	  (f)	  values	  previously	  determined	  for	  X-­‐31	  and	  X-­‐31	  HAM	  binding	  to	  6SLN-­‐
VS#V#+#S# kon#koff#
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PAA	   and	   3SLN-­‐PAA	   shown	   in	   Figure	   3.1	   using	   a	   rearrangement	   of	   Equation	   3.1	   to	  produce	  Equation	  3.2:	  
	   	   	   	   (3.1)	  
	   	   	   	   (3.2)	  
The	   association	   rate	   constant	   (kon)	   was	   determined	   by	   carrying	   out	  experiments	  in	  which	  the	  binding	  of	  virus	  at	  different	  concentrations	  (125-­‐1000	  pM)	  was	  studied	  in	  the	  presence	  of	  NA	  inhibitors.	  In	  these	  experiments	  the	  sensors	  were	  all	   loaded	   with	   the	   same	   (saturated)	   amount	   of	   immobilised	   sugar.	   The	   binding	  curves	   for	   the	   different	   virus	   concentrations	   were	   fitted	   to	   a	   double	   exponential	  function	  and	  the	  fast	  observed	  rate	  component	  (kobs)	  of	  the	  association	  phase,	  which	  accounted	   for	   the	  majority	   of	   the	   reaction	   amplitude,	   was	   plotted	   as	   a	   function	   of	  virus	  concentration,	  shown	  in	  Figure	  3.6.	  This	  is	  a	  pseudo	  first-­‐order	  reaction	  because	  the	   concentration	   of	   the	   virus	   is	   far	   greater	   than	   the	   concentration	   of	   immobilized	  sugar.	  A	  linear	  fit	  then	  gave	  an	  apparent	  association	  rate	  constant	  (kon)	  of	  ~4	  x	  107	  M-­‐






Figure	  3.6:	  Determination	  of	  kon	  for	  X-­‐31	  binding.	  Virus	  binding	  was	  measured	  to	  sensors	   saturated	  with	   sialoglycopolymers	   bearing	   6SLN	  or	   3SLN	   at	   different	   virus	  concentrations,	   in	   the	   presence	   of	   NA	   inhibitors.	   Binding	   curves	   were	   fitted	   to	   a	  double	  exponential	  function.	  The	  fast	  rate	  component	  (kobs)	  was	  plotted	  as	  a	  function	  of	   virus	   concentration.	   Lines	   of	   best	   fit	   were	   plotted,	   forcing	   the	   line	   through	   the	  origin.	  Equations	  of	  the	  fitted	  lines	  are	  shown.	  












6SLN: y = 4.40*107x
3SLN: y = 4.48*107x



























This	  kon	  value	  of	  4	  x	  107	  M-­‐1s-­‐1	  seems	  fast	  for	  a	  virus-­‐surface	  interaction.	  The	  upper	  limit	  for	  a	  protein-­‐protein	  interaction	  association	  rate	  constant,	  kon,	  is	  ~109	  M-­‐
1s-­‐1,	  which	  is	  limited	  by	  the	  speed	  of	  diffusion.	  The	  determined	  kon	  for	  virus	  binding	  is	  therefore	   very	   high	   for	   the	   interaction	   of	   a	   virus,	   which	   will	   have	   a	   much	   slower	  diffusion	   rate.	  However,	   kon	   values	   also	   depend	   on	  what	   fraction	   of	   encounters	   are	  productive.	   For	   small	   molecules	   this	   fraction	   is	   small	   but	   in	   the	   case	   of	   influenza	  viruses	  it	  is	  likely	  to	  be	  close	  to	  1.	  A	  study	  identified	  an	  association	  rate	  constant,	  kon,	  value	   for	  viruses	  binding	   to	  cells	  of	  ~1012	  M-­‐1s-­‐1	   (Nunes-­‐Correia,	  Ramalho-­‐Santos	  &	  Nir,	  1999).	  This	  value	  cannot	  be	  correct	  due	  to	  the	  constraint	  of	  the	  rate	  of	  diffusion.	  Two	  other	   studies	  by	  Meng	  et	  al.	  and	  Hidari	  et	  al.	  measured	   the	  kon	  of	   a	  number	  of	  different	  influenza	  viruses	  binding	  to	  gangliosides	  or	  sialylated	  glycoproteins	  to	  give	  the	   more	   reasonable	   value	   of	   1	   x	   106	   M-­‐1s-­‐1	  (Hidari	   et	   al.,	   2007;	   Meng	   &	  Marriott,	  2010).	  
Figure	  3.7	  shows	  the	  residence	  time	  for	  a	  bound	  virus	  plotted	  as	  a	  function	  of	  sugar	   loading	   over	   the	   range	   used	   in	   these	   experiments.	   It	   is	   apparent	   from	   these	  estimated	  values	  that	  the	  residence	  time	  of	  a	  virus	  at	  low	  sugar	  loadings	  is	  expected	  to	  be	  very	  short.	  The	  differences	  in	  HA	  receptor	  binding,	  for	  example	  the	  preference	  of	  X-­‐31	   for	  6SLN-­‐PAA	  over	  3SLN-­‐PAA	   is	  amplified	  at	   low	  sugar	   loadings	  and	   this	   is	  reflected	  in	   large	  differences	   in	  residence	  time.	  At	  saturated	  loading	  (RSL	  =	  0.6	  nm)	  the	   residence	   time	  of	  X-­‐31	  on	  6SLN-­‐PAA	   is	  3.4	   x	  105	   s,	   compared	   to	  1.4	   x	  105	   s	   on	  3SLN-­‐PAA,	  a	  difference	  of	  ~2.4-­‐fold.	  	  At	  one	  fifth	  of	  the	  saturated	  loading	  value	  (RSL	  =	  0.12)	  the	  residence	  times	  are	  reduced	  to	  1.2	  x	  103	  s	  for	  6SLN-­‐PAA	  and	  51	  s	  for	  3SLN-­‐PAA,	   a	   difference	   of	   ~23-­‐fold.	   At	   very	   high	   sugar	   loadings	   the	   virus	   binds	   to	   both	  sugars	  with	  a	  similar	  (very	  low)	  Kd	  and	  the	  residence	  times	  are	  therefore	  similar.	  At	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lower	   sugar	   loadings	   the	   Kd	   values	   for	   the	   two	   sugars	   increase	   and	   the	   difference	  between	   them	   becomes	   greater,	   accounting	   for	   the	   difference	   between	   residence	  times.	   The	   differences	   between	   receptor	   binding	   properties	   of	   X-­‐31	   and	   X-­‐31	  HAM	  (Fig.	  3.2)	  can	  be	  seen	  in	  the	  calculated	  values	  for	  residence	  times.	  The	  slight	  increase	  in	  affinity	  of	  the	  virus	  for	  3SLN-­‐PAA	  causes	  an	  increase	  in	  residence	  time.	  The	  large	  reduction	  in	  affinity	  for	  6SLN-­‐PAA	  can	  be	  seen	  in	  a	  large	  reduction	  in	  virus	  residence	  time	  at	  all	  values,	  particularly	  at	  lower	  sugar	  loading	  values.	  
For	  both	  X-­‐31	  and	  X-­‐31	  HAM	  with	  both	  receptor	  types	  the	  slowest	  dissociation	  rate	  constant	  estimated	  for	  experiments	  performed	  at	  saturating	  sugar	  is	  probably	  of	  the	  order	  of	  10-­‐5	  s-­‐1.	  This	  is	  similar	  to	  values	  determined	  for	  virus	  dissociation	  from	  a	  sugar-­‐coated	   surface	   using	   surface	   plasmon	   resonance	   (SPR)	   (Stephen	   Martin,	  personal	   communication).	   These	   data	   were	   not	   replicated	   using	   BLI	   for	   practical	  reasons.	   Determining	   slow	   dissociation	   rate	   constants	   requires	   very	   long	   data	  collection	  times	  (>12	  hrs)	  and	  too	  much	  sample	  evaporation	  occurs	  over	  such	  a	  long	  time,	  which	  will	  alter	  the	  virus	  concentration.	  
3.2.7 Kinetic	  characterisation	  of	  X-­‐31	  NA	  
It	  is	  clear	  that	  any	  explanation	  of	  the	  balance	  measurements	  described	  above	  must	   consider	   the	   interplay	   between	   the	   HA	   binding	   and	   NA	   sialidase	   activities.	  Although	  the	  binding	  properties	  of	  X-­‐31	  HA	  have	  been	  extensively	  characterized	  the	  kinetic	  properties	  of	   the	  NA	  from	  this	  virus	  are	  much	   less	  well	  understood.	  What	   is	  known	   is	   that	   the	   kinetic	   properties	   of	   the	   NA	   are	   highly	   dependent	   on	   pH	   and	  temperature.	   Experiments	   described	   in	   this	   section	   were	   designed	   to	   determine	  enzymatic	  properties	   for	  X-­‐31	  NA	  under	  different	  solution	  conditions.	  Purified	  X-­‐31	  NA	  was	  used	   in	  order	   to	   allow	   the	  measurement	  of	   an	  enzyme	   turnover	   rate	   (kcat).	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This	  protein	  was	  purified	  from	  bromelain	  digested	  purified	  egg-­‐propagated	  virus	  and	  was	  kindly	  provided	  by	  Dr.	  Patrick	  Collins.	  Kinetic	  parameters	  were	  measured	  for	  the	  fluorogenic	   substrate	   2’-­‐(4-­‐methylumbelliferyl)-­‐α-­‐D-­‐N-­‐acetylneuraminic	   acid	  (MUNANA)	  and	  also	  for	  the	  sugar	  substrates	  6SLN	  and	  3SLN	  in	  their	  monomeric	  form.	  
3.2.7.1 MUNANA	  kinetics	  
Kinetic	   parameters	   for	   MUNANA	   were	   measured	   using	   fluorimetry.	   This	  substrate	   consists	   of	   a	   sialic	   acid	   with	   a	   methylumbelliferyl	   (MU)	   group	   attached,	  which	  when	  cleaved	  by	  the	  NA	  releases	  the	  MU	  group,	  resulting	  in	  a	  large	  increase	  in	  fluorescence.	  Measurements	  were	  made	   using	   an	   unconventional	   continuous	   assay	  format.	   A	   very	   low	   concentration	   of	   NA	   was	   used	   (~0.2	   nM	   monomeric	  concentration)	  and	  substrate	  was	  added	  to	  the	  reaction	  in	  a	  number	  of	  steps,	  with	  the	  rate	   of	   the	   reaction	  measured	   after	   each	   addition.	   This	  method	   of	   carrying	   out	   the	  assay	  works	  because	  the	  very	  low	  NA	  concentration	  ensures	  that	  the	  total	  depletion	  of	   the	   substrate	   over	   the	   whole	   time	   course	   is	   negligible	   and	   therefore	   one	   can	  assume	   that	   this	   does	   not	   affect	   the	   kinetic	   parameters	   determined.	  Measurements	  were	  made	  under	  two	  buffer	  conditions:	  MES	  buffer	  (32.5	  mM	  MES-­‐NaOH,	  pH	  6.5,	  4	  mM	   CaCl2),	   which	   is	   the	   buffer	   commonly	   used	   for	   NA	   assays;	   and	   HBS-­‐P	   +	   CaCl2	  (HBS)	  (10	  mM	  HEPES-­‐NaOH	  pH	  7.4,	  150	  mM	  NaCl,	  0.005%	  Tween-­‐20,	  4	  mM	  CaCl2),	  which	   is	   the	   buffer	   used	   for	   the	   BLI	   balance	   measurements.	   Two	   different	  temperatures	  were	   also	   used	   for	   enzyme	   assays:	   37˚C,	   the	   temperature	   commonly	  used	  for	  NA	  assays,	  as	   it	  gives	  maximal	  activity;	  and	  25˚C,	   the	  temperature	  used	  for	  the	   majority	   of	   BLI	   experiments.	   Measurements	   were	   made	   and	   corrected	   for	   the	  effects	  of	  temperature	  and	  pH	  on	  fluorescence	  as	  described	  in	  Materials	  and	  Methods,	  section	  2.2.11.1.1.	  Michaelis-­‐Menten	  plots	   for	  X-­‐31	  NA	  MUNANA	  cleavage	  under	  the	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different	  buffer	  and	  temperature	  conditions	  listed	  above	  are	  shown	  in	  Figure	  3.8,	  and	  the	   fitted	   kinetic	   parameters	   are	   shown	   in	   Table	   3.1,	   determined	   as	   described	   in	  
Materials	  and	  Methods,	  section	  2.2.11.1.1.	  
X-­‐31	   NA	   shows	   good	   activity	   both	   in	   HBS	   and	  MES	   buffers	   but	   surprisingly	  both	  the	  kcat	  and	  the	  Km	  are	  higher	   in	   the	  HBS	  buffer.	  The	  difference	  between	  these	  buffers	  most	   likely	  to	  affect	  MUNANA	  cleavage	   is	   the	  pH,	  with	  the	  MES	  buffer	  at	  pH	  6.5	  and	  the	  HBS-­‐P	  +	  CaCl2	  at	  pH	  7.4.	  NA	  is	  generally	  considered	  to	  be	  more	  active	  at	  lower	   pH	   and	   this	   is	   the	   reason	   that	   most	   NA	   assays	   are	   carried	   out	   below	  physiological	  pH.	  The	  HBS	  buffer	  also	  contains	  NaCl,	  at	  a	  concentration	  similar	  to	  that	  of	  an	  isotonic	  solution.	  In	  contrast,	  the	  MES	  buffer	  is	  hypotonic,	  containing	  no	  added	  NaCl	  and	  only	  small	  amounts	  of	  CaCl2.	  	  
One	   possible	   explanation	   for	   the	   differences	   seen	   in	   the	   kinetic	   parameters	  could	  be	  instability	  of	  the	  NA	  in	  low	  salt	  buffers.	  Experiments	  were	  therefore	  carried	  out	   with	   an	   NA	   sample	   left	   diluted	   in	   the	   hypotonic	   MES	   buffer	   for	   extended	  periods(~1	  hr)	   before	  use.	  No	   reduction	   in	  MUNANA	   cleavage	  was	   seen,	   indicating	  that	  X-­‐31	  NA	  truly	  does	  have	  a	  higher	  turnover	  rate	  and	  Km	  at	  physiological	  pH	  in	  the	  presence	  of	  salt	  (data	  not	  shown).	  For	  both	  buffers	  the	  kcat	  values	  at	  25°C	  were	  ~2	  –	  3-­‐fold	   lower	   than	   those	   determined	   at	   37°C.	   	   This	   is	   a	   normal	   difference	   for	   this	  temperature	  range	  and	  is	  consistent	  with	  the	  fact	  IAV	  NA	  has	  a	  temperature	  optimum	  of	  37°C.	  Likewise,	   for	  both	  buffers,	  the	  Km	  values	  at	  25°C	  were	  ~2-­‐fold	  smaller	  than	  those	  determined	   at	   37°C.	   This	   difference	   is	   typical	   for	   this	   temperature	  difference	  and	  indicates	  that	  the	  affinity	  of	  the	  NA	  for	  MUNANA	  increases	  as	  the	  temperature	  is	  decreased.	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Figure	   3.8:	   Michaelis-­‐Menten	   plot	   for	   X-­‐31	   NA	   cleaving	   MUNANA.	   Carried	   out	  under	  different	  conditions	  of	  buffer	  (MES	  and	  HBS-­‐P	  +	  CaCl2)	  and	  temperature	  (25˚C	  and	   37˚C).	   All	  measurements	   shown	  were	  made	   using	   the	   same	   NA	   concentration.	  Observed	   rate	   shown	   is	   determined	   by	   dividing	   the	  measured	   reaction	   rate	   by	   the	  concentration	  of	  protein	  used.	  	  	   	  























	  	  	  	  
Substrate	   Buffer/Temp	   Km	  ±	  S.E.
§	  
(µM)	  





MES*	  37˚C	   9.3	  ±	  0.6	   22.4	  ±	  0.3	   2.41	  
MES	  25˚C	   4.8	  ±	  0.2	   6.1	  ±	  0.1	   1.27	  
HBS†	  37˚C	   27.7	  ±	  1.1	   56.6	  ±	  0.9	   2.04	  
HBS	  25˚C	   17.7	  ±	  0.8	   20.3	  ±	  0.4	   1.15	  
6SLN	   HBS	  37˚C	   8070	  ±	  615	   18.5	  ±	  0.9	   0.0023	  
3SLN	   HBS	  37˚C	   562.3	  ±	  20	   97.5	  ±	  1.5	   0.173	  	  *MES	  	   =	  	   MES	  Buffer	  (32.5	  mM	  MES-­‐NaOH,	  pH	  6.5,	  4	  mM	  CaCl2)	  †HBS	  	   =	  	   HBS-­‐P	  +	  CaCl2	  Buffer	  (10	  mM	  HEPES-­‐NaOH,	  pH	  7.4,	  150	  mM	  NaCl,	  	  0.005%	  Tween-­‐20)	  §S.E.	  	   =	  	   Standard	  Error	  of	  the	  mean	  	  
Table	  3.1:	  Steady	  state	  kinetic	  parameters	  determined	  for	  X-­‐31	  NA	  	  
	  	  	  	  	  	  
	  
	  
Figure	   3.9:	   	   Reaction	   scheme	   of	   enzyme	   reporter	   system	   for	  measuring	   6SLN	  
and	  3SLN	  kinetic	  parameters.	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3.2.7.2 6SLN	  and	  3SLN	  kinetics	  
In	  order	  to	  study	  the	  kinetics	  of	  X-­‐31	  NA	  cleavage	  of	  6SLN	  and	  3SLN	  an	  assay	  was	   developed	   based	   on	   an	   enzyme	   reporter	   system,	   which	   had	   been	   used	   in	  previous	   studies	   (Cabezas	   et	   al.,	   1980).	   This	   system	   uses	   β-­‐galactosidase	   and	   β-­‐galactose	   dehydrogenase	   as	   reporter	   enzymes,	   with	   the	   measurement	   of	   activity	  based	  on	  the	  conversion	  of	  NAD+	  to	  NADH	  by	  β-­‐galactose	  dehydrogenase,	  which	  can	  be	  monitored	  by	  measuring	  the	  increase	  in	  absorbance	  at	  340	  nm	  (reaction	  scheme	  shown	  in	  Figure	  3.9).	  The	  assay	  was	  optimized	  to	  ensure	  that	  the	  reporter	  enzymes	  were	   not	   present	   at	   limiting	   concentrations,	   guaranteeing	   that	   the	   rate	   of	   reaction	  seen	   was	   that	   of	   the	   NA.	   This	   was	   verified	   by	   doubling	   the	   NA	   concentration	   and	  ensuring	  that	  it	  gave	  double	  the	  rate	  at	  both	  the	  highest	  and	  lowest	  concentrations	  of	  substrate	  used	  (data	  not	  shown).	  Measurements	  were	  all	  made	  using	  HBS-­‐P	  +	  CaCl2	  supplemented	  with	  1	  mM	  MgCl2	   to	  allow	  for	  optimal	  activity	  of	   the	  β-­‐galactosidase.	  All	   reactions	  were	  measured	   at	   37°C,	   as	   this	   is	   the	  optimal	   temperature	  of	   enzyme	  activity	   for	   both	   the	   β-­‐galactosidase	   and	   β-­‐galactose	   dehydrogenase.	   Experiments	  were	  carried	  out	  as	  described	  in	  Materials	  and	  Methods,	  section	  2.2.11.2.	  X-­‐31	  NA	  was	  used	  at	  a	  monomeric	  concentration	  of	  8.3	  nM	  for	  6SLN	  kinetics	  and	  0.83	  nM	  for	  3SLN	  kinetics.	  
Figure	   3.10	   shows	   Michaelis-­‐Menten	   plots	   for	   X-­‐31	   NA	   cleaving	   6SLN	   and	  3SLN,	  and	  the	  enzymatic	  parameters	  obtained	  from	  the	  fits	  are	  shown	  in	  Table	  3.1.	  It	  is	  clear	  from	  these	  results	  that	  X-­‐31	  NA	  is	  much	  more	  efficient	  at	  cleaving	  3SLN	  than	  6SLN,	  with	  a	  Km	  ~15-­‐fold	   lower	  and	  a	  kcat	  ~5-­‐fold	  higher	  (kcat/Km	  ~75-­‐fold	  higher).	  Although	   it	   has	   been	   observed	   before	   that	   IAV	   NA	   has	   an	   overall	   preference	   for	  cleaving	  α2,3	  linked	  sugars,	  as	  described	  in	  Introduction,	  section	  1.3.2.2,	  it	  is	  not	  clear
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Figure	   3.10:	   Michaelis-­‐Menten	   plots	   of	   X-­‐31	   NA	   cleaving	   6SLN	   and	   3SLN.	  Measurements	   carried	   out	   in	   HBS-­‐P	   +	   CaCl2	   +	   1	  mM	  MgCl2	   at	   37˚C.	   Cleavage	   of	   A)	  6SLN	  and	  B)	  3SLN	  was	  monitored	  by	   the	   reporter	  enzymes:	  β-­‐galactosidase	  and	  β-­‐galactose	  dehydrogenase.	  Rate	  of	  reaction	  was	  measured	  as	  the	  rate	  of	  conversion	  of	  NAD+	  into	  NADH	  by	  the	  β-­‐galactose	  dehydrogenase	  by	  monitoring	  the	  absorbance	  at	  340	  nm.	  Observed	  rate	  shown	  is	  determined	  by	  dividing	  the	  measured	  reaction	  rate	  by	  the	  concentration	  of	  protein	  used.	  	   	  









































if	  this	  is	  a	  property	  of	  this	  particular	  enzyme	  or	  if	  it	  is	  due	  to	  the	  ketosidic	  bond	  being	  inherently	  more	  cleavable	  in	  the	  α2,3	  linked	  form.	  
Comparing	   these	   results	   with	   the	   results	   obtained	   for	   MUNANA	   cleavage	  under	   the	   same	   buffer	   and	   temperature	   conditions	   (Table	   3.1)	   shows	   that	   the	   Km	  values	   for	   6SLN	   and	  3SLN	   are	  much	  higher	   than	   those	   for	  MUNANA.	   This	   suggests	  that	  MUNANA	  is	  bound	  more	  strongly	  than	  the	  natural	  sugars.	  This	  is	  likely	  to	  be	  due	  to	  the	  highly	  hydrophobic	  methylumbelliferyl	  group	  of	  MUNANA	  interacting	  in	  some	  way	  with	   the	   active	   site	   of	  NA	   (which	   contains	   a	  number	  of	   hydrophobic	   residues)	  and	   contributing	   to	   the	   free	   energy	   (and	   hence	   affinity)	   of	   the	   interaction.	   The	  turnover	  rate	  (kcat)	  is,	  however,	  ~2-­‐fold	  higher	  for	  3SLN	  cleavage	  than	  for	  MUNANA	  cleavage,	  indicating	  that	  although	  the	  NA	  can	  bind	  MUNANA	  more	  efficiently	  it	  can	  be	  more	   efficient	   at	   cleaving	   the	  natural	   polysaccharide	   substrates.	   The	   kcat/Km	   values	  indicate	  that	  the	  NA	  of	  X-­‐31	  is	  much	  more	  efficient	  at	  cleaving	  MUNANA	  than	  6SLN	  or	  3SLN,	  with	  the	  value	  ~12-­‐fold	  higher	  for	  MUNANA	  than	  the	  more	  efficiently	  cleaved	  of	  the	  natural	  substrates,	  3SLN.	  These	  experiments	  highlight	  the	  requirement	  for	  NA	  kinetics	  to	  be	  measured	  for	  sugar	  substrates	  in	  order	  to	  fully	  interpret	  their	  influence	  on	  affecting	  the	  balance	  of	  HA	  and	  NA	  activities.	  
3.2.8 Characterisation	  of	  NA	  activity	  on	  sugar	  depletion	  
The	   differences	   between	   the	   curves	   presented	   above	   with	   inhibited	   and	  uninhibited	  NA	  must	  be	  due	  to	  the	  action	  of	  the	  NA	  on	  the	  surface	  immobilised	  sugars.	  Kinetic	   parameters	   determined	   for	   the	   cleavage	   of	   6SLN	   and	   3SLN	   presented	   in	  section	  3.2.7.2	  provide	  useful	  information	  on	  the	  relative	  abilities	  of	  the	  NA	  to	  cleave	  different	  substrates	  in	  solution.	  However,	  they	  do	  not	  give	  information	  on	  the	  effects	  of	  NA	  on	  a	  virus	  on	  these	   immobilised	  sugars,	  where	  the	   interaction	  of	   the	  NA	  with	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the	  substrate	  will	  be	  influenced	  by	  the	  fact	  that	  HAs	  are	  bound	  to	  some	  of	  the	  sugars	  and	   by	   the	   fact	   that	   the	   NA	   may	   have	   restricted	   access	   to	   the	   surface	   attached	  substrate.	  Determining	  the	  cleavage	  of	  surface	  bound	  sugars	  is	  important	  in	  order	  to	  allow	   the	   understanding	   of	   NA	   cleavage	   in	   a	   more	   natural	   form	   of	   substrate	  presentation.	  
In	   order	   to	   determine	   the	   effects	   of	   NA	   on	   the	   surface,	   experiments	   were	  conducted	   to	   estimate	   the	   levels	   of	   sialic	   acid	   depletion	   from	   the	   sensor	   surface	   at	  different	  time	  points.	  These	  experiments	  consisted	  of	  starting	  a	  typical	  measurement	  of	   100pM	   virus	   (X-­‐31)	   binding	   in	   the	   absence	   of	   inhibitors	   and	   then	   stopping	   the	  measurement	  at	  specific	  times	  and	  transferring	  the	  sensors	  into	  wells	  containing	  the	  same	   concentration	   of	   virus	   in	   the	   presence	   of	   NA	   inhibitors.	   The	   remaining	   virus	  binding	  capacity	  of	  the	  sensor	  can	  then	  be	  estimated.	  3SLN-­‐PAA	  measurements	  were	  stopped	  at	  times	  ranging	  from	  30	  –	  3600	  s	  and	  6SLN-­‐PAA	  320	  –	  3600	  s.	  From	  these	  measurements	   the	   total	   response	   at	   long	   times	   is	   measured	   and	   converted	   to	  fractional	   saturation	   by	   comparison	  with	   previously	  measured	   binding	   curves	  with	  inhibited	   NA.	   These	   data	   were	   then	   converted	   to	   sugar	   loading	   values	   using	   the	  parameters	  obtained	  by	   fitting	   the	  data	  presented	   in	  Figure	  3.2.	  These	  curves	  were	  fitted	  using	  a	  modified	  version	  of	  the	  Hill	  equation,	  Equation	  3.3:	  
	   	   	   	   (3.3)	  





Final	   fractional	   saturation	   values	   to	   determine	   sugar	   depletion	   at	   different	  time	  points	  were	   converted	   into	   sugar	   loadings	  using	   a	   rearrangement	   of	   Equation	  3.3	  (Equation	  3.4):	  
	   	   	   	   (3.4)	  These	   calculated	   sugar	   loading	   values	  were	   then	   converted	   to	   percentage	   of	  remaining	  sialic	  acid	  by	  assuming	  that	  at	  100%	  saturation	  RSL	  =	  0.6	  nm.	  An	  example	  of	   the	   raw	   data	   for	   these	   measurements	   is	   shown	   in	   Figure	   3.11,	   which	   shows	  measurements	  initiated	  in	  the	  absence	  of	  NA	  inhibitors	  before	  adding	  NA	  inhibitors	  at	  different	  set	  time	  points.	  










Figure	  3.11:	  Raw	  data	  from	  X-­‐31	  sialic	  acid	  depletion	  experiments.	  X-­‐31	  binding	  measured	  in	  the	  absence	  of	  NA	  inhibitors	  was	  stopped	  at	  defined	  time	  points	  and	  the	  remaining	   receptor	   is	   saturated	   with	   virus	   in	   the	   presence	   of	   NA	   inhibitors.	   Data	  shown	   are	   for	   virus	   binding	   to	   sensors	   saturated	   with	   6SLN-­‐PAA	   with	   reactions	  stopped	  at	  a	  small	  number	  of	  illustrative	  time	  points.	  
Figure	   3.12:	   Measurement	   of	   the	   depletion	   of	   sialic	   acid	   from	   6SLN-­‐PAA	   and	  
3SLN-­‐PAA	  by	  X-­‐31.	  Data	  were	  collected	  to	  measure	  the	  total	  virus	  binding	  capacity	  of	  a	  sugar	  coated	  sensor	  at	  different	  time	  points	  during	  virus	  binding	  in	  the	  absence	  of	   NA	   inhibitors.	   Data	   shown	   are	   the	   mean	   of	   3	   independent	   measurements,	   with	  error	   bars	   showing	   standard	   deviation	   from	   the	   mean.	   Dashed	   lines	   indicate	   the	  sugar	  values	  at	  which	  the	  virus	  binds	  the	  different	  receptor	  at	  95%	  binding	  capacity,	  therefore	   the	   level	   of	   depletion	   which	   will	   start	   to	   affect	   HA	   mediated	   receptor	  binding.	  	  










































Figure	  3.13:	  	  Comparison	  of	  X-­‐31	  sugar	  depletion	  data	  with	  HA/NA	  balance	  data.	  Both	   parameters	   measured	   for	   sialoglycopolymers	   bearing	   the	   two	   receptor	  analogues	  A)	  6SLN	  and	  B)	  3SLN.	  	  
	  








































From	  these	  data	  it	  is	  clear	  that	  the	  cleavage	  of	  3SLN-­‐PAA	  is	  much	  quicker	  than	  that	   seen	   for	   6SLN-­‐PAA,	   with	   >50%	   of	   sialic	   acid	   depleted	   by	   30	   s	   for	   3SLN-­‐PAA	  compared	   to	   320	   s	   for	   6SLN-­‐PAA.	   This	   is	   likely	   due	   to	   the	   much	   greater	   catalytic	  efficiency	   of	   X-­‐31	   NA	   in	   cleaving	   α2,3-­‐linked	   sialic	   acid,	   as	   seen	   from	   the	   enzyme	  kinetic	  parameters	  shown	  in	  Table	  3.1.	  	  
An	   interesting	   feature	  of	   the	   sugar	  depletion	   curves	   shown	   in	  Figure	  3.12	   is	  that	  the	  amount	  of	  3SLN-­‐PAA	  remaining	  at	  later	  time	  points	  is	  higher	  than	  that	  seen	  with	  6SLN-­‐PAA.	  This	  is	  presumably	  due	  to	  shorter-­‐lived	  HA-­‐mediated	  interactions	  of	  the	  virus	  with	  the	  3SLN-­‐PAA	  when	  the	  sugar	  loading	  has	  been	  reduced	  to	  low	  levels.	  	  
3.2.9 Effect	  of	  altering	  HA	  receptor	  binding	  affinity	  
All	   of	   the	   data	   presented	   above	   were	   obtained	   with	   the	   same	   virus,	   X-­‐31.	  Experiments	   described	   in	   this	   section	   were	   carried	   out	   to	   examine	   the	   effect	   of	  altering	  HA	  receptor	  specificity.	  X-­‐31	  HAM	  is	  a	  mutant	  of	  X-­‐31	  containing	  the	  single	  substitution	  L226Q	  in	  the	  HA,	  selected	  by	  passaging	  the	  virus	  in	  the	  presence	  of	  horse	  serum	   (Rogers	   et	   al.,	   1983).	   All	   other	   viral	   characteristics	   remain	   unchanged.	   This	  mutation	  causes	  major	  changes	  in	  the	  HA-­‐mediated	  receptor	  binding	  characteristics	  of	  the	  virus;	  binding	  to	  6SLN-­‐PAA	  is	  significantly	  weakened	  and	  binding	  to	  3SLN-­‐PAA	  is	  somewhat	  strengthened,	  as	  seen	  in	  Figure	  3.1	  (Xiong	  et	  al.,	  2013a).	  The	  affinities	  of	  monomeric	  sugars	  for	  isolated	  HA	  have	  been	  measured	  by	  NMR	  (Sauter	  et	  al.,	  1989)	  and	  more	   recently	   by	   microscale	   thermophoresis	   (MST)	   (Xiong	   et	   al.,	   2013a).	   The	  L226Q	  substitution	  decreased	  the	  affinity	  of	  the	  HA	  for	  monomeric	  6SLN	  (Kd	  =	  2.1	  ±	  0.3	  mM	  (X-­‐31)	  and	  Kd	  =	  5.9	  ±	  0.7	  mM	  (X-­‐31	  HAM))	  whereas	  the	  substitution	  resulted	  in	  a	  small	   increase	   in	  affinity	  of	  HA	  for	  monomeric	  3SLN	  (Kd	  =	  3.2	  ±	  0.6	  mM	  (X-­‐31)	  and	  Kd	  =	  2.9	  ±	  0.3	  mM	  (X-­‐31	  HAM))	  (Sauter	  et	  al.,	  1989).	  These	  small	  differences	   in	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the	  dissociation	   constants	   for	  monomeric	   interactions	   translate	   into	   the	   substantial	  affinity	  differences	   seen	  when	   studying	   the	  multivalent	   interaction	  between	  a	  virus	  and	  a	  sugar	  coated	  surface	  (Fig.	  3.1).	  	  
Experiments	  to	  determine	  alterations	  of	  the	  HA	  and	  NA	  balance	  characteristics	  seen	  with	   a	   virus	   carrying	   this	   substitution	  were	   carried	   out.	   Figure	   3.14	   shows	   a	  comparison	  of	  the	  binding	  curves	  for	  the	  two	  viruses,	  X-­‐31	  and	  X-­‐31	  HAM.	  The	  largest	  difference	  can	  be	  seen	   in	   the	  experiments	  with	  6SLN-­‐PAA	  binding,	  where	   there	   is	  a	  large	   reduction	   in	   overall	   virus	   binding,	   with	   the	   inhibited	   and	   uninhibited	   curves	  diverging	   at	   much	   shorter	   times,	   for	   X-­‐31	   HAM.	   This	   must	   be	   associated	   with	  decreased	  affinity	  of	   the	  HA	   for	  6SLN.	  This	   reduction	   in	  affinity	   results	   in	   the	  virus	  having	  shorter-­‐lived	  interactions	  with	  the	  biosensor	  surface,	  as	  calculated	  in	  section	  3.2.6.	  The	  change	  seen	  in	  experiments	  with	  3SLN-­‐PAA	  goes	  in	  the	  opposite	  direction,	  with	  X-­‐31	  HAM	  overall	  showing	  more	  virus	  binding	  than	  X-­‐31.	  This	  is	  consistent	  with	  the	  observation	  that	  X-­‐31	  HAM	  has	  a	  slightly	  higher	  affinity	  for	  3SLN	  than	  does	  X-­‐31.	  	  
3.2.10 Effect	  of	  NA	  stalk	  length	  on	  HA/NA	  Balance	  The	  NA	  of	  IAVs,	  upon	  adaptation	  of	  the	  virus	  to	  new	  hosts,	  can	  mutate	  to	  lose	  sections	  of	  the	  NA	  stalk,	  as	  described	  in	  Introduction,	  section	  1.3.2.4.	  This	  reduction	  of	  NA	   stalk	   length	   will	   move	   the	   catalytic	   head	   region	   of	   the	   NA	   closer	   to	   the	   viral	  membrane.	  Such	  deletions	  would	  therefore	  be	  likely	  to	  restrict	  the	  ability	  of	  the	  NA	  to	  effectively	  encounter	  substrate.	  	  





Figure	  3.14:	  BLI	  HA/NA	  balance	  data	  for	  the	  binding	  of	  X-­‐31	  (100pM)	  and	  X-­‐31	  
HAM.	   Measurements	   made	   in	   the	   presence	   and	   absence	   of	   inhibitors	   (inhib)	   to	  sensors	   saturated	   sialoglycopolymers	   bearing	   receptor	   analogues	   A)	   6SLN	   and	   B)	  3SLN.	  
	   	  









































as	  described	  in	  Materials	  and	  Methods,	  section	  2.2.6.12.1.	  The	  NA	  was	  then	  subjected	  to	   deletion	   mutagenesis	   to	   make	   a	   number	   of	   different	   lengths	   of	   deletion,	   as	  described	   in	  Materials	   and	  Methods,	   section	   2.2.6.13.2.	   Plasmids	   were	   constructed	  with	  deletions	  of:	  5	  (60	  –	  64),	  10	  (60	  –	  69),	  15	  (60	  –	  74),	  20	  (60	  –	  79),	  21	  (60	  –	  80)	  and	  28	  (54	  –	  81)	  residues.	  Numbers	  in	  brackets	  indicate	  amino	  acid	  numbers	  of	  the	  residues	  deleted.	  The	  deletions	  of	  21	  and	  27	  were	  based	  on	  previously	  reported	  stalk	  mutants	  generated	  in	  N2	  NAs	  (Castrucci	  &	  Kawaoka,	  1993;	  Sorrell	  et	  al.,	  2010).	  Virus	  rescue	   was	   attempted	   for	   all	   of	   the	   stalk	   deletions	   listed	   above,	   as	   described	   in	  
Materials	  and	  Methods,	  section	  2.2.5.	  The	  transfections	  were	   inoculated	  directly	   into	  eggs.	  On	  passage	  the	  only	  virus	  that	  propagated	  efficiently	  in	  eggs	  was	  the	  virus	  with	  the	  10	  amino	  acid	  deletion,	  henceforth	  to	  be	  referred	  to	  as	  X-­‐31	  NA	  Δ10.	  	  
Figure	  3.15	  shows	  HA/NA	  balance	  measurements	  in	  which	  the	  binding	  of	  X-­‐31	  and	  X-­‐31	  NA	  Δ10	  is	  compared.	  The	  binding	  of	  X-­‐31	  and	  X-­‐31	  NA	  Δ10	  in	  the	  presence	  of	  NA	  inhibitors	  to	  6SLN-­‐PAA	  and	  3SLN-­‐PAA	  is	  very	  similar	  indicating	  no	  difference	  in	  the	  HA	  mediated	  binding	  characteristics.	  In	  the	  absence	  of	  NA	  inhibitors	  X-­‐31	  NA	  Δ10	  shows	  more	  extensive	  virus	  binding,	  with	  the	  turning	  point	  at	  a	   later	  time	  point	   for	  both	   6SLN-­‐PAA	   and	   3SLN-­‐PAA.	   	   This	   shows	   that	   the	   NA	  with	   the	   stalk	   deletion	   is	  significantly	   less	  efficient	  at	  removing	  the	  surface	   immobilised	  sugars.	  The	  sialidase	  activities	   of	   X-­‐31	   and	   X-­‐31	   NA	   Δ10	   cleaving	   small	   substrates	   were	   compared	   by	  measuring	  MUNANA	  cleavage	  activity	  of	   the	   two	  viruses	  at	   the	  same	  concentration.	  The	   cleavage	   rates	  were	   very	   similar	   (data	   not	   shown),	   indicating	   that	   there	   is	   no	  effect	   of	   the	   stalk	   deletion	   on	   the	   sialidase	   activity	   for	   small	   substrates.	   The	  differences	  seen	  in	  Figure	  3.15	  must	  therefore	  be	  due	  to	  a	  geometric	  difference	  in	  the	  positioning	  of	  the	  NA	  on	  the	  virion.	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Figure	  3.15:	  BLI	  HA/NA	  balance	  data	   for	  the	  binding	  of	  X-­‐31	  and	  X-­‐31	  NA	  Δ10	  
viruses.	   X-­‐31	   NA	   Δ10	   virus	   has	   residues	   60-­‐69	   removed	   from	   the	   NA	   stalk.	  Measurements	   made	   in	   the	   presence	   and	   absence	   of	   NA	   inhibitors	   (Inhib)	   for	   the	  binding	  to	  sialoglycopolymers	  bearing	  the	  receptor	  analogues	  A)	  6SLN	  and	  B)	  3SLN	   	  










































The	  experiments	  presented	  in	  this	  chapter	  are	  a	  new	  biophysical	  approach	  to	  answering	  questions	  regarding	  the	  balance	  between	  the	  activities	  of	  IAV	  HA	  and	  NA.	  This	  biophysical	  approach	  allows	  a	  better	  understanding	  of	  the	  processes	  involved	  in	  virus	  binding	  and	  release,	  which	  have	  previously	  been	  inferred	  from	  isolated	  kinetic	  and	   thermodynamic	   parameters	   for	   HA	   and	   NA,	   without	   consideration	   of	   the	  complexities	  associated	  with	  the	  multivalent	  nature	  of	  the	  interaction	  of	  a	  virus	  with	  a	   surface.	   It	   is	   clear	   from	   the	   data	   presented	   in	   this	   chapter	   that	   the	   binding	   and	  release	  of	  virus	  from	  surface	  immobilised	  sugars	  depends	  critically	  on	  the	  balance	  of	  activities:	  the	  ability	  of	  HA	  to	  bind	  receptors	  and	  the	  catalytic	  efficiency	  of	  the	  NA	  in	  depleting	  the	  sugars.	  	  
The	  interaction	  of	  HA	  with	  an	  isolated	  sialic	  acid	  is	  very	  weak,	  with	  Kds	  in	  the	  mM	  range	  (Sauter	  et	  al.,	  1989;	  1992b;	  Xiong	  et	  al.,	  2013a).	  Because	  these	  interactions	  are	   so	  weak	   the	   virus	  must	   form	   several	   HA-­‐receptor	   interactions	   in	   a	  multivalent	  fashion	  in	  order	  to	  achieve	  stable	  attachment	  to	  a	  surface.	  If	  only	  a	  small	  number	  of	  interactions	  are	  formed	  the	  affinity	  is	  likely	  to	  be	  low	  and	  there	  is	  a	  high	  probability	  that	   the	   virus	   will	   dissociate	   before	   forming	   enough	   interactions	   to	   form	   a	   high	  affinity	   (and	   therefore	   long-­‐lived)	   complex.	   In	   the	   case	   of	   a	   virus	   with	   inactive	  (inhibited)	  NA	  there	  are	   likely	  to	  be	  a	   large	  number	  of	  short-­‐lived	   interactions	  with	  virus	  associating	  and	  rapidly	  dissociating.	  The	  Kd(receptor)	  values	  determined	  for	  single	  receptor	   interactions	  with	   single	   sugars	   can	   be	   related	   to	   the	  multivalent	   apparent	  Kd(virus)	   values.	   Kd(virus)	   =	   Kd(receptor)mc,	   where	   mc	   =	   the	   multiplicity	   coefficient.	   The	  multiplicity	  coefficient	  was	  estimated	  to	  be	  in	  the	  range	  3	  –	  5.5	  (Xiong	  et	  al.,	  2013a)	  for	  the	  range	  of	  sugar	  loadings	  covered	  in	  this	  study.	  For	  a	  receptor	  with	  Kd(Receptor)	  =	  3	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mM	   this	   would	   correspond	   to	   Kd(Virus)	   values	   in	   the	   range	   27	   nM	   to	   0.24	   pM.	   It	   is	  important	  to	  note	  that	  that	  the	  multiplicity	  coefficient	   is	  not	  equal	  to	  the	  number	  of	  HA-­‐receptor	   interactions	   that	   are	   formed.	   This	   would	   only	   be	   the	   case	   if	   each	  interaction	  contributed	  the	  same	  free	  energy,	  which	  is	  unlikely	  to	  be	  the	  case.	  
The	  combination	  of	  the	  results	  for	  X-­‐31	  binding	  in	  the	  presence	  and	  absence	  of	  inhibitors	   (Fig.	  3.2),	   the	  results	   for	   the	  sugar	  depletion	  experiments	   (Fig.	  3.12),	  and	  the	   values	   estimated	   for	   virus	   residence	   times	   (Fig.	   3.7)	   allow	   a	   number	   of	  conclusions	   to	   be	   drawn	   concerning	   the	   interaction	   of	   the	   virus	   with	   the	   sensor	  surface	  in	  the	  absence	  of	  NA	  inhibitors.	  Initially	  the	  virus	  cleaves	  a	  very	  large	  amount	  of	   sugar	   from	   the	   surface	   surprisingly	   quickly,	   as	   shown	   in	   the	   sugar	   depletion	  experiments	  (Fig.	  3.12).	  This	  rapid	  cleavage	  of	  sugars	  happens	  before	  a	  large	  amount	  of	  virus	  has	  bound	  to	  the	  sensor	  surface	  and	  has	  increased	  the	  signal	  measured.	  This	  is	  particularly	  clear	  when	  comparing	  the	  curves	  for	  X-­‐31	  binding	  to	  3SLN-­‐PAA	  in	  the	  presence	  and	  absence	  of	  inhibitors.	  The	  curves	  diverge	  after	  ~30	  s	  giving	  a	  maximum	  response	   (fractional	   saturation)	   of	   ~0.1,	   indicating	   that	   only	   10%	   of	   the	   surface	   is	  saturated	  before	  the	  NA	  has	  depleted	  so	  much	  of	  the	  sugar	  that	  the	  virus	  affinity	  has	  been	  dramatically	  reduced.	  This	  appears	  to	  be	  due	  to	  many	  short-­‐lived	  interactions	  of	  the	   virus	  with	   the	   surface	  which,	   as	   reasoned	   above,	   are	   still	   long	   enough	   to	   allow	  time	  for	  the	  NA	  to	  cleave	  large	  amounts	  of	  sugar.	  This	  is	  particularly	  apparent	  for	  X-­‐31	  binding	   to	  3SLN-­‐PAA,	   likely	  due	   to	   the	  much	  higher	  efficiency	  of	   the	  sialidase	  at	  cleaving	   2,3	   linked	   sugars.	   At	   first	   sight	   the	   notion	   of	   transient	   virus	   interactions	  appears	   to	   be	   inconsistent	   with	   calculated	   residence	   times	   for	   a	   saturated	   sensor	  (RSL	  =	  0.6	  nm)	  of	  the	  order	  of	  ~105	  s.	  These	  residence	  times	  will,	  however,	  only	  apply	  to	  viruses	  that	  have	  bound	  and	  have	  formed	  enough	  HA-­‐receptor	  contacts	  to	  yield	  a	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high	   affinity	   interaction.	   	   In	   practice	   this	   is	   likely	   to	   take	   some	   time	   as	  many	   such	  interactions	  must	  be	  formed	  and	  any	  particular	  low	  affinity	  HA-­‐sugar	  contact	  is	  likely	  to	  be	  very	  short-­‐lived.	  	  
These	  initial	  transient	  interactions	  could	  be	  considered	  to	  be	  similar	  to	  those	  at	  very	  low	  sugar	  loadings.	  For	  instance,	  if	  the	  interactions	  were	  similar	  to	  those	  at	  a	  low	  sugar	  loading	  of	  0.02	  nm	  the	  estimated	  residence	  times	  (Fig.	  3.7)	  would	  be	  ~30	  –	  50	  ms	  for	  3SLN-­‐PAA	  and	  ~2	  –	  5	  s	  for	  6SLN-­‐PAA.	  What	  is	  important,	  however,	  is	  how	  much	  sugar	  the	  virus	  can	  cleave	  in	  these	  short-­‐lived	  interactions.	  This	  will	  depend	  on	  a	  number	  of	   factors	   including:	   the	  positioning	  and	  amounts	  of	  NA	  on	   the	  virus,	   the	  position	  and	  distribution	  of	  substrate,	  and,	  what	  seems	  most	  important,	  the	  catalytic	  efficiency	  of	   the	  enzyme	  for	  cleaving	  substrate	  (kcat/Km).	  The	  much	  greater	  catalytic	  activity	  of	  X-­‐31	  NA	  for	  cleaving	  3SLN,	  with	  Km	  ~15-­‐fold	  lower	  and	  kcat	  ~5-­‐fold	  higher	  than	   for	   6SLN	   (Table	   3.1),	   appears	   to	   be	   sufficient	   to	   give	  much	  more	   rapid	   sugar	  depletion	  in	  spite	  of	  the	  fact	  that	  the	  lower	  affinity	  of	  HA	  for	  3SLN-­‐PAA	  is	  associated	  with	  significantly	  shorter	  virus	  residence	  times.	  	  
After	   these	   initial	   fast	   cleavage	   events	   the	   rate	   of	   sugar	   depletion	   begins	   to	  decline	   very	   close	   to	   the	   time	   at	  which	   the	   curves	   show	  a	   turning	   point.	   This	   slow	  down	   in	   sugar	  depletion	   therefore	  begins	   at	   the	  point	  where	   the	   largest	   amount	  of	  virus	   is	   bound.	   This	   might	   be	   considered	   to	   be	   the	   best	   opportunity	   for	   the	   viral	  attached	  NA	  to	  cleave	  sugars;	  however,	  this	  does	  not	  appear	  to	  be	  the	  case.	  It	  appears	  that	  for	  the	  most	  efficient	  cleavage	  the	  virus	  needs	  to	  be	  undergoing	  the	  short-­‐lived	  interactions	  present	  in	  the	  early	  parts	  of	  the	  binding	  assays,	  presumably	  as	  the	  viral	  attached	  NA	   is	  meeting	  more	  substrate.	  Virus	  particles	  will	  briefly	   interact	  with	   the	  sensor	  surface	  in	  a	  range	  of	  random	  orientations.	  The	  virus	  will	  then	  either	  dissociate	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due	  to	  weak	  HA	  interactions	  or	  due	  to	  NA	  cleavage	  of	  the	  receptors.	  This	  fast	  turnover	  of	  virus	  appears	  to	  allow	  very	  efficient	  cleavage	  of	  the	  sugars.	  
The	  slow	  down	   in	   receptor	  cleavage	  could	  be	  due	   to	  a	  number	  of	   factors:	  1)	  longer	  more	   established	   HA	  mediated	   virus	   interactions	  with	   the	   surface	   could	   be	  shielding	   the	   remaining	   sugars	   in	   the	   footprint	   of	   the	   virus;	   2)	   long-­‐lived	   virus	  interactions	   may	   have	   geometric	   constraints	   preventing	   the	   NA	   from	   meeting	   the	  substrate	   on	   the	   surface;	   or	   3)	   shorter	   interaction	   times	   may	   prevent	   NA	   from	  interacting	  with	  the	  remaining	  surface	  sugars.	  
Some	  of	   the	  HA/NA	  balance	  curves	  recorded	   in	   the	  absence	  of	  NA	   inhibitors	  never	   reach	  a	   response	  value	  of	   zero.	   For	   example	  X-­‐31	  binding	   to	  6SLN-­‐PAA	  after	  3600	  s	   is	   still	  evident	  at	  a	  binding	   level	   (fractional	  saturation)	  of	  0.2	  or	  20%	  of	   the	  saturation	  capacity	  when	  the	  NA	  is	  inhibited	  (Fig.	  3.2).	  This	  is	  likely	  to	  be	  due	  to	  two	  possible	   scenarios:	   1)	   a	   population	   of	   irreversibly	   attached	   viruses;	   or	   2)	   viruses	  making	   interactions	   that	   are	   too	   short	   for	   the	   NA	   to	   efficiently	   meet	   any	   of	   the	  remaining	  (heavily	  depleted)	  substrate.	  The	  sialic	  acid	  depletion	  curves	  displayed	  in	  Figure	  3.12	  tend	  towards	  a	  level	  of	  remaining	  sugar	  of	  ~10%	  for	  both	  6SLN-­‐PAA	  and	  3SLN-­‐PAA.	  At	   this	   level	   of	   sugar	   loading	   (0.06	  nm)	   the	  mean	   virus	   residence	   times	  would	   be	   ~100	   s	   for	   6SLN-­‐PAA	   and	   ~1.7	   s	   for	   3SLN-­‐PAA	   (see	   Fig.	   3.7).	   These	  residence	   times	   do	   not	   appear	   to	   allow	   for	   the	   hypothesis	   of	   irreversibly	   attached	  viruses.	   This	   implies	   that	   the	   remaining	  binding	   of	   the	   virus	  must	   be	  due	   to	   short-­‐lived	   interactions,	   which	   do	   not	   allow	   the	   NA	   to	   cleave	   significant	   amounts	   of	   the	  reaming	  sugar.	  
The	   results	   from	   the	  experiments	  with	  CPNA	  and	   inhibited	  viral	  NA	   indicate	  that	   the	   initial	   cleavage	   of	   sugars	   from	   the	   surface	   is	   similar	   whether	   the	   NA	   is	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attached	   to	   the	   virus	   or	   not.	   The	   depletion	   of	   the	   sugars	   by	   the	   soluble	   CPNA,	   if	  measured,	  would	  be	  a	  simple	  single	  exponential	  decay,	  as	  the	  rate	  of	  sugar	  cleavage	  would	  reduce	  proportionally	  with	  the	  amount	  of	  sugar	  still	  remaining	  on	  the	  surface.	  The	  sugar	  depletion	  by	  the	  viral	  NA	  fits	  much	  better	  to	  a	  double	  exponential	  function	  (Fig.	   3.12),	   although	   the	   number	   of	   data	   points	   is	   limited,	   suggesting	   two	   different	  phases	   of	   depletion:	   an	   initial	   fast	   depletion,	   followed	   by	   a	  much	   slower	   depletion.	  The	   effect	   of	   tethering	   the	   NA	   to	   the	   virus	   is	   to	   reduce	   its	   ability	   to	   cleave	   sugars	  when	  the	  amount	  of	  sugar	  on	  the	  sensor	  has	  been	  reduced	  to	  low	  levels.	  
When	  looking	  at	  the	  results	  comparing	  the	  binding	  of	  X-­‐31	  with	  X-­‐31	  HAM	  (Fig.	  3.14)	  it	  is	  apparent	  that	  the	  reduction	  in	  overall	  receptor	  binding	  to	  6SLN-­‐PAA	  in	  the	  absence	  of	  NA	  inhibitors	  is	  directly	  attributable	  to	  the	  decrease	  in	  the	  affinity	  of	  this	  HA	  for	  6SLN-­‐PAA	  (Fig.	  3.1).	  The	  turning	  points	  for	  X-­‐31	  HAM	  binding	  to	  both	  6SLN-­‐PAA	  and	  3SLN-­‐PAA	  are	  very	  similar	  (Fig.	  3.14),	  indicating	  that	  the	  reduction	  in	  6SLN	  receptor	   binding	   affinity	   balances	   out	   the	   reduced	   ability	   of	   the	   NA	   to	   cleave	   α2,6	  linked	  sugars.	  	  
Comparing	  the	  stalk	  deletion	  mutant	  X-­‐31	  NA	  Δ10	  with	  X-­‐31	  (Fig.	  3.15)	  shows	  significantly	  increased	  overall	  binding	  to	  6SLN-­‐PAA	  and	  3SLN-­‐PAA,	  with	  the	  binding	  curves	  diverging	  at	  longer	  times.	  This	  is	  due	  to	  the	  reduced	  ability	  of	  the	  viral	  NA	  to	  interact	   with	   substrate,	   reducing	   the	   effective	   cleavage	   rate,	   despite	   the	   NA	   being	  equally	   active	   at	   cleaving	   small	   substrates.	   This	   is	   the	   first	   time	   that	   a	   stalk	   length	  reduction	  has	  been	  directly	   shown	   to	   reduce	  NA	  activity	   in	  a	   context	   similar	   to	   the	  interactions	  of	  IAVs	  with	  the	  cell	  surface.	  
The	  techniques	  developed	  in	  this	  chapter	  provide	  a	  good	  new	  tool	  for	  looking	  at	  HA/NA	  balance	   in	  a	  more	  quantitative	  manner,	   allowing	  better	  understanding	  of	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this	  highly	  complex	  process	  involving	  many	  aspects	  of	  cooperativity	  and	  multivalency.	  This	   developed	   system	   comes	   with	   a	   number	   of	   caveats.	   The	   virus	   concentrations	  used	   (100	   pM	   ≈	   1010	   virus	   particles/ml)	   is	   high	   compared	   to	   virus	   concentrations	  present	  upon	  infection.	  The	  density	  of	  these	  surface	  immobilised	  sugars	  is	  thought	  to	  be	   similar	   to	   that	   of	   a	   cell	   surface	   (Xiong	   et	   al.,	   2013a);	   however,	   these	   receptor	  analogues	   used	   are	   also	   short	   polysaccharides	   compared	   to	   complex	   glycosylation	  present	   on	   cell	   surface	   glycoproteins	   and	   glycolipids.	   The	   shortness	   of	   the	   glycan	  chains	   of	   these	   receptor	   analogues	   could	   alter	   the	   binding	   and	   cleavage	  characteristics	  measured	  in	  these	  experiments.	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4 Biophysical	  Characterisation	  of	  the	  Involvement	  of	  
Neuraminidase	  in	  H7N9	  Receptor	  Binding	  
4.1 Introduction	  
H7N9	   viruses	   were	   first	   isolated	   in	   February	   2013	   and	   reported	   by	   the	  Chinese	  Centre	  for	  Disease	  Control	  in	  March	  2013.	  These	  viruses	  are	  thought	  to	  be	  a	  direct	   zoonosis	   from	   wild	   birds.	   They	   have	   caused	   extensive	   infections	   within	  mainland	  China	  and	  have	  been	  responsible	   for	  a	   large	  number	  of	  human	   infections,	  672	   laboratory-­‐confirmed	   cases	   as	   of	   the	   23rd	   June	   2015.	   These	   viruses	   have	   been	  found	  do	  have	  a	  high	  case	   fatality	  ratio	  of	  ~40%	  but	  appear	  to	  be	  unable	  to	  readily	  transmit	   between	   humans	   (World	   Health	   Organisation,	   2015c).	   Owing	   to	   the	  antigenically	  novel	  nature	  of	  these	  viruses	  and	  their	  ability	  to	  infect	  humans	  the	  cell	  interaction	  characteristics	  and	  consequently	  transmission	  properties	  of	  these	  viruses	  are	  of	  considerable	  importance.	  	  
Previous	   studies	   have	   shown	   that	   H7N9	   viruses	   bind	   preferentially	   to	   the	  avian-­‐like	  receptor,	  α2,3-­‐linked	  sialic	  acid	  but	  also	  have	  strong	  binding	  to	  α2,6-­‐linked	  sialic	  acid.	  This	  has	  been	  shown	  by	  BLI	  (Xiong	  et	  al.,	  2013b;	  Yang	  et	  al.,	  2013),	  surface	  plasmon	   resonance	   (SPR)	   (Shi	   et	  al.,	   2013),	   glycan	  microarray	   (Belser	   et	  al.,	   2013;	  Yang	  et	  al.,	  2013;	  Dortmans	  et	  al.,	  2013)	  and	  other	  solid	  phase	  binding	  assays	  (Zhou	  
et	   al.,	   2013;	   Ramos	   et	   al.,	   2013;	   Shi	   et	   al.,	   2013;	   Dortmans	   et	   al.,	   2013;	   Xu	   et	   al.,	  2014b).	   It	   is	   unclear,	   however,	   whether	   these	   binding	   characteristics	   are	   a	   reason	  that	  the	  human-­‐human	  transmission	  of	  these	  viruses	  is	  limited.	  
N9	  NAs	  have	  previously	  been	  shown	  to	  contain	  a	  secondary	  sialic	  acid	  binding	  site,	   known	   as	   the	   Haemadsorption	   (Hb)	   site,	   which	   is	   separate	   from	   the	   catalytic	  sialidase	   site	   (for	   more	   detail	   see	   Introduction,	   section	   1.3.2.3).	   The	   NA	   of	   H7N9	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isolates	   contains	   all	   the	   residues	   thought	   to	   be	   required	   to	   make	   this	   secondary	  binding	   site	   active,	   involving	   residues:	   366	   –	   373,	   399	   –	   404	   and	   430	   –	   433	   (N2	  Numbering)	  (Varghese	  et	  al.,	  1997;	  Uhlendorff	  et	  al.,	  2009).	  
This	  chapter	  examines	  the	  role	  of	   this	  secondary	  binding	  site	   in	   the	  receptor	  binding	  activity	  of	  the	  H7N9	  virus.	  Receptor	  analogue	  binding	  assays	  were	  carried	  out	  with	  the	  WT	  virus	  and	  with	  mutant	  viruses	  in	  which	  the	  Hb	  site	  was	  knocked	  out	  in	  order	  to	   investigate	  the	  effects	  of	  the	  Hb	  site	  on	  solid	  phase	  receptor	  binding	  of	  the	  virus.	  Recombinant	  NAs	  in	  the	  WT	  and	  mutant	   forms	  were	  used	  for	  binding	  studies	  and	  to	  determine	  enzyme	  kinetic	  parameters.	  
4.2 Results	  
4.2.1 Construction	  of	  viruses	  used	  for	  studies	  
The	  viruses	  constructed	  for	  these	  studies	  were	  designed	  to	  assess	  the	  effect	  of	  altering	   the	  NA	   from	   the	  H7N9	  virus	   in	   a	   number	  of	   different	   viral	   contexts.	   There	  were	   a	   number	   of	   safety	   considerations	   that	   had	   to	   be	   made	   when	   designing	   the	  viruses	  for	  these	  studies.	  WT	  H7N9	  viruses	  are	  classed	  as	  a	  high-­‐risk	  pathogen	  owing	  to	  their	  high	  case	  fatality	  ratio	  and	  also	  their	  perceived	  pandemic	  potential.	  Therefore,	  all	   viruses	  made	   in	   this	   study,	   excluding	   the	  7	  +	  1	   reassortants	  of	  PR8	  with	   the	  NA	  from	   H7N9,	   were	   all	   generated	   and	   handled	   under	   BSL-­‐4	   conditions.	   Dr.	   Stephen	  Wharton	  was	  responsible	  for	  the	  rescue	  of	  the	  viruses	  by	  reverse	  genetics	  and	  their	  propagation	  and	  preparation	  for	  receptor	  binding	  studies	  under	  high	  containment.	  I	  was	  responsible	  for	  carrying	  out	  all	  of	  the	  molecular	  biology	  required	  to	  prepare	  the	  plasmids	  for	  transfection	  at	  lower	  containment	  levels,	  making	  the	  BLI	  measurements,	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where	   the	   instrument	  was	  moved	   into	   the	  BSL-­‐4	   laboratory	   and	   the	   samples	  were	  analysed	  by	  controlling	  the	  instrument	  remotely.	  	  
H7N9	   viruses	   were	   constructed	   using	   plasmids	   for	   the	   HA	   and	   NA	   of	  A/Anhui/1/2013	  (H7N9)	  (Anhui13)	  cloned	  into	  the	  pHW2000	  vector.	  Plasmids	  were	  a	  kind	  gift	  from	  the	  laboratory	  of	  Dr.	  Munir	  Iqbal	  (The	  Pirbright	  Institute).	  The	  H7N9	  viruses	  were	   rescued	  with	   the	  HA	  and	  NA	   from	  Anhui13	  and	   the	   remaining	  6	  gene	  segments	  from	  PR8.	  Viruses	  were	  rescued	  with	  both	  the	  WT	  and	  a	  point	  mutant	  NA,	  with	  the	  substitution	  S367N	  (N2	  Numbering).	  This	  substitution	  had	  previously	  been	  found	   to	   abolish	   the	   haemadsorption	   activity	   of	   an	   NA	   with	   a	   binding	   Hb	   site	  (Uhlendorff	  et	  al.,	  2009).	  	  	  
As	  well	  as	  the	  H7N9	  viruses	  a	  pair	  of	  H3N9	  viruses	  were	  constructed	  with	  the	  HA	   from	   an	   exclusively	   tissue	   culture-­‐propagated	   virus,	   A/Victoria/361/2011	  (H3N2),	   using	   a	   plasmid	   kindly	   donated	   by	   Dr.	   Lauren	   Parker.	   This	   is	   a	   seasonal	  H3N2	   virus,	   which	   does	   not	   show	   any	   measurable	   binding	   to	   either	   6SLN-­‐PAA	   or	  3SLN-­‐PAA	   in	   BLI	   experiments	   (Lauren	   Parker,	   unpublished	   data).	   These	   H3N9	  viruses	   were	   constructed	   with	   both	   the	   WT	   and	   S367N	   mutant	   NA	   in	   a	   PR8	  background	   to	   determine	   if	   the	   presence	   of	   the	   Hb	   site	   in	   the	   NA	   was	   capable	   of	  rescuing	   receptor	   binding	   for	   viruses	   containing	   an	  HA	  with	   poor	   affinity	   for	   sialic	  acids.	   An	   H7N1	   virus	   was	   also	   constructed	   with	   the	   HA	   from	   Anhui13	   and	   the	  remaining	   7	   gene	   segments	   from	   PR8.	   This	   virus	   was	   constructed	   to	   examine	   the	  nature	  of	  H7	  binding	   in	  a	  virus	  with	  an	  NA	  without	  an	  active	  Hb	  site.	  H1N9	  viruses	  containing	   the	   NA	   from	   Anhui13	   in	   the	   WT	   and	   S367N	   mutant	   forms	   and	   the	  remaining	  7	  gene	  segments	  from	  PR8	  were	  constructed	  under	  BSL-­‐2	  conditions.	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All	  viruses	  were	   rescued	  by	   transfecting	  293T	  cells	  with	   the	  eight	   individual	  gene	   segment	   containing	   plasmids,	   as	   described	   in	  Materials	   and	  Methods,	   section	  2.2.5.	   The	   H7N9	   and	   H7N1	   viruses	   were	   further	   propagated	   in	   parent	  MDCK	   cells	  whereas	  the	  H3N9	  viruses	  were	  propagated	  in	  MDCK-­‐SIAT	  cells,	  which	  are	  required	  for	  efficient	  propagation	  of	  viruses	  with	  the	  weakly	  binding	  H3	  HAs	  (Lin	  et	  al.,	  2012).	  These	  viruses	  were	  propagated	  in	  large-­‐scale	  quantities	  (~750	  ml)	  and	  the	  virus	  was	  concentrated	  by	   a	   long	  medium-­‐speed	   centrifugation,	   as	  described	   in	  Materials	  and	  
Methods	   section	   2.2.3.2.	  H1N9	   viruses	  were	   propagated	   in	   hens’	   eggs	   directly	   from	  the	   transfection	   supernatant.	   These	   viruses	  were	   concentrated	   by	   centrifugation	   of	  the	  allantoic	  fluid	  and	  purified	  through	  a	  sucrose	  gradient,	  as	  described	  in	  Materials	  
and	  Methods,	  section	  2.2.3.1.	  
4.2.2 N9	  protein	  expression	  and	  purification	  
In	   order	   to	   allow	   detailed	   biochemical	   analyses	   of	   the	   N9	   binding	   and	  enzymatic	   characteristics	   both	   the	   WT	   and	   S367N	   mutant	   Anhui13	   NA	   were	  expressed	  in	  insect	  cells	  using	  a	  recombinant	  baculovirus	  system.	  The	  gene	  encoding	  the	  Anhui13	  NA	  ectodomain	  (residues	  75	  –	  465)	  had	  been	  previously	  synthesised	  and	  cloned	   into	   an	   insect	   expression	   vector	   for	   use	   with	   the	   BaculoGold	   system	   (BD	  Biosystems).	   The	   BaculoGold	   system	   had	   been	   discontinued,	   therefore	   the	   protein	  was	   expressed	   using	   the	   Bac-­‐to-­‐Bac	   system	   (Life	   Technologies).	   The	   expression	  construct	  was	  subcloned	  into	  a	  suitable	  vector,	  as	  described	  in	  Materials	  and	  Methods,	  section	  2.2.6.12.2.	  The	  expression	  construct	  consisted	  of	  residues	  75	  –	  465	  with	  an	  N	  terminal	   tag	   consisting	   of	   a	   6	   x	   His-­‐tag,	   a	   human	   vasodilator-­‐stimulated	  phosphoprotein	   tetramerisation	  domain	   (Kühnel	  et	  al.,	   2004;	  Xu	  et	  al.,	   2008)	   and	  a	  TEV	  cleavage	  site	  under	  the	  control	  of	  the	  polyhedrin	  promoter	  with	  a	  gp67	  secretion	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signal	  peptide.	  See	  Appendix	  for	  construct	  sequence.	  The	  gene	  was	  prepared	  in	  a	  WT	  form	   and	   was	   also	   mutagenised	   to	   carry	   the	   S367N	   substitution,	   as	   described	   in	  
Materials	  and	  Methods,	  section	  2.2.6.13.1.	  The	  recombinant	  baculoviruses	  for	  WT	  and	  the	   S367N	   mutant	   were	   generated	   as	   described	   in	  Materials	   and	  Methods,	   section	  2.2.7.2.	  The	  virus	  generated	  in	  this	  way	  was	  used	  to	  infect	  large	  volumes	  (~3	  litres)	  of	  a	  suspension	  of	  Sf9	  insect	  cells,	  as	  described	  in	  Materials	  and	  Methods,	  section	  2.2.7.3.	  	  
The	   expressed	   protein	   was	   concentrated	   to	   a	   smaller	   volume	   using	   hollow	  fibre	  filtration	  and	  purified	  using	  a	  cobalt	  resin	  column,	  as	  described	  in	  Materials	  and	  
Methods,	  section	  2.2.8.4.	  Figure	  5.1A	  shows	  SDS-­‐PAGE	  analysis	  of	   fractions	  collected	  from	  the	  elution	  of	  the	  WT	  protein	  from	  the	  cobalt	  column.	  The	  initial	  four	  fractions	  that	  contained	  protein	  of	  the	  elution	  step	  (as	  numbered	  on	  Fig.	  4.1A)	  were	  discarded	  because	  contaminants	  were	  visible	  on	  the	  gel.	  The	  remaining	   fractions	  were	  pooled	  (fractions	   5	   –	   14	   as	   shown	   in	   Fig.	   4.1A),	   concentrated	   and	   buffer	   exchanged.	   The	  concentrated	   protein	  was	   then	   further	   purified	   by	   gel	   filtration	   to	   ensure	   that	   any	  protein	  used	  for	   later	  analyses	  was	   in	  the	  tetrameric	   form	  with	  the	  purification	  and	  tetramerisation	  tags	  still	  attached.	  This	  step	  ensured	  that	  any	  monomeric	  protein	  or	  aggregated	   protein	   was	   removed	   from	   the	   sample.	   The	   process	   is	   described	   in	  
Materials	   and	   Methods,	   section	   2.2.8.4.	   Figure	   4.1B	   shows	   SDS-­‐PAGE	   of	   fractions	  collected	   from	   the	   gel	   filtration	   and	   Figure	  4.1C	   shows	   the	   elution	  profile	   from	   the	  column.	   The	   major	   peak	   of	   elution	   from	   the	   column	   was	   at	   65	   ml,	   which	   is	   the	  appropriate	  size	  for	  tetrameric	  NA,	  based	  on	  previous	  purifications	  carried	  out.	  The	  gel	   filtration	   profile	   indicated	   that	   the	   sample	  was	   of	   high	   purity,	  with	   only	   a	   very	  small	   amount	   of	   large	   aggregates,	   at	   lower	   retention	   volumes,	   and	   no	   visible	   peak	  corresponding	  to	  monomeric	  NA,	  at	  higher	  retention	  volumes.	  Fractions	  were	  pooled	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Figure	   4.1:	   SDS-­‐PAGE	   and	   gel	   filtration	   FPLC	   elution	   profile	   of	   N9	   protein	  
purification.	  A+B)	  SDS-­‐PAGE	  analysis	  of	  fractions	  from	  FPLC	  protein	  purification	  of	  Anhui13	  WT	  NA.	  Gels	  were	  run	  of	  5	  µl	  of	  elution	   fractions,	   run	  under	  non-­‐reducing	  conditions.	   A)	   Protein	   containing	   elution	   fractions	   from	   cobalt	   column	   his-­‐tag	  purification.	  B)	  Protein	  containing	  elution	  fractions	  from	  gel	  filtration	  purification.	  C)	  Elution	  profile	  of	  gel	  filtration	  purification	  of	  Anhui13	  WT	  NA.	  
	  









































kDa$ 15" 16" 17"
167	  
from	  the	  major	  tetrameric	  peak	  and	  concentrated	  to	  a	  smaller	  volume	  (fractions	  7	  –	  15,	  as	  numbered	  in	  Figure	  4.1B).	  SDS-­‐PAGE	  and	  elution	  profiles	  shown	  in	  Figure	  4.1	  are	   of	   the	  WT	  protein;	   however,	   the	   elution	   profiles	   for	   the	  mutant	   S367N	  protein	  were	  very	  similar.	  All	  further	  experiments	  were	  carried	  out	  with	  the	  purification	  tag	  still	   attached	   to	   the	  N9	  NAs	   in	  order	   to	   ensure	   the	  protein	   remains	   in	   a	   tetrameric	  form.	  
4.2.3 N9	  red	  blood	  cell	  pull	  down	  
The	  NA	  from	  H7N9	  viruses	  contains	  the	  motifs	  in	  the	  NA	  that	  suggest	  that	  the	  Hb	   site	  of	   this	  NA	   should	  bind	   to	   sialic	   acids.	  Assays	  were	   carried	  out	   to	   verify	   the	  presence	  of	  haemagglutination	  properties	  in	  the	  recombinant	  N9	  and	  the	  loss	  of	  these	  properties	  upon	  the	  mutation	  S367N.	  These	  assays	   involve	   testing	   the	  ability	  of	   the	  recombinant	  protein	  attached	  to	  magnetic	  beads	  to	  bind	  to	  and	  pull	  down	  turkey	  red	  blood	  cells	  (TRBCs).	  This	  assay	  was	  developed	  to	  study	  the	  NA	  of	  some	  H3N2	  viruses,	  which	   can	   use	   the	   sialidase	   site	   of	   the	   NA	   for	   receptor	   binding	   (Stephen	  Wharton,	  unpublished	  data).	  
Recombinant	   N9	   protein	   was	   attached	   to	   His-­‐tag	   binding	   magnetic	   beads.	  Unbound	  protein	  was	  washed	  away	  and	  beads	  were	  mixed	  with	  TRBCs	  and	  incubated	  to	  allow	  time	   for	  binding.	  The	  beads	  were	  washed	  and	   then	  mixed	  with	  TRBCs	  and	  the	  magnetic	   beads	   immediately	   pulled	   down	  with	   a	  magnet.	   The	   supernatant	  was	  removed	  and	  any	  remaining	  blood	  allowed	  to	  settle	   in	  a	  96-­‐well	  microplate,	  as	   in	  a	  standard	  haemagglutination	  assay.	  If	  the	  protein	  shows	  haemagglutination	  ability	  the	  blood	  will	   be	   attached	   to	   the	  magnetic	   beads	   and	   therefore	   there	  will	   be	   no	   blood	  remaining	  in	  the	  supernatant	  to	  settle	  out	  and	  vice	  versa.	  The	  procedure	  is	  described	  in	  more	  detail	  in	  Materials	  and	  Methods,	  section	  2.2.8.5.	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Assays	  were	  carried	  out	  with	   the	  WT	  and	  mutant	  S367N	  N9	  proteins.	  Figure	  4.2A	  shows	  an	  image	  of	  a	  representative	  experiment,	  showing	  the	  supernatant	  of	  the	  pulldown	   after	   settling	   in	   a	  microplate.	   A	   control	   experiment	  was	   also	   carried	   out	  using	   beads	   without	   protein	   attached,	   as	   a	   test	   for	   non-­‐specific	   binding.	   This	   ‘no	  protein	   control’	   could	   then	  be	   compared	   to	   the	   ‘no	   bead	   control’	  with	   blood	   at	   the	  same	  concentration	  as	  that	  used	  in	  the	  pull	  down.	  
It	  is	  clear	  from	  these	  experiments	  that	  the	  WT	  N9	  has	  the	  ability	  to	  pull	  down	  a	  large	  quantity	  of	  TRBCs	  compared	  to	  the	  no-­‐protein	  control,	  effectively	  removing	  any	  visible	   settled	   blood.	   The	   mutant	   S367N,	   however,	   appears	   to	   not	   pull	   down	   any	  blood,	  leaving	  an	  amount	  of	  blood	  in	  the	  supernatant	  similar	  to	  that	  seen	  with	  the	  no	  protein	  control.	  This	  indicates	  that	  the	  haemagglutination	  activity	  present	  in	  the	  WT	  protein	   is	   mediated	   via	   the	   Hb	   site	   and	   that	   the	   S367N	   substitution	   efficiently	  removes	   this	   activity.	   There	   is	   no	   clear	   visual	   difference	   in	   the	   settled	   bloods	   for	  experiments	  performed	  in	  the	  presence	  and	  absence	  of	  the	  NA	  inhibitor	  oseltamivir	  carboxylate,	  which	  will	  block	  the	  sialidase	  site,	   therefore	  suggesting	  that	  there	  is	  no	  contribution	  from	  the	  sialidase	  site	  to	  blood	  pull	  down.	  
In	   order	   to	   quantitatively	  measure	   the	   amount	   of	   blood	   present	   in	   the	   pull	  down	   supernatant	   blood	  was	   lysed	   in	   0.5%	   SDS,	   debris	   removed	   by	   centrifugation	  and	  the	  amount	  of	  haemoglobin	  assayed	  by	  measuring	  the	  absorbance	  at	  540	  nm.	  For	  experimental	   detail	   see	  Materials	   and	   Methods,	   section	   2.2.8.5.	   Figure	   4.2B	   shows	  results	   for	   the	   percentage	   of	   blood	   remaining	   in	   the	   pull	   down	   supernatant	   from	  three	   replicate	   experiments.	   The	   results	   have	   been	   normalised	   to	   the	   no	   protein	  control.	  These	  results	  give	  a	  similar	  pattern	  to	  that	  seen	  with	  the	  blood	  settled	  in	  the	  wells,	   showing	   a	   reduction	   of	   ~80%	   of	   blood	   present	   with	   the	   WT	   protein	   with	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oseltamivir	  carboxylate	  present,	  with	  the	  S367N	  showing	  no	  significant	  reduction	  in	  blood	  pull	   down	   compared	   to	   both	   the	  no	  protein	   and	  no	  bead	   controls.	   There	   are	  differences	   between	   the	   experiments	   carried	   out	   in	   the	   presence	   and	   absence	   of	  oseltamivir.	   For	   both	   the	  WT	   and	   S367N	   proteins	   there	   is	   more	   pull	   down	   of	   the	  TRBCs	  when	  oseltamivir	  carboxylate	  is	  absent,	  giving	  a	  reduction	  of	  remaining	  blood	  cells	   by	   a	   further	   10	   –	   15%	   compared	   to	  when	   oseltamivir	   carboxylate	   is	   present.	  These	   observations	   are	   counterintuitive,	   as	   these	   experiments	   are	   carried	   out	   at	  room	  temperature	  where	  the	  sialidase	  activity	  would	  be	  thought	  to	  reduce	  the	  overall	  binding	  to	  TRBCs.	  This	  suggests	  that	  the	  sialidase	  site	  could	  be	  involved	  in	  enhancing	  the	  binding	  of	  the	  NA	  to	  the	  TRBCs	  under	  the	  conditions	  of	  these	  experiments,	  which	  could	  not	  be	  seen	  with	  the	  settled	  blood	  (Fig.	  4.2A).	  	  
4.2.4 Removal	  of	  HA1	  from	  H1N9	  viruses	  
H1N9	  viruses	  were	  constructed	  with	  the	  HA	  of	  PR8	  and	  the	  NA	  of	  Anhui13,	  as	  described	   in	   section	   4.2.1.	   These	   viruses	   were	   constructed	   in	   order	   to	   attempt	   to	  remove	  the	  HA1	  by	  proteolysis	  whilst	  leaving	  the	  NA	  intact	  and	  unaffected.	  Since	  this	  virus	  would	  then	  only	  have	  NA	  remaining,	  with	  an	  inactive	  remnant	  of	  HA,	  which	  is	  incapable	  of	  receptor	  binding,	  it	  could	  be	  used	  to	  see	  if	  the	  NA	  was	  capable	  of	  acting	  as	   a	   receptor	   binding	   protein	   in	   a	   multivalent	   situation.	   In	   principle,	   such	   an	  interaction	   might	   be	   measurable	   by	   BLI	   and	   this	   would	   allow	   a	   measure	   of	   the	  relative	  contribution	  of	  the	  NA	  to	  the	  overall	  receptor	  binding	  affinity.	  	  
HA	  was	  cleaved	  from	  the	  surface	  by	  first	  exposing	  the	  virus	  to	  low	  pH	  (4.95	  –	  5.05)	  in	  order	  to	  induce	  the	  conformational	  change	  in	  the	  HA	  which	  makes	  the	  HA1	  susceptible	  to	  protease	  cleavage.	  The	  pH	  of	  the	  solution	  was	  then	  neutralised	  and	  the	  virus	  treated	  with	  trypsin.	  Protease	  digestion	  was	  inhibited	  and	  the	  remaining	  virus	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pelleted	  out	  of	   solution,	   the	  supernatant	  was	  discarded	  and	   the	  pellet	   resuspended,	  using	  a	  technique	  similar	  to	  that	  used	  in	  previous	  studies	  (Skehel	  et	  al.,	  1982;	  Ruigrok	  
et	   al.,	   1986),	   see	   Materials	   and	   Methods,	   section	   2.2.12,	   for	   experimental	   details.	  Figure	  4.3	  shows	  SDS-­‐PAGE	  of	  viruses	  before	  and	  after	  the	  low	  pH	  treatment.	  This	  gel	  shows	   that	   under	   non-­‐reducing	   conditions	   the	   HA	   band	   is	   removed	   by	   the	   trypsin	  digestion.	   There	   are	   also	   bands	   at	   lower	  molecular	   weights	   which	   are	   likely	   to	   be	  parts	  of	  the	  HA	  which	  are	  still	  attached	  to	  the	  virus,	  as	  seen	  in	  (Skehel	  et	  al.,	  1982).	  The	  gel	  run	  under	  reducing	  conditions	  shows	  a	   loss	  of	  the	  HA1	  band	  upon	  protease	  digestion,	  while	   the	  HA2	  band	  remains	  unchanged	  by	   the	   treatment.	  The	  density	  of	  the	  NA	  band	  also	  appears	  unchanged	  by	  the	  protease	  treatment.	  














































Figure	  4.4:	  Residual	  NA	  activity	  after	   low	  pH	  treatment.	  Measurements	  made	  of	  untreated	  virus	  (virus),	  virus	  after	   low	  pH	  treatment	  and	   trypsin	  digestion	  (low	  pH	  treated)	   and	   virus	   pellet	   and	   supernatant	   after	   ultracentrifugation	   of	   the	   low	   pH	  treated	  virus.	  Rate	  of	  MUNANA	  cleavage	  measured	  for	  a	  small	  volume	  of	  each	  sample	  with	  a	  set	  concentration	  of	  50	  µM	  of	  MUNANA.	  The	  value	  shown	  is	  rate	  of	  change	  of	  fluorescence	  intensity	  (AU).	  	   	  	  	  	  	  	  *	  	  	   Low	  pH	  treated	  and	  trypsin	  digested	  virus	  prior	  to	  ultracentrifugation	  §	  	   -­‐	  	  	  	  	  	  	  denotes	  no	  visible	  elution	  of	  virus	  from	  TRBCs.	  †	  	   á denotes	  elution	  from	  the	  highest	  virus	  concentration	  	  ‡	  	   â denotes	  elution	  from	  the	  lowest	  virus	  concentration	  
	  
Table	   4.1:	  HA	   titres	   and	  TRBC	   elution	   properties	   of	  H1N9	   viruses	   before	   and	  
after	  low	  pH	  treatment.	  	  	   	  
Virus	  
	  
HA	  Titre	  (log2(Titre))	  
	  
Elution	  (log2(Titre	  Difference))	  
























































The	  HA	  titre	  of	  the	  viruses	  post	  treatment	  was	  measured.	  Table	  4.1	  shows	  the	  HA	  titres	  of	  viruses	  binding	  to	  TRBCs.	  The	  binding	  of	  the	  native	  virus	  is	  high	  (HA	  titre	  of	  217)	  owing	  to	   the	  high	  concentration	  of	  virus	  used	   in	   the	   low	  pH	  treatment	  (~10	  nM).	  Upon	  the	  low	  pH	  treatment	  and	  trypsin	  digestion	  the	  HA	  titre	  drops	  by	  11	  wells,	  a	  reduction	  of	  2048-­‐fold.	  The	  residual	  binding	  detected	  (HA	  titre	  =	  26)	  is	  present	  for	  the	  PR8	  control	  as	  well	  as	  the	  H1N9	  viruses,	  showing	  that	  the	  residual	  binding	  is	  the	  same	   for	   both	   the	   binding	   (N9	   WT)	   and	   non-­‐binding	   (PR8	   and	   N9	   S367N)	   NAs,	  indicating	  that	  it	   is	  most	  likely	  from	  residual	  HA	  or	  non-­‐specific	  binding	  rather	  than	  NA	   binding.	   There	   could	   be	   a	   difference	   in	   HA	   titre	   with	   the	   WT	   and	   S367N	   NA;	  however,	   this	   may	   not	   be	   seen,	   as	   the	   HA	   assay	   is	   relatively	   insensitive,	   with	  haemagglutination	  titres	  being	  separated	  by	  2-­‐fold	  dilutions	  of	  virus.	  
Measurement	   of	   the	   binding	   of	   the	   virus	  with	   HA1	   removed	  was	   attempted	  using	  BLI.	  There	  was	  very	  little	  binding	  signal	  to	  sensors	  saturated	  with	  either	  6SLN-­‐PAA	  or	  3SLN-­‐PAA.	  Binding	  studies	  were	  performed	  with	  virus	  at	  1	  x	  (100	  pM),	  10	  x	  (1	  nM)	   and	   50	   x	   (5	   nM)	   virus	   concentration.	   The	   signal	   increased	   at	   higher	  concentrations;	   however,	   the	   binding	  measured	   to	   the	   sialoglycopolymers	  was	   not	  much	   larger	   than	   that	   of	   non-­‐specific	   binding	   to	   an	   unloaded	   sensor.	   The	   HA1	  removal	   procedure	   was	   repeated	   and	   the	   same	   results	   were	   obtained	   (data	   not	  shown).	  
This	   lack	   of	   binding	   signal	   above	   background	   non-­‐specific	   binding	   indicates	  that	   if	   the	  NA	  does	  act	   in	   receptor	  binding	   it	   is	  not	  of	  adequate	  binding	  strength	   to	  allow	   significant	   virus	   binding	   in	   the	   absence	   of	   HA	   binding.	   This	   could	   be	   due	   to	  there	   being	   only	   low	   levels	   of	   NA	   present	   on	   the	   viral	   surface,	   as	   NA	   is	   the	  minor	  glycoprotein	  constituent	  of	  the	  viral	  membrane.	  The	  Hb	  site	  of	  the	  NA	  could	  also	  have	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a	   very	   low	   affinity	   for	   receptor	   analogues.	   It	  was	   noted	   that	   the	   low	   pH	   treatment	  increased	  the	  non-­‐specific	  binding	  of	  the	  virus	  to	  unloaded	  sensors.	  The	  low	  pH	  and	  trypsin	  treated	  HA	  would	  likely	  be	  in	  a	  conformation	  similar	  to	  a	  structure	  obtained	  of	  the	  post-­‐fusion	  form	  of	  HA,	  EHA2	  (see	  Introduction,	  Figure	  1.5),	  which	  could	  have	  altered	  binding	  properties	  to	  the	  biosensor	  surface.	  There	  was	  also	  a	  similar	  level	  of	  binding	  measured	  with	  full	  8-­‐segment	  PR8,	  included	  as	  a	  negative	  control,	  indicating	  that	   the	   binding	   seen	   was	   either	   from	   residual	   uncleaved	   HA1	   or	   non-­‐specific	  interactions	  with	  the	  sensor.	  Attempts	  were	  made	  to	  try	  and	  reduce	  the	  non-­‐specific	  binding	  by	  adding	  BSA	  and	  increasing	  the	  amount	  of	  Tween-­‐20	  present	  in	  the	  buffer;	  however,	   neither	   of	   these	   approaches	   improved	   the	   data	   (not	   shown).	   The	   H1N9	  viruses	  were	  also	  rescued	  with	  a	  WSN	  background,	  which	  has	  previously	  been	  found	  to	  increase	  the	  amount	  of	  NA	  present	  in	  a	  virus,	  in	  order	  to	  increase	  the	  NA	  binding	  signal	  above	  that	  of	  non-­‐specific	  binding.	  These	  viruses	  also	  did	  not	  yield	  significantly	  improved	  data	  (not	  shown).	  
4.2.5 Elution	  of	  H1N9	  viruses	  from	  TRBCs	  
The	   ability	   of	   the	   H1N9	   viruses	   to	   cleave	   sialic	   acid	   in	   both	   native	   and	   low	  pH/protease	  digested	  forms	  was	  assessed	  by	  measuring	  the	  ability	  of	  the	  viruses	  to	  elute	   from	   TRBCs.	   Elution	   was	   carried	   out	   by	   covering	   the	   microtitre	   plate	   and	  placing	  it	  in	  a	  37°C	  incubator	  for	  ~18	  hrs.	  The	  difference	  in	  HA	  titre	  from	  the	  values	  measured	  previously	  was	  noted.	  The	  results	  for	  these	  assays	  are	  shown	  in	  Table	  4.1.	  The	  PR8	  control	  virus	  did	  not	   show	  any	  elution	   from	  TRBCs	  either	   in	   the	  native	  or	  low	  pH	  treated	  forms,	  which	  is	  surprising,	  as	  PR8	  NA	  would	  be	  thought	  to	  be	  highly	  active	  due	  to	  its	  efficient	  propagation	  in	  eggs.	  The	  low	  pH	  and	  trypsin	  digested	  H1N9	  viruses	   both	   showed	   a	   1	   well	   reduction	   in	   HA	   titre	   from	   the	   highest	   dilution	   that	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previously	   showed	   haemagglutination	   activity.	   The	   native	   viruses,	   however,	   eluted	  from	  the	  lowest	  virus	  dilutions	  (highest	  virus	  concentration).	  The	  WT	  NA	  virus	  eluted	  7	   wells	   from	   the	   lowest	   dilution	   to	   the	   27	   virus	   dilution	  whereas	   the	   S367N	   virus	  eluted	  5	  wells,	  a	  4-­‐fold	  difference	  in	  the	  concentration	  of	  virus	  required	  to	  elute	  from	  the	  TRBCs.	  This	  suggests	  that	  the	  loss	  of	  the	  Hb	  site	  reduces	  the	  ability	  of	  the	  NA	  to	  cleave	  the	  sialic	  acid	  from	  red	  blood	  cells.	  	  
4.2.6 Biolayer	  interferometry	  receptor	  binding	  studies	  
A	  number	  of	  experiments	  were	  carried	  out	  to	  quantitatively	  assess	  the	  impact	  of	   the	   presence	   of	   sialic	   acid	   binding	   capabilities	   via	   the	   Hb	   site.	   These	   involve	  measuring	  equilibrium	  virus	  binding	  as	  a	  function	  of	  sugar	  loading	  in	  the	  presence	  of	  NA	   inhibitors	   as	   well	   as	   measurements	   to	   determine	   the	   balance	   between	   the	  activities	  of	  HA	  and	  NA	  in	  altering	  virus	  receptor	  binding.	  	  
4.2.6.1 H7N9	  and	  H1N9	  BLI	  equilibrium	  measurements	  
The	   equilibrium	   receptor	   binding	   of	   the	   various	   constructed	   viruses	   was	  measured	  using	  BLI	   in	   the	  presence	  of	  NA	   inhibitors,	   as	  described	   in	  Materials	  and	  
Methods,	  section	  2.2.10.1.	  These	  measurements	  were	  made	  on	  a	  pair	  of	  viruses	  with	  Anhui13	  HA	  and	  NA	  (H7N9)	  and	  also	  viruses	  with	  PR8	  HA	  and	  Anhui13	  NA	  (H1N9)	  as	  well	  as	  full	  8	  segment	  PR8	  as	  a	  control.	  Both	  sets	  of	  viruses	  were	  made	  with	  the	  NA	  both	   in	   WT	   and	   S367N	   mutant	   forms	   in	   order	   to	   determine	   if	   there	   was	   any	  contribution	   of	   the	   secondary	   binding	   site	   to	   equilibrium	   virus	   binding	   in	   the	  presence	  of	  NA	  inhibitors	  used	  to	  block	  the	  sialidase	  site.	  





Figure	  4.5:	  H7N9	  virus	  binding	  to	  receptor	  analogues.	  Measurements	  made	  in	  the	  presence	  of	  NA	   inhibitors.	  100	  pM	  virus	  binding	   to	  A)	  6SLN-­‐PAA	  and	  B)	  3SLN-­‐PAA.	  Binding	  shown	  of	  virus	  with	  WT	  NA	  and	  Hb	  site	  mutant	  S367N.	  
	   	  









































stronger	  for	  the	  avian-­‐like	  receptor	  analogue	  3SLN-­‐PAA	  with	  slightly	  weaker	  binding	  to	   the	   human-­‐like	   receptor	   analogue	   6SLN-­‐PAA.	   These	   results	   are	   similar	   to	   those	  seen	   when	   the	   binding	   of	   the	   original	   egg-­‐propagated	   clinical	   isolate	   virus	   was	  measured	  by	  BLI	  (Xiong	  et	  al.,	  2013b).	  It	  is	  clear	  from	  these	  experiments	  that	  there	  is	  a	  slight	  decrease	  in	  receptor	  binding	  to	  both	  6SLN-­‐PAA	  and	  3SLN-­‐PAA	  when	  the	  NA	  is	  mutated	  (S367N).	  This	  drop	  is	  an	  increase	  in	  relative	  Kd	  of	  ~2-­‐fold.	  	  
Figure	  4.6	  shows	  the	  same	  measurements	  for	  H1N9	  binding.	  This	  PR8	  HA	  used	  has	   a	   receptor	   binding	   preference	   for	   the	   human-­‐like	   receptor	   analogue	   6SLN-­‐PAA	  with	  weaker	  binding	  to	  the	  avian-­‐like	  receptor	  analogue	  3SLN-­‐PAA.	  The	  mutation	  of	  the	   N9	   from	  WT	   to	   S367N	   gives	   a	   similar	   reduction	   in	   receptor	   binding	   for	   both	  6SLN-­‐PAA	  and	  3SLN-­‐PAA	  as	  seen	  for	  the	  H7N9	  viruses	  (Fig.	  4.5).	  It	  has	  a	  similar	  effect	  on	   the	   relative	  Kd	   increasing	   it	  ~2-­‐fold.	  The	   loss	  of	   the	  Hb	  activity	  makes	   the	  virus	  binding,	   to	   both	   6SLN-­‐PAA	   and	   3SLN-­‐PAA,	   indistinguishable	   from	   that	   of	   the	   full	   8	  segment	  PR8,	  which	  does	  not	  have	  Hb	  properties	  (Fig.	  4.6).	  






Figure	  4.6:	  H1N9	  virus	  binding	  to	  receptor	  analogues.	  Measurements	  made	  in	  the	  presence	  of	  NA	   inhibitors.	  100	  pM	  virus	  binding	   to	  A)	  6SLN-­‐PAA	  and	  B)	  3SLN-­‐PAA.	  Binding	   shown	   of	   virus	  with	  WT	  NA	   and	   Hb	   site	  mutant	   S367N.	   Binding	   of	   full	   8-­‐segment	  PR8	  shown	  for	  comparison.	  
	   	  











































4.2.6.2 H3N9	  Receptor	  Binding	  
Viruses	   were	   generated	   with	   the	   HA	   of	   tissue	   culture-­‐propagated	  A/Victoria/361/2012	   (H3N2)	   with	   both	   the	   WT	   and	   S367N	   N9	   NA.	   Viruses	  containing	   this	   HA	   have	   no	   detectable	   binding	   to	   receptor	   analogues	   in	   BLI	  experiments	   (Lauren	  Parker,	   unpublished	  data).	   These	   viruses	  were	   constructed	   to	  determine	  if	  the	  Hb	  site	  of	  the	  N9	  would	  be	  capable	  of	  restoring	  binding	  capacity	  to	  a	  previously	   unmeasurable	   binding	   interaction.	   Binding	   to	   sensors	   saturated	   with	   a	  range	  of	  different	  sialoglycopolymers	  was	  measured,	  in	  the	  presence	  of	  NA	  inhibitors,	  at	   the	  usual	  virus	  concentration	  of	  100	  pM	  and	  at	  10	  x	  concentration	  (1nM)	  and	  no	  binding	  was	  measurable	  for	  either	  WT	  or	  S367N.	  Virus	  concentration	  was	  increased	  to	  50	  x	  concentration	  (5	  nM)	  and	  a	  small	  amount	  of	  binding	  was	  measurable	  but	  only	  to	  6SLN-­‐PAA,	  shown	  in	  Figure	  4.7.	  The	  binding	  of	  the	  virus	  with	  WT	  NA	  to	  6SLN-­‐PAA	  is	   very	   weak	   with	   a	   saturation	   value	   of	   binding	   of	   ~0.8	   nm.	   This	   is	   very	   weak	  compared	   to	   the	   binding	  measured	   of	   H7N9	   viruses,	   which	   saturate	   the	   sensor	   at	  ~3.5	   nm	   at	   these	   saturated	   sugar	   loading	   levels.	   This	   binding	   is	   reduced	  when	   the	  S367N	   mutation	   is	   introduced	   into	   the	   NA	   to	   a	   saturation	   level	   of	   ~0.25	   nm.	   No	  significant	  binding	  was	  visible	  to	  any	  of	  the	  other	  receptor	  analogues	  tested	  (Fig.	  4.7).	  
These	  data	  for	  H3N9	  binding	  again	  highlight	  the	  fact	  that	  the	  presence	  of	  the	  Hb	  site	  in	  the	  N9	  NA	  can	  enhance	  virus	  receptor	  binding.	  The	  presence	  of	  the	  Hb	  site	  in	  the	  WT	  N9	  appears	  to	  allow	  binding	  of	  this	  virus	  which	  otherwise	  would	  be	  much	  weaker.	   The	   virus	   has	   a	   receptor	   preference	   for	   6SLN-­‐PAA;	   however,	   this	   is	   not	  necessarily	   due	   to	   a	   receptor	   specificity	   of	   the	   Hb	   site,	   rather	   that	   the	   H3	   has	   a	  preference	   for	   binding	   to	   6SLN-­‐PAA	   over	   the	   other	   analogues,	   which	   is	   below	   the	  threshold	   of	   measurement,	   and	   the	   inclusion	   of	   the	   N9	   with	   the	   Hb	   site	   increases	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Figure	  4.7:	  BLI	  data	  of	  H3N9	  virus	  binding	  to	  sialoglycopolymers.	  Viruses	  consist	  of	  the	  low	  binding	  H3N2	  HA	  Vic361	  coupled	  with	  the	  N9	  NA	  in	  WT	  and	  S367N	  forms	  in	   a	   PR8	   background.	   Binding	   measured	   in	   the	   presence	   of	   NA	   inhibitors	   at	   50	   x	  typical	   virus	   concentration	   (5	   nM).	   Binding	   measured	   to	   sensors	   saturated	   with	  sialoglycopolymers	   bearing	   the	   receptor	   analogues:	   6SLN,	   α2,6-­‐Sialyl-­‐N-­‐acetyllactosamine;	  3SLN,	  α2,3-­‐Sialyl-­‐N-­‐acetyllactosamine;	  6SL,	  α2,6-­‐Sialyllactose;	  3SL,	  α2,3-­‐Sialyllactose;	  6’-­‐Su-­‐3SLN,	  3SLN	  6’	  sulphated	  on	  GlcNAc;	  SiaLex,	  Sialyl-­‐Lewis	  X;	  6-­‐Su-­‐SiaLex,	  SiaLex	  6’	  sulphated	  on	  GlcNAc.	  Response	  is	  not	  normalised	  as	  proportion	  of	  saturation	  value.	  	   	  

















































overall	  sialic	  acid	  binding	  and	  allows	  the	  virus	  to	  pass	  over	  this	  threshold	  of	  binding,	  with	   the	   receptor	   specificity	   still	   determined	  by	   the	  HA.	  This	  binding	  was	   still	   very	  weak	   with	   a	   virus	   concentration	   of	   5	   nM	   necessary	   in	   order	   to	   gain	   measurable	  receptor	   binding	   and	   the	   overall	   response	   of	   binding	   very	   low.	   These	   results	  correspond	  well	  with	  the	  lack	  of	  measurable	  binding	  of	  low	  pH	  treated	  H1N9	  in	  BLI	  experiments,	  see	  section	  4.2.4.	  
4.2.6.3 Measurement	  of	  H7N9	  and	  H1N9	  HA/NA	  balance	  





Figure	  4.8:	  HA/NA	  balance	  measurements	  of	  H7N9	  virus	  binding	  to	  6SLN-­‐PAA.	  100	   pM	   virus	   binding	   measured	   to	   sialoglycopolymers	   bearing	   receptor	   analogue	  6SLN	  in	  the	  presence	  and	  absence	  of	  NA	  inhibitors	  (Inhib).	  Binding	  measured	  of	  virus	  with	  A)	  WT	  NA	  and	  B)	  S367N	  NA.	  	   	  






































Figure	  4.9:	  HA/NA	  balance	  measurements	  of	  H7N9	  virus	  binding	  to	  3SLN-­‐PAA.	  100	   pM	   virus	   binding	   measured	   to	   sialoglycopolymers	   bearing	   receptor	   analogue	  3SLN	  in	  the	  presence	  and	  absence	  of	  NA	  inhibitors	  (Inhib).	  Binding	  measured	  of	  virus	  with	  A)	  WT	  NA	  and	  B)	  S367N	  NA.	  
	   	  





































curves	  diverge	  at	  an	  early	  time	  point	  and	  then	  decrease	  to	  very	  low	  binding	  levels	  at	  later	  time	  points.	  These	  results	  are	  similar	  to	  those	  seen	  of	  X-­‐31	  binding	  to	  3SLN-­‐PAA	  (Fig.	   3.2).	   Binding	   of	   the	   H7N9	   viruses	   to	   6SLN-­‐PAA	   coated	   surfaces	   show	   an	  interesting	  effect	  with	  the	  WT	  NA,	  where	  there	  is	  an	  initial	  enhancement	  of	  receptor	  binding	  in	  the	  absence	  of	  NA	  inhibitors.	  This	  enhancement	  of	  receptor	  binding	  is	  lost	  when	   the	   S367N	  mutation	   is	   introduced.	   This	   increase	   of	   binding	  with	   the	  WT	  NA	  implies	  that	  there	  is	  cooperativity	  between	  the	  sialidase	  site,	  which	  is	  blocked	  by	  the	  NA	  inhibitors,	  and	  the	  active	  haemadsorption	  site,	  as	  the	  increase	  in	  binding	  is	  only	  seen	  when	  the	  sialidase	  site	  is	  uninhibited	  and	  the	  Hb	  site	  present.	  This	  enhancement	  is	  not	  seen	  when	  the	  viruses	  are	  binding	  to	  3SLN-­‐PAA	  (Fig.	  4.9).	  The	  overall	  balance	  between	   HA	   and	   NA	   activities	   of	   these	   viruses	   must,	   therefore,	   be	   considered	   in	  greater	  detail	  in	  order	  to	  understand	  these	  effects.	  	  
The	  NA	  of	  the	  H7N9	  appears	  to	  be	  efficient	  at	  cleaving	  the	  α2,3	  linked	  3SLN-­‐PAA,	  as	  the	  virus	  does	  not	  show	  a	  large	  binding	  signal	  in	  the	  absence	  of	  NA	  inhibitors	  (Fig.	  4.9),	  as	  seen	   for	   the	  same	  experiment	  with	  X-­‐31	  (Fig.	  3.2).	  The	  activity	  against	  the	   α2,6	   linked	   sialic	   acid	   seems	   low,	   as	   there	   is	   extensive	   virus	   binding	   in	   the	  absence	  of	  NA	  inhibitors	  (Fig.	  4.8),	  with	  a	  similar	  level	  of	  virus	  binding	  to	  both	  6SLN-­‐PAA	  and	  3SLN-­‐PAA	  when	  measured	   in	   equilibrium	  experiments	  with	  NA	   inhibitors	  present	   (Fig.	   4.5).	   This	   poor	   enzymatic	   cleavage	   of	   6SLN	   by	   the	   N9	   NA	   could	   be	  responsible	  for	  the	  enhanced	  receptor	  binding	  seen	  with	  the	  H7N9	  WT	  NA	  binding	  to	  6SLN-­‐PAA	  (Fig.	  4.8),	  as	  an	  enzyme	  with	  an	  enhanced	  substrate	  binding	  capacity	  (low	  Km)	  and/or	  low	  catalytic	  rate	  (kcat)	  can	  have	  a	  higher	  proportion	  of	  stronger	  binding	  events	   which	   do	   not	   result	   in	   substrate	   cleavage,	   turning	   the	   NA	   into	   more	   of	   a	  substrate	  binding	  protein.	  This	  substrate	  binding	  by	  the	  sialidase	  site	  could	  then	  act	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cooperatively	  with	  the	  haemadsorption	  site	  to	  enhance	  receptor	  binding	  to	  give	  the	  results	  as	  seen	  in	  Figure	  4.8.	  	  	  
As	  well	  as	  the	  phenomenon	  of	  enhanced	  initial	  receptor	  binding	  to	  6SLN-­‐PAA	  there	  also	  appears	  to	  some	  increase	  in	  the	  ability	  of	  the	  NA	  to	  cleave	  6SLN	  when	  the	  haemadsorption	  site	  is	  present,	  as	  the	  peak	  of	  maximal	  virus	  binding	  in	  the	  absence	  of	   NA	   inhibitors	   is	   lower	  with	   the	  WT	  NA	   than	  with	   the	   virus	   carrying	   the	   S367N	  substitution.	  This	  could	  be	  due	  to	  the	  ability	  of	  the	  secondary	  binding	  site	  to	  enhance	  NA	  activity	  against	  large	  substrates.	  	  






Figure	  4.10:	  HA/NA	  balance	  measurements	  of	  H1N9	  virus	  binding	  to	  6SLN-­‐PAA.	  100	   pM	   virus	   binding	   measured	   to	   sialoglycopolymers	   bearing	   receptor	   analogue	  6SLN	  in	  the	  presence	  and	  absence	  of	  NA	  inhibitors	  (Inhib).	  Binding	  measured	  of	  virus	  with	  A)	  WT	  NA	  and	  B)	  S367N	  NA.	  	   	  








































Figure	  4.11:	  HA/NA	  balance	  measurements	  of	  H1N9	  virus	  binding	  to	  3SLN-­‐PAA.	  100	   pM	   virus	   binding	   measured	   to	   sialoglycopolymers	   bearing	   receptor	   analogue	  3SLN	  in	  the	  presence	  and	  absence	  of	  NA	  inhibitors	  (Inhib).	  Binding	  measured	  of	  virus	  with	  A)	  WT	  NA	  and	  B)	  S367N	  NA.	   	  





































points	  seen	  with	  the	  H7N9	  viruses	  (Fig.	  4.8).	  This	  could	  be	  due	  to	  the	  greater	  affinity	  of	  the	  virus	  for	  6SLN-­‐PAA	  (Fig.	  4.6),	  making	  the	  enhanced	  NA	  activity	  less	  noticeable.	  
4.2.7 Measurement	   of	   N9	   receptor	   analogue	   affinity	   by	   microscale	  
thermophoresis	  
The	  Hb	   site	   of	   the	  NA	  has	   been	   shown	   in	  BLI	   experiments	   to	   enhance	   virus	  receptor	   binding	   (Figs.	   4.5	   and	   4.6).	   Experiments	   were	   carried	   out	   to	   attempt	   to	  measure	  a	  binding	  constant	  of	  monomeric	  receptor	  for	  this	  second	  binding	  site.	  The	  affinity	  of	  HA	  for	  monomeric	  receptor	  analogues	  has	  recently	  been	  determined	  using	  a	   new	   technology,	   microscale	   thermophoresis	   (MST)	   (Xiong	   et	   al.,	   2013a).	   This	  technique	  works	  by	  measuring	   the	  diffusion	  of	   a	   fluorescently	   labelled	   analyte	   at	   a	  constant	   concentration	   in	   a	   temperature	   gradient	   in	   the	   presence	   of	   different	  concentrations	  of	  a	  binding	  partner.	  This	  technique	  has	  been	  used	  for	  HA	  binding,	  as	  the	   sample	   volume	   required	   is	   very	   low,	   consequently	   the	   weak	   binding	   of	   HA	   to	  receptor	   analogues,	   Kd	   in	   mM	   range,	   can	   be	   measured	   without	   the	   need	   to	   use	  excessive	   quantities	   of	   the	   monomeric	   receptor	   analogues.	   A	   similar	   protocol	   was	  carried	  out	  to	  attempt	  to	  measure	  the	  binding	  of	  N9	  to	  receptor	  analogues	  via	  the	  Hb	  site.	  Baculovirus	  expressed	  recombinant	  WT	  and	  S367N	  N9,	  expressed	  as	  described	  in	   section	   4.2.2,	   was	   fluorescently	   labelled	   with	   a	   reactive	   amine	   linked	   dye,	   as	  described	   in	   Materials	   and	   Methods,	   section	   2.2.13.	   The	   labeling	   procedure	   was	  optimised	  to	  allow	  a	  low	  level	  of	  loading,	  ~	  1	  fluorophore	  per	  NA	  tetramer.	  	  
These	   labelled	   proteins	   were	   analysed	   for	   binding	   to	   both	   6SLN	   and	   3SLN	  using	   2-­‐fold	   serial	   dilutions	   of	   receptor	   analogues	   from	   a	   starting	   concentration	   of	  150	  mM	   in	   the	   presence	   of	   100	   µM	  oseltamivir	   carboxylate.	   The	   assay	   buffer	   used	  was	  altered	  from	  HBS-­‐P	  +	  CaCl2	  to	  include	  50	  mM	  HEPES-­‐NaOH	  pH	  7.4.	  The	  increased	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concentration	   of	   HEPES	   was	   included	   in	   order	   to	   counteract	   the	   pH	   perturbation	  caused	   by	   the	   high	   concentration	   of	   sialic	   acid	   present.	   Thermophoresis	   was	  measured	  at	  a	  number	  of	  different	  strengths	  of	  temperature	  gradients	  by	  altering	  the	  instrument	   laser	   power.	   Unfortunately,	   there	   was	   no	   measurable	   difference	   in	  thermophoresis	  at	  the	  different	  sugar	  concentrations	  used	  (data	  not	  shown).	  
4.2.8 N9	  enzyme	  kinetics	  
HA/NA	  balance	  data	  presented	  above	  (section	  4.2.6.3)	  suggest	  that	  the	  binding	  of	   H7N9	   and	  H1N9	   viruses	   bearing	   the	   H7N9	  NA	   have	   enhanced	   initial	   binding	   to	  α2,6-­‐linked	  sialic	  acid	  when	  the	  sialidase	  site	  of	  the	  NA	  is	  uninhibited.	  This	  suggests	  a	  possible	  role	   for	  the	  sialidase	  site	   in	  receptor	  binding.	  Characterising	  the	  kinetics	  of	  substrate	  cleavage	  of	   the	  N9	   is	   consequently	  of	   interest.	  Experiments	  are	  described	  below	  which	  characterise	  the	  cleavage	  of	  the	  soluble	  monomeric	  substrates	  MUNANA,	  6SLN	  and	  3SLN.	  There	  are	  also	  suggestions	  in	  HA/NA	  balance	  experiments	  above	  (Fig.	  4.8),	  TRBC	  elution	  results	  (Table	  4.1)	  and	  also	  in	  previous	  reports	  (Uhlendorff	  et	  al.,	  2009)	  that	  having	  the	  Hb	  site	  present	  enhances	  the	  ability	  of	  the	  NA	  to	  cleave	   large	  sialic	   acid	   containing	   substrates	   such	   as	   the	   heavily	   glycosylated	   protein	   fetuin	   or	  sugar	  coated	  surfaces	  as	  in	  BLI	  experiments.	  The	  kinetics	  of	  fetuin	  cleavage	  by	  the	  N9	  proteins	   have	   therefore	   also	   been	   characterised.	   Recombinant	   N9s	   were	   used	   for	  these	   kinetic	  measurements.	   The	   expression	   and	   purification	   of	   these	   proteins	   has	  been	  described	  in	  section	  4.2.2.	  	  
4.2.8.1 MUNANA	  kinetics	  
The	   kinetics	   of	   cleavage	   of	   MUNANA	   by	   WT	   and	   S367N	   N9	   NA	   was	  characterised	  by	  fluorimetry,	  correcting	  fluorescence	  data	  for	  the	  different	  buffers	  as	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previously	  described,	  in	  section	  3.2.7.1	  and	  Materials	  and	  Methods,	  section	  2.2.11.1.1.	  Measurements	   were	   made	   with	   both	   WT	   and	   S367N	   NA	   (at	   a	   monomeric	  concentration	   of	   0.25	   nM)	   using	   the	   MUNANA	   substrate	   at	   concentrations	   in	   the	  range	  10	  –	  175	  μM	  in	  both	  MES	  and	  HBS-­‐P	  +	  CaCl2	  buffers.	  Michaelis-­‐Menten	  plots	  for	  the	  WT	  and	  S367N	  proteins	  are	  shown	  in	  Figure	  4.12	  and	  the	  fitted	  parameters	  are	  shown	  in	  Table	  4.2.	  	  
The	   WT	   and	   S367N	   N9	   proteins	   have	   very	   similar	   Km	   and	   kcat	   values	   for	  measurements	  made	  with	  MUNANA	   in	   both	   buffers.	   This	   indicates	   that	   the	   S367N	  mutation	   does	   not	   affect	   the	   sialidase	   activity	   of	   the	   NA	   for	   small	   monomeric	  substrates.	  The	  WT	  NA	  has	  a	  Km	  value	  of	  38.5	  ±	  2.1	  μM	  in	  MES	  buffer,	  with	  a	  Km	  ~	  4-­‐fold	  higher	  in	  the	  HBS-­‐P	  buffer	  (137.9	  ±	  12.8	  μM).	  This	  indicates	  that	  the	  NA	  binds	  to	  substrate	   better	   at	   a	   lower	   pH,	   although	   this	   is	   not	   the	   only	   alteration	   in	   the	   two	  buffers,	  as	  there	  is	  also	  a	  difference	  in	  ionic	  strength.	  These	  Km	  values	  are	  similar	  to	  those	  previously	  reported	  for	  similar	  expressed	  N9	  protein	  (Wu	  et	  al.,	  2013).	  	  Under	  both	  buffer	  conditions	  the	  enzyme	  has	  a	  similar	  turnover	  rate	  with	  a	  kcat	  value	  of	  ~90	  s-­‐1.	  Comparing	  these	  kinetic	  parameters	  with	  those	  obtained	  for	  X-­‐31	  NA	  indicate	  that	  this	  N9	  NA	  is	  less	  efficient,	  having	  a	  higher	  Km	  and	  a	  lower	  kcat.	  	  
4.2.8.2 6SLN	  and	  3SLN	  kinetics	  
The	  kinetic	  parameters	  for	  MUNANA	  cleavage	  determined	  above	  are	  useful	  in	  confirming	   that	   the	   WT	   and	   S367N	   proteins	   have	   identical	   sialidase	   activities	   for	  cleaving	   small	   substrate.	  These	  values,	   however,	   do	  not	   allow	  understanding	  of	   the	  role	   of	   linkage	   specificity	   for	   the	   NA.	   Experiments	   were	   carried	   out	   based	   on	   the	  system	  previously	  described	  in	  Chapter	  3	  (section	  3.2.7.2)	  using	  the	  coupled	  enzymes
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Figure	  4.12:	  Michaelis-­‐Menten	  plots	  of	  MUNANA	  cleavage	  by	  WT	  and	  S367N	  N9	  
NA.	  Measurements	  made	  at	  37°C	  in	  either	  HBS	  (HBS-­‐P	  +	  CaCl2:	  10	  mM	  HEPES	  pH	  7.4,	  150	  mM	  NaCl,	  0.005%	  Tween-­‐20,	  4	  mM	  CaCl2)	  or	  MES	  (32.5mM	  MES	  pH	  6.5,	  4	  mM	  CaCl2)	   buffers.	   Each	   point	   is	   the	  mean	   of	   three	   replicates	  with	   error	   bars	   showing	  standard	  deviation	  from	  the	  mean.	  Least	  squares	  fit	  of	  Michaelis-­‐Menten	  equation	  is	  shown.	  Raw	  reaction	  rate	  data	  are	  converted	  to	  an	  observed	  rate	  by	  dividing	  rates	  by	  NA	  concentration	  used	  in	  assay.	  	  
Substrate	   Protein	   Buffer/Temp	   Km	  ±	  S.E.
§	  
(µM)	  






MES*	  37˚C	   38.5	  ±	  2.1	   90.7	  ±	  1.6	   2.36	  
HBS†	  37˚C	   137.9	  ±	  12.8	   90.1	  ±	  4.7	   0.654	  
S367N	  N9	  
MES	  37˚C	   43.4	  ±	  2.9	   91.5	  ±	  2.1	   2.11	  
HBS	  37˚C	   134.2	  ±	  12.9	   88.6	  ±	  4.7	   0.660	  
6SLN	  
3SLN	   WT	  N9	  
HBS	  37˚C	  
HBS	  37˚C	  
4179	  ±	  615	  
810.0	  ±	  100	  
2.2	  ±	  0.2	  




WT	  N9	   HBS	  37˚C	   197.5	  ±	  37.3	   71.6	  ±	  8.3	   0.363	  
S367N	  N9	   HBS	  37˚C	   346.4	  ±	  95.6	   73.0	  ±	  14.5	   0.211	  *MES	   	   MES	  Buffer	  (32.5	  mM	  MES-­‐NaOH,	  pH	  6.5,	  4	  mM	  CaCl2)	  †HBS	  	   	   HBS-­‐P	  +	  CaCl2	  Buffer	  (10	  mM	  HEPES-­‐NaOH,	  pH	  7.4,	  150	  mM	  NaCl,	  	  0.005%	  Tween-­‐20,	  4	  mM	  CaCl2)	  §S.E.	  	   	   Standard	  Error	  of	  the	  mean	  
	  
Table	  4.2:	  Steady	  state	  kinetic	  parameters	  determined	  for	  N9	  WT	  and	  S367N	  NA.	  
	   	  
























β-­‐galactosidase	   and	  β-­‐galactose	  dehydrogenase,	   using	   the	  production	  of	  NADH	  as	   a	  reporter	  for	  the	  NA	  cleavage	  rate	  of	  the	  monomeric	  sugars	  6SLN	  and	  3SLN	  (reaction	  scheme	   shown	   in	   Figure	   3.9),	   experimental	   details	   described	   in	   Materials	   and	  
Methods,	   section	   2.2.11.2.	   It	   was	   decided	   that	   the	   MUNANA	   cleavage	   kinetic	  parameters	  determined	  were	  adequate	  evidence	   for	   the	   fact	   that	   the	  activity	  of	   the	  NA	  was	  unaltered	  by	   the	  S367N	  substitution	  and	   that	   this	  was	  also	   likely	   to	  be	   the	  case	   for	   the	  monomeric	   sugars	   (6SLN	   and	   3SLN).	   The	   experiments	   detailed	   below	  were	  therefore	  only	  performed	  with	  the	  WT	  protein	  in	  order	  to	   limit	  the	  amount	  of	  sugar	  consumed	  in	  the	  experiments.	  
Figure	   4.13A	   shows	   the	  Michaelis-­‐Menten	   plot	   for	   the	   cleavage	   of	   the	   3SLN	  substrate	   by	   Anhui13	   NA,	   with	   the	   fitted	   kinetic	   parameters	   shown	   in	   Table	   4.2.	  These	  parameters	  for	  3SLN	  were	  measured	  with	  NA	  at	  a	  monomeric	  concentration	  of	  0.5	  nM.	  The	  cleavage	  of	  3SLN	  by	  the	  WT	  NA	  appears	  to	  be	  efficient	  with	  a	  Km	  of	  810.0	  ±	  100	  µM	  and	  a	  kcat	  of	  159.5	  ±	  8.5	  s-­‐1.	  These	  values	  are	  similar	  to	  those	  determined	  for	  X-­‐31	  (Km	  =	  562.3	  ±	  20	  µM	  and	  kcat	  =	  97.5	  ±	  1.5	  s-­‐1).	  The	  N9	  has	  a	  slightly	  higher	  Km,	  indicating	  that	  it	  is	  less	  efficient	  at	  binding	  to	  the	  substrate,	  but	  also	  has	  a	  higher	  kcat,	  indicating	   a	   higher	   rate	   of	   substrate	   turnover.	  Despite	   these	  differences	   the	   overall	  catalytic	  efficiency(kcat/Km)	  is	  similar	  (0.197	  µM-­‐1s-­‐1	  for	  the	  N9	  and	  0.173	  µM-­‐1s-­‐1	  for	  X-­‐31).	  When	  comparing	  3SLN	  cleavage	  with	  that	  of	  MUNANA	  it	  is	  apparent	  that	  there	  is	  a	  similar	  pattern	  to	  that	  seen	  with	  X-­‐31	  NA	  with	  a	  higher	  Km	  for	  3SLN,	   indicating	  weaker	  substrate	  binding,	  but	  a	  higher	  kcat	   for	  substrate	  cleavage.	  This	   indicates,	  as	  discussed	  previously	  in	  section	  3.2.7.2,	  that	  the	  sialidase	  site	  of	  the	  NA	  can	  bind	  better	  to	  the	  artificial	  hydrophobic	  MUNANA	  but	  has	  a	  lower	  cleavage	  rate	  than	  the	  natural	  substrate	   3SLN.	   These	   3SLN	   cleavage	   data	   agree	  well	  with	   the	  HA/NA	   balance	   BLI
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Figure	  4.13:	  Michaelis-­‐Menten	  plots	  of	   the	  kinetics	  of	  6SLN	  and	  3SLN	  cleavage	  
by	  WT	  N9	  NA.	  Plots	  are	  shown	  for	  A)	  3SLN	  and	  B)	  6SLN.	  Cleavage	  rate	  measured	  by	  measuring	   rate	   of	   N-­‐acetyllactosamine	   release	   using	   coupled	   enzyme	   system	   of	   β-­‐galactosidase	   and	   β-­‐galactose	   dehydrogenase	   using	   the	   absorbance	   of	   generated	  NADH	   as	   the	   reporter	   of	   rate.	   Each	   point	   is	  mean	   of	   three	   repeats	  with	   error	   bars	  showing	   standard	   deviation	   from	   the	   mean.	   Least	   squares	   fit	   of	   Michaelis-­‐Menten	  equation	   is	   shown.	   Raw	   reaction	   rate	   data	   are	   converted	   to	   an	   observed	   rate	   by	  dividing	  rates	  by	  NA	  concentration	  used	  in	  assay.	  






































experiments	  for	  H7N9	  and	  H1N9	  viruses	  with	  WT	  NA	  binding	  to	  3SLN-­‐PAA	  (Figs.	  4.9	  and	  4.11),	  where	  the	  viruses	  do	  not	  bind	  extensively	  to	  the	  sensor	  in	  the	  absence	  of	  NA	  inhibitors	  despite	  strong	  binding	  to	  3SLN-­‐PAA	  by	  both	  the	  H1	  and	  H7	  HAs	  (Figs.	  4.5	  and	  4.6),	  in	  a	  fashion	  similar	  to	  that	  seen	  with	  X-­‐31	  binding	  to	  3SLN-­‐PAA	  (Fig.	  3.2).	  	  
Figure	   4.13B	   shows	   a	   Michaelis-­‐Menten	   curve	   determined	   for	   the	   WT	   N9	  cleaving	   6SLN	   and	   Table	   4.2	   shows	   the	   fitted	   parameters.	   Cleavage	   of	   6SLN	   was	  measured	   with	   NA	   at	   a	   50-­‐fold	   higher	   monomeric	   concentration	   (25	   nM).	   The	   Km	  value	  determined	  was	  4179	  ±	  615	  µM,	  which	  is	  ~5-­‐fold	  higher	  than	  that	  determined	  for	  3SLN	  (810	  ±	  100	  µM).	  The	  turnover	  rate	  (kcat)	  for	  6SLN	  is	  very	  low	  (2.2	  ±	  0.2	  s-­‐1)	  compared	   with	   that	   measured	   for	   3SLN	   (159.5	   ±	   8.5	   s-­‐1).	   When	   compared	   to	   the	  results	  obtained	  for	  X-­‐31	  NA	  the	  N9	  has	  ~2-­‐fold	  lower	  Km	  and	  ~10-­‐fold	  lower	  kcat	  for	  6SLN	   cleavage,	   indicating	   that	   the	   sialidase	   site	   has	   greater	   affinity	   for	   binding	   to	  6SLN	   but	   has	   a	   much	   lower	   likelihood	   of	   this	   interaction	   resulting	   in	   substrate	  cleavage,	  making	  it	  potentially	  more	  effective	  as	  a	  receptor	  binding	  site.	  	  
If	   one	   assumes	   the	   simplest	   possible	   enzymatic	   	   reaction	   and	   takes	   a	  reasonable	  value	  for	  the	  association	  constant	  (k1)	  of	  sialic	  acid	  for	  the	  NA	  active	  site	  of	   5	   x	   105	   M-­‐1	   s-­‐1	   (Sung,	   Wynsberghe	   &	   Amaro,	   2010)	   one	   can	   calculate	   the	  dissociation	  constant	  (k-­‐1)	  using	  the	  Km	  and	  kcat	  values	  determined	  for	  the	  N9	  using	  a	  simple	  rearrangement	  of	  Equation	  4.1	  to	  produce	  Equation	  4.2:	  
	  	   	   	   	   (4.1)	  




k−1 = Km.k1 − kcat
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From	   the	   calculated	   k-­‐1	   and	   the	   experimentally	   determined	   kcat	   one	   can	  determine	  the	  probability	  of	  the	  formation	  of	  an	  enzyme	  substrate	  complex	  leading	  to	  a	  cleavage	  event	  or	  to	  the	  substrate	  dissociating	  by	  determining	  the	  ratio	  between	  kcat	  and	   k-­‐1.	   The	   N9	   is	   ~1000-­‐fold	   more	   likely	   to	   dissociate,	   rather	   than	   cleave	   6SLN	  compared	  to	  a	  ~1.5-­‐fold	   likelihood	   for	  3SLN.	  The	  comparable	  probabilities	   for	  X-­‐31	  are	   a	  ~200-­‐fold	  higher	  probability	   of	   6SLN	  dissociation	   rather	   than	   cleavage	   and	   a	  ~1.8-­‐fold	   likelihood	   for	  3SLN.	  These	  kinetic	  parameters	   therefore	  show	  that	   the	  N9	  has	   a	   ~5-­‐fold	   increased	   likelihood	   of	   6SLN	   dissociation	   from	   the	   N9	   NA	   when	  compared	  to	  X-­‐31	  NA.	  This	  coupled	  with	  the	  observation	  of	  a	  lower	  Km,	  compared	  to	  X-­‐31	   NA,	   reinforces	   the	   hypothesis	   that	   substrate	   binding	   via	   the	   sialidase	   site	   is	  responsible	  for	  the	  enhanced	  initial	  binding	  of	  H7N9	  and	  H1N9	  viruses	  with	  the	  WT	  NA	  to	  6SLN-­‐PAA	  (Figs	  4.8	  and	  4.10).	  
4.2.8.3 Multivalent	  substrate	  kinetics	  
It	   has	   been	   previously	   shown	   that	   the	   presence	   of	   the	   Hb	   site	   in	   an	   NA	  enhances	   the	   cleavage	   of	   large	  multivalent	   substrates	   such	   as	   heavily	   glycosylated	  glycoproteins	  (Uhlendorff	  et	  al.,	  2009).	  The	  elution	  of	  H1N9	  viruses	  from	  TRBCs	  also	  suggests	  an	  enhanced	  NA	  activity	  when	  the	  Hb	  site	  is	  absent	  (Table	  4.1).	  Experiments	  were	   therefore	   carried	   out	   to	   investigate	  whether	   this	  N9	  NA	   also	   shows	   the	   same	  enhancement	   of	   cleavage.	   An	   enzyme	   assay	   was	   devised	   to	   monitor	   the	   rate	   of	  cleavage	  of	  the	  glycoprotein	  fetuin.	  The	  previously	  designed	  system	  used	  to	  quantify	  6SLN	   and	   3SLN	   cleavage	   using	   β-­‐galactosidase	   and	   β-­‐galactose	   dehydrogenase	   did	  not	  work	  in	  preliminary	  experiments	  carried	  out	  using	  fetuin.	  This	  is	  most	  probably	  due	  to	  problems	  with	  the	  β-­‐galactosidase	  cleavage	  step.	  In	  the	  previous	  system	  the	  β-­‐galactosidase	   was	   used	   to	   cleave	   the	   disaccharide	   N-­‐acetyllactosamine,	   which	   is	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released	  from	  both	  6SLN	  and	  3SLN	  after	  NA	  cleavage.	  This	  released	  sugar	  consists	  of	  a	  galactose	  connected	  by	  a	  β1,4	  linkage	  to	  an	  N-­‐acetylglucosamine	  moiety.	  There	  are	  two	  potential	  problems	  with	  using	  fetuin	  as	  the	  NA	  substrate	  which	  could	  affect	  the	  efficiency	  of	  the	  β-­‐galactosidase	  used	  in	  the	  assay.	  The	  linkages	  present	  on	  the	  fetuin	  (β1,4	   or	   β1,3)	   could	   be	   different	   and	   the	   substrate	  will	   also	   be	   presented	   in	   forms	  longer	   than	   a	   trisaccharide,	   either	   of	   which	   scenarios	   could	   alter	   β-­‐galactosidase	  activity.	  	  
A	   new	   system	   was	   devised	   to	   measure	   the	   released	   sialic	   acid,	   rather	   than	   the	  remaining	  glycans	  of	  the	  fetuin.	  This	  system	  was	  based	  on	  the	  two	  coupling	  enzymes	  N-­‐acetyl	  neuraminic	  acid	  aldolase	  (NANA	  aldolase)	  and	  lactate	  dehydrogenase	  (LDH).	  The	   NANA	   aldolase	   catalyses	   the	   release	   of	   pyruvate	   from	   sialic	   acid	   and	   the	   LDH	  converts	   the	   released	   pyruvate	   into	   lactate,	  while	   converting	  NADH	   into	  NAD+,	   the	  conversion	  of	  which	  can	  be	  monitored	  by	  measuring	  the	  reduction	  of	  absorbance	  at	  340	  nm,	  see	  reaction	  scheme	  in	  Figure	  4.14.	  The	  quantities	  of	  enzyme	  were	  optimised	  to	  ensure	  that	  enough	  of	  both	  coupling	  enzymes	  were	  present	  to	  correctly	  report	  NA	  rate,	   as	  was	   done	   for	   the	   development	   of	   the	   previous	   system	   (section	   3.2.7.2),	   by	  ensuring	   that	   at	   the	   highest	   and	   lowest	   concentrations	   of	   substrate	   the	   initial	   rate	  doubled	   when	   the	   amount	   of	   NA	   was	   doubled	   (data	   not	   shown).	   The	   reaction	  components	   in	   a	  100	  µl	   reaction	  were:	   0.5	  U	  NANA	  aldolase,	   5	  U	  LDH	  and	  200	  µM	  NADH.	  Fetuin	  concentrations	  were	  calculated	  assuming	  a	  molecular	  mass	  of	  48.4	  kDa.	  Experiments	   were	   done	   in	   the	   BLI	   assay	   buffer	   HBS-­‐P	   +	   CaCl2.	   See	  Materials	   and	  




Figure	   4.14:	   Reaction	   scheme	   of	   coupled	   enzyme	   assay	   used	   to	   monitor	  
cleavage	  of	  sialic	  acid	  from	  fetuin.	  
	  
Figure	  4.15:	  Michaelis-­‐Menten	  plot	  of	  fetuin	  cleavage	  by	  WT	  and	  S367N	  N9	  NAs.	  Rate	   measured	   by	   assaying	   released	   sialic	   acid	   using	   NANA	   aldolase	   and	   lactate	  dehydrogenase	  as	  coupled	  reporter	  system,	  measuring	  rate	  of	  conversion	  of	  NADH	  to	  NAD+	   by	   absorbance	   as	   reporter	   of	   NA	   rate.	   Each	   point	   shown	   is	   mean	   of	   three	  repeats	  with	  error	  bars	  indicating	  standard	  deviation	  from	  the	  mean.	  Least	  squares	  fit	  of	  Michaelis-­‐Menten	  equation	   is	   shown.	  Raw	  reaction	  rate	  data	  are	  converted	   to	  an	  observed	  rate	  by	  dividing	  rates	  by	  NA	  concentration	  used	  in	  assay.	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Figure	   4.15	   shows	   the	   Michaelis-­‐Menten	   plot	   for	   fetuin	   cleavage	   by	   the	  expressed	  WT	  and	  S367N	  NA	  N9	  proteins	  at	  a	  monomeric	  NA	  concentration	  of	  5	  nM.	  Table	  4.2	  shows	  the	  fitted	  parameters	  for	  these	  plots.	  Both	  plots	  give	  sufficient	  data	  to	  allow	  determination	  of	  Km	  and	  kcat	  values.	  Results	  at	  higher	  fetuin	  concentrations	  would	  have	  been	  desirable	  but	   the	  maximum	  concentration	  used	   (200	  µM)	   is	  ~	  10	  mg/ml.	  It	  was	  considered	  likely	  that	  there	  could	  be	  problems	  with	  fetuin	  solubility	  at	  higher	  concentrations	  and	  also	  that	  the	  pH	  could	  be	  perturbed	  by	  the	  large	  amounts	  of	   sialic	   acid	   present.	   The	   pH	   of	   the	   200	   µM	   fetuin	   was	   checked	   and	   this	   protein	  concentration	  did	  not	  affect	  the	  pH	  of	  the	  buffered	  solutions	  used.	  	  
The	   WT	   N9	   protein	   has	   a	   low	   Km	   (197.5	   ±	   37.3	   µM)	   compared	   to	   the	  comparable	   monomeric	   sugar	   substrates	   6SLN	   and	   3SLN	   (Km	   =	   4173	   ±	   615	   µM	  [6SLN]	   and	   810.0	   ±	   100	   µM	   [3SLN]).	   This	   does	   not	   necessarily	   indicate	   a	   stronger	  binding	  affinity	   for	  the	  sialic	  acid	  on	  the	   fetuin	  but	  rather	  that	   the	   fetuin	   is	   likely	  to	  contain	  multiple	  sialic	  acid	  moieties	  on	  each	  protein,	  thus	  lowering	  the	  Km.	  The	  kcat	  is,	  however,	   a	   direct	   measure	   of	   the	   amount	   of	   released	   sialic	   acid	   and	   is	   therefore	  directly	   comparable	   to	   the	   values	   for	   6SLN	   and	   3SLN.	   The	   kcat	   value	   for	   the	   WT	  protein	  is	  71.6	  ±	  8.3	  s-­‐1,	  which	  ~2-­‐fold	  lower	  than	  the	  value	  for	  3SLN	  (159.5	  ±	  8.5	  µM)	  and	   ~30-­‐fold	   higher	   than	   the	   value	   for	   6SLN	   (2.2	   ±	   0.2	   s-­‐1).	   This	   difference	   in	   kcat	  values	   could	   be	   due	   to	   there	   being	   a	  mixture	   of	   the	  more	   efficiently	   cleaved	   α2,3-­‐linked	  sialic	  acid	  and	  the	  less	  well	  cleaved	  α2,6-­‐linked	  sialic	  acid,	  thus	  making	  the	  rate	  somewhere	   in	   the	  middle	   of	   the	   two.	   It	   could	   also	   be	   due	   to	   the	   altered	   substrate	  characteristics	  when	   it	   is	   attached	   to	   a	   larger	  protein	   rather	   than	   a	   freely	  diffusing	  trisaccharide	  moiety.	  The	  sialic	  acid	  will	  have	  a	  slower	  diffusion	  rate	  being	  attached	  to	   a	   protein,	   as	  well	   as	   the	   other	   possible	   confounding	   factors	   such	   as	   the	  way	   the	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substrate	   is	   presented	   on	   the	   protein	   surface.	   There	   are	   also	   the	   complications	   of	  multivalency.	  The	  expressed	  protein	  used	   is	   in	   a	   tetrameric	   form	  and	   consequently	  will	   have	   active	   sites	   that	   could	  be	   spaced	   in	   a	  way	   that	   allows	   sialic	   acid	   residues	  from	  the	  same	  fetuin	  molecule	  to	  bind	  multiple	  sialidase	  sites	  simultaneously.	  
The	  data	  obtained	  for	  the	  cleavage	  of	  fetuin	  by	  the	  S367N	  mutant	  N9	  show	  a	  higher	  Km	  value	  of	  346.4	  ±	  95.6	  µM	  (WT	  Km	  =	  197.5	  ±	  37.3)	  an	  increase	  of	  ~1.75-­‐fold;	  however	  the	  kcat	  is	  very	  similar	  (kcat	  =	  71.6	  ±	  8.3	  s-­‐1	  [WT]	  and	  73.0	  ±	  14.5	  s-­‐1	  [S367N]).	  This	   indicates	   that	   the	  presence	  of	   the	  Hb	  site	  enhances	  binding	  of	   fetuin	   to	   the	  N9	  but	   does	   not	   alter	   the	   overall	   cleavage	   rate	   when	   substrate	   concentration	   is	   not	  limiting.	   The	  Hb	   site	   is	   therefore	   likely	   to	   be	   involved	   in	   tethering	   the	   substrate	   in	  order	  that	  the	  sialidase	  site	  can	  bind	  and	  cleave	  the	  substrate	  more	  efficiently.	  	  	  
4.3 Discussion	  
The	  experiments	  using	   the	  TRBC	  pull	  down	  assays	  presented	   in	   this	   chapter	  confirm	  that	  the	  N9	  of	  H7N9	  viruses	  has	  sialic	  acid	  binding	  properties,	  and	  that	  this	  binding	   can	   be	   eliminated	   by	   inserting	   the	   substitution	   S367N	   into	   the	  N9	  NA	   (Fig	  4.2).	  The	  removal	  of	  the	  Hb	  binding	  site	  by	  mutagenesis	  was	  found	  to	  reduce	  overall	  virus	  binding	  in	  the	  presence	  of	  NA	  inhibitors.	  This	  was	  seen	  when	  measuring	  overall	  virus	  binding	  as	  a	  function	  of	  sugar	  loading	  by	  BLI	  for	  H7N9	  (Fig	  4.5)	  and	  for	  H1N9	  (Fig	  4.6),	  and	  also	  in	  the	  reduction	  in	  binding	  amplitude	  for	  6SLN-­‐PAA	  binding	  for	  the	  very	   weak	   binding	   H3N9	   viruses	   constructed	   in	   this	   work	   (Fig	   4.7).	   This	   loss	   of	  binding	   is	   solely	   due	   to	   this	   S367N	   substitution	   eliminating	   binding	   at	   the	   second	  binding	  site.	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HA/NA	   balance	  measurements	  made	   of	   H7N9	   and	   H1N9	   viruses	   binding	   to	  6SLN-­‐PAA	   indicate	   that	   the	   sialidase	   site	   has	   a	   role	   in	   binding	   to	   α2,6	   linked	   sialic	  acid,	  seen	  by	  the	  presence	  of	  an	  initial	  enhancement	  of	  binding	  to	  6SLN-­‐PAA	  when	  the	  Hb	  site	  is	  present	  and	  the	  sialidase	  site	  is	  uninhibited	  (Figs.	  4.8	  and	  4.10),	  indicating	  that	   there	   is	   a	   cooperativity	   in	   receptor	   binding	   via	   the	   two	   binding	   sites.	   These	  observations	  of	   the	   involvement	  of	   the	  sialidase	  site	   in	  α2,6	  binding	  was	  reinforced	  by	  NA	  kinetic	  measurements	  made	   for	   the	  cleavage	  of	  6SLN,	   indicating	  that	   the	  WT	  N9	   NA	   has	   ~2-­‐fold	   lower	   Km	   and	   ~10-­‐fold	   lower	   kcat	   when	   compared	   to	   the	  previously	  measured	  parameters	  for	  X-­‐31	  NA	  (Table	  3.1),	  indicating	  that	  the	  NA	  has	  stronger	  interactions	  with	  the	  receptor	  but	  a	  much	  lower	  probability	  of	  this	  binding	  resulting	  in	  a	  cleavage	  event.	  	  
Understanding	  the	  potential	  impact	  of	  these	  changes	  on	  overall	  virus	  receptor	  binding	  is	  more	  difficult.	  The	  inclusion	  of	  the	  secondary	  binding	  site	  clearly	  causes	  an	  increase	   in	   the	  apparent	  Kd	   for	  virus	  binding	  (~2-­‐fold)	  but	  estimating	   the	  energetic	  contribution	   from	   the	   secondary	   site	   is	   difficult	   without	   more	   information.	   The	  binding	  constant	   for	   the	  second	  binding	  site	   is	  not	  known	  and	  attempts	   to	  measure	  this	   using	   the	   MST	   experiments	   detailed	   in	   section	   4.2.7	   were	   unsuccessful.	   The	  binding	   is	  most	   likely	   to	   be	   very	  weak,	   with	   a	   Kd	  most	   likely	   in	   the	  mM	   range,	   as	  previously	  determined	  crystal	  structures	  of	  a	  similar	  N9	  with	  receptor	  bound	  in	  the	  secondary	  site	  required	  20	  mM	  sialic	  acid	  in	  order	  to	  see	  electron	  density	  (Varghese	  
et	  al.,	  1997)	  and	  crystal	  structures	  of	  the	  Anhui13	  NA	  studied	  here	  required	  50	  mM	  of	  receptor	  in	  order	  to	  see	  good	  electron	  density	  (Xiaoli	  Xiong,	  unpublished	  data).	   It	   is	  worth	  noting	  that	  if	  the	  Kd	  for	  the	  interaction	  is	  indeed	  in	  the	  low	  mM	  range	  then	  it	  is	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similar	  to	  values	  determined	  for	  the	  interaction	  of	  HA	  with	  receptors	  measured	  using	  NMR	  and	  MST	  (Sauter	  et	  al.,	  1989;	  1992b;	  Xiong	  et	  al.,	  2013a).	  
The	   presence	   of	   this	   site	   in	   the	   NA	   rather	   than	   the	   HA	   adds	   a	   number	   of	  geometrical	   complications	   to	   receptor	  binding.	  NA	   is	  present	  on	  viruses	   in	   clusters,	  which	   are	   thought	   to	   be	   at	   the	   area	   of	   the	   virus	   closest	   to	   the	   host	   cell	  membrane	  upon	  budding	  and	  membrane	  scission	  (Calder	  et	  al.,	  2010),	  see	  Introduction,	  section	  1.4.4,	  for	  more	  details.	  The	  effect	  of	  this	  clustering	  of	  NA	  upon	  binding	  to	  a	  surface	  is	  unclear.	   When	   experiments	   are	   carried	   out	   with	   the	   sialidase	   site	   inhibited	   the	  clustered	  NA	  could	  increase	  overall	  binding	  if	  the	  affinity	  for	  sialic	  acid	  is	  higher	  than	  the	   NA	   or	   the	   binding	   sites	   could	   be	   more	   accessible	   to	   the	   surface	   immobilised	  receptor	  either	  due	  to	  the	  wider	  spacing	  of	  binding	  sites,	  compared	  to	  HA,	  or	  due	  to	  the	  binding	  mode	  of	  sialic	  acid	  by	  the	  Hb	  site,	  where	  the	  sialic	  acid	  binds	  to	  allow	  the	  attached	  sugars	  to	  attach	  perpendicular	  to	  the	  surface	  of	  the	  protein,	  rather	  than	  the	  more	  integrated	  binding	  of	  HA	  (Varghese	  et	  al.,	  1997)	  (Fig.	  1.9B).	  	  
As	  well	  as	  this	  complication	  of	  NA	  clustering	  the	  height	  of	  the	  NA	  ‘head	  region’	  compared	  to	  the	  height	  of	  the	  HA	  can	  be	  mediated	  by	  altering	  the	  NA	  stalk	  length.	  A	  reduction	   in	   stalk	   height	   leads	   to	   a	   lower	   activity	   of	   NA	   at	   cleaving	   surface	  immobilised	  sialic	  acid,	  as	  shown	  in	  section	  3.2.10.	  The	  stalk	  of	  the	  N9	  reduced	  by	  five	  residues	   when	   compared	   to	   other	   similar	   N9	   proteins	   from	   wild	   birds,	   deleting	  residues	  68	  –	  72	  (Chen	  et	  al.,	  2015).	  This	  reduction	  in	  stalk	  length	  would	  likely	  reduce	  the	  effective	  NA	  	  sialidase	  activity,	  similar	  to	  the	  10	  residue	  deletion	  measured	  of	  X-­‐31	   NA	   Δ10	   (Fig.	   3.15).	   A	   5	   residue	   deletion	   from	   the	   stalk	   would	   likely	   bring	   the	  globular	   head	   of	   the	  NA	   to	   a	   similar	   height	   as	   the	  HA,	   as	   a	   typical	   stalk	   length	  NA	  protrudes	   above	   the	   level	   of	  HA	   (Harris	  et	  al.,	   2006).	   The	   reduction	   in	   stalk	   length	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would	  alter	   the	  geometry	  of	   the	  NA	  binding	  properties	  measured	   in	   this	   chapter.	   It	  could,	  logically,	  either	  strengthen	  or	  weaken	  the	  overall	  virus	  binding	  via	  HA	  and	  NA.	  The	  reduction	  of	  stalk	  length	  could	  prevent	  the	  interaction	  of	  NA	  which	  is	  present	  in	  a	  neighbouring	   area	   to	   the	   virus	   binding	   ‘footprint’	   which	   could	   be	   enhancing	   the	  overall	  virus	  binding.	  The	  reduction	  of	  stalk	  length	  could	  also	  increase	  virus	  binding	  by	  making	  the	  surface	  of	   the	  virus	   flatter,	  without	  the	  NA	  protruding	  above	  the	  HA,	  therefore	  allowing	  better	  binding	  of	  all	  proteins.	  	  
A	   reduction	   in	   NA	   stalk	   is	   typically	   considered	   a	   replicative	   adaptation	   of	  viruses	  to	  poultry	  (see	  Introduction,	  section	  1.3.2.4).	  The	  reduction	  of	  stalk	  length	  in	  these	  H7N9	  viruses	  appears	  to	  be	  an	  adaptive	  change	  in	  the	  NA	  which	  is	  required	  for	  human	  infection,	  as	  there	  have	  been	  very	  few	  H7N9	  human	  isolates	  containing	  a	  full	  length	   stalk	   (2	   of	   174	   full	   length	   NA	   sequences,	   A/Guandong/3/2013	   and	  A/Shanghai/5/2013,	   GISAID	   (http://gisaid.org)	   accessed	   22.4.15).	   It	   is	   also	   worth	  noting	   that	   there	   have	   been	   no	   avian	  H7N9	   viruses	   isolated	   since	   2011	  with	   a	   full	  length	   NA	   stalk	   including	   viruses	   isolated	   during	   the	   period	   of	   much	   enhanced	  surveillance	   of	   H7N9	   viruses	   in	   avian	   species	   since	   the	   outbreak	   began	   in	   2013.	   It	  appears	   counterintuitive	   that	   a	   reduction	   in	   stalk	   length	   would	   be	   a	   selective	  advantage	   in	   terms	   of	   reducing	   sialidase	   activity	   for	   a	   virus	  with	   an	  NA	   so	   poor	   at	  cleaving	   the	   human	   α2,6-­‐linked	   receptors.	   It	   therefore	   appears	   that	   it	   could	   be	   a	  selective	  advantage	  for	  the	  receptor	  binding	  properties	  of	  the	  NA.	  	  
Overall	  virus	  binding	  affinity	  has	  been	  previously	  related	  to	  the	  affinity	  of	  HA	  for	  monomeric	  sugars	  using	  a	  multiplicity	  coefficient	  (Xiong	  et	  al.,	  2013a).	  Trying	  to	  include	  energetic	  contributions	  from	  a	  binding	  site	  on	  an	  additional	  protein	  (the	  NA)	  would	   clearly	   be	   very	  difficult.	  On	   the	   one	  hand	   the	  presence	   of	   additional	   binding	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partners	  would	  obviously	  be	  expected	  to	  increase	  the	  overall	  affinity	  for	  the	  virus	  and	  the	   fact	   that	   the	   NA	   is	   generally	   taller	   than	   the	   HA	   could	   effectively	   increase	   the	  surface	   of	   the	   virus	   able	   to	  make	   contacts	  with	   the	   surface.	  On	   the	   other	   hand	   any	  binding	   by	   the	  NA	  might	   actually	   reduce	   the	   number	   of	   HA	  molecules	   in	   the	   virus	  ‘footprint’	  that	  can	  interact	  with	  the	  surface	  sugars	  thus	  weakening	  the	  interaction.	  	  
There	  have	  been	  suggestions	  in	  previous	  reports	  that	  oseltamivir	  carboxylate	  can	  bind	  to	  the	  Hb	  site	  of	  NA	  (Lai	  et	  al.,	  2012).	  There	  is	  no	  apparent	  evidence	  of	  this	  binding	   in	   the	   experiments	   carried	   out	   in	   this	   chapter	   at	   the	   concentrations	   of	   the	  drugs	  used.	  The	  TRBC	  pull	  down	  assay	  showed	  strong	  binding	  in	  the	  presence	  of	  the	  high	  concentration	  of	  100	  µM	  of	  oseltamivir	  carboxylate,	   indicating	  no	   inhibition	  of	  the	   Hb	   site,	   (Fig.	   4.2).	   These	   experiments	   are	   consistent	   with	   previous	   work	   that	  concluded	   that	   there	  was	  no	  effect	  of	  NA	   inhibitors	  on	   the	  haemadsorption	  activity	  (Laver	  et	  al.,	  1984).	  
The	   enhanced	   binding	   of	   the	   N9	   to	   6SLN	   through	   the	   sialidase	   site	   is	  associated	  with	  a	  low	  Km	  and	  a	  very	  low	  kcat	  and	  is	  similar	  to	  variants	  of	  the	  NA	  from	  H3N2	   viruses,	   which	   gain	   substitutions	   upon	   adaptation	   to	   propagation	   in	   tissue	  culture.	   These	   H3N2	   viruses	   have	   substitutions	   in	   the	   NA	   at	   positions	   151	   which	  typically	  occur	  when	  viruses	  are	  propagated	   in	  MDCK	  cells	   rather	   than	  MDCK-­‐SIAT	  cells	   which	   have	   elevated	   levels	   of	   α2,6	   sugars	   (Lin	   et	   al.,	   2010).	   Expressed	   N2	  proteins	  with	  these	  mutations	  have	  MUNANA	  cleavage	  kinetics	  with	  low	  Km	  and	  low	  kcat	   and	   reduced	   overall	   receptor	   cleavage	   (Zhu	   et	   al.,	   2012a)	   (Stephen	   Wharton,	  unpublished	  data).	  The	  sialidase	  site	  in	  the	  N9	  does	  not	  have	  the	  same	  properties	  as	  that	  of	   the	  binding	  N2	  with	  a	  151	  substitution,	  as	   the	  N9	  retains	  efficient	  MUNANA	  and	  3SLN	  cleavage	  but	  only	  has	  poor	  6SLN	  cleavage.	  It	  is	  unclear	  whether	  this	  6SLN	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binding	  activity	  is	  an	  evolved	  trait	  or	  requirement	  for	  human	  infection	  or	  whether	  it	  is	  simply	  a	  property	  that	  is	  inherent	  to	  the	  avian	  NA.	  	  
What	  are	  the	  implications	  of	  the	  binding	  properties	  of	  these	  H7N9	  viruses	  for	  human	  infection?	  The	  H7N9	  virus	  is	  from	  an	  avian	  source	  and	  the	  binding	  properties	  are	  similar	  to	  those	  of	  other	  avian	  viruses.	  It	  has	  an	  overall	  preference	  for	  the	  surface	  immobilised	   avian-­‐like	   receptor	   analogue	   3SLN-­‐PAA	   (Fig	   4.5)	   and	   the	  NA	   is	   highly	  active	   against	   the	   monomeric	   sugar	   substrate	   3SLN	   (Table	   4.2).	   There	   is	   also,	  however,	   strong	   binding	   for	   the	   human-­‐like	   receptor	   analogue	   6SLN-­‐PAA,	  which	   is	  not	  a	  common	  feature	  in	  a	  number	  of	  other	  avian	  H7	  and	  H5	  viruses.	  The	  presence	  of	  binding	  to	  6SLN-­‐PAA	  is	  likely	  to	  be	  a	  result	  of	  the	  Q226L	  mutation	  present	  in	  the	  H7	  HA	  (Xiong	  et	  al.,	  2013b;	  Dortmans	  et	  al.,	  2013).	  
When	  looking	  at	  the	  binding	  properties	  to	  the	  receptors	  more	  pertinent	  to	  the	  majority	   of	   human	   infections,	   α2,6	   linked	   sialic	   acid,	   the	   viruses	   show	   interesting	  properties,	   with	   the	   overall	   virus	   binding	   in	   the	   presence	   of	   NA	   inhibitors	   being	  strong	  for	  6SLN-­‐PAA,	  although	  not	  as	  strong	  as	  for	  3SLN-­‐PAA	  (Fig	  4.5).	  The	  NA	  is	  also	  ineffective	  at	  cleaving	  6SLN,	  as	  seen	  when	  measuring	  the	  enzyme	  kinetics	  (Table	  4.2)	  and	  the	  virus	  release	  is	  comparatively	  slow	  in	  the	  HA/NA	  balance	  experiments	  (Fig.	  4.8),	  when	  compared	   to	  X-­‐31	   (Fig	  3.2).	  The	  kinetic	  parameters	   for	   the	  NA	   for	  6SLN	  cleavage	  show	  a	  very	  low	  overall	  catalytic	  rate,	  kcat,	  and	  an	  enhanced	  binding,	  low	  Km,	  when	  compared	  to	  the	  parameters	  determined	  for	  X-­‐31.	  This	  suggests	  that	  the	  N9	  NA	  sialidase	   site	   has	   enhanced	   binding	   properties,	   making	   it	   contribute	   to	   receptor	  binding	  to	  α2,6-­‐linked	  sialic	  acids.	  	  
Consideration	   of	   all	   the	   data	   presented	   here	   suggests	   that	   the	   NA	   of	   H7N9	  viruses	   enhances	   overall	   virus	   binding	   to	   α2,6-­‐linked	   sialic	   acids,	   which	   are	   the	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receptors	  present	  in	  the	  primary	  site	  of	  	  human	  infection,	  the	  upper	  respiratory	  tract	  epithelial	  cells.	  This	  enhancement	  of	  binding	  from	  the	  dual	  effects	  of	  the	  Hb	  site	  and	  the	   sialidase	   site	   could	   aid	   initial	   virus	   infection	   but	  may	   act	   as	   a	   restrictive	   factor	  when	  the	  virus	  is	  released	  from	  the	  cell	  to	  initiate	  infection	  elsewhere.	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5 Biophysical	   Receptor	   Binding	   Studies	   of	   H1N1	   2009	  
Pandemic	  Emergence	  
5.1 Introduction	  
A	  new	   lineage	  of	  H1N1	   IAVs	  emerged	   in	  2009,	   causing	  a	  pandemic,	  which	   is	  thought	   to	   have	   infected	   an	   estimated	   60	   million	   people	   between	   April	   2009	   and	  April	  2010	   in	   the	  USA	  alone	  (Shrestha	  et	  al.,	  2011),	  as	  well	  as	  similarly	  widespread	  infections	   worldwide.	   These	   2009	   pandemic	   (pdm09)	   viruses	   were	   the	   result	   of	   a	  reassortment	   of	   viruses	   from	   four	   different	   lineages,	   as	   described	   in	   Introduction,	  section	  1.8.2.4	  (Fig.	  1.11).	  This	  novel	  lineage	  of	  reassortant	  viruses	  is	  thought	  to	  have	  infected	   humans	   as	   a	   zoonosis	   from	   swine.	   Preceding	   the	   emergence	   of	   the	   2009	  pandemic	   virus	   there	   had	   been	   viruses	   circulating	   in	   swine	   that	   contained	   viral	  segments	  from	  three	  of	  the	  sources	  in	  the	  pdm09	  viruses,	  known	  as	  triple-­‐reassortant	  swine	  (TRS).	  These	  TRS	  viruses	  differ	  from	  the	  pdm09	  in	  the	  source	  of	  the	  M	  and	  NA	  segments	  as	  well	  as	  a	  number	  of	  amino	  acid	  substitutions	  in	  the	  HA.	  TRS	  viruses	  were	  responsible	  for	  a	  number	  of	  sporadic	  human	  zoonoses	  (Shinde	  et	  al.,	  2009);	  however,	  there	  was	  no	  evidence	  for	  direct	  human-­‐to-­‐human	  transmission	  of	  these	  viruses.	  
As	  described	  previously	  a	  major	   factor	   in	  determining	   the	   transmissibility	  of	  IAVs	  is	  the	  interactions	  of	  the	  surface	  glycoproteins	  HA	  and	  NA	  with	  the	  cell	  surface.	  Experiments	  presented	   in	   this	   chapter	  were	   carried	  out	  with	  both	  TRS	   and	  pdm09	  viruses	   in	   an	  attempt	   to	   increase	  our	  understanding	  of	  which	   factors	   increased	   the	  transmissibility	  of	  the	  virus	  and	  led	  to	  the	  pandemic.	  Experiments	  were	  carried	  out	  to	  investigate	   the	   HA	   mediated	   receptor	   binding	   of	   pre-­‐pandemic	   TRS	   viruses	   and	  pdm09	  to	  receptor	  analogues,	  which	  vary	  at	  a	  number	  of	  positions	  owing	  to	  a	  number	  of	  drift	  mutations	  of	  the	  csw	  H1	  HA.	  Investigations	  were	  also	  carried	  out	  into	  the	  HA	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and	  NA	  balance	  characteristics	  of	   these	   two	   lineages	  of	  viruses,	  examining	  both	   the	  HA,	   from	   classical	   swine	   (csw)	   sources,	   and	   the	   NA,	  which	   is	   from	   Eurasian	   swine	  sources.	  	  
5.2 Results	  
5.2.1 Choice	  of	  viruses	  for	  studies	  
Prototypic	   viruses	   were	   chosen	   to	   represent	   the	   pre-­‐pandemic	   TRS	   viruses	  and	  the	  pdm09	  virus.	  A/Iowa/1/2006	  (Iowa06)	  was	  chosen	  as	  a	  representative	  TRS	  virus.	   This	   virus	   was	   isolated	   from	   a	   human	   zoonotic	   infection	   of	   a	   swine	   H1N1	  (Shinde	   et	   al.,	   2009).	   A/California/7/2009	   (Cal7)	   was	   chosen	   as	   a	   representative	  pdm09	  virus.	  It	  was	  one	  of	  the	  first	  isolates	  obtained	  upon	  the	  emergence	  of	  pdm09	  viruses.	   Cal7	   has	   been	   the	  H1N1	   vaccine	   virus	   since	   the	   first	   inclusion	   of	   a	   pdm09	  virus	   in	   the	   trivalent/quadravalent	   inactivated	   vaccine.	   Both	   Iowa06	   and	   Cal7	   also	  have	  full	  reverse	  genetics	  background	  systems	  (6	  segments	  PB2,	  PB1,	  PA,	  NP,	  M	  and	  NS)	  previously	  cloned	  in	  the	  McCauley	  laboratory	  by	  Dr.	  Haixia	  Xiao.	  
5.2.2 Analysis	  of	  HA	  sequences	  pertaining	  to	  pdm09	  emergence	  
Sequence	   alignments	   of	   pdm09	   and	   pre-­‐pandemic	   TRS	   virus	   HA	   sequences	  were	  carried	  out.	  A	  selection	  of	  TRS	  viruses	  containing	  an	  H1	  glycoprotein	  from	  the	  classical	   swine	   lineage	   and	   also	   a	   selection	   of	   the	   first	   tissue	   culture-­‐propagated	  pdm09	   isolates	   were	   gathered	   from	   the	   GISAID	   database	   (http://gisaid.org)	   and	  aligned.	  These	  alignments	  were	  carried	  out	  to	  identify	  conserved	  substitutions	  in	  the	  HA,	  which	  occurred	  between	  TRS	  viruses,	  carrying	  a	  classical	  swine	  (csw)	  lineage	  H1	  HA,	   and	   the	   emergence	   of	   the	   first	   strains	   of	   pdm09	   viruses.	   The	   conserved	  substitutions	  found	  during	  these	  alignments	  were	  mapped	  onto	  a	  crystal	  structure	  of	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a	   pdm09	   HA	   (Xu	   et	   al.,	   2012a).	   The	   common	   substitutions	   occurring	   around	   the	  receptor	  binding	   site	  of	   the	  HA	  were	   selected	   for	   further	   investigation.	  The	   sites	  of	  interest,	  as	  well	  as	  other	  residues	  known	  to	  play	  a	  major	  role	  in	  determining	  receptor	  specificity	  are	  shown	  in	  Table	  5.1.	  The	  location	  of	  these	  residues	  with	  respect	  to	  the	  receptor	  binding	  site	   is	  shown	  in	  Figure	  5.1.	  An	  alignment	  of	   the	  sequences	  of	  Cal7,	  Iowa06	  and	  a	  number	  of	  strains	  used	  in	  previous	  studies	  is	  also	  included	  in	  Figure	  5.2.	  The	  conserved	  differences	  (Table	  5.1)	  thought	  to	  have	  the	  potential	  to	  alter	  receptor	  binding	  of	  viruses	  are	  generally	  in	  regions	  of	  the	  HA	  which	  are	  known	  to	  alter	  sialic	  acid	   receptor	   binding,	   such	   as	   the	   130-­‐loop,	   the	   190-­‐helix	   and	   the	   220-­‐loop.	  Conserved	  amino	  acid	  substitutions,	  between	  TRS	  and	  pdm09	  H1	  HAs,	  were	  found	  at	  the	   following	  positions:	  132,	  149,	  and	  227	  (H3	  numbering).	  Residues	  134,	  186,	  219	  and	  225	   show	  a	   conserved	   residue	   in	   early	  pdm09	  viruses	  but	   show	  a	   variation	   in	  csw	  HA	  sequences.	  Residue	  134	  is	  typically	  a	  Lys	  in	  pdm09	  and	  an	  Arg	  in	  csw	  viruses,	  however	   the	   Iowa06	   virus	   used	   here,	   and	   a	   number	   of	   other	   csw	   H1	   containing	  isolates,	  contain	  the	  pdm09-­‐like	  Lys.	  Residue	  186	  and	  189	  are	  conserved	  as	  a	  Ser	  186	  and	  Ala	  189	  in	  pdm09	  viruses;	  however,	  there	  appears	  to	  be	  polymorphism	  at	  these	  positions	  in	  csw	  HA	  sequences,	  with	  viruses	  either	  carrying	  the	  Ser	  186	  and	  Ala	  189	  as	  with	   pdm09	   viruses	   or	   Pro	   186	   and	   Thr	   189.	   Residue	   219	   is	   a	   conserved	   Ile	   in	  pdm09	  viruses	  but	  shows	  polymorphism	  between	  Thr	  and	  Ala	  in	  csw	  viruses.	  
5.2.3 Construction	  of	  reverse	  genetics	  viruses	  
The	   HA	   and	   NA	   of	   Cal7	   and	   Iowa06	   were	   cloned	   into	   the	   reverse	   genetics	  plasmid	  pHW2000,	  as	  described	  in	  Materials	  and	  Methods,	  section	  2.2.6.12.1.	  The	  Cal7	  virus	   that	   the	   HA	   was	   cloned	   from	   was	   egg-­‐adapted	   and	   carried	   the	   adaptive	  substitution	   Q226R,	   which	   is	   not	   present	   in	   the	   sequences	   of	   tissue	   culture-­‐
210	  
	  
Table	   5.1:	   Table	   of	   the	   sequences	   of	   HA	   residues	   under	   investigation	   for	   a	  
number	  of	  representative	  csw	  and	  pdm09	  HAs.	  	  	  
Figure	  5.1:	  Structural	  location	  of	  H1	  HA	  residues	  studied.	  Plotted	  on	  to	  structure	  of	   A/California/4/2009	   HA	   complexed	   with	   6SLN	   (PDB:	   3UBN)	   (Xu	   et	   al.,	   2012a).	  Shown	   in	   red	   is	   the	   receptor	   analogue	   6SLN.	   Diagram	   made	   using	   PyMol	   (PyMol	  Molecular	  Graphics	  System,	  Schrödinger).	   	  
132 134 149 186 189 190 200 208 219 225 226 227 228 H3,Numbering
Virus 128 130 146 183 186 187 197 205 216 222 223 224 225 H11Numbering
pdm09
A/California/7/09 S K K S A D A R I D Q E G
A/California/4/09 S K K S A D T R I D Q E G
A/Texas/05/09 S K K S A D A R I D Q E G
A/England/195/09 S K K S A D A R I D Q E G
Classical,Swine
A/Ohio/1/07 T R R S A D A R T D Q A G
A/Iowa/1/06 T K R P T D A K A N Q A G
A/swine/Iowa/00239/04 T R R P T D A K A D Q A G
A/swine/Illinois/100084/01 T R R S A D A R T D Q A G
A/swine/Ohio/891/01 T R R S A D A R T D Q A G
A/swine/Indiana/P12439/00 T R R S A D A R A D Q A G



















Figure	  5.2:	  Alignment	  of	  H1	  HA1	  sequences.	  HA1	  sequences	  are	  aligned	  for	  the	  two	  viruses	  under	  study	  (Cal7	  and	  Iowa06)	  and	  viruses	  used	   for	  other	  receptor	  binding	  studies	  of	  pdm09	  emergence.	  A/California/4/09	  and	  A/swine/Ohio/891/01	  used	  in	  (de	   Vries	   et	   al.,	   2011).	   A/California/4/09	   and	   A/swine/Indiana/P12439/2000	  (A/swine/Indiana/00)	   used	   in	   (Xu	   et	   al.,	   2012b).	   Residues	   are	   shaded	   which	   are	  studied	  in	  this	  chapter.	  Alignment	  made	  is	  in	  H1	  numbering.	  132	  (H3	  numbering)	  is	  128	   (H1	  numbering),	   134	   (H3)	   is	  130	   (H1),	  149	   (H3)	   is	  146	   (H1),	  186	   (H3)	   is	  183	  (H1),	  189	  (H3)	  is	  186	  (H1),	  208	  (H3)	  is	  205	  (H1),	  219	  (H3)	  is	  216	  (H1),	  227	  (H3)	  is	  224	  (H1).	  	   	  
                               10        20        30        40        50        60            
                      ....|....|....|....|....|....|....|....|....|....|....|....| 
Cal7                  DTLCIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDKHNGKLCKLRGVAPLHLGKCNIAGW  
A/California/4/09     ............................................................  
Iowa06                Q.................................N..D......................  
A/swine/Ohio/891/01   ...................................R........................  
A/swine/Indiana/2000  ...................................R........................  
 
                               70        80        90       100       110       120         
                      ....|....|....|....|....|....|....|....|....|....|....|....| 
Cal7                  ILGNPECESLSTASSWSYIVETPSSDNGTCYPGDFIDYEELREQLSSVSSFERFEIFPKT  
A/California/4/09     ............................................................  
Iowa06                L.........F............N............N......H...............A  
A/swine/Ohio/891/01   L.........F...........SN............N.......................  
A/swine/Indiana/00    L.........F...........S.............N.......................  
 
                              130       140       150       160       170       180      
                      ....|....|....|....|....|....|....|....|....|....|....|....| 
Cal7                  SSWPNHDSNKGVTAACPHAGAKSFYKNLIWLVKKGNSYPKLSKSYINDKGKEVLVLWGIH  
A/California/4/09     ............................................................  
Iowa06                N......T.........Y...N...R.....................N.K.....I....  
A/swine/Ohio/891/01   .......T.R...............R..............I......N.E..........  
A/swine/Indiana/00    .......T.R.......Y.......R........E............N............  
 
                              190       200       210       220       230       240      
                      ....|....|....|....|....|....|....|....|....|....|....|....| 
Cal7                  HPSTSADQQSLYQNADAYVFVGSSRYSKKFKPEIAIRPKVRDQEGRMNYYWTLVEPGDKI  
A/California/4/09     ................T...........................................  
Iowa06                ..P..T...T..............K...R......A.......A.........I....T.  
A/swine/Ohio/891/01   ...................................T.......A................  
A/swine/Indiana/00    ...................................A.......A..I.............  
 
                              250       260       270       280       290       300      
                      ....|....|....|....|....|....|....|....|....|....|....|....| 
Cal7                  TFEATGNLVVPRYAFAMERNAGSGIIISDTPVHDCNTTCQTPKGAINTSLPFQNIHPITI  
A/California/4/09     ............................................................  
Iowa06                .................K.GS.....V..A...........................V..  
A/swine/Ohio/891/01   ................LK..S.........S..........................V..  
A/swine/Indiana/00    ....................S.........S..........................V..  
 
                              310       320          
                      ....|....|....|....|....|.. 
Cal7                  GKCPKYVKSTKLRLATGLRNIPSIQSR  
A/California/4/09     ........................... 
Iowa06                .E...........M............. 
A/swine/Ohio/891/01   .E...........M............. 
A/swine/Indiana/00    .E...........M......V...... 
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propagated	   isolates	   of	   Cal7	   deposited	   in	   GISAID	   (http://gisaid.org).	   This	   mutation	  was	   reversed	   by	   site	   directed	  mutagenesis,	   as	   described	   in	  Materials	   and	  Methods,	  section	  2.2.6.13.1.	   Iowa06	  HA	  was	  cloned	  from	  an	  egg-­‐propagated	  stock	  of	  the	  virus.	  Upon	   sequencing	   the	   cloned	   HA	   gene	   of	   Iowa06	   all	   clones	   analysed	   contained	   the	  substitutions	  D131E	   and	  G157E	   (H3	  numbering),	  when	   compared	   to	   the	   published	  sequence	  deposited	   in	  GISAID	   (http://gisaid.org).	  These	  changes	  were	  converted	   to	  the	  wild	  type	  sequence	  by	  site	  directed	  mutagenesis.	  The	  HA	  of	  Iowa06	  also	  contains	  an	  Asn	  at	  position	  225,	  which	   is	  different	   from	  other	   classical	   swine	  HA	   isolates.	   It	  was	   decided	   to	   mutate	   the	   HA	   to	   a	   more	   classical	   swine-­‐like	   sequence	   by	  mutagenising	  the	  plasmid	  to	  contain	  the	  substitution	  N225D.	  This	  mutagenised	  form	  of	  Iowa06	  will	  be	  referred	  to	  as	  wild	  type	  in	  the	  studies	  presented	  here.	  	  
Recombinant	   viruses	  were	   generated	   by	   transfecting	   the	   cloned	  HA	   and	  NA	  plasmids,	   with	   the	   remaining	   six	   gene	   segments	   from	   PR8,	   into	   293T	   cells,	   as	  described	   in	   Materials	   and	   Methods,	   section	   2.2.5.	   Iowa06,	   rescued	   with	   a	   PR8	  background	   and	   subsequently	   propagated	   well	   in	   tissue	   culture.	   Cal7	   did	   not	  propagate	  when	  the	  transfections	  were	  carried	  out	  using	  a	  PR8	  background;	  however,	  the	   virus	   rescued	   and	   propagated	   successfully	   when	   using	   a	   full	   6	   segment	   Cal7	  background.	   Viruses	   used	   for	   HA	   avidity	   receptor	   binding	   studies	   were:	   Iowa06	  based	  viruses	  in	  a	  PR8	  background	  and	  Cal7	  based	  viruses	  with	  a	  full	  6	  segment	  Cal7	  background.	  
Viruses	  were	  initially	  propagated	  in	  minipig	  kidney	  (MPK)	  cells,	  as	  they	  were	  found	   to	   give	   the	   best	   titres	   for	  WT	   and	  mutant	   versions	   of	   both	   Iowa06	   and	   Cal7	  viruses.	  Iowa06	  viruses	  propagated	  well	  and	  had	  the	  correct	  sequence	  after	  passage;	  however,	   although	   the	   Cal7	   viruses	   propagated	   well	   they	   were	   found	   upon	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sequencing	   to	   have	   gained	   polymorphisms	   at	   positions	   157	   –	   159	   with	   the	  substitutions:	  K157E,	  G158E	  or	  N159E.	  These	  mutations	  have	  been	  found	  previously	  upon	   pdm09	   virus	   passage	   (Klimov	   et	   al.,	   2012),	   particularly	   in	   MDCK-­‐SIAT	   cells,	  which	   are	  MDCK	   cells	   stably	   transfected	  with	   a	   plasmid	   expressing	   additional	   α2,6	  sialyltransferases	  (Matrosovich	  et	  al.,	  2003).	  A	  range	  of	  MDCK	  cell	   lines	  were	  tested	  for	  optimal	  virus	  titre,	  without	  altering	  the	  HA	  sequence.	  The	  cells	  that	  gave	  the	  best	  viral	  yield	  were	  ECACC	  MDCK	  cells.	  These	  were	  used	  for	  further	  propagation	  of	  these	  viruses.	  	  
Biophysical	   analyses	   required	   large	   amounts	   of	   concentrated	   virus.	   Viruses	  were	  passaged	  three	  times,	  from	  the	  transfection	  supernatant,	  with	  the	  final	  passage	  in	  a	   large	  volume	   (~1	  Litre),	   as	  described	   in	  Materials	  and	  Methods,	   section	  2.2.3.2.	  Viruses	  were	  concentrated	  by	  centrifugation	  and	  quantified	  as	  described	  in	  Materials	  
and	   Methods,	   section	   2.2.9.2.	   Virus	   HA	   and	   NA	   genes	   in	   these	   preparations	   were	  sequenced	   to	   verify	   the	   absence	   of	   undesired	   mutations	   and	   sequence	  polymorphisms,	  as	  described	  in	  Materials	  and	  Methods,	  section	  2.2.6.11.	  	  
5.2.4 Biolayer	  interferometry	  measurements	  of	  virus	  affinity	  
Receptor	   binding	   assays	  were	   carried	   out	   based	   on	   a	   previously	   established	  assay,	   where	   virus	   binding	   is	   measured	   by	   BLI	   to	   sensors	   loaded	   with	   different	  amounts	  of	  the	  receptor	  analogues	  6SLN-­‐PAA	  and	  3SLN-­‐PAA.	  As	  described	  previously	  data	   for	  virus	   fractional	  saturation	  were	   then	  plotted	  as	  a	   function	  of	  sugar	   loading	  (Materials	  and	  Methods,	  section	  2.2.10.1).	  
Binding	   for	   all	   H1N1	   viruses	   studied	  was	   only	   detectable	   to	   the	   human-­‐like	  receptor	  analogue	  6SLN-­‐PAA.	  Although	  measurements	  of	  binding	  to	  3SLN-­‐PAA	  were	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carried	   out	   there	   was	   no	   measurable	   signal	   for	   any	   of	   the	   viruses	   constructed	   at	  saturated	   sugar	   loading	   (~0.6	   nm)	   both	   at	   1	   x	   (100	   pM)	   and	   10	   x	   (1	   nM)	   virus	  concentrations.	  	  
Results	   are	   presented	   (Figures	   5.3,	   5.4,	   5.6	   and	   5.8)	   for	   the	   various	  mutant	  viruses	   constructed.	  The	  difference	   in	   relative	  Kd	  of	   virus	  binding	   to	  6SLN-­‐PAA	  has	  also	  been	  determined,	  as	  described	  in	  Materials	  and	  Methods,	  section	  2.2.10.1.	  These	  are	  presented	  in	  Table	  5.2	  and	  are	  expressed	  relative	  to	  the	  relevant	  wild	  type	  virus,	  which	  is	  given	  a	  normalised	  Kd	  of	  1.	  Values	  with	  an	  increase	  or	  decrease	  greater	  than	  2-­‐fold	  are	  considered	  significant.	  	  
5.2.4.1 Wild-­‐type	  pdm09	  Cal7	  and	  TRS	  Iowa06	  viruses	  
Figure	  5.3	  shows	  the	  BLI	  data	  for	  the	  WT	  viruses	  (at	  100	  pM)	  binding	  to	  both	  receptor	   analogues	   6SLN-­‐PAA	   and	   3SLN-­‐PAA.	   Both	   Iowa06	   and	   Cal7	   show	   very	  strong	   binding	   to	   6SLN-­‐PAA,	   similar	   to	   that	   seen	   with	   X-­‐31	   (Fig.	   3.1),	   with	   no	  measurable	   binding	   to	   3SLN-­‐PAA.	   The	   6SLN-­‐PAA	   binding	   is	   very	   similar	   for	   both	  Iowa06	  and	  Cal7.	  
5.2.4.2 Mutant	  viruses:	  HA	  residues	  132,	  134	  and	  149	  
Figure	   5.4	   shows	   the	   binding	   of	   Iowa06	   and	   Cal7	   viruses	   with	   amino	   acid	  substitutions	   at	   positions	   132,	   134	   and	   149.	   The	   substitution	   S132T	   in	   Cal7	   HA	  reduces	  overall	  binding	  of	   the	  virus	   to	  6SLN-­‐PAA,	  with	  an	   increase	   in	  relative	  Kd	  of	  ~4-­‐fold,	  whereas	  the	  equivalent	  mutation	  in	  the	  Iowa06	  HA	  has	  no	  significant	  effect	  on	   receptor	   binding.	   Position	   134	   displays	   polymorphism	   between	   Lys	   and	   Arg	   in	  classical	   swine	   HA	   sequences	   but	   is	   always	   Lys	   in	   pdm09	   viruses.	   Both	   Cal7	   and	  Iowa06	  WT	  viruses	  have	  a	  Lys	  at	  this	  position.	  Cal7	  K134R	  and	  Iowa06	  K134R	  show
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Figure	  5.3:	  Equilibrium	  binding	  of	  WT	  Cal7	  and	  Iowa06	  to	  6SLN-­‐PAA	  and	  3SLN-­‐
PAA.	  Fractional	  saturation	  of	  virus	  binding	  measured	  as	  a	  function	  of	  sugar	  loading	  in	  the	  presence	  of	  NA	  inhibitors.	  
	  
Table	   5.2:	   Relative	   Kd	   values	   of	   mutant	   Cal7	   and	   Iowa06	   viruses	   binding	   to	  
6SLN-­‐PAA.	  Values	  are	  calculated	  relative	  to	  the	  relevant	  wild	  type	  virus,	  as	  described	  in	  Materials	  and	  Methods,	   section	  2.2.10.1.	  Values	  shown	   in	  bold	  are	  differences	  <2-­‐fold	  and	  therefore	  considered	  not	  significantly	  different	  from	  the	  wild-­‐type.	  	   	  




















Virus Relative,Kd Virus Relative,Kd
Cal7%WT 1 Iowa06%WT 1
Cal7%S132T 4.37 Iowa06%T132S 0.61
Cal7%K134R 1.25 Iowa06%K134R 0.63
Cal7%K149R 7.03 Iowa06%R149K 8.79
Cal7%S186P 0.10 Iowa06%P186S 4.16
Cal7%A189T 2.98 Iowa06%T189A 0.13
Cal7%R208K 0.94 Iowa06%K208R 15.66
Cal7%I219T 0.15 Iowa06%A219I 0.14
Cal7%I219A 0.33 Iowa06%A219T 1.33
Cal7%E227A 0.07 Iowa06%A227E 1.19
Cal7%I219A%E227A 0.04 Iowa06%A219I%A227E 3.79
Cal7%I219T%E227A 0.05 Iowa06%A219T%A227E 3.91






Figure	  5.4:	  Equilibrium	  virus	  binding	  to	  6SLN-­‐PAA	  of	  Cal7	  and	  Iowa06	  viruses	  
with	   HA	   residue	   substitutions	   at	   positions	   132,	   134	   and	   149.	   Fractional	  saturation	  of	  virus	  binding	  measured	  as	  a	  function	  of	  sugar	  loading	  in	  the	  presence	  of	  NA	  inhibitors.	  	  	   	  











































no	  significant	  difference	  in	  the	  binding	  to	  6SLN-­‐PAA	  compared	  to	  the	  WT	  viruses.	  The	  substitution	   K149R	   in	   Cal7	   HA	   causes	   a	   decrease	   in	   6SLN-­‐PAA	   receptor	   binding	  affinity,	  with	  an	  increase	  in	  relative	  Kd	  of	  ~7-­‐fold.	  The	  opposite	  substitution	  R149K	  in	  Iowa06	  HA	  also	  causes	  a	  reduction	  in	  receptor	  affinity	  of	  a	  similar	  magnitude,	  with	  a	  reduction	  in	  relative	  Kd	  of	  ~9-­‐fold.	  	  
Differences	   in	  binding	  affinity	  are	   seen	  when	  substitutions	  are	   introduced	  at	  positions	  132	  and	  149.	  Neither	  of	  these	  residues	  are	  directly	  involved	  in	  interacting	  with	   the	   receptor,	   see	   Figure	   5.5A.	   The	   role	   of	   these	   residues	   in	   altering	   receptor	  binding	   is	   likely	   to	   be	   due	   to	   alterations	   in	   the	   coordination	   of	   the	   130-­‐loop.	   This	  could	   interfere	  with	  a	  number	  of	   interactions	   such	  as	   the	  backbone	  carboxyl	  of	  Val	  135	  with	  the	  nitrogen	  of	  the	  acetamido	  group	  of	  sialic	  acid	  and	  the	  interactions	  of	  the	  hydroxyl	  of	  Thr	  136	  and	  the	  backbone	  amine	  of	  Ala	  137	  with	  the	  carboxyl	  group	  of	  the	  sialic	  acid	  (Fig.	  5.5A).	  The	  alterations	  at	  position	  149	  could	  also	  be	  responsible	  for	  interfering	  with	  the	  interaction	  of	  Lys	  145	  with	  the	  4’	  hydroxyl	  of	  the	  sialic	  acid	  (Fig.	  5.5A).	  
5.2.4.3 Mutant	  viruses:	  HA	  residues	  186,	  189	  and	  208	  




Figure	   5.5:	   Structure	   of	   interactions	   of	   the	   130-­‐loop	   and	   190-­‐helix	   of	  































Figure	  5.6:	  Equilibrium	  virus	  binding	  to	  6SLN-­‐PAA	  of	  Cal7	  and	  Iowa06	  viruses	  
with	   HA	   residue	   substitutions	   at	   positions	   186,	   189	   and	   208.	   Fractional	  saturation	  of	  virus	  binding	  measured	  as	  a	  function	  of	  sugar	  loading	  in	  the	  presence	  of	  NA	  inhibitors.	  	  	   	  












































relative	  Kd	  of	  ~3-­‐fold).	  The	  substitution	  T189A	  introduced	  into	  Iowa06	  HA	  causes	  an	  increase	   in	   6SLN-­‐PAA	   receptor	   binding	   (reduction	   in	   relative	   Kd	   of	   ~7.5-­‐fold).	   The	  substitution	  R208K	  does	  not	  cause	  a	  significant	  alteration	   in	  binding	  characteristics	  to	   6SLN-­‐PAA	   when	   introduced	   into	   Cal7	   HA;	   however,	   the	   opposite	   substitution	  (K208R)	   introduced	   into	   Iowa06	  HA	  causes	  a	   large	  decrease	   in	   receptor	  binding	   to	  6SLN-­‐PAA,	  equivalent	  to	  an	  increase	  in	  the	  relative	  Kd	  of	  ~15-­‐fold.	  
Residue	  186,	  when	  a	  Ser,	   is	   involved	  in	  forming	  a	  hydrogen	  bond	  with	  the	  9’	  hydroxyl	  of	  sialic	  acid	  through	  a	  water	  molecule,	  as	  can	  be	  seen	   in	  Figure	  5.5B.	  The	  change	   of	   this	   Ser	   to	   Pro	   in	   Cal7	   causes	   an	   increase	   in	   receptor	   binding	   affinity	  whereas	  the	  mutation	  of	  Pro	  to	  Ser	  in	  Iowa06	  causes	  a	  decrease	  in	  receptor	  binding	  affinity,	   implying	  that	  for	  optimal	  receptor	  binding	  a	  Pro	  needs	  to	  be	  present	  at	  this	  site.	   It	   seems	   counterintuitive	   that	   the	   loss	   of	   a	   hydrogen	   bond	   should	   be	  accompanied	  by	  an	  increase	  in	  receptor	  binding	  affinity;	  however,	  the	  presence	  of	  a	  Pro	  will	  likely	  perturb	  the	  backbone	  arrangement	  due	  to	  the	  increased	  rigidity,	  owing	  to	   restricted	  movement	   around	   the	   amide	  bond.	   This	   could	   then	   interfere	  with	   the	  hydrogen	   bond	   between	   Thr187	   and	   Asp190	   and	   allow	   the	   Asp190	   to	   bind	   to	   the	  acetamido	   nitrogen	   of	   the	   GlcNAc,	   forming	   a	   new	   hydrogen	   bond	   that	   would	   be	  stronger	   than	   the	   lost	   bond	   from	   Ser186,	   as	   it	   would	   be	   a	   direct	   hydrogen	   bond	  rather	  than	  via	  bound	  water,	  see	  Figure	  5.5B.	  
Residue	   189	   needs	   to	   be	   an	   Ala	   for	   optimal	   6SLN-­‐PAA	   receptor	   binding	  characteristics.	   The	   A189T	   substitution	   reduces	   6SLN-­‐PAA	   binding	   in	   Cal7	   and	   the	  T189A	  substitution	  increases	  receptor	  binding	  in	  Iowa06.	  The	  presence	  of	  a	  Thr189	  could	  also	  be	   responsible	   for	  perturbing	  a	  hydrogen	  bond	   formed	  between	  Asp190	  and	  the	  sialic	  acid.	  The	  linkage	  between	  positions	  186	  and	  189	  can	  be	  seen	  with	  the	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Iowa06	  double	  mutant	  P186S	  T189A	  that	  has	  a	  very	  similar	  binding	  profile	  to	  P186S	  alone	  (Fig.	  5.6),	  indicating	  that	  the	  enhanced	  binding	  due	  to	  the	  loss	  of	  Thr189	  is	  lost	  when	  the	  Ser186	  is	  present.	  
The	   difference	   seen	   in	   6SLN-­‐PAA	   binding	   when	   the	   substitution	   K208R	   is	  introduced	  in	  Iowa06	  HA	  is	  difficult	   to	  explain,	  as	   it	   is	  a	  considerable	  distance	  from	  the	  receptor	  binding	  site,	  see	  Figure	  5.7.	  The	  location	  of	  the	  residue	  is	  at	  the	  interface	  between	   HA	   monomers.	   This	   residue	   could	   therefore	   be	   involved	   in	   altering	  interactions	  between	  subunits	  and	  possibly	  changing	  the	  positioning	  of	  the	  220-­‐loop,	  thus	   altering	   receptor	   binding	   properties.	   The	   reason	   that	   the	   opposite	   mutation	  (R208K)	  makes	  no	  difference	  to	  Cal7	  receptor	  binding	  could	  be	  due	  to	  the	  nature	  of	  the	  other	  residues	  in	  the	  220-­‐loop,	  such	  as	  the	  alterations	  in	  219	  and	  227	  described	  below.	   Amino	   acid	   substitutions	   at	   this	   interface	   between	  monomers,	   residue	   218,	  has	  been	  previously	  found	  to	  cause	  alterations	  in	  receptor	  binding	  in	  H3	  HA	  (Daniels	  
et	  al.,	  1987).	  
5.2.4.4 Mutant	  viruses:	  HA	  residues	  219	  and	  227	  








Figure	   5.7:	   Structure	   of	   interactions	   of	   the	   220-­‐loop	   and	   190-­‐helix	   of	  
























Figure	  5.8:	  Equilibrium	  virus	  binding	  to	  6SLN-­‐PAA	  of	  Cal7	  and	  Iowa06	  viruses	  
with	  HA	  residue	  substitutions	  at	  positions	  219	  and	  227.	  Fractional	  saturation	  of	  virus	  binding	  measured	  as	  a	  function	  of	  sugar	  loading	  in	  the	  presence	  of	  NA	  inhibitors.	  
	  
	   	  

















































































the	   opposite	  mutation	   (A227E)	   does	   not	   have	   a	   significant	   effect	   on	   the	   binding	   of	  Iowa06	  (Figs.	  5.8A	  and	  C).	  
Owing	   to	   the	   proximity	   of	   the	   219	   and	   227	   residues	   combination	   mutants	  were	  constructed	  with	  substitutions	  at	  both	  positions.	  The	  substitutions	  I219T	  E227A	  and	  I219A	  E227A	  increase	  binding	  to	  6SLN-­‐PAA	  when	  introduced	  into	  Cal7	  HA	  (Fig.	  5.8B).	  When	  either	  219	  substitution	  is	  combined	  with	  E227A,	  in	  Cal7	  HA,	  there	  is	  an	  additive	   effect	   of	   enhancement	   of	   receptor	   binding	   to	   6SLN-­‐PAA	   (a	   decrease	   in	  relative	  Kd	  of	  ~25-­‐fold	  for	  I219A	  E227A	  and	  ~20-­‐fold	  for	  I219T	  E227A)	  (Fig.	  5.8B).	  The	  substitution	  A219I	  in	  Iowa06	  HA	  causes	  an	  increase	  in	  receptor	  binding	  to	  6SLN-­‐PAA;	  however,	  when	  combined	  with	  A227E	  there	  is	  a	  decrease	  in	  6SLN-­‐PAA	  receptor	  binding	  (increase	  in	  relative	  Kd	  of	  ~4-­‐fold)	  (Figs.	  5.8C	  and	  D).	  The	  substitution	  A219T	  in	   Iowa06	   does	   not	   have	   a	   significant	   effect	   on	   6SLN-­‐PAA	   receptor	   binding	   when	  compared	  to	  wild	  type;	  however,	  when	  combined	  with	  A227E	  there	  is	  a	  reduction	  in	  receptor	  binding	  to	  6SLN-­‐PAA	  (increase	  in	  relative	  Kd	  of	  ~4-­‐fold)	  (Fig.	  5.8D).	  
Neither	   residue	   (219	   or	   227)	   is	   directly	   involved	   in	   interacting	   with	   the	  receptor.	  Residue	  219	  is	  situated	  behind	  the	  220	  loop	  (Fig.	  5.7).	  The	  role	  of	  219	  may	  be	   that	   of	   forming	   a	   hydrophobic	   wall	   to	   ensure	   that	   the	   227	   residue	   is	   correctly	  located	   in	   order	   that	   it	   can	   coordinate	   Lys222	   to	   ensure	   that	   it	   interacts	   correctly	  with	  the	  3’	  hydroxyl	  of	  the	  galactose.	  No	  difference	  is	  seen	  in	  Iowa06	  receptor	  binding	  with	  the	  alteration	  of	  Iowa06	  HA	  from	  A227E	  unless	  219	  is	  an	  Ile	  or	  Thr	  upon	  which	  there	   is	   a	   reduction	   in	   binding	   to	   6SLN-­‐PAA	   compared	   to	   the	   WT.	   Cal7	   behaves	  slightly	  differently	  with	  the	  E227A	  mutation	  causing	  an	  increase	  in	  receptor	  binding	  to	  a	  similar	  extent	  whether	  the	  219	  is	  an	  Ala,	  Ile	  or	  Thr.	  This	  difference	  could	  be	  due	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to	   altered	   220-­‐loop	   coordination	   due	   to	   differences	   at	   208,	   which	   altered	   Iowa06	  6SLN-­‐PAA	  binding.	  
5.2.5 H1N1	  HA	  expression	  and	  purification	  
In	  order	  to	  study	  the	  binding	  of	  individual	  trimers	  Cal7	  and	  Iowa06	  HAs	  were	  expressed	   in	   insect	   cells	   using	   a	   recombinant	   baculovirus	   system.	   	   Expression	  constructs	  of	  Cal7	  and	  Iowa06	  HA	  ectodomain	  were	  synthesised	  and	  cloned	  into	  the	  HA	   expression	   plasmid	   pHAEM1,	   as	   described	   in	   Materials	   and	   Methods,	   section	  2.2.6.12.2.	   The	   HA	   gene	   was	   synthesised	   for	   residues	   1	   –	   502	   (H1	   numbering),	  without	   the	   17	   residue	   N-­‐terminal	   signal	   peptide	   and	   the	   cytoplasmic	   tail.	   The	  pHAEM1	  plasmid	  encodes	  a	  gp67	  secretion	  signal	  peptide	  at	  the	  N-­‐terminus,	  which	  is	  removed	   post	   translationally,	   and	   a	   C-­‐terminal	   purification	   tag	   consisting	   of	   a	   TEV	  protease	  cleavage	  site,	  a	  foldon	  (T4	  Fibritin)	  trimerisation	  motif	  and	  a	  6	  x	  His	  tag.	  The	  sequences	   of	   expression	   constructs	   are	   shown	   in	   the	   Appendix.	   Recombinant	  baculoviruses	   were	   generated	   containing	   these	   cloned	   genes	   using	   the	   Baculogold	  system,	   as	   described	   in	  Materials	  and	  Methods,	   section	   2.2.7.1.	   These	   baculoviruses	  were	  used	  to	   infect	  bulk	  cultures	  of	  Sf9	  cells	   for	  protein	  expression,	  as	  described	   in	  
Materials	   and	  Methods,	   section	   2.2.7.3.	   The	   expressed	   protein	  was	   concentrated	   by	  hollow	   fibre	   filtration	   and	  purified	   using	   a	   cobalt	   column	   as	   described	   in	  Materials	  
and	   Methods,	   section	   2.2.8.4.	   Figure	   5.9A	   shows	   SDS-­‐PAGE	   analysis	   of	   elution	  fractions	  from	  this	  his-­‐tag	  purification.	  There	  was	  significant	  contamination	  in	  earlier	  elution	  fractions,	  visible	  by	  SDS-­‐PAGE.	  Fractions	  7	  –	  17,	  as	  numbered	  in	  Figure	  5.9A,	  were	   pooled	   and	   concentrated.	   The	   typical	   purification	   procedure	   for	   recombinant	  HA	   then	   includes	   a	   digestion	   with	   TPCK-­‐trypsin,	   followed	   by	   gel	   filtration.	   This	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Figure	  5.9:	   SDS-­‐PAGE	  analysis	  of	  Cal7	  HA	  purification.	  A)	  Elution	  fractions	  from	  cobalt	   column	   purification.	   B)	   Peak	   fractions	   of	   gel	   filtration	   purification.	   All	   gels	  were	  run	  under	  non-­‐reducing	  conditions.	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digestion	  cleaves	   the	  purified	  HA0,	   into	  HA1	  and	  HA2,	  and	  simultaneously	  removes	  the	  purification-­‐tag	  by	  cleaving	  at	  the	  TEV	  protease	  recognition	  sequence.	  Figure	  5.10	  shows	  SDS-­‐PAGE	  analysis	  of	  trypsin	  and	  TEV	  protease	  digested	  Cal7	  and	  Iowa06	  HA	  as	  well	   as	   a	   positive	   control	   of	   an	   insect	   expressed	  H5	  HA,	   kindly	   provided	   by	   Dr.	  Xiaoli	  Xiong.	  There	  is	  a	  small	  amount	  of	  cleaved	  HA,	  giving	  HA1	  (~50	  kDa)	  and	  HA2	  (~25	  kDa)	  bands	  in	  the	  undigested	  samples	  for	  the	  H1	  and	  H5	  proteins,	  most	   likely	  due	  to	  cleavage	  of	  the	  HA	  during	  expression	  by	  insect	  cell	  proteases.	  It	  is	  clear	  from	  this	  gel	  that	  both	  H1	  proteins	  are	  digested	  into	  incorrectly	  sized	  products	  by	  trypsin,	  compared	   to	   the	   H5	   control,	   suggesting	   protein	   instability.	   When	   the	   proteins	   are	  digested	  with	  TEV	  protease	  there	  is	  a	  slight	  reduction	  in	  the	  size	  of	  the	  HA0	  due	  to	  the	  removal	  of	  the	  purification	  tag.	  	  




	   	  
	  
	  
Figure	   5.10:	   SDS-­‐PAGE	   analysis	   of	   protease	   susceptibility	   of	   Cal7	   and	   Iowa06	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based	  on	  previous	  experiments.	  As	  additional	  proof	  of	  the	  oligomeric	  nature	  of	  these	  fractions	  there	  are	  also	  multimeric	  HA	  bands	  present	  at	  higher	  molecular	  weights	  on	  the	  non	  reducing	  gel	  shown,	  at	  100	  –	  150	  kDa.	  There	  is	  also	  a	  minor	  peak	  at	  higher	  retention	   volumes	   (~70ml),	   which	   is	   a	   small	   amount	   of	   monomer	   present	   in	   the	  sample,	   fractions	  16	  –	  22	  Fig	  5.9B.	  Fractions	  8	  –	  14	  were	  pooled	  and	  concentrated.	  Purification	   gels	   shown	   are	   for	   the	   purification	   of	   Cal7	   HA;	   however,	   Iowa06	   HA	  purified	  in	  a	  very	  similar	  manner.	  
5.2.6 Measurement	  of	  H1	  binding	  by	  microscale	  thermophoresis	  
The	   monomeric	   binding	   of	   Cal7	   and	   Iowa06	   was	   measured	   by	   microscale	  thermophoresis	   (MST).	   This	   technique	   has	   been	   previously	   used	   to	   measure	   the	  affinity	  of	  purified	  HA	   for	  monomeric	  receptor	  analogues	   (Xiong	  et	  al.,	  2013a).	  This	  method	   measures	   the	   movement	   of	   a	   constant	   concentration	   of	   a	   fluorescently	  labelled	   analyte	   in	   a	   temperature	   gradient	   in	   the	   presence	   of	   a	   range	   of	  concentrations	  of	  a	  binding	  partner.	  	  
The	  purified	  HA,	  generated	  as	  described	  in	  section	  5.2.5,	  was	  labelled	  with	  an	  amine-­‐reactive	  fluorescent	  dye,	  as	  described	  in	  Materials	  and	  Methods,	  section	  2.2.13.	  This	  labeling	  was	  optimised	  in	  order	  to	  attach	  1	  –	  2	  dye	  molecules	  per	  HA	  trimer.	  MST	  was	   performed	   with	   the	   labelled	   protein	   at	   a	   constant	   concentration	   and	   using	   a	  range	   of	   different	   concentrations	   of	   6SLN	   (0.05	   –	   30	   mM),	   and	   the	   Kd	   values	  calculated	  as	  described	  in	  Materials	  and	  Methods,	  section	  2.2.13.	  MST	  measurements	  were	  only	  made	  of	  binding	  of	  the	  HA	  to	  6SLN.	  Experiments	  using	  3SLN	  were	  omitted	  due	   to	   the	   lack	   of	   measurable	   binding	   of	   the	   viruses	   containing	   these	   HAs	   in	   BLI	  experiments.	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Figure	  5.11	  shows	  the	  plotted	  data	  and	  Table	  5.3	  the	  plotted	  Kd	  values	  for	  the	  MST	  of	  Cal7	  and	  Iowa06	  HA	  binding	  to	  6SLN.	  It	  is	  apparent	  from	  these	  MST	  data	  that	  the	  monomeric	  binding	  of	  both	  Cal7	  and	  Iowa06	  to	  6SLN	  are	  very	  similar,	  as	  with	  the	  BLI	   data	   for	   receptor	   binding	   (Figure	   5.3),	   giving	   a	  Kd	   value	   of	  ~3.5	  mM.	   The	   data	  obtained	  are	  not	  of	  high	  quality,	  with	  significant	  variability,	  as	  the	  protein	  appeared	  to	   denature	  when	   greater	   temperature	   gradients	  were	   applied	   to	   the	   samples.	   The	  labeling	  of	  the	  reactive	  amines	  of	  the	  protein	  also	  appears	  to	  be	  problematic,	  as	  there	  is	  a	  Lys	  residue	  present	  in	  both	  the	  Cal7	  and	  Iowa06	  receptor	  binding	  sites	  at	  position	  134.	  This	  Lys	  is	  also	  likely	  to	  be	  highly	  accessible	  to	  solvent	  and	  will	  consequently	  be	  one	   of	   the	   more	   easily	   labelled	   free	   lysine	   residues,	   possibly	   interfering	   with	   the	  measurements	  made.	   It	   is	  notable	  that	  the	  presence	  of	  a	   lysine	   in	  the	  vicinity	  of	  the	  receptor	  binding	  site	  (Lys	  137)	  also	  caused	  similar	  issues	  for	  measuring	  MST	  binding	  parameters	   for	   an	   H10	  HA	   (Vachieri	   et	  al.,	   2014).	   These	  MST	   results	   reinforce	   the	  similarity	  of	  binding	  of	  Cal7	  and	  Iowa06	  NA	  to	  6SLN	  similar	   to	   the	  results	  obtained	  for	  BLI	  (Fig.	  5.3).	  
5.2.7 H1N1	  NA	  purification	  
Purification	  of	   soluble	  NA	   from	  viruses	   containing	   the	  NA	  of	  Cal7	  or	   Iowa06	  was	  attempted	   in	  order	   to	  allow	  detailed	  kinetic	  analyses	  of	   these	  proteins.	  Viruses	  were	  constructed	  containing	  the	  NA	  of	  Iowa06	  or	  Cal7	  in	  a	  7+1	  reassortment	  with	  the	  lab-­‐adapted	   WSN	   strain.	   Reassortment	   with	   this	   virus,	   rather	   than	   PR8,	   has	   been	  found	  to	  give	  higher	  yields	  of	  NA	  when	  extracted	  from	  purified	  virus	  (Patrick	  Collins,	  personal	  communication).	  These	  recombinant	  viruses	  were	  propagated	  in	  bulk	  using	  hens’	  eggs	  (~1500	  eggs).	  Both	  viruses	  were	  then	  purified	  from	  the	  allantoic	  fluid,	  as	  described	   in	  Materials	   and	   Methods,	   section	   2.2.3.1.	   Figure	   5.12	   shows	   SDS-­‐PAGE	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Figure	  5.11:	  Microscale	  thermophoresis	  data	  for	  Cal7	  and	  Iowa06	  HA	  binding	  to	  
6SLN.	  Data	   obtained	   for	  monomeric	   6SLN	  binding	   to	   insect	   cell	   expressed	   protein.	  Data	   shown	   are	   for	   duplicate	   experiments.	   Fit	   to	   determine	   Kd	   shown.	   6SLN	  concentrations	  are	  presented	  as	   [6SLN]/3	   to	   correct	  Kd.	   See	  Materials	  and	  Methods,	  section	  2.2.13	  for	  more	  details	  and	  (Xiong	  et	  al.,	  2013a).	  	  
Protein	   Corrected	  Kd	  ±	  S.E.*	  (mM)	  
Cal7	  HA	   3.3	  ±	  0.8	  
Iowa06	  HA	   3.8	  ±	  0.9	  *	  S.E.:	  Standard	  Error	  of	  the	  mean	  
Table	  5.3:	  Fitted	  kinetic	  parameters	  of	  MST	  experiments	  measuring	  the	  binding	  
of	  Cal7	  and	  Iowa06	  HA	  to	  6SLN.	  	  	   	  

































analysis	  of	  these	  purified	  viruses.	  Both	  Cal7	  and	  Iowa06	  NA	  containing	  viruses	  have	  a	  band	  corresponding	  to	  NA,	  running	  at	  ~70	  kDa.	  
Purification	  of	  NA	   from	  the	  virus	  was	  attempted	  using	  a	  number	  of	  different	  methods.	   The	   first	  method	  was	  digestion	  with	   the	   protease	   bromelain,	   followed	  by	  removal	   of	   the	   virus	   core	   by	   ultracentrifugation,	   as	   described	   in	   Materials	   and	  
Methods,	  section	  2.2.8.3.	  The	  Cal7	  NA	  was	  successfully	   cleaved	   from	  the	  virus	  using	  bromelain,	  as	  had	  been	  previously	  done	  with	  pdm09	  NA	  (van	  der	  Vries	  et	  al.,	  2012),	  whereas	  the	  Iowa06	  virus	  showed	  no	  significant	  cleavage	  of	  NA	  from	  the	  virus	  even	  at	   high	   bromelain	   concentrations.	   Figure	   5.13	   shows	   SDS-­‐PAGE	   of	   the	   bromelain	  digestion	  of	  the	  viruses	  containing	  Cal7	  or	  Iowa06	  NA.	  In	  Figure	  5.13A	  the	  cleavage	  of	  NA	  from	  the	  Cal7	  virus	  leads	  to	  two	  bands	  in	  the	  supernatant,	  which	  are	  both	  NA.	  This	  was	  shown	  after	  gel	  filtration	  experiments	  described	  below	  where	  the	  two	  products	  were	  partially	  separated	  by	  gel	   filtration	  (Fig.	  5.14).	  Fractions	  containing	  a	  majority	  of	  the	  larger	  or	  smaller	  product	  had	  a	  similar	  NA	  activity	  proportional	  to	  the	  amount	  of	   protein	  present	   in	   the	   fraction	   (data	  not	   shown).	  These	   two	  bands	   seen	  by	   SDS-­‐PAGE	   are	   likely	   to	   be	   different	   bromelain	   cleavage	   products.	   One	   is	   at	   ~70	   kDa,	  similar	  in	  size	  to	  that	  seen	  in	  the	  undigested	  virus	  NA,	  and	  the	  other	  is	  ~40	  kDa.	  They	  are	   likely	  to	  have	  different	  amounts	  of	  the	  NA	  stalk	  removed,	  with	  the	  70	  kDa	  band	  corresponding	  to	  soluble	  protein	  with	  the	  majority	  of	  the	  stalk	  still	  attached	  and	  the	  smaller	  40	  kDa	  band	  with	  more	  of	  the	  stalk	  removed.	  The	  two	  bands	  are	  of	  a	  similar	  intensity.	  Also	  present	  in	  the	  supernatant	  is	  some	  HA2	  (~25	  kDa)	  but	  no	  visible	  HA1,	  which	  should	  run	  at	  ~50	  kDa.	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Figure	  5.12:	  SDS-­‐PAGE	  of	  7+1	  reassortant	  viruses	  used	  for	  Cal7	  and	  Iowa06	  NA	  
purification.	  Viruses	  contain	  Cal7	  or	  Iowa06	  NA	  with	  the	  remaining	  7	  segments	  from	  WSN.	  Viruses	  were	  propagated	  in	  hens’	  eggs	  and	  purified	  through	  sucrose	  gradients.	  Samples	  were	  analysed	  under	  both	  reducing	  and	  non-­‐reducing	  conditions.	  	  
Figure	   5.13:	   SDS-­‐PAGE	   analysis	   of	   bromelain	   digestion	   of	   Cal7	   and	   Iowa06	  



























































The	  Cal7	  NA	  extracted	  by	  bromelain	  digestion	  was	   further	  purified	  by	  anion	  exchange	   chromatography	   to	   remove	   contaminating	   HA,	   as	   described	   in	  Materials	  
and	  Methods,	  section	  2.2.8.3.	  The	  column	  flow	  through	  was	  retained,	  which	  contained	  the	   NA.	   This	   flow	   through	   was	   concentrated	   and	   purified	   further	   by	   gel	   filtration.	  Figure	  5.14	   shows	  SDS-­‐PAGE	  analysis	  of	   the	  peak	   fractions.	  The	  protein	  eluted	   in	  a	  broad	  single	  peak	  ranging	  from	  ~55	  –	  70	  ml.	  The	  gel	  filtration	  partially	  separated	  the	  two	  bromelain	  digestion	  products	  of	  NA	  seen	  previously	  (Fig.	  5.13A).	  The	  larger	  ~70	  kDa	   form	   of	   the	   NA	   formed	  what	   appears	   to	   be	   a	   dimer,	   which	   runs	   at	   ~120	   kDa	  when	   the	  SDS-­‐PAGE	   is	  performed	  under	  non-­‐reducing	   conditions.	   It	  was	   concluded	  that	   the	  cleavage	  of	   the	  NA	   into	   these	  different	  products	   is	  unlikely	   to	  affect	  kinetic	  measurements.	   Fractions	   2	   –	   18	   were	   pooled	   and	   concentrated.	   Aliquots	   of	   the	  concentrated	  NA	  were	  snap	  frozen	  in	  liquid	  nitrogen	  and	  stored	  at	  -­‐80°C.	  
The	  Iowa06	  NA	  could	  not	  be	  removed	  from	  the	  virus	  by	  bromelain	  digestion	  (Fig.	   5.13B).	   It	   was	   therefore	   decided	   to	   extract	   the	   virus	   glycoproteins	   using	  detergent	  and	  then	  protease	  digest	  the	  NA	  ectodomain	  from	  the	  cytoplasmic	  tail	  and	  stalk.	  Detergent	  extraction	  of	   the	  viral	   glycoproteins	  was	  attempted	   in	  a	  number	  of	  different	   detergents	   and	   the	   most	   efficient	   detergent	   extraction	   was	   found	   by	  extracting	  the	  proteins	   in	  2%	  Brij-­‐36T.	  This	  condition	  did	  not	  extract	  any	  M1	  or	  NP	  into	   the	  ultracentrifugation	  supernatant,	  monitored	  by	  SDS-­‐PAGE	  (data	  not	  shown).	  The	   HA	   was	   removed	   from	   the	   detergent	   extracted	   protein	   by	   anion	   exchange	  chromatography	  in	  the	  presence	  of	  detergent.	  The	  flowthrough	  fraction	  was	  applied	  to	  a	  gel	  filtration	  column	  to	  remove	  contaminating	  lipid	  and	  also	  to	  buffer	  exchange	  to	  a	  lower	  concentration	  of	  detergent	  (0.5%	  Brij-­‐36T).	  The	  fractions	  containing	  NA	  were	  pooled.	   Trypsin	   and	   bromelain	   cleavage	   of	   the	   detergent	   solubilised	   NA	   was
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Figure	   5.14:	   SDS-­‐PAGE	   analysis	   of	   Cal7	   NA	   gel	   filtration	   purification.	   Flow	  through	  fraction	  of	  ion	  exchange	  of	  bromelain	  cleaved	  WSN	  +	  Cal7	  NA	  purified	  by	  gel	  filtration.	  Samples	  of	  fractions	  run	  under	  both	  non-­‐reducing	  and	  reducing	  conditions.	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attempted	   under	   a	   number	   of	   different	   conditions,	   varying	   ratios	   of	   proteases,	  different	  salt	  concentrations	  and	  concentrations	  of	  β-­‐mercaptoethanol	  (for	  bromelain	  digestions);	   however,	   cleavage	   was	   unsuccessful.	   The	   detergent	   extracted	   protein	  was	  converted	   into	  rosettes	  by	  removal	  of	   the	  detergent	  by	  hydrophobic	  adsorbent	  beads,	  as	  described	  in	  Materials	  and	  Methods,	  section	  2.2.8.3.	  Protease	  cleavage	  of	  the	  NA	   rosettes	   was	   also	   attempted	   under	   a	   range	   of	   different	   conditions	   and	   protein	  cleavage	  could	  not	  be	  achieved.	  It	  was	  decided	  to	  use	  the	  protein	  rosettes	  directly	  for	  measuring	  NA	  kinetics;	  however,	  when	  carrying	  out	  preliminary	  experiments	  the	  NA	  rosettes	   had	   largely	   lost	   NA	   activity	   and	   the	   activity	   degraded	   further	   upon	   brief	  incubation	  at	  37°C.	  It	  was	  decided	  to	  measure	  the	  NA	  kinetics	  for	  Iowa06	  only	  using	  purified	  virus.	  	  
5.2.8 H1N1	  NA	  kinetic	  characterisation	  
NA	  kinetic	  characterisation	  was	  carried	  out	  both	  Cal7	  NA	  and	  Iowa06	  NA.	  The	  Cal7	  NA	  was	   purified	   from	   virus,	   as	   described	   above	   in	   section	   5.2.7.	   This	   purified	  protein	   allows	   the	   determination	   of	   kcat,	   as	   the	   protein	   concentration	   can	   be	  determined.	  The	  Iowa06	  NA	  could	  not	  be	  purified	  from	  the	  virus	  whilst	  still	  retaining	  activity	  comparable	  to	  when	  it	  was	  attached	  to	  the	  virus.	  Purified	  virus	  was	  used	  for	  kinetic	  characterisation.	  The	  purified	  virus	  used	  was	  a	  7	  +	  1	  reassortant	  of	  WSN	  with	  Iowa06	  NA.	  The	  concentration	  of	  the	  NA	  present	  in	  the	  purified	  virus	  cannot	  be	  easily	  measured	  and	  consequently	   the	  kcat	  value	  cannot	  be	  determined;	  however.	   the	  Vmax	  value	  can	  be	  determined,	  which	  allows	  the	  comparison	  of	  measurements	  made	  with	  the	  same	  virus	  concentration	  under	  different	  reaction	  conditions.	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5.2.8.1 MUNANA	  kinetics	  
Kinetic	   measurements	   were	   made	   for	   Cal7	   and	   Iowa06	   NA	   cleaving	   the	  fluorogenic	   substrate	   MUNANA,	   as	   described	   in	   Materials	   and	   Methods,	   section	  2.2.11.1,	  and	  section	  3.2.7.1.	  Measurements	  were	  made	  both	  in	  MES	  buffer	  (32.5	  mM	  MES-­‐NaOH,	  pH	  6.5,	  4	  mM	  CaCl2)	   and	  HBS	  buffer	   (10	  mM	  HEPES-­‐NaOH	  pH	  7.4,	  150	  mM	  NaCl,	   0.005%	  Tween-­‐20,	   4	  mM	  CaCl2)	   and	   at	   two	  different	   temperatures,	   25°C	  and	   37°C.	   Figure	   5.15	   shows	   Michaelis-­‐Menten	   plots	   of	   MUNANA	   cleavage	  determined	   for	   Cal7	   and	   Iowa06	   NA	   and	   shown	   in	   Table	   5.4	   are	   the	   fitted	   kinetic	  parameters.	  	  
Cal7	  NA	  has	  low	  Km	  and	  high	  kcat	  values	  and	  consequently	  high	  kcat/Km	  values	  for	   MUNANA	   cleavage	   under	   all	   conditions	   tested,	   indicating	   high	   enzymatic	  efficiency.	   The	   Km	   and	   kcat	   values	   determined	   in	   MES	   buffer	   are	   similar	   to	   those	  measured	   for	   X-­‐31	   (Table	   3.1),	   indicating	   a	   highly	   active	   NA	   at	   cleaving	  MUNANA.	  There	   is,	   however,	   a	   difference	   seen	   when	   comparing	   the	   two	   buffer	   conditions	  between	  Cal7	  and	  X-­‐31	  NA.	  Both	  Cal7	  and	  X-­‐31	  NA	  show	  a	  2	  –	  3	  fold	  increase	  in	  Km	  when	  measurements	  are	  made	  in	  the	  HBS	  buffer,	  however	  X-­‐31	  has	  an	  increased	  kcat	  in	  HBS,	  indicating	  an	  increased	  turnover	  rate,	  whereas	  Cal7	  NA	  has	  similar	  kcat	  values	  under	  both	  buffer	  conditions.	  This	   indicates	  a	  possible	  difference	   in	  pH	  dependency	  of	  NA	  activity,	  although	  the	  difference	  between	  the	   two	  buffers	   is	  not	  simply	  pH,	  as	  there	  are	  also	  differences	  in	  the	  concentration	  of	  NaCl.	  
Iowa06	  NA	  also	  has	  low	  Km	  values,	  indicating	  high	  affinity	  binding	  of	  MUNANA	  by	  this	  NA.	  The	  Km	  values	  measured	  in	  MES	  buffer	  are	  ~1.5-­‐fold	  higher,	  under	  both	  temperature	   conditions,	   when	   compared	   to	   those	   measured	   for	   Cal7,	   indicating	  slightly	  weaker	  binding	  of	  MUNANA;	  however,	  when	  measured	  in	  HBS	  the	  Iowa06	  Km	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Figure	   5.15:	   Michaelis-­‐Menten	   plots	   of	   Cal7	   and	   Iowa06	   NA	   cleavage	   of	  
MUNANA.	  Measurements	  made	  using:	  A)	  Cal7	  purified	  NA,	  converting	  obtained	  rate	  values	  to	  observed	  rate	  by	  dividing	  by	  the	  rate	  by	  the	  concentration	  of	  NA	  used;	  B)	  7+1	  reassortant	  of	  WSN	  +	  Iowa06	  NA	  purified	  virus,	  data	  could	  not	  be	  converted	  to	  observed	  rate,	  as	  the	  concentration	  of	  NA	  present	  is	  not	  known.	  All	  graphs	  show	  least	  squares	  fit	  of	  Michaelis-­‐Menten	  equation.	  	  
















































	  	  	  	  	  	  
Protein	   Substrate	   Buffer/	  Temp	  
Km	  ±	  S.E.	  §	  
(µM)	  
Kcat	  ±	  S.E.	  
(s-­‐1)	  








MES*	  37°C	   9.0	  ±	  0.6	   30.4	  ±	  0.5	   -­‐	   3.38	  
MES	  25°C	   3.5	  ±	  0.1	   6.7	  ±	  0.1	   -­‐	   1.91	  
HBS†	  37°C	   26.6	  ±	  1.6	   26.0	  ±	  0.6	   -­‐	   0.97	  
HBS	  25°C	   13.3	  ±	  0.7	   7.8	  ±	  0.2	   -­‐	   0.59	  
6SLN	  
3SLN	  
HBS	  37°C	   600	  ±	  45	   -­‐	   -­‐	   -­‐	  





MES	  37°C	   15.4	  ±	  0.2	   -­‐	   0.625	  ±	  0.007	   -­‐	  
MES	  25°C	   5.0	  ±	  0.3	   -­‐	   0.111	  ±	  0.001	   -­‐	  
HBS	  37°C	   8.7	  ±	  0.5	   -­‐	   0.568	  ±	  0.007	   -­‐	  
HBS	  25°C	   3.6	  ±	  0.2	   -­‐	   0.122	  ±	  0.002	   -­‐	  
6SLN	  
3SLN	  
HBS	  37°C	   463	  ±	  14	   -­‐	   -­‐	   -­‐	  
HBS	  37°C	   105	  ±	  5	   -­‐	   -­‐	   -­‐	  *MES	   MES	  Buffer	  (32.5	  mM	  MES-­‐NaOH,	  pH	  6.5,	  4	  mM	  CaCl2)	  †HBS	  	   HBS-­‐P	   +	   CaCl2	   Buffer	   (10	  mM	   HEPES-­‐NaOH,	   pH	   7.4,	   150	  mM	   NaCl,	   0.005%	  Tween-­‐20	  +	  4	  mM	  CaCl2)	  §S.E.	  	   Standard	  Error	  of	  the	  mean	  -­‐	   Value	  not	  determined	  	  
Table	  5.4:	  Steady	  state	  NA	  kinetic	  Parameters	  for	  Cal7	  and	  Iowa06	  NA.	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values	  are	  ~3-­‐fold	   lower,	   indicating	  a	  more	  efficient	  binding	  of	  MUNANA.	  There	  are	  no	  kcat	  data	  for	  Iowa	  06	  NA.	  These	  cannot	  be	  determined	  because	  the	  measurements	  were	  made	  using	  purified	  virus	  and	  the	  NA	  concentration	  is	  not	  known.	  Consequently,	  no	   comparison	   of	   overall	   catalytic	   efficiency	   can	   be	  made	   for	   the	   Cal7	   and	   Iowa06	  NAs.	  The	  Vmax	  values	  determined	  for	  Iowa	  06	  NA	  show	  a	  similar	  pattern	  to	  those	  seen	  with	   the	   kcat	   values	   determined	   for	   Cal7	  with	   similar	   values	  when	   the	   experiments	  were	   carried	   out	   at	   37°C	   when	   compared	   to	   25°C,	   similar	   to	   the	   kcat	   values	  determined	  for	  X-­‐31	  and	  Cal7.	  
5.2.8.2 6SLN	  and	  3SLN	  kinetics	  
Owing	  to	  the	  lack	  of	  available	  purified	  Iowa06	  NA	  it	  was	  decided	  not	  to	  carry	  out	   the	   detailed	  measurements	   of	   NA	   cleavage	   of	   6SLN	   and	   3SLN,	   as	   described	   in	  section	  3.2.7.2,	  as	  the	  kcat	  for	  Iowa06	  NA	  could	  not	  be	  determined.	  The	  Km	  of	  6SLN	  and	  3SLN	  was	  determined	  by	  measuring	  the	  Ki	  of	  6SLN	  or	  3SLN	  for	  inhibition	  of	  MUNANA	  cleavage.	  By	  measuring	   the	  uninhibited	  and	   inhibited	  rate,	  at	  a	  set	  concentration	  of	  6/3SLN,	   the	   Ki	   can	   be	   determined,	   as	   described	   in	  Materials	   and	  Methods,	   section	  2.2.11.1.2.	  The	  Ki	  of	  MUNANA	  inhibition	  by	  6SLN	  or	  3SLN	  is	  directly	  equivalent	  to	  the	  Km,	   as	   it	   is	   the	   concentration	   required	   to	   half	   saturate	   the	   sialidase	   site.	   These	   Ki	  values	  for	  MUNANA	  inhibition	  were	  found	  to	  be	  similar	  to	  measurements	  of	  Km	  made	  using	  the	  enzyme-­‐coupled	  assay,	  previously	  described	  in	  section	  3.2.7.2.	  
The	  Km	   values	   determined	   for	   6SLN	   and	   3SLN	   are	   shown	   in	   Table	   5.4.	   Both	  Cal7	  and	  Iowa06	  NA	  exhibit	  a	  relatively	  low	  Km	  for	  6SLN	  (Cal7	  =	  600	  ±	  45	  µM,	  Iowa06	  =	   463	   ±	   14	   µM)	  when	   compared	   to	   X-­‐31	   (8070	   ±	   615	   µM),	  with	   both	  N1	   proteins	  exhibiting	   a	   Km	   >10-­‐fold	   lower,	   indicating	   a	   much	   higher	   affinity	   binding	   of	   6SLN.	  Iowa06	  NA	  has	  a	  Km	  for	  6SLN	  which	  is	  ~1.3-­‐fold	  lower	  than	  Cal7	  indicating	  a	  slightly	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higher	  affinity.	  The	  Km	  values	  for	  3SLN	  are	  also	  lower	  (Cal7	  =	  42.8	  ±	  0.6	  µM,	  Iowa06	  =	  105	  ±	  5	  µM)	  when	  compared	  to	  X-­‐31	  (562.3	  ±	  20	  µM),	  with	  both	  N1	  proteins	  giving	  Km	   values	   >5-­‐fold	   lower.	   Cal7	  NA	   has	   a	   Km	   value	  which	   is	   ~2-­‐fold	   lower	   than	   that	  measured	  for	  Iowa06	  indicating	  enhanced	  binding	  to	  3SLN.	  
The	   Km	   data	   show	   that	   the	   N1	   NAs	   studied	   have	   high	   binding	   affinities	   for	  6SLN	  and	  3SLN	  compared	   to	  X-­‐31;	  however,	   this	   information	   is	  not	  enough	   to	   fully	  understand	  the	  NA	  characteristics,	  as	  there	  is	  no	  information	  on	  the	  relative	  rates	  of	  enzymatic	  turnover.	  
5.2.9 Measurement	  of	  HA	  and	  NA	  balance	  
The	   emergence	   of	   the	   pdm09	   viruses	   was	   accompanied	   with	   a	   novel	  combination	  of	  HA	  and	  NA,	  consequently	  there	  is	  likely	  to	  be	  an	  impact	  on	  the	  balance	  between	  the	  activities	  of	  these	  two	  glycoproteins.	  Assays	  were	  carried	  out	  to	  measure	  the	   activities	   of	   the	   different	   proteins	   in	   altering	   the	   interaction	   of	   virus	   with	   a	  receptor-­‐coated	  surface,	  using	  the	  system	  previously	  developed	  in	  section	  3.2.2.	  
Virus	   interaction	   studies	   carried	   out	   in	   the	   presence	   of	   NA	   inhibitors,	  described	  in	  section	  5.2.4,	  were	  performed	  using	  viruses	  with	  the	  full	  8-­‐segment	  Cal7	  virus;	  however,	   Iowa06	  viruses	  were	  a	  6	  +	  2	  reassortant	  using	  the	  HA	  and	  NA	  from	  Iowa06	  and	  the	  background	  from	  PR8.	  It	  is	  known	  that	  the	  background	  of	  a	  virus	  can	  alter	   the	  morphology	   and	   also	   the	   proportions	   of	   HA	   and	  NA	   present	   on	   the	   virus	  surface	   and	   consequently	   the	   virus	  used	   for	  HA/NA	  balance	   studies	  was	   the	   full	   8-­‐segment	   Iowa06	   virus.	   Viruses	   based	   on	   the	   Iowa06	   background	   were	   not	   used	  previously	  for	  studies	  of	  viruses	  with	  mutant	  HAs,	  as	  they	  have	  much	  more	  inefficient	  propagation	   characteristics.	   Reassortant	   viruses	   were	   constructed	   by	   generating	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viruses	   with	   the	   HA	   and	   NA	   of	   Cal7	   and	   Iowa06	   in	   both	   the	   Cal7	   and	   Iowa06	  backgrounds	  by	  reverse	  genetics.	  A	  virus	  with	  Cal7	  HA	  and	  Iowa06	  NA	  rescued	  and	  propagated	  well	  with	  both	  Cal7	  and	  Iowa06	  genetic	  backgrounds	  and	  both	  have	  very	  similar	  equilibrium	  binding	  characteristics,	  when	  compared	  to	  WT	  Cal7	  and	  Iowa06	  viruses,	  measured	  in	  the	  presence	  of	  NA	  inhibitors,	  shown	  in	  Figure	  5.16.	  Reassortant	  viruses	  with	   Iowa06	  HA	  and	  Cal7	  NA	  rescued	  and	  propagated	  well;	  however,	  when	  the	   binding	   of	   these	   viruses	   was	   measured	   they	   had	   unusual	   kinetics	   of	   binding,	  which	  were	  very	  slow	  compared	   to	   the	  WT	  and	   the	  other	  reassortant	  viruses	   (data	  not	   shown).	   These	   viruses	   were	   not	   used	   further	   because	   of	   these	   unusual	  characteristics.	  
Figure	  5.17	  shows	  the	  HA	  and	  NA	  balance	  measurements	  for	  viruses	  binding	  to	   biosensor	   surface	   saturated	   with	   6SLN	   in	   the	   presence	   and	   absence	   of	   NA	  inhibitors.	  The	  measurements	  made	  of	  the	  wild	  type	  viruses	  made	  in	  the	  absence	  of	  NA	   inhibitors	   show	   a	   number	   of	   differences.	   Iowa06	  WT	   has	  more	   extensive	   virus	  binding,	  with	   a	   peak	   virus	   binding	   of	  ~0.4	  whereas	   Cal7	   has	   a	   lower	  peak	   of	   virus	  binding	   of	   ~0.25.	   This	   indicates	   that	   the	   Cal7	   virus	   has	   either	   more	   powerful	   NA	  activity	   for	   cleaving	   6SLN	   or	   that	   the	   particular	   HA	   of	   the	   virus	   causes	   shorter	  residence	  times.	  	  The	  reduction	  in	  binding	  seen	  after	  the	  peak	  virus	  binding	  shows	  a	  similar	  shape	  for	  both	  Cal7	  and	  Iowa06	  viruses;	  however,	  the	  Iowa06	  virus	  appears	  to	  have	  a	  higher	  rate	  of	  decline	  in	  binding	  after	  the	  turning	  point.	  The	  level	  of	  virus	  remaining	  on	  the	  sensor	  at	  the	  end	  of	  the	  measurement	  is	  higher	  for	  Iowa06	  despite	  this	  enhanced	  rate	  of	  virus	  dissociation	  after	  the	  peak	  of	  virus	  binding.	  
When	  examining	  the	  measurements	  made	  for	  the	  reassortant	  virus	  with	  Cal7	  HA	  and	   Iowa06	  NA	  with	  a	  Cal7	  background	   the	   initial	  peak	  of	  binding	   is	   similar	   to	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Figure	   5.16:	   Comparison	   of	   equilibrium	   virus	   binding	   to	   6SLN-­‐PAA	   of	   Cal7,	  
Iowa06	   and	   reassortant	   viruses.	   Fractional	   saturation	   of	   100	   pM	   virus	   binding	  measured	   for	   a	   constant	   concentration	   of	   virus	   as	   a	   function	   of	   sugar	   loading.	   All	  measurements	  made	  in	  the	  presence	  of	  NA	  inhibitors.	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Figure	   5.17:	   HA/NA	   balance	   binding	   data	   for	   Cal7,	   Iowa06	   and	   reassortant	  
viruses	  binding	  to	  6SLN-­‐PAA.	  Measurements	  made	  of	  100	  pM	  virus	  in	  the	  presence	  and	  absence	  of	  NA	  inhibitors	  (Inhib).	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that	   seen	  with	   the	  Cal7	  WT	  virus	   indicating	   similar	   levels	   of	   initial	   sugar	  depletion	  and	  virus	  residence	  times;	  however,	  the	  binding	  decays	  to	  a	  lower	  level	  than	  that	  seen	  with	  the	  full	  Cal7	  virus	  suggesting	  that	  the	  reduction	  in	  binding	  at	  later	  time	  points	  is	  due	  to	  the	  substitution	  of	  the	  NA	  from	  Cal7	  for	  that	  of	  Iowa06.	  This	  virus	  also	  appears	  to	  have	  the	  same	  curve	  shape	  of	  that	  seen	  with	  the	  full	  Iowa06	  WT	  virus	  with	  a	  higher	  rate	  of	  virus	  binding	  decay,	  suggesting	  that	  this	  higher	  rate	  of	  virus	  dissociation	  seen	  is	  due	  to	  the	  presence	  of	  the	  Iowa06	  NA	  within	  the	  virus.	  The	  same	  reassortant	  virus	  constructed	  with	  the	  Iowa06	  genetic	  background	  has	  different	  binding	  characteristics	  from	  those	  seen	  with	  the	  Cal7	  background.	  The	  peak	  of	  virus	  binding	  is	  lower	  and	  the	  end	  point	  of	  virus	  binding	  is	  much	  lower	  in	  the	  presence	  of	  the	  Iowa06	  background.	  This	   implies	   that	   the	  background	  can	  alter	   the	  virus	  binding	   characteristics.	  This	   is	  likely	  to	  be	  due	  either	  to	  a	  change	  in	  virus	  morphology	  or	  the	  amount	  or	  proportions	  of	  HA	  and	  NA	  present	  on	  the	  virus	  particle.	  	  
5.2.10 Measurement	  of	  virus	  size	  by	  nanoparticle	  tracking	  analysis	  
The	   previous	   data	   presented	   regarding	   HA	   and	   NA	   balance	   of	   the	   studied	  H1N1	   viruses	   suggests	   that	   the	   background	   of	   the	   reassortant	   HA	   and	   NA	   viruses	  were	   responsible	   for	   a	   difference	   in	   virus	   binding	   characteristics.	   One	   factor	   that	  could	  be	  responsible	  for	  these	  differences	  could	  be	  virus	  morphology,	  which	  is	  mainly	  determined	  by	  the	  M1	  protein,	  as	  described	  in	  Introduction,	  section	  1.1.4.1.	  	  
Nanoparticle	  tracking	  analysis	  (NTA)	  was	  carried	  out	  on	  the	  virus	  used	  for	  the	  receptor	   binding	   assays.	   This	   technique	   records	   a	   video	   of	   the	   light	   scattered	   by	  particles	   in	   a	   suspension	   illuminated	   by	   a	   laser.	   Software	   tracks	   the	   movement	   of	  particles	  over	  time	  and	  based	  on	  the	  speed	  of	  movement	  the	  diffusion	  coefficient	  and	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therefore	   the	   particle	   size	   can	   be	   determined.	   The	   method	   used	   is	   described	   in	  
Materials	  and	  Methods,	  section	  2.2.14.	  
The	  particle	  size	  profile	  for	  the	  viruses	  used	  in	  HA/NA	  balance	  experiments	  is	  very	  similar,	  with	  a	  mode	  peak	  particle	  size	  of	  ~160	  nm	  and	  a	  mean	  particle	  size	  of	  ~180	  nm,	  Figure	  5.18.	  The	  distribution	   is	  not	  Gaussian	  with	  a	  skew	  towards	  higher	  particle	   sizes.	   The	   similarity	   of	   these	   data	   suggest	   that	   virus	   morphology	   is	   not	  responsible	   for	   the	   differences	   seen	   in	   the	   balance	  measurements	   for	   viruses	  with	  different	   backgrounds	   presented	   in	   the	   previous	   section.	   These	   virus-­‐sizing	  measurements	  do	  have	  a	  number	  of	  caveats	  due	  to	  the	  analysis	  methods	  and	  the	  virus	  preparation	   techniques	  used.	   The	   virus	   used	   for	   these	  measurements	   and	  previous	  HA/NA	   balance	   measurements	   are	   simply	   pelleted	   from	   the	   tissue	   culture	  supernatant	   and	  used	  without	   further	  purification.	  This	   form	  of	  NTA	   relies	  only	  on	  visualising	  particles	  based	  on	  their	  ability	  to	  scatter	  light	  without	  any	  way	  of	  knowing	  if	   the	   particles	  measured	   are	   virus	   or	   some	   other	   particle	   of	   the	   same	   size,	   as	   any	  other	   particles	   will	   also	   be	   biological	   material	   and	   will	   therefore	   scatter	   light	   in	   a	  similar	   manner	   to	   virus.	   A	   portion	   of	   the	   particles	   measured	   could	   be	   exosomes,	  reviewed	  in	  (Théry,	  Zitvogel	  &	  Amigorena,	  2002).	  
5.3 Discussion	  










Figure	   5.18:	   Nanoparticle	   tracking	   analysis	   of	   Cal7,	   Iowa06	   and	   reassortant	  
viruses.	  Measurements	  made	  of	  10	  000	  –	  20	  000	  independent	  particle	  tracks.	  Particle	  size	  made	  into	  a	  frequency	  distribution	  using	  a	  bin	  size	  of	  20	  nm.	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either	  pdm09	  or	  TRS	  H1	  binding	  (Childs	  et	  al.,	  2009;	  Maines	  et	  al.,	  2009;	  Yang,	  Carney	  &	  Stevens,	  2010;	  Chen	  et	  al.,	  2011;	  Yen	  et	  al.,	  2011;	  Bradley	  et	  al.,	  2011;	  de	  Vries	  et	  al.,	  2011;	  Xu	  et	  al.,	  2012a;	  2012b).	  
Somewhat	  different	  results	  were	  obtained	  when	  binding	  of	  pdm09	  and	  TRS	  H1	  containing	   viruses	  was	  measured	   using	   a	   sialylated	   glycan	  microarray.	   Childs	   et	  al.	  used	  very	  similar	  viruses	  to	  those	  used	  in	  this	  chapter,	  using	  two	  pdm09	  viruses:	  Cal4	  (A/California/4/2009),	  and	  A/Hamburg/5/2009,	  which	  are	  both	  very	  similar	  to	  Cal7	  and	  also	  the	  same	  TRS	  Iowa06	  virus,	  as	  well	  as	  the	  historical	  csw	  A/New	  Jersey/8/76.	  When	  measuring	   virus	   binding	   to	   sialylated	   glycan	  microarrays	   the	   results	   show	   a	  similar	   binding	   pattern	   for	   both	   the	   pdm09	   and	   TRS/csw	   viruses;	   however,	   virus	  binding	  was	  detectable	  for	  a	  number	  of	  the	  α2,3	  linked	  receptors	  in	  the	  array,	  which	  is	  not	   seen	   in	   the	   experiments	  presented	   in	   this	   chapter	   (Childs	  et	  al.,	   2009).	   Later	  studies	  by	  Chen	  et	  al.,	  Yen	  et	  al.	  and	  Bradley	  et	  al.	  examined	  the	  binding	  of	  a	  range	  of	  other	  pdm09	  H1N1	  viruses	  and	  TRS	  H1	  containing	  viruses	  by	  glycan	  microarray.	  All	  of	  these	  papers	  show	  a	  similar	  pattern	  to	  that	  seen	  in	  the	  earlier	  work	  by	  Childs	  et	  al.,	  where	  the	  early	  pdm09	  isolates	  show	  a	  major	  preference	  for	  α2,6-­‐linked	  sialic	  acid.	  There	   is,	   however	   little	   or	   no	   evidence	   for	   binding	   to	   α2,3-­‐linked	   sugars.	   The	  contemporary	  TRS	  H1	  containing	  viruses	  appear	   to	  bind	   to	   	   a	  wider	   range	  of	  α2,6-­‐linked	   receptors	   	   when	   compared	   to	   the	   pdm09	   viruses,	   but	   there	   is	   still	   little	  measurable	   binding	   to	   α2,3-­‐linked	   receptors	   (Chen	   et	   al.,	   2011;	   Yen	   et	   al.,	   2011;	  Bradley	  et	  al.,	  2011).	  	  
There	   have	   been	   two	   studies	   carried	   out	  measuring	   the	   binding	   of	   antibody	  complexed	   expressed	   H1	   HA	   from	   TRS	   and	   pdm09	   sources.	   de	   Vries	   et	   al.	   show	   a	  much-­‐reduced	  binding	  of	  pdm09	  HA	  compared	  to	  csw	  HA	  to	  immobilised	  fetuin.	  This	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is	   also	   combined	   with	   glycan	   microarray	   data,	   which	   show	   binding	   only	   to	   α2,6-­‐linked	   receptors	   with	   the	   same	   pattern	   of	   reduced	   binding	   of	   pdm09	   HA	   when	  compared	   to	   the	  csw	  HA.	  There	  was	  also	  no	  measurable	  binding	   to	  any	  α2,3-­‐linked	  sialic	  acid	  receptors	  in	  the	  microarrays	  for	  either	  pdm09	  or	  csw	  HAs	  (de	  Vries	  et	  al.,	  2011).	  Xu	  et	  al.	  also	  show	  a	  reduced	  binding	  of	  pdm09	  virus	  HA	  when	  compared	  to	  that	  of	  csw	  HA	  measured	  both	  by	  solid	  phase	  binding	  assay	  to	  the	  receptor	  analogue	  6SLNLN	  and	  also	  glycan	  microarrays	  (Xu	  et	  al.,	  2012b).	  
The	  results	  presented	  in	  this	  chapter	   for	  the	  binding	  of	  Cal7	  and	  Iowa06	  WT	  viruses	   (Fig.	   5.3)	   agree	  more	  with	   those	  measured	   for	   virus	   binding,	   (Childs	   et	  al.,	  2009;	   Chen	   et	  al.,	   2011;	   Yen	   et	  al.,	   2011;	   Bradley	   et	  al.,	   2011)	   rather	   than	   purified	  protein	  binding	  (de	  Vries	  et	  al.,	  2011;	  Xu	  et	  al.,	  2012a;	  2012b).	  These	  previous	  virus	  binding	  experiments	  give	   results	   that	   imply	   similar	  binding	   characteristics	   for	  both	  csw	   H1	   containing	   and	   early	   pdm09	   viruses,	   rather	   than	   the	   large	   difference	   in	  receptor	  binding	  characteristics	  seen	  when	  measured	  with	  purified	  protein	  (de	  Vries	  
et	  al.,	  2011;	  Xu	  et	  al.,	  2012a;	  2012b).	  
The	  difference	  seen	  when	  measuring	  purified	  HA	  and	  virus	  binding	  could	  be	  explained	   by	   a	   number	   of	   different	   factors.	   The	   purified	   HAs	   are	   expressed	   as	   a	  soluble	   ectodomain,	   similar	   to	   those	   expressed	   for	   this	   chapter.	   These	   soluble	  ectodomains	  are	  then	  complexed	  with	  two	  different	  antibodies	  giving	  a	  maximum	  of	  4	  HA	  trimers	  present	  in	  each	  complex,	  which	  as	  well	  as	  being	  a	  different	  presentation	  to	   that	   of	   a	   virus,	   with	   different	   flexibility	   between	   proteins,	   could	   also	   provide	  insufficient	  cooperativity,	  thus	  lowering	  the	  sensitivity	  of	  the	  assays.	  The	  soluble	  H1	  HAs	  under	  study	  in	  this	  chapter	  also	  appear	  to	  be	  highly	  unstable,	  as	  can	  be	  seen	  in	  the	   trypsin	  susceptibility	  assays	   (Fig.	  5.10).	  This	   instability	  of	   the	  proteins	  could	  be	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responsible	   for	   altering	   the	   receptor	   binding	   characteristics	   of	   the	   proteins	   seen	  when	  the	  HA	  is	  not	  stabilised	  by	  being	  attached	  to	  a	  virus.	  There	  could	  be	  a	  difference	  in	   stability	   between	   the	   TRS	   and	   pdm09	  HAs,	   as	   there	   are	   a	   significant	   number	   of	  differences	   in	  the	  protein	  sequence	   in	  areas	  which	  could	  be	  responsible	   for	  altering	  subunit	   interactions	   such	  as	   those	  at	   the	   interface	  of	   the	   subunits	  both	   in	  HA1	  and	  HA2	   subunits.	   The	   presentation	   of	   the	   HA	   on	   the	   viruses	   is	   clearly	   the	   most	  biologically	   relevant	   form	   and	   consequently	   the	   results	   obtained	   for	   whole	   virus	  binding	  are	  likely	  to	  be	  more	  representative	  of	  virus-­‐cell	  interactions.	  
de	  Vries	  et	  al.	  use	  unaltered	  HA	  proteins	  for	  their	  binding	  studies	  but	  	  they	  do	  not	  provide	  any	  details	  about	  the	  relative	  stability	  of	  the	  different	  proteins	  used	  (de	  Vries	   et	   al.,	   2011).	   Xu	   et	   al.	   adopt	   a	   different	   approach	   where	   they	   engineer	   a	  disulphide	  bond	  into	  the	  HA1	  between	  residues	  205	  and	  220	  in	  order	  to	  stabilise	  the	  HAs	   under	   study	   (Xu	   et	   al.,	   2012b).	   Although	   this	   could	   partially	   alleviate	   the	  problems	  of	  protein	  stability	  it	  could	  also	  alter	  the	  receptor	  binding	  characteristics	  of	  the	  proteins	  studied	  by	  altering	  the	  flexibility	  of	  the	  220	  loop.	  This	  disulphide	  is	  also	  very	  close	  to	  residue	  208,	  which	  was	  found	  to	  alter	  receptor	  binding	  characteristics	  of	  Iowa06	  in	  this	  chapter	  (Fig.	  5.5B).	  
The	  receptor	  binding	  studies	  of	  mutant	  Cal7	  and	  Iowa06	  viruses	  presented	  in	  this	   chapter,	   section	   5.2.4,	   demonstrate	   that	   substituting	   a	   number	   of	   residues	   can	  have	   an	   effect	   on	   the	   6SLN-­‐PAA	   receptor	   binding	   properties	   of	   the	   H1N1	   viruses	  under	  study.	  Differences	  in	  6SLN-­‐PAA	  binding	  were	  found	  when	  altering	  residues	  132,	  134,	  149,	  186,	  189,	  208,	  219	  and	  227.	  The	   combination	  of	   the	  differences	  between	  Cal7	  and	  Iowa06	  imply	  that	  the	  various	  residues	  that	  are	  changed,	  which	  individually	  do	   alter	   receptor	   binding,	   when	   combined	   result	   in	   viruses	   with	   similar	   receptor	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binding	  properties,	  suggesting	  a	  compensatory	  network	  of	  mutations	  present,	  which	  leaves	  overall	  virus	  binding	  characteristics	  unchanged.	  
The	   two	   studies	   detailed	   above	   which	   analyse	   the	   binding	   of	   different	  expressed	  H1	  proteins	  with	  respect	   to	  pdm09	  emergence	  both	  suggest	  a	  number	  of	  mutations	   responsible	   for	   the	  alterations	   in	   receptor	  binding	   that	   they	  measure	   for	  wild-­‐type	   proteins.	   de	   Vries	   et	   al.	   suggest	   that	   the	   double	   substitution	   T200A	   and	  A227E	   is	   responsible	   for	   the	  difference	   in	   receptor	  binding	   that	   they	  measure.	   The	  reported	  T200A	  substitution	  is	  a	  peculiarity	  of	  the	  particular	  pdm09	  strain	  used	  for	  those	   studies,	   Cal4,	   and	   is	   not	   present	   in	   Cal7	   or	   the	   vast	   majority	   of	   other	   early	  pdm09	  strains.	  This	  T200A	  substitution	  is	  the	  only	  difference	  between	  Cal7	  and	  Cal4	  and	   consequently	   the	   panel	   of	  mutants	  made	   by	   de	  Vries	   et	  al.	   bearing	   this	   T200A	  substitution	   in	   combination	   with	   other	   mutations	   is	   directly	   comparable	   to	   the	  results	   obtained	   for	   Cal7	   mutant	   viruses	   constructed	   in	   this	   chapter.	   The	   only	  mutation	   present	   in	   combination	  with	   the	   T200A,	   reported	   by	   de	   Vries	   et	   al.,	   that	  gives	  a	  difference	  in	  binding	  assays	  to	  fetuin	  is	  A227E,	  which	  increases	  the	  receptor	  binding	  of	  the	  pdm09	  HA,	  which	  is	  similar	  to	  the	  results	  for	  Cal7	  binding	  to	  6SLN-­‐PAA	  presented	   in	   this	   chapter	   (Fig.	   5.7)	   (de	   Vries	   et	   al.,	   2011).	   There	   are	   two	   other	  mutations	   which	   are	  made	   in	   the	   pdm09	   virus	   HA	   by	   de	   Vries	   et	   al.	   which	   are	   in	  common	   with	   the	   studies	   presented	   above:	   K149R	   and	   I219T.	   Neither	   of	   these	  mutations	   in	   combination	   with	   T200A	   show	   a	   difference	   in	   pdm09	   HA	   receptor	  binding	  (de	  Vries	  et	  al.,	  2011).	  This	  does	  not	  agree	  with	  results	  presented	  in	  section	  5.2.4	  which	  show	  that	  these	  mutations	  introduced	  into	  Cal7	  HA	  alter	  receptor	  binding.	  The	   pre-­‐pandemic	   swine	  HA	  used	   in	   de	  Vries	   et	  al.,	   A/swine/Ohio/891/01	   (H1N2)	  does	   not	   contain	   a	   number	   of	   the	   substitutions	   seen	   in	   Iowa06	  when	   compared	   to	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pdm09	  viruses,	  including	  substitutions	  at	  134,	  186,	  189	  208	  and	  219.	  The	  differences	  in	  the	  swine	  HA	  used	  when	  compared	  to	  Iowa06	  (R134K,	  P186S,	  T189A,	  K208R	  and	  T219A,	  see	  Figure	  5.2)	  one	  could	  consider	  likely	  to	  decrease	  the	  overall	  virus	  binding,	  as	   the	   186	   and	   189	   mutations	   in	   combination	   and	   the	   208	   mutation	   alone	   would	  cause	   a	   large	   decrease	   in	   6SLN-­‐PAA	   binding,	   decreasing	   the	   overall	   binding	   of	   the	  ‘wild-­‐type’	  TRS	  HA	  (Fig.	  5.6)	  rather	  than	  the	  increase	  in	  binding	  reported	  by	  de	  Vries	  
et	  al.	  (de	  Vries	  et	  al.,	  2011).	  
Xu	  et	  al.	   examine	   the	  binding	  of	  Cal4	  HA	  and	  mutants	   thereof	   as	  well	   as	   the	  pre-­‐pandemic	   swine	   HA	   from	   A/swine/Indiana/P12439/2000	   (H1N2)	   and	  associated	  mutations.	   The	  Cal4	  differs	   from	  Cal7	   at	   position	  200	   as	   detailed	   above.	  The	   swine	   virus	   HA	   used	   in	   this	   previous	   study	   varies	   from	   the	   Iowa06	   HA	   at	   a	  number	  of	  positions,	  carrying	   the	   following	  substitutions	  which	  are	   located	   in	  close	  proximity	  to	  the	  receptor	  binding	  site:	  K134R,	  G158E,	  P186S,	  T189A	  and	  K208R	  (H3	  Numbering)	  (Fig.	  5.2).	  This	   large	  number	  of	  mutations	  makes	  it	  difficult	  to	  compare	  the	   swine	   virus	  used	  with	   Iowa06.	  The	  majority	   of	   the	   substitutions	  present	   in	   the	  swine	   virus	   used	   by	   Xu	   et	   al.	   are	   typical	   of	   other	   isolated	   strains.	   The	   G158E	  substitution	   is,	   however,	   atypical	   in	   csw	   H1	   proteins.	   This	   substitution	   has	   been	  selected	  in	  experiments	  carried	  out	  when	  viruses	  were	  passaged	  in	  an	  inappropriate	  cell	   line,	   see	   section	   5.2.3.	   This	   mutation	   also	   appears	   in	   isolated	   pdm09	   viruses,	  particularly	  when	  they	  are	  passaged	  in	  MDCK-­‐SIAT	  cells	  as	  well	  as	  the	  substitutions	  K157E	  and	  N159E.	  The	  selection	  of	   this	  mutant	   in	   tissue	  culture	   implies	   that	   it	   is	  a	  receptor	  binding	  alteration	  and	  consequently	  likely	  to	  perturb	  the	  HA	  binding	  results	  of	   this	   previous	   study.	   Xu	   et	   al.	   attribute	   the	   reduction	   of	   binding	   that	   they	   see	   in	  pdm09	   HA	   to	   the	   following	   mutations:	   K134R,	   I219A	   and	   E227A,	   which	   increase	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binding	  to	  6SLNLN	  and	  make	  the	  binding	  pattern	  more	  like	  that	  of	  a	  TRS	  H1.	  All	  of	  the	  mutations	  listed	  above	  were	  reported	  to	  give	  an	  increase	  of	  binding	  when	  introduced	  alone	  and	  in	  combination	  gave	  the	  greatest	  increase	  in	  receptor	  binding.	  The	  results	  from	  Xu	  et	  al.	   regarding	   I219A	  and	  E227A	   introduced	   into	   a	  pdm09	  HA	  both	  alone	  and	   in	   combination	   agree	   with	   the	   results	   of	   this	   chapter,	   with	   both	   mutations	  increasing	   the	   binding	   of	   Cal7	   to	   6SLN-­‐PAA	   (Fig	   5.8);	   however,	   the	   substitution	  K134R	  did	  not	  cause	  a	  difference	  in	  binding	  of	  Cal7	  (Fig.	  5.4).	  Xu	  et	  al.	  also	  report	  that	  the	   increased	   binding	   that	   they	  measure	   for	   the	  TRS	  H1	   can	   be	   reduced	   to	   pdm09	  levels	  by	   introducing	  the	   inverse	  mutations	  (R134K,	  A219I	  and	  A227E).	  The	  results	  presented	   in	   this	   chapter	   show,	   as	  with	   Cal7,	   substitution	   at	   position	   134	   (K134R)	  does	  not	  affect	  6SLN-­‐PAA	  binding	  of	  Iowa06.	  The	  A227E	  substitution	  does	  not	  affect	  6SLN-­‐PAA	  binding	  of	  Iowa06	  when	  introduced	  alone.	  The	  A219I	  mutation	  increases	  Iowa06	  binding	  when	  introduced	  alone,	  however	  this	  increase	  in	  binding	  is	  reversed	  to	   a	   reduction	   of	   binding	   when	   combined	   with	   A227E,	   agreeing	   in	   part	   with	   the	  results	  of	  Xu	  et	  al.	  (Xu	  et	  al.,	  2012b).	  
The	  previous	  studies	  discussed	  above	  (de	  Vries	  et	  al.,	  2011;	  Xu	  et	  al.,	  2012b)	  attempt	  to	  explain	  the	  receptor	  binding	  of	  pandemic	  emergence	  by	  a	  small	  number	  of	  differences	   in	   receptor	  binding	   residues	   and	  both	  present	   a	   combination	  of	   a	   small	  number	  of	  substitutions	  which	  give	  receptor	  binding	  profiles	  similar	  to	  the	  pdm09	  or	  TRS	   H1	   that	   they	   have	  mutated	   their	   proteins	   towards;	   however,	   the	  mutagenesis	  studies	  presented	   in	   this	   chapter	  demonstrate	   that	   it	   is	   unlikely	   to	   be	   so	   simple	   as	  two	   or	   three	   substitutions,	   rather	   that	   there	   is	   an	   incomplete	   picture	   of	   other	  receptor	   binding	   changes	   present	   with	   a	   lack	   of	   understanding	   of	   the	   interrelated	  nature	  of	  the	  residues	  of	  the	  receptor	  binding	  site.	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The	  characterisation	  of	  the	  NA	  from	  pdm09	  and/or	  TRS	  has	  been	  carried	  out	  in	  a	  number	  of	  different	  studies	  (Yen	  et	  al.,	  2011;	  van	  der	  Vries	  et	  al.,	  2012;	  Xu	  et	  al.,	  2012b;	  Gerlach	  et	  al.,	  2012;	  Blumenkrantz	  et	  al.,	  2013;	  Abed	  et	  al.,	  2014;	  Campbell	  et	  
al.,	   2014).	  The	   results	  described	   in	   this	   chapter	  of	   the	  Km	   for	  MUNANA	  cleavage	  by	  Cal7	  NA	  are	  similar	  to	  a	  number	  of	  other	  studies	  of	  pdm09	  NAs,	  which	  all	  gave	  a	  low	  Km	  (Yen	  et	  al.,	  2011;	  van	  der	  Vries	  et	  al.,	  2012;	  Blumenkrantz	  et	  al.,	  2013;	  Abed	  et	  al.,	  2014;	  Campbell	  et	  al.,	  2014).	  The	  measured	  low	  Km	  value	  for	  Iowa06	  NA	  cleavage	  of	  MUNANA	  is	  also	  similar	  to	  a	  reported	  value	  for	  a	  TRS	  N1	  NA	  (Yen	  et	  al.,	  2011).	  Xu	  et	  
al.,	  however,	  obtained	  kinetic	  values	  for	  purified	  pdm09	  NA	  which	  give	  both	  a	  high	  Km	  and	  low	  kcat	  (Xu	  et	  al.,	  2012b)	  when	  compared	  to	  the	  results	  presented	  in	  this	  chapter	  for	  Cal7	  NA,	  see	  Table	  5.4,	  suggesting	  a	  partially	  inactive	  protein.	  
The	  Km	  values	  for	  6SLN	  and	  3SLN	  of	  Cal7	  and	  Iowa06	  presented	  in	  this	  chapter,	  Table	  5.4,	  indicate	  that	  both	  NAs	  bind	  the	  3SLN	  more	  efficiently	  than	  the	  6SLN,	  likely	  indicating	  a	  greater	  efficiency	  of	  cleavage	  of	  3SLN.	  The	  Km	  values	  obtained	  are	  similar	  to	  values	  determined	  for	  both	  pdm09	  NA	  and	  TRS	  NA	  cleaving	  6SL	  and	  3SL	  (Yen	  et	  al.,	  2011).	  Yen	  et	  al.	  also	  measures	  a	  lower	  relative	  Vmax	  for	  TRS	  N1	  NA	  when	  compared	  to	   pdm09	   NA.	   There	   are	   two	   other	   studies	   that	   compare	   the	   overall	   efficiency	   of	  cleavage	  by	  measuring	  sialic	  acid	  removal	  from	  a	  microarray	  (Xu	  et	  al.,	  2012b)	  or	  an	  end	   point	   measure	   of	   released	   sialic	   acid	   from	   a	   single	   fixed	   concentration	   of	  substrate	   (Gerlach	   et	   al.,	   2012).	   Both	   of	   these	   studies	   demonstrate	   an	   overall	  preference	   for	   α2,3-­‐linked	   sialic	   acid	   and	   a	   lower	   overall	   activity	   of	   TRS	   NA,	   as	   is	  found	  in	  experiments	  presented	  in	  section	  5.2.8.	  
Measurements	   made	   for	   HA/NA	   balance	   presented	   in	   this	   chapter,	   section	  5.2.9,	   demonstrate	   that	   there	   is	   a	   difference	   in	   overall	   virus	   binding	   to	   6SLN-­‐PAA	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between	  Cal7	  and	  Iowa06	  in	  the	  absence	  of	  NA	  inhibitors,	  indicating	  an	  overall	  lower	  binding	   capacity	   of	   pdm09	   viruses.	   	   The	   binding	   capacity	   appears	   to	   be	   reduced	  further	  when	  the	  NA	  from	  Iowa06	  is	  introduced	  (in	  the	  same	  Cal7	  background).	  This	  appears	  counterintuitive,	  as	  the	  WT	  Iowa06	  virus	  has	  a	  higher	  binding	  level	  than	  Cal7,	  with	   a	   very	   similar	   binding	   of	   the	   HA	   in	   the	   presence	   of	   NA	   inhibitors,	   indicating	  lower	  overall	  NA	  activity.	  This	  difference	  in	  binding	  of	  the	  reassortant	  virus	  could	  be	  due	  to	  two	  different	   factors:	  1)	  different	  characteristics	  of	  kon	  and	  koff	  between	  Cal7	  and	  Iowa06	  HAs,	  which	  could	  lead	  to	  similar	  equilibrium	  binding	  (Kd)	  characteristics	  but	   alter	   the	   residence	   times	   of	   the	   virus;	   and	   2)	   the	   amounts	   and	   proportions	   of	  proteins	  on	  the	  virus	  surface	  could	  be	  altered	  due	  to	  the	  different	  virus	  background,	  possibly	  caused	  by	  the	  different	  M	  protein.	  
The	   involvement	   of	   the	  M	  protein	   in	   the	   binding	   characteristics	   of	   the	   virus	  appears	   to	   be	   likely	   owing	   to	   the	   different	   binding	   characteristics	   seen	   for	   the	  reassortant	  (Cal7	  HA	  Iowa	  NA)	  virus	  when	  rescued	  with	  an	  Iowa06	  background.	  The	  inclusion	   of	   the	   Iowa	   background	   leads	   to	   a	   further	   reduction	   in	   virus	   binding	  indicating	  either	  greater	  levels	  of	  NA	  activity	  or	  a	  reduction	  in	  HA	  mediated	  residence	  time;	   however,	   without	   further	   reassortment	   studies	   and	   biochemical	   data	   on	   the	  levels	  of	  protein	  present	  on	  the	  different	  reassortant	  viruses	  it	  is	  not	  possible	  to	  draw	  firm	  conclusions	  as	   to	   the	   relative	  protein	  contents	  and	   the	   importance	  of	   the	  gene	  segments	  in	  altering	  the	  HA/NA	  balance	  data	  obtained.	  It	  does,	  however,	  not	  appear	  to	  be	  a	  matter	  of	  altered	  virus	  morphology,	  which	  is	  very	  similar	  for	  all	  viruses	  (Fig.	  5.18).	  	  
The	   involvement	   of	   the	   M	   protein	   in	   the	   pdm09	   virus	   emergence	   has	   been	  studied	  previously.	  Campbell	  et	  al.	  showed	  that	  introducing	  a	  pdm09	  M	  protein	  into	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PR8	   increases	   the	   amount	   of	   NA	   present	   and	   also	   leads	   to	   more	   viruses	   with	   an	  extended	  filamentous	  morphology	  (Campbell	  et	  al.,	  2014).	  This	  study,	  however,	  does	  not	   include	   any	   information	   on	   the	   activity	   of	   a	   TRS	   M	   protein	   in	   altering	   virus	  characteristics.	  A	  number	  of	  studies	  have	  found	  that	  the	  presence	  of	  both	  the	  M	  and	  NA	   from	   pdm09	   viruses	   enhances	   virus	   transmission	   in	   guinea	   pigs	   (Chou	   et	   al.,	  2011),	   ferrets	   (Lakdawala	  et	  al.,	  2011)	  and	  pigs	   (Ma	  et	  al.,	  2012).	  These	  differences	  found	  in	  virus	  transmissibility,	  in	  a	  range	  of	  hosts	  upon	  altering	  NA	  and	  M	  segments,	  are	  not	  possible	  to	  relate	  to	  the	  biophysical	  data	  obtained	  in	  this	  chapter.	  	  
Xu	   et	   al.	   described	   the	   HA	   and	   NA	   balance	   of	   TRS	   and	   pdm09	   viruses	   by	  plotting	  relative	  6SLNLN	  affinity	  of	   the	  HA	  against	   the	  catalytic	  efficiency	  of	   the	  NA	  (kcat/Km)	   at	   cleaving	  MUNANA	   and	   drawing	   the	   conclusion	   that	   there	   is	   a	   required	  correlation	   of	   relative	   HA	   and	   NA	   characteristics	   in	   order	   for	   efficient	   human	  infection	   and	   transmissibility	   that	   the	   TRS	   viruses	   appear	   not	   to	   have	   (Xu	   et	   al.,	  2012b).	  This	  technique	  of	  relating	  HA	  and	  NA	  activity	  appears	  to	  be	  over	  simplistic,	  as	  results	  obtained	   in	   this	  chapter	  demonstrate	   that:	  1)	   the	  HA	  binding	   is	  very	  similar	  between	   pdm09	   and	   TRS	   viruses,	   Fig.	   5.3;	   2)	   the	   NA	   characteristics	   at	   cleaving	  MUNANA	  do	  not	  appear	   to	  be	  significantly	  different	   for	  pdm09	  and	  TRS	  NAs,	  Table	  5.4;	  3)	  MUNANA	  cleavage	  by	  NA	  is	  likely	  not	  to	  be	  a	  good	  model	  for	  predicting	  the	  NA	  activity	   on	   cellular	   glycans,	   as	   the	  MUNANA	   cleavage	   kinetic	   parameters	   vary	   from	  those	  for	  natural	  substrates,	  6SLN	  and	  3SLN,	  in	  an	  unpredictable	  fashion,	  see	  	  Tables	  3.1,	  4.2	  and	  5.4;	  4)	  HA/NA	  balance	  measurements	  of	  the	  WT	  Cal7	  and	  Iowa06	  viruses	  are	  not	  very	  different	  from	  each	  other,	  Fig.	  5.17;	  and	  5)	  the	  genetic	  background	  of	  the	  virus	  could	  be	  important	  in	  altering	  the	  HA/NA	  balance	  characteristics,	  as	  seen	  when	  looking	   at	   the	   reassortant	   (Cal	   HA	   Iowa	   NA)	   viruses	   with	   either	   Cal7	   or	   Iowa06	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backgrounds,	  Figure	  5.17,	  which	  is	  non	  seen	  experimentally	  when	  simply	  looking	  at	  purified	  proteins.	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6 Final	  Discussion	  
One	  of	   the	  major	  aims	  of	   influenza	  virus	  research	   is	   to	  be	  able	  to	  predict	   the	  next	  pandemic	  strain.	  The	  major	  factor	  underlying	  pandemic	  emergence,	  apart	  from	  immune	   novelty,	   is	   the	   need	   for	   the	   virus	   to	   have	   the	   high	   fitness	   required	   for	  efficient	   transmission.	   The	  process	   of	   virus	   transmission	   is	   complex	   and	   involves	   a	  number	   of	   different	   factors.	   Currently	   the	   methods	   for	   understanding	   IAV	  transmissibility	  rely	  on	  a	  number	  of	  different	   in	  vivo	  and	   in	  vitro	  methods,	  which	  all	  have	  their	  own	  advantages	  and	  disadvantages	  and	  when	  used	  in	  combination	  provide	  the	   most	   complete	   picture	   of	   transmissibility.	   A	   major	   factor	   underlying	   the	   viral	  fitness	  and	  therefore	  transmissibility	  is	  the	  initial	  stage	  of	  IAV	  attachment	  to	  the	  cell	  surface,	  which	  is	  controlled	  by	  the	  two	  surface	  glycoproteins	  HA	  and	  NA.	  	  
This	   thesis	   presents	   a	   new	   in	   vitro	   biophysical	  method	   for	   investigating	   the	  relationship	  between	  the	  antagonistic	  activities	  of	  the	  two	  IAV	  surface	  glycoproteins.	  This	  technique	  has	  been	  implemented	  to	  examine	  a	  number	  of	  different	  viruses	  both	  in	  order	   to	  understand	   fundamental	   characteristics	  of	  virus	  attachment	  and	  release	  from	  a	  receptor	  coated	  surface	  and	  to	  be	  able	  to	  investigate	  a	  number	  of	  viruses,	  with	  a	  view	  to	  relating	  binding	  characteristics	  to	  virus	  fitness	  and	  transmissibility.	  	  
The	   binding	   of	   H7N9	   viruses	   was	   examined,	   particularly	   with	   a	   view	   to	  examining	   the	   role	   of	   the	   NA	   in	   receptor	   binding.	   These	   experiments	   demonstrate	  that	  the	  N9	  NA	  present	  in	  these	  viruses	  enhances	  receptor	  binding	  to	  both	  α2,6-­‐	  and	  α2,3-­‐linked	  sialic	  acid	  receptors	  via	  the	  secondary	  Hb	  site.	  An	  initial	  enhancement	  of	  virus	  receptor	  binding	  to	  α2,6-­‐linked	  receptors	  was	  also	  seen	  when	  the	  Hb	  site	  was	  present	   and	   the	   NA	   uninhibited,	   which	   could	   be	   explained	   by	   the	   kinetic	  characteristics	   of	   the	   sialidase	   site	   that	   favour	   α2,6-­‐linked	   sialic	   acid	   binding	   at	   a	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higher	  affinity	  accompanied	  with	  a	  lower	  cleavage	  probability	  upon	  substrate	  binding,	  turning	   the	   sialidase	   site	   into	   more	   of	   a	   receptor	   binding	   site.	   The	   binding	  characteristics	  of	  a	  number	  of	  H1N1	  viruses	  were	  also	  examined	  in	  order	  to	  attempt	  to	   understand	   the	   differences	   in	   virus	   binding	   which	   could	   be	   responsible	   for	   the	  emergence	  of	  the	  2009	  H1N1	  pandemic.	  The	  effect	  of	  a	  number	  of	  conserved	  amino	  acid	  substitutions	  between	  the	  pre-­‐pandemic	  TRS	  H1	  HAs	  and	  the	  pdm09	  H1	  HAs	  on	  receptor	  binding	  was	  examined	  as	  well	  as	  the	  novel	  combination	  of	  HA	  and	  NA	  seen	  upon	  the	  emergence	  of	  this	  novel	  virus	  lineage.	  
IAV	  receptor	  binding	  is	  a	  complex	  multivalent	  interaction	  that	  is	  often	  viewed	  as	   a	   rather	   static	   process	   of	   virus	   attaching	   irreversibly	   to	   a	   cell	   surface,	   with	   the	  interaction	  resulting	  in	  virus	  internalisation	  and	  initiation	  of	  infection.	  The	  reality	  is	  much	  more	  complex.	  The	  interaction	  of	  a	  virus	  with	  a	  surface	  will	  require	  a	  number	  of	  interactions	  of	  an	  HA	  subunit	  with	  single	  sialic	  acids	  to	  allow	  a	  residence	  time	  long	  enough	  to	  allow	  virus	  internalisation.	  The	  role	  of	  the	  NA,	  if	  any,	  in	  altering	  initial	  virus	  attachment	  is	  unclear.	  Although	  there	  is	  extensive	  evidence	  that	  adequate	  NA	  activity	  is	  required	  for	  virus	  release	  and	  disaggregation,	  there	  is	  little	  evidence	  that	  too	  much	  viral	  NA	  activity	  at	  the	  stage	  of	  virus	  attachment	  is	  detrimental	  to	  infectivity.	  This	  is	  most	   likely	  a	  matter	  of	  virus	  concentration.	  Virus	  infection	  is	  typically	   initiated	  by	  a	  small	  number	  of	  particles,	  which	   can	  attach	   to	  a	   large	  area	  of	   cell	   surface,	  with	   the	  viruses	  at	  ~100	  nm	  in	  size	  and	  the	  cell	  ~10	  –	  50	  µm	  in	  diameter.	  The	  probability	  that	  a	  small	  number	  of	  virus	  particles	  could	  deplete	  enough	  sugar	   from	  such	  a	   large	  cell	  surface	  and	  thereby	  have	  a	  major	  effect	  on	  HA	  binding	  is	  almost	  certainly	  low.	  A	  more	  active	  NA	  may	  reduce	  the	  residence	  time	  of	  individual	  viruses,	  but	  it	  appears	  unlikely	  that	  this	  would	  truly	  impinge	  on	  the	  internalisation	  of	  the	  virus,	  other	  than	  by	  slightly	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extending	   the	   attachment	   stage.	   It	   appears	   that	   the	   role	   of	   the	   NA	  would	   be	  most	  important	   for	   virus	   release	  where	   virus	  will	   be	   at	   a	  much	   higher	   concentration.	   It	  would	   not	   be	   unreasonable	   for	   localised	   virus	   concentration	   upon	   release	   to	   reach	  well	   into	   nM	   levels	   (1	   nM	   ≈	   0.6	   virus/µm3).	   There	   will	   also	   be	   a	   quantity	   of	  unincorporated	  NA	  present	  in	  the	  apical	  cell	  membrane	  at	  the	  site	  of	  budding	  which	  will	  also	  help	  virus	  release.	  The	  lack	  of	  importance	  of	  too	  much	  NA	  activity	  compared	  to	  the	  HA	  binding	  characteristics	  can	  be	  seen	  when	  looking	  at	  recent	  H3N2	  seasonal	  viruses	  which	  have	  very	  low	  binding	  to	  α2,6-­‐linked	  receptors	  and	  maintain	  high	  NA	  sialidase	   activity	   and	   yet	   they	   remain	   epidemic	   strains,	   indicating	   sufficient	   virus	  fitness	  and	  transmissibility.	  
The	  only	  example	  of	  reduced	  NA	  activity	  being	  a	  selective	  advantage	  is	  the	  NA	  stalk	  deletion	  that	  occurs	  upon	  the	  adaptation	  of	  viruses	  from	  wild	  birds	  to	  domestic	  poultry.	   Experiments	   carried	   out	   in	   this	   thesis	   have	   shown	   that	   a	   stalk	   deletion	  reduces	  effective	  NA	  activity	   (section	  3.2.10).	  This	   reduction	   in	  NA	  activity	  must	  be	  necessary	   for	   enhancing	   virus	   attachment,	   as	   it	   does	   not	   appear	   that	   reduced	   NA	  activity	  would	  ever	  be	  an	  advantage	   for	  virus	   release.	  There	  appear	   to	  be	  only	   two	  plausible	  explanations	  for	  this	  evolutionary	  advantage	  of	  reduced	  NA	  activity:	  1)	  the	  density	   of	   the	   receptors	   on	   the	   cell	   surface	   in	   domestic	   poultry	   may	   be	   low	   and	  consequently	  the	  increased	  NA	  activity	  dramatically	  impinges	  on	  the	  virus	  attaching	  for	  enough	  time	  to	  initiate	  infection;	  or	  2)	  the	  number	  of	  virus	  particles	  present	  at	  the	  site	   of	   infection	   in	   domestic	   poultry	   could	   be	   higher	   than	   that	   for	   wild	   bird	   and	  mammalian	   infection,	   therefore	   depleting	   the	   sugar	   at	   a	   greater	   rate	   and	   reducing	  overall	  receptor	  binding.	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The	  understanding	  of	  HA	  and	  NA	  balance	  in	  controlling	  cell	  infection	  becomes	  far	  more	  complicated	  when	  the	  NA	  also	  possesses	  receptor	  binding	  characteristics,	  as	  seen	  for	  some	  H3N2	  viruses	  and	  also	  as	  shown	  for	  the	  N9	  from	  H7N9	  viruses	  in	  this	  thesis	  (Chapter	  4).	  The	  N2	  binding	  via	  the	  sialidase	  site	  is	  somewhat	  simpler	  than	  for	  the	  N9	  owing	  to	  the	  absence	  of	  the	  complication	  of	  the	  binding	  contribution	  from	  the	  Hb	   site.	   For	   the	   N9	  with	   the	   sialidase	   site	   acting	   as	   a	   receptor	   binding	   protein	   for	  α2,6-­‐linked	   receptors	   and	   with	   the	   Hb	   site	   also	   enhancing	   receptor	   binding	   and	  substrate	   cleavage	   simultaneously	   it	   makes	   it	   difficult	   to	   dissect	   the	   relative	  contributions	  of	  these	  various	  roles	  of	  the	  NA	  and	  their	  energetic	  contributions	  to	  the	  binding	   characteristics	   of	   the	   virus.	   In	   some	   respects,	   however,	   it	   is	   irrelevant	  how	  the	  different	  proteins	  contribute	  to	  the	  binding	  and/or	  release	  characteristics	  of	  the	  virus,	   as	   it	   is	   only	   the	   combination	   of	   these	   activities	   that	   will	   alter	   the	   infectious	  characteristics	  of	  the	  virus.	  
The	   big	   question	   that	   arises	   from	   these	   experiments	  measuring	   HA	   and	   NA	  balance	   is:	   what	   is	   the	   combination	   of	   HA	   and	   NA	   activities	   required	   for	   optimal	  transmissibility	  between	  humans	  and	  therefore	  the	  emergence	  of	  a	  human	  pandemic	  virus?	  One	  way	  to	  examine	  this	  question	  would	  be	  to	  use	  the	  techniques	  described	  in	  this	  thesis	  to	  examine	  the	  HA	  and	  NA	  balance	  characteristics	  of	  previous	  viruses	  that	  have	  made	  a	  successful	   jump	  from	  animal	  to	  human	  reservoirs	  and	  which	  therefore	  formed	   pandemic	   strains.	   Of	   the	   four	   pandemics,	   for	   which	   virus	   samples	   are	  available,	  only	  the	  1918	  H1N1	  and	  2009	  H1N1	  pandemic	  viruses	  could	  be	  relied	  upon	  to	  be	  representative	  of	  the	  circulating	  pandemic	  strains	  of	  the	  time.	  The	  1918	  H1N1	  virus	  was	  reconstructed	  from	  gene	  sequences	  obtained	  from	  infected	  individuals	  and	  should	   therefore	   be	   the	   correct	   sequence	   and	   the	   2009	   H1N1	   virus	   has	   a	   large	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number	  of	   samples	   isolated	  by	   tissue	   culture,	  which	  does	  not	  have	   such	  a	   selective	  pressure	   for	   altering	  HA	   receptor	  binding	  properties	   as	   egg-­‐propagation.	  There	  are	  also	   a	   large	   number	   of	   sequences	   of	   pdm09	   viruses	   obtained	   directly	   from	   clinical	  isolates,	  without	   virus	   propagation.	   The	   1957	  H2N2	   and	   1968	  H3N2	   virus	   isolates	  available	  are	  all	  egg-­‐adapted,	  as	  this	  was	  the	  customary	  method	  of	  virus	  propagation	  at	   the	   time,	   and	   consequently	   it	   is	   quite	   possible	   that	   the	   viruses	   have	   acquired	   a	  number	  of	  egg-­‐adaptive	  substitutions	  in	  the	  HA.	  These	  substitutions	  will	  be	  acquired	  to	  allow	  efficient	  propagation	  of	   the	  virus	  by	  enhancing	  binding	   to	   the	   spectrum	  of	  receptors	  present	  in	  the	  allantoic	  membrane	  of	  hens’	  eggs,	  which	  is	  thought	  to	  have	  a	  high	  density	  of	  α2,3-­‐linked	  receptors.	   	  Apart	   from	  the	  egg	  propagated	  nature	  of	   the	  isolates	  the	  earliest	  RNA	  sequencing	  methods	  required	  large	  quantities	  of	  viral	  RNA.	  The	  viruses	  therefore	  had	  to	  be	  propagated	  on	  a	  large	  scale	  and	  clinical	  isolates	  could	  not	   be	   analysed.	   This	   lack	   of	   samples	   to	   analyse	   for	   pandemic	   emergence	  characteristics	   makes	   it	   difficult,	   therefore,	   to	   draw	   robust	   conclusions	   about	   the	  required	   HA	   and	   NA	   characteristics	   for	   optimal	   fitness	   and	   transmissibility	   in	   the	  human	  context.	  	  
There	  are	  a	  number	  of	  implications	  for	  virus	  binding	  when	  one	  considers	  the	  range	  of	  virus	  morphologies	  that	  can	  occur.	  IAV	  morphology	  is	  variable	  in	  a	  spectrum	  of	  sizes	  from	  the	  ‘spherical’	  viruses	  of	  ~100	  nm	  in	  diameter	  to	  filamentous	  viruses	  >1	  µm	   in	   length.	   It	  has	  been	  previously	   suggested	   that	   the	   filamentous	  viruses	  may	  be	  important	  in	  the	  infection	  cycle	  within	  humans.	  The	  receptor	  binding	  characteristics	  of	   these	  elongated	  viruses	  has	  not	  been	   individually	  characterised	   in	  comparison	  to	  the	  smaller	  spherical	  particles.	  In	  terms	  of	  the	  simple	  HA	  mediated	  receptor	  binding	  characteristics	  of	  these	  filaments,	  one	  would	  expect	  that	  the	  viruses	  would	  bind	  with	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greater	  affinity	  with	  the	  filaments	  lying	  flat	  to	  the	  cell	  surface,	  as	  this	  would	  allow	  a	  larger	   number	   of	  HA	   interactions	  with	   the	   cell	   surface.	   The	  way	   that	   these	   viruses	  would	  interact	  with	  the	  BLI	  sensors	  used	  for	  the	  studies	  shown	  in	  this	  thesis	  should	  be	   similar	   to	   that	   of	   a	   cell	   membrane;	   however,	   it	   is	   unclear	   how	   the	   binding	   of	  filamentous	   virus	   would	   affect	   the	   amplitude	   of	   the	   measurement	   made.	   If	   the	  filaments	   attached	   flat	   against	   the	   surface	   of	   the	   sensor	   it	   could	   lower	   the	   overall	  density	  of	  virus	  binding	  compared	  to	  the	  measurements	  made	  for	  spherical	  virus,	  as	  the	   overall	   density	   of	   bound	   virus	   could	   be	   reduced.	   If	   a	   population	   of	   the	   viruses	  attached	  perpendicular	  to	  the	  sensor	  surface	  with	  only	  the	  tip	  of	  the	  filament	  bound	  it	  could	  lead	  to	  a	  much-­‐increased	  signal,	  as	  the	  effective	  thickness	  of	  the	  surface	  of	  the	  BLI	   sensor	  would	   increase	   greatly.	   The	   role	   of	   the	  NA	   in	   the	   filaments	   is	   harder	   to	  predict.	   It	   is	   not	   thought	   that	   the	   proportions	   of	   HA	   and	   NA	   are	   different	   for	  filamentous	   viruses,	   when	   compared	   to	   ‘spherical’	   viruses,	   and	   consequently	   the	  same	  surface	  area	  of	  virus	  membrane	  would	  likely	  deplete	  the	  sugar	  from	  the	  sensor	  surface	  to	  the	  same	  extent	  as	  for	  a	  spherical	  virus.	  The	  difference,	  however,	  is	  in	  the	  interaction	  kinetics	  of	  the	  virus.	  The	  filamentous	  virus	  particles	  are	  much	  greater	  in	  size	  and	  will	  consequently	  have	  a	  slower	  diffusion	  rate	  compared	  to	  spherical	  viruses.	  If	  there	  are	  transient	  interactions	  as	  shown	  in	  this	  thesis	  they	  are	  likely	  to	  be	  longer	  in	  duration	  owing	  to	  this	  slower	  diffusion,	  therefore	  giving	  the	  filamentous	  particles	  a	  greater	   probability	   of	   forming	   enough	   interactions	  with	   the	   surface,	   causing	   longer	  virus	  residence	  times,	  which	  would	  be	  sufficient	  to	  initiate	  virus	  infection.	  One	  does,	  however,	   need	   to	   consider	   the	   different	   modes	   and	   therefore	   possible	   different	  speeds	  of	  virus	  entry:	  spherical	  particles	  enter	  via	  endocytosis	  whereas	  filamentous	  virus	   enters	   by	   macropinocytosis.	   The	   longer	   interactions	   of	   filamentous	   viruses	  could	  also	  increase	  the	  depletion	  of	  sugar	  from	  the	  surface	  or,	  as	  appears	  more	  likely	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from	  the	  experiments	  shown	  in	  this	  thesis,	  the	  longer	  interactions	  would	  reduce	  the	  overall	   NA	   cleavage,	   as	   the	  most	   efficient	   sialic	   acid	   depletion	   is	   seen	   in	   the	   early	  stages	  of	  virus	  binding	  when	  the	  interactions	  are	  short-­‐lived.	  	  
An	  interesting	  feature	  of	  the	  HA/NA	  balance	  measurements	  made	  for	  both	  X-­‐31,	   in	   Chapter	   1,	   and	   H7N9	   viruses,	   in	   Chapter	   2,	   is	   the	   large	   difference	   in	   virus	  binding	  to	  the	  α2,3-­‐	  and	  α2,6-­‐linked	  receptors	  when	  the	  NA	  is	  not	  inhibited.	  There	  is	  a	  general	  pattern	  of	  lower	  overall	  virus	  binding	  to	  the	  receptor	  analogue	  3SLN-­‐PAA,	  when	  the	  NA	  is	  not	  inhibited.	  This	  appears	  to	  be	  mainly	  due	  to	  the	  preference	  of	  the	  NA	   for	   cleaving	   the	  α2,3-­‐linked	   receptors.	  The	   reason	   for	   this	  overall	   preference	  of	  NA	   for	   α2,3-­‐linked	   sugars	   is	   unclear,	   whether	   it	   is	   an	   evolved	   characteristic	   or	   an	  inherent	   property	   of	   the	   naturally	   higher	   cleavability	   of	   α2,3-­‐linked	   sugars.	   The	  implications	  for	  this	   linkage	  preference	  are	   interesting	  when	  comparing	  human	  and	  avian	   virus	   characteristics.	   Human	   viruses	   typically	   infect	   URT	   cells	   which	   mainly	  express	   α2,6-­‐linked	   receptors	   (as	   described	   in	   Introduction,	   section	   1.3.1.2.2).	   Also	  present	  in	  the	  URT	  is	  mucus,	  which	  is	  thought	  to	  be	  rich	  in	  α2,3-­‐linked	  receptors	  (as	  described	   in	   Introduction,	   section	   1.7).	   In	   order	   to	   escape	   inhibition	   by	   this	  mucus	  human	   viruses	  must	   have	   low	   avidity	   for	   α2,3-­‐linked	   receptors	   and/or	   an	  NA	   that	  cleaves	  α2,3-­‐linked	  receptors	  efficiently.	  Whereas	   for	  efficient	   infection	  of	  URT	  cells	  the	  virus	  must	  have	  a	  strong	  avidity	  for	  α2,6-­‐linked	  receptors	  and	  also	  an	  NA	  that	  is	  efficient	   at	   cleaving	  α2,6-­‐linked	   receptors.	   The	   adaptation	  of	   IAV	  HA	   to	  α2,6-­‐linked	  receptor	   preference	   has	   been	   extensively	   characterised	   and	   linked	   to	   a	   number	   of	  individual	   substitutions	   in	   the	   receptor	   binding	   site;	   however,	   the	   adaption	   of	   the	  receptor	  specificity	  of	  the	  NA	  is	  less	  well	  understood.	  There	  has	  not	  been	  any	  in-­‐depth	  kinetic	  analysis	  of	  other	  avian	  virus	  NAs	  which	  would	  allow	  comparison	  with	  the	  N9	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data	  presented	  in	  this	  thesis	  making	  it	  unclear	  whether	  NA	  from	  wild	  birds	  typically	  possesses	   activity	   for	   cleaving	   α2,6-­‐linked	   receptors.	   The	   N9	   characterised	   in	   this	  thesis	   (Chapter	   4),	   which	   is	   similar	   to	   NAs	   found	   in	   wild	   birds,	   has	   very	   poor	  enzymatic	  turnover	  rates	  and	  strong	  substrate	  binding	  characteristics	  for	  α2,6-­‐linked	  receptors,	  which	  make	   it	  act	  as	  a	  receptor	  binding	  protein.	  Whether	   this	   is	   the	  case	  for	   a	   number	   of	   other	   avian	   NAs	   is	   unclear.	   It	   would,	   therefore,	   be	   of	   interest	   to	  characterise	  the	  cleavage	  specificity	  and	  kinetic	  parameters	  of	  a	  number	  of	  NAs	  from	  different	   hosts	   and	   at	   different	   stages	   of	   adaptation	   to	   the	   human	   host	   to	   fully	  understand	  the	  consequences	  of	  this	  linkage	  specificity.	  
Another	  virus	  characteristic	   that	  has	  been	  poorly	  characterised	  and	  could	  be	  of	  great	   importance	   in	  affecting	   the	  HA	  and	  NA	  balance	  characteristics	  of	  viruses	   is	  the	   relative	   amounts,	   proportions	   and	   distribution	   of	   the	   HA	   and	   NA	   on	   the	   virus	  surface.	   The	   proportions	   of	   these	   proteins	   on	   different	   viruses	   have	   been	   reported	  anecdotally	   to	  vary	  significantly	   for	  viruses	  of	  different	   subtypes	  and	  with	  different	  genetic	  backgrounds.	  It	  would	  be	  of	  interest	  to	  carry	  out	  a	  systematic	  analysis	  of	  the	  quantities	   of	   the	   two	   glycoproteins	   on	   the	   virus	   surface	   and	   also	   to	   attempt	   to	  understand	  which	  viral	  component	  is	  responsible	  for	  altering	  these	  characteristics	  by	  measuring	   the	  molar	   quantities	   of	   the	   two	   proteins	   and	   relating	   these	   back	   to	   the	  number	  of	  viral	  particles	  present.	  	  
The	   technique	   described	   in	   this	   thesis	   for	  measuring	   HA	   and	   NA	   balance	   is	  useful	   for	   determining	   virus	   binding	   characteristics	   in	   more	   detail	   and	   in	   more	  mechanistic	  detail	  than	  seen	  before.	  However,	  there	  are	  a	  number	  of	  caveats	  with	  this	  particular	   technique	   that	   need	   to	   be	   considered.	   The	   virus	   concentration	   used	   in	  these	  experiments	   is	  high	   (100	  pM	  ≈	  1010	  particles/ml)	  and	   the	  sugars	  used	  are	  an	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artificial	  system	  of	  the	  terminal	  trisaccharide	  moiety	  from	  much	  more	  complex	  long	  chain	  glycans,	  as	  described	  in	  Chapter	  3.	  It	  would	  therefore	  be	  interesting	  to	  carry	  out	  these	  balance	  experiments	  using	  possibly	  more	  relevant	  receptors.	  There	  are	  a	  large	  number	  of	  alternative	  receptors	  available,	  such	  as	  those	  used	  on	  glycan	  microarrays;	  however,	   they	   are	   not	   available	   in	   the	  multimeric	   polyacrylamide	   attached	   variety	  required	  for	  the	  BLI	  experiments	  described	  in	  this	  thesis.	  	  
The	   sialylated	   glycans	   present	   on	   the	   cell	   surface	   present	   a	   wide	   range	   of	  different	  structures	  and	  linkages	  which	  have	  been	  characterized	  to	  an	  extent	  by	  mass	  spectrometry	  (Bateman	  et	  al.,	  2010;	  Walther	  et	  al.,	  2013;	  Bern	  et	  al.,	  2013;	  Chan	  et	  al.,	  2013;	   Jia	  et	  al.,	  2014).	  Glycan	  microarrays	  have	  also	  been	  constructed	   from	  glycans	  directly	  isolated	  from	  tissues	  relevant	  to	  IAV	  infection	  (Song	  et	  al.,	  2011;	  Byrd-­‐Leotis	  
et	   al.,	   2014),	   which	   as	   well	   as	   allowing	   the	   characterisation	   of	   different	   glycans	  present	  in	  these	  tissues	  allow	  a	  semi-­‐quantitative	  measurement	  of	  the	  affinity	  of	  each	  of	  these	  species	  in	  the	  binding	  of	  viruses	  and	  can	  therefore	  be	  used	  to	  define	  putative	  receptors.	   Both	   the	   mass	   spectroscopy	   and	   glycan	   microarray	   methods	   detailed	  above	   do,	   however,	   have	   a	   number	   of	   problems	   in	   giving	   a	   full	   picture	   of	   the	  importance	  of	  different	  glycans.	  Conventional	  mass	  spectrometry	  studies	  do	  not	  give	  reliable	  quantitative	  measures	  of	  the	  relative	  amounts	  of	  each	  glycan	  species	  and	  the	  differentiation	  of	  different	   linkages	   (α2,6-­‐	   and	  α2,3-­‐linked	   sialic	   acid)	   is	   difficult	   by	  conventional	   mass	   spectrometry	   techniques,	   as	   glycan	   species	   with	   these	   two	  different	   linkages	   have	   identical	   masses.	   Studies	   are	   required	   which	   quantify	   the	  glycans	  of	   the	  cell	   surface	  of	  defined	  cell	   types	   from	  specific	   tissues,	  with	  a	  method	  that	  can	  differentiate	  different	  sialic	  acid	  linkages,	  coupled	  with	  microarrays	  to	  define	  which	  are	  most	  relevant	  to	  the	  receptor	  binding	  of	  different	  viruses.	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The	  technique	  for	  measuring	  the	  balance	  of	  HA	  and	  NA	  activities,	  presented	  in	  this	   thesis,	   combined	  with	   the	  NA	   kinetic	   characterisation	  methods,	   provide	   a	   new	  way	   to	   understand	   the	   role	   of	   these	   two	   proteins	   in	   receptor	   binding	   in	   an	  unprecedented	  quantitative	  manner.	  These	  techniques	  can	  then	  be	  used	  to	  infer	  the	  biochemical	  characteristics	  of	  viruses	  that	  are	  responsible	  for	  mediating	  transmission	  and	  therefore	  pandemic	  potential	  of	  a	  virus.	  It	  is	  clear	  that	  there	  is	  a	  requirement	  for	  both	   the	   relevant	   biochemical	   and	   biophysical	   studies	   to	   be	   combined	  with	   in	   vivo	  experiments	  of	  virus	  transmission	  and	  adaption	  in	  order	  to	  get	  the	  fullest	  picture	  of	  virus	  transmission	  characteristics.	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Appendix	  
N9	  NA	  expression	  construct	  sequence	  
	  Sequence	  of	  expression	  construct	  for	  A/Anhui/1/2013	  NA	  ectodomain.	  Residues	  1	  –	  6	   are	   the	   hexa-­‐his	   tag	   (underlined),	   residues	   7	   –	   47	   are	   the	   vasodilator-­‐stimulated	  phosphoprotein	  (VASP)	   tetramerisation	  domain	  (italics)	  and	  residues	  49	  –	  55	  are	  a	  TEV	   protease	   recognition	   sequence	   (shaded).	   Residues	   59	   –	   449	   correspond	   to	  residues	  75	  –	  465	  of	  the	  viral	  NA	  open	  reading	  frame.	  Construct	  was	  under	  the	  control	  of	  the	  polyhedrin	  promoter	  and	  also	  contained	  an	  N-­‐terminal	   gp67	   secretion	   signal	   peptide*	   not	   shown	   in	   construct	   sequences	   as	   it	   is	  post-­‐translationally	  cleaved.	  *	  gp67	  signal	  peptide:	  MLLVNQSHQGFNKEHTSKMVSAIVLYVLLAAAAHSAFA	  	   	  
                         10        20        30        40        50        60            
                ....|....|....|....|....|....|....|....|....|....|....|....| 
A/Anhui/1/2013  HHHHHHSSSDYSDLQRVKQELLEEVKKELQKVKEEIIEAFVQELRKRGENLYFQGPSRRT  
 
                         70        80        90       100       110       120         
                ....|....|....|....|....|....|....|....|....|....|....|....| 
A/Anhui/1/2013  SRNFNNLTKGLCTINSWHIYGKDNAVRIGESSDVLVTREPYVSCDPDECRFYALSQGTTI  
 
                        130       140       150       160       170       180      
                ....|....|....|....|....|....|....|....|....|....|....|....| 
A/Anhui/1/2013  RGKHSNGTIHDRSQYRALISWPLSSPPTVYNSRVECIGWSSTSCHDGKSRMSICISGPNN  
 
                        190       200       210       220       230       240      
                ....|....|....|....|....|....|....|....|....|....|....|....| 
A/Anhui/1/2013  NASAVVWYNRRPVAEINTWARNILRTQESECVCHNGVCPVVFTDGSATGPADTRIYYFKE  
 
                        250       260       270       280       290       300      
                ....|....|....|....|....|....|....|....|....|....|....|....| 
A/Anhui/1/2013  GKILKWESLTGTAKHIEECSCYGERTGITCTCRDNWQGSNRPVIQIDPVAMTHTSQYICS  
 
                        310       320       330       340       350       360      
                ....|....|....|....|....|....|....|....|....|....|....|....| 
A/Anhui/1/2013  PVLTDNPRPNDPNIGKCNDPYPGNNNNGVKGFSYLDGANTWLGRTISTASRSGYEMLKVP  
 
                        370       380       390       400       410       420      
                ....|....|....|....|....|....|....|....|....|....|....|....| 
A/Anhui/1/2013  NALTDDRSKPIQGQTIVLNADWSGYSGSFMDYWAEGDCYRACFYVELIRGRPKEDKVWWT  
 
                        430       440        
                ....|....|....|....|....|.... 
A/Anhui/1/2013  SNSIVSMCSSTEFLGQWNWPDGAKIEYFL  
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H1	  HA	  expression	  construct	  sequences	  
Sequence	   expression	   constructs	   for	   Cal7	   and	   Iowa06	   HA	   ectodomain	   expression.	  Residues	   1	   –	   502	   equate	   to	   residues	   1	   –	   502	   (H1	   numbering)	   of	   the	   HA	   after	   the	  removal	   of	   the	   signal	   peptide	   (first	   17	   residues	   of	   the	  H1	  HA	  open	   reading	   frame).	  Residues	  505	  –	  511	  consist	  of	  a	  TEV	  protease	  cleavage	  site	  (shaded);	  residues	  514	  –	  543	  consist	  of	  a	  foldon	  trimerisation	  motif	  (italics)	  and	  residues	  544	  –	  549	  consist	  of	  a	  hexa-­‐his-­‐tag	  (underlined).	  Construct	  was	  under	  the	  control	  of	  the	  polyhedrin	  promoter	  and	  also	  contained	  an	  N-­‐terminal	   gp67	   secretion	   signal	   peptide*	   not	   shown	   in	   construct	   sequences	   as	   it	   is	  post-­‐translationally	  cleaved.	  *	  gp67	  signal	  peptide:	  MLLVNQSHQGFNKEHTSKMVSAIVLYVLLAAAAHSAFA	  
                               10        20        30        40        50        60            
                      ....|....|....|....|....|....|....|....|....|....|....|....| 
A/California/7/09 HA  DTLCIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDKHNGKLCKLRGVAPLHLGKCNIAGW  
A/Iowa/1/06 HA        ..................................N..D......................  
 
                               70        80        90       100       110       120         
                      ....|....|....|....|....|....|....|....|....|....|....|....| 
A/California/7/09 HA  ILGNPECESLSTASSWSYIVETPSSDNGTCYPGDFIDYEELREQLSSVSSFERFEIFPKT  
A/Iowa/1/06 HA        L.........F............N............N......H...............A  
 
                              130       140       150       160       170       180      
                      ....|....|....|....|....|....|....|....|....|....|....|....| 
A/California/7/09 HA  SSWPNHDSNKGVTAACPHAGAKSFYKNLIWLVKKGNSYPKLSKSYINDKGKEVLVLWGIH  
A/Iowa/1/06 HA        N......T.........Y...N...R.....................N.K.....I....  
 
                              190       200       210       220       230       240      
                      ....|....|....|....|....|....|....|....|....|....|....|....| 
A/California/7/09 HA  HPSTSADQQSLYQNADAYVFVGSSRYSKKFKPEIAIRPKVRDQEGRMNYYWTLVEPGDKI  
A/Iowa/1/06 HA        ..P..T...T..............K...R......A.......A.........I....T.  
 
                              250       260       270       280       290       300      
                      ....|....|....|....|....|....|....|....|....|....|....|....| 
A/California/7/09 HA  TFEATGNLVVPRYAFAMERNAGSGIIISDTPVHDCNTTCQTPKGAINTSLPFQNIHPITI  
A/Iowa/1/06 HA        .................K.GS.....V..A...........................V..  
 
                              310       320       330       340       350       360      
                      ....|....|....|....|....|....|....|....|....|....|....|....| 
A/California/7/09 HA  GKCPKYVKSTKLRLATGLRNIPSIQSRGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSG  
A/Iowa/1/06 HA        .E...........M......................L.......I...............  
 
                              370       380       390       400       410       420      
                      ....|....|....|....|....|....|....|....|....|....|....|....| 
A/California/7/09 HA  YAADLKSTQNAIDEITNKVNSVIEKMNTQFTAVGKEFNHLEKRIENLNKKVDDGFLDIWT  
A/Iowa/1/06 HA        ....Q........G.......I................Q......S..N...........  
 
                              430       440       450       460       470       480      
                      ....|....|....|....|....|....|....|....|....|....|....|....| 
A/California/7/09 HA  YNAELLVLLENERTLDYHDSNVKNLYEKVRSQLKNNAKEIGNGCFEFYHKCDNTCMESVK  
A/Iowa/1/06 HA        ....M.......................................................  
 
                              490       500       510       520       530       540      
                      ....|....|....|....|....|....|....|....|....|....|....|....| 
A/California/7/09 HA  NGTYDYPKYSEEAKLNREEIDGGRENLYFQGGGGSGYIPEAPRDGQAYVRKDGEWVLLST  
A/Iowa/1/06 HA        ............................................................  
 
                             
                      ....|.... 
A/California/7/09 HA  FLGHHHHHH  
A/Iowa/1/06 HA        .........  
